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or centuries, quinoline-based drugs have formed the cornerstone of antimalarial treatment. 
Despite recent challenges posed by resistance, interest in these molecules persists. It is thus 
surprising that crucial details of their mechanism of action against the most virulent malaria 
parasite, Plasmodium falciparum, remain unresolved. This thesis develops new tools to generate 
deeper insights into the modes of action of the two major classes of the quinoline antimalarials 
against P. falciparum. These are the quinoline methanols, represented by the diastereomeric 
Cinchona alkaloids quinine and quinidine, and the 4-aminoquinolines, represented by 
chloroquine. 
Mechanistic studies of these antimalarials have typically focused on the inhibition of haemozoin 
biocrystallisation within the acidic digestive vacuole of P. falciparum. In order to conduct a 
comprehensive survey of the subcellular localisation of these antimalarials across the entire 
infected erythrocyte, a suite of novel fluorescent derivatives was designed and synthesised. Key 
physicochemical properties of these antimalarials were retained in order to preserve the 
interactions of these drugs with their putative target, ferriprotoporphyrin IX or Fe(III)PPIX. 
Versatile derivatisation of the alkaloids was enabled by a regioselective radical-mediated thiol-
ene click reduction. 7-Nitrobenz-2-oxa-1,3-diazole (NBD) was identified as a suitable reporter 
fluorophore and was attached to the quinoline core by nucleophilic aromatic substitution. The 
length of the spacer chain between the quinoline and the fluorophore was varied by preparing 
NBD-labelled amino acids and their corresponding succinimidyl esters. A novel NBD-labelled 
chloroquine derivative was prepared by using its N-dealkylated analogue as a key intermediate. 
A single quinine derivative with an alternative fluorophore, bimane, was also prepared.  
In order to determine whether these fluorescent derivatives were suitable analogues of the 
parent antimalarials, their photophysical and physicochemical properties were thoroughly 
evaluated. Spectrophotometric titrations revealed that characteristic features of association 
with Fe(III)PPIX were retained for most of the NBD-labelled alkaloids, vindicating the design 
choice to functionalise their vinyl groups. For chloroquine and its NBD-labelled derivative, 
μ-oxo dimerisation of Fe(III)PPIX was conserved. A detergent-mediated assay indicated that all 
fluorescently-labelled derivatives possessed improved activity against β-haematin formation 
compared to their parent antimalarials. Crucially, all fluorescent derivatives, with the exception 
of the bimane-labelled alkaloid, exhibited low to moderate nanomolar activities against a 
chloroquine-sensitive strain of P. falciparum. Taken together, these results showed that some of 
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the fluorescent-labelled derivatives were suitable analogues of the parent molecules and were 
thus appropriate for use in microscopy studies.  
Live-cell imaging revealed selective accumulation of the fluorescently-labelled analogues within 
P. falciparum-infected erythrocytes. All three analogues were found in close proximity to
haemozoin and hence the region corresponding to the digestive vacuole, especially in the case of 
chloroquine, consistent with haemozoin inhibition as their primary mechanism of action. 
Quantitative analysis of cells co-stained with the alkaloid analogues and LysoTracker Red 
demonstrated extensive colocalisation between these signals, indicating a preference of these 
analogues for phospholipid bilayers in acidic environments. Quantitative analysis also revealed 
that these analogues did not localise to the nucleus. This observation makes the claims that 
these molecules disrupt DNA replication in P. falciparum very unlikely. To overcome resolution 
limitations, super-resolution structured-illumination microscopy (SR-SIM) was employed. This 
indicated clear colocalisation between the analogues of all three quinoline antimalarials with 
the endoplasmic reticulum in P. falciparum. Colocalisation between these analogues and the 
mitochondrion was also evident but less conclusive. These observations corroborate previous 
ultrastructural studies implicating these organelles in the modes of action of these quinolines.  
Chemical proteomics was used to investigate whether the observed accumulation in 
P. falciparum corresponded to the binding of these antimalarials to protein targets. Drug-
labelled matrices were used to capture binding targets of the quinoline antimalarials from 
uninfected erythrocytes and P. falciparum. Several binding targets specific for these drugs were 
detected from human erythrocytes, especially from the chloroquine-labelled beads. On the other 
hand, SDS-Page revealed only a single prominent band between 200-250 kDa from the 
membrane-associated fraction recovered from P. falciparum lysate. Proteomic analysis revealed 
that this band corresponded to P. falciparum multidrug resistance-associated protein (PfMRP1). 
This is intriguing as PfMRP1 has been implicated in resistance mechanisms of chloroquine and 
quinine. Disrupting this gene has previously been shown to make cells more susceptible to these 
drugs, indicating that this protein plays a role in transport and hence must bind these 
substrates. That PfMRP1 was detected in the binding sub-proteomes corresponding to each of 
the drug-labelled matrices shows that this protein dynamically binds to all three of the 
quinoline antimalarials investigated in this study. 
Taken together, these results support haemozoin inhibition by accumulation in the digestive 
vacuole as the primary mechanism of action of these quinoline antimalarials, with Fe(III)PPIX as 
their primary target. Only a single protein binding target of these quinoline antimalarials, 






be responsible for modulating the activity of these compounds as a transporter. It may be 
speculated that secondary effects due to association with organelles such as the endoplasmic 
reticulum, the mitochondrion and membranous structures such as phospholipid bilayers may 
be responsible for additional metabolic disruption caused by these antimalarials. Overall, this 
thesis has developed new tools for generating deeper insights into the mechanistic details of 
these prototypical antimalarials. The observations described herein and subsequent studies 
using these novel tools may facilitate the identification of hitherto unexplored targets for new 
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Poets say science takes away from the beauty of the stars – mere globs of gas atoms.  
Nothing is “mere”. I too can see the stars on a desert night, and feel them. But do I see less or more? 
The vastness of the heavens stretches my imagination – stuck on this carousel my little eye can 
catch one-million-year-old light. A vast pattern – of which I am a part… What is the pattern, or the 
meaning, or the why? It does not do harm to the mystery to know a little about it. For far more 
marvellous is the truth than any artists of the past imagined! Why do the poets of the present not 
speak of it? What men are poets who can speak of Jupiter if he were like a man, but if he is an 




A poet once said, “The whole universe is in a glass of wine.” We will probably never know in what 
sense he meant that, for poets do not write to be understood. But it is true that if we look at a glass 
of wine closely enough we see the entire universe. There are the things of physics:  
the twisting liquid which evaporates depending on the wind and weather, the reflections in the 
glass, and our imagination adds the atoms. The glass is a distillation of the Earth's rocks, and in its 
composition we see the secrets of the universe's age, and the evolution of stars. What strange 
arrays of chemicals are in the wine? How did they come to be? There are the ferments, the 
enzymes, the substrates, and the products. There in wine is found the great generalisation:  
all life is fermentation. Nobody can discover the chemistry of wine without discovering, as did Louis 
Pasteur, the cause of much disease. How vivid is the claret, pressing its existence into the 
consciousness that watches it! If our small minds, for some convenience, divide this glass of wine, 
this universe, into parts – physics, biology, geology, astronomy, psychology, and so on – remember 
that nature does not know it! So let us put it all back together, not forgetting ultimately  
what it is for. Let it give us one more final pleasure: drink it and forget it all! 
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1.1. Overview  
 
alaria is a devastating infectious disease that places a large proportion of the population 
at risk and impedes economic development, especially in the developing world. For 
centuries, quinoline-based antimalarials have formed the cornerstone of treatment regimes. 
Despite challenges posed by resistance, interest in these molecules remains. Surprisingly, their 
modes of action against the malaria parasite remain incompletely resolved and, indeed, may 
differ in their details. 
 
This study aims to develop novel tools to generate deeper insights into the mechanism of action 
of the two most important classes of these antimalarials, the quinoline methanols and the  
4-aminoquinolines, represented by the diastereomeric Cinchona alkaloids, quinine and 
quinidine, and a synthetic analogue, chloroquine, respectively (Figure 1.1). 
 
This chapter will outline the broader context of this study. The disease burden posed by malaria 
as well as the life cycle of its most virulent parasite, Plasmodium falciparum, will be discussed 
with an emphasis on its pathogenic intraerythrocytic stage. During this period of its life cycle, 
the parasite faces several metabolic challenges that are relevant to work contained herein. 
These include haemoglobin catabolism and the challenge faced by the disposal of the cytotoxic 
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iron species ferriprotoporphyrin IX. The structure of malaria pigment (haemozoin) and recent 
progress in understanding its formation will be discussed. Lipid metabolism during the 




Figure 1.1. The structures of the representative quinoline antimalarials investigated in this study.  
The quinoline methanol and 4-aminoquinoline motifs are highlighted in blue and orange, respectively. 
 
The origins of the quinoline antimalarials and the development of their synthetic derivatives 
will be discussed in the context of current antimalarial treatment strategies. Challenges posed 
by membrane transporter proteins in facilitating drug resistance in P. falciparum will be 
highlighted. Various aspects of contemporary antimalarial drug discovery will be presented 
including efforts to identify novel β-haematin inhibitors.  
 
As the inhibition of haemozoin formation is suspected to be the primary target of many 
quinoline antimalarials, there is much interest in understanding the mechanism of this process. 
A central aspect of this process is the interaction of these drugs with ferriprotoporphyrin IX. 
Recent advances in understanding these interactions both in solution and the solid state will be 
presented. Brief reference will also be made to alternative hypotheses that have been presented 
to account for the activity of the quinoline antimalarials. 
 
Although similar in some respects, the quinoline methanol alkaloids and chloroquine possess 
considerable physicochemical differences that are highlighted by differences in accumulation 
within P. falciparum. They have also been found to elicit differential morphological effects on 
the parasite such as modulation of endocytosis and vesicle trafficking. Various efforts to identify 
proteinaceous binding targets will be presented. This chapter concludes with an outline of the 
major objectives of this study in line with the aim of developing new tools to generate novel 
insights into the modes of action of these two classes of antimalarials within P. falciparum.  





1.2. The global disease burden and life cycle of the malaria parasite 
 
1.2.1. The scourge of malaria 
 
Malaria imposes an intolerable burden on global health. According to the most recent report by 
the World Health Organisation, the disease is responsible for nearly half a million deaths every 
year of which approximately 90% occur in Africa.1 Infants and children are most affected by the 
disease which is thought to account for one in every ten child deaths.1 Furthermore, malaria is 
recognised as a cause of poverty and poses a major hindrance to economic development in 
affected regions: “Where malaria prospers most, human societies have prospered least.”2 
 
In 2008, as one of its Millennium Development Goals, the United Nations called for a concerted 
international effort to halt and reverse the global incidence of malaria by 2015. While this target 
has unquestionably been achieved, much remains to be done and ambitious new goals have 
been set for 2030 to reduce global incidence and mortality by at least 90%.1 
 
Malaria is an infectious disease caused by protozoan parasites belonging to the genus 
Plasmodium. Four species of Plasmodium are chiefly responsible for infection in humans, namely 
P. falciparum, P. malariae, P. ovale and P. vivax. Of these, P. falciparum is the most virulent, 
especially in Africa where it is also the most prevalent species.1 Common symptoms of malaria 
include recurrent fever and headaches. In serious cases, infection can lead to long-term liver 
damage, neurological damage, coma and death. 
 
The primary hosts and transmission vectors of the malaria parasites are female Anopheles 
mosquitoes. For this reason, the prevalence of the disease varies across the globe according to 
exposure to the mosquito. Hence malaria is typically endemic to the tropical and subtropical 
regions of sub-Saharan Africa, Asia and the Americas.  
 
1.2.2. The life cycle of the malaria parasite, Plasmodium falciparum 
 
While the four species of Plasmodium mainly responsible for malaria in humans all share similar 
life cycles, only the life cycle of P. falciparum will be described in detail.  
 
Human infection begins with the injection of sporozoites into the bloodstream by an infected 
female Anopheles mosquito during a blood meal. The sporozoites travel to the liver and invade 
hepatocytes where they multiply asexually to form liver schizonts over the course of 
approximately one week.3 This is followed by the release of merozoites into the bloodstream. 





Merozoite release is followed by the rapid invasion of red blood cells, or erythrocytes, initiating 
the intraerythrocytic cycle (Figure 1.2). This asexual development phase is complex and 
comprises three successive morphological stages. During the ring stage, the expression of 
parasite proteins exported into the host erythrocyte peaks, suggesting that host cell 
modifications are a major task of this stage.4,5 The trophozoite stage is characterised by rapid 
parasite growth and the distinct appearance of malaria pigment, the remnant of catabolised 
haemoglobin. Finally, the parasite enters the schizont stage during which it generates up to 32 




Figure 1.2. An illustration of the main stages of the intraerythrocytic life cycle of P. falciparum.  
Merozoite invasion of erythrocytes is followed by the ring, trophozoite and schizont stages,  
after which the host cell ruptures to release further populations of merozoites. 
 
It is during the 48-hour intervals of this cycle that the periodic chills and fevers, characteristic of 
malaria, are experienced. This is triggered by the rupture of mature schizonts and the release of 
cell debris, both of which stimulate the host’s innate immune response. This cycle also produces 
the disease pathology associated with malaria. Most deaths occur due to complications arising 
from P. falciparum infections whereby infected erythrocytes adhere to the endothelium of 
capillaries and venules, particularly in the brain. This vascular occlusion may lead to coma, after 
Merozoite invasion 















which the patient has little chance of survival even with optimal care.6 Although the blood 
stages of the parasite cause most of the pathology related to the disease, they are also the stages 
that are the most susceptible to treatment by antimalarial agents. 
 
A fraction of merozoites form sexual gametocytes, the only form of the parasite that is capable 
of transmission from humans to the mosquito vector. Immature gametocytes are sequestered in 
the bone marrow but, once mature, they circulate in peripheral blood. At this point, when an 
Anopheles mosquito feeds on an infected human, P. falciparum gametocytes are ingested along 
with the blood and the mosquito itself becomes infected.3 Following maturation of a gametocyte 
into a gamete within the mosquito midgut, gamete fusion produces ookinetes which penetrate 
the midgut wall and form oocysts. These enlarge over time and burst to release sporozoites that 
migrate to the salivary gland of the mosquito, from where they can infect humans during the 
mosquito’s next blood meal.3  
 
1.2.3. Ultrastructural features of the intraerythrocytic life cycle 
 
It was only after continuous in vitro cultures of P. falciparum were established in 1976 that a 
definitive ultrastructural description of the parasite could be given.7 Since then, 
immunolabelling, serial electron tomography and other imaging techniques have vastly 
improved our understanding of the ultrastructure of P. falciparum. However, extensive sample 
preparation and the harsh conditions required for transmission electron microscopy mean that 
dynamic information is lost and imaging artefacts are easily introduced.  
 
As described above, the intraerythrocytic stage of the P. falciparum life cycle commences with 
merozoite invasion of host erythrocytes, signalling the beginning of a continuous and dynamic 
process which takes approximately 48 hours. The merozoites are ellipsoid with an apical 
prominence and are similar in dimension to a large bacterium.8 They contain the equipment 
needed for invasion of the erythrocytes; these are the “apical organelles” which comprise 
rhoptries, micronemes, mononemes and dense granules (Figure 1.3A).9 Merozoites also possess 
other organelles including ribosomes, a single acrystate mitochondrion, a non-photosynthetic 
plastid called an apicoplast and a nucleus.  
 
After adhesion to the erythrocyte the parasite re-orientates itself so that the apical prominence 
is in contact with the erythrocyte membrane. The complex mechanism of this invasion has been 
thoroughly investigated using super-resolution fluorescence and immunoelectron microscopy.10 
Once inside the erythrocyte, the parasite encloses itself in its own compartment, separate from 
the erythrocyte cytosol. This compartment is bounded by the parasitophorous vacuolar 
membrane which is in close proximity to the parasite plasma membrane.  







Figure 1.3. Electron micrographs of the merozoite and ring stages of the intraerythrocytic P. falciparum.  
(A) A merozoite showing the apical prominence (ap) with a rhoptry (r), dense granules (d) and an indented 
nucleus (n). (B) A ring stage parasite exhibiting the nucleus (n), surrounded by ribosomes and endoplasmic 
reticulum. Scale bars represent 0.5 μm. Reproduced from Bannister et al., Parasitol. Today, 2000, 16, 427 
with permission from Elsevier. 
 
In the early ring stage, the central region is thin while the peripheral region, containing the 
nucleus and other organelles, is thicker (Figure 1.3B). Giemsa-stained smears depict a signet 
ring-shaped structure which gives this stage its name.8 The mid-ring stage, about 10-15 hours 
after invasion, was originally thought to be a metabolically-nondescript phase. However, there 
is now evidence that haemoglobin ingestion and catabolism begin at this stage as well as the 
synthesis of proteins for export to the host cell.5,11 The parasite feeds on the erythrocyte cytosol 
via a cytostome (“cell mouth”) and haemoglobin catabolism most likely commences in small 
acidic vesicles. An increase in protein synthesis is indicated via a proliferation of ribosomes and 
an extensive endoplasmic reticulum.8 The erythrocyte is gradually altered by proteins exported 
from the parasite, many of which are incorporated into the surface of the host cell. This 
increases the adhesiveness of the erythrocyte membrane and is eventually responsible for the 
pathogenic obstruction of the vasculature characteristic of severe malaria.8 
 
The trophozoite stage occurs approximately 20-38 hours after invasion and is the most active 
metabolic stage (Figure 1.4A). During this stage the cell increases the most in size. The enlarged 
Golgi complex is located close to the nucleus which is already involved in the first rounds of 
nuclear division.8 The mitochondrion is surrounded by a double membrane while the apicoplast 
is observed to be contained within four membranes. These organelles are elongated and 
branched but remain in close apposition at a number of points.9 The mature digestive vacuole is 
readily distinguishable by the crystals of malaria pigment (haemozoin), a by-product of 
haemoglobin catabolism. During this stage, haemoglobin metabolism continues in earnest.  
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Figure 1.4. Electron micrographs of the trophozoite and schizont stages of intraerythrocytic P. falciparum. 
(A) Mid-trophozoite stage showing the nucleus (n), digestive vacuole (p) and a cytostome with a forming 
food vacuole (v). (B) A schizont showing a series of nuclei (n) and developing merozoites (m). Note the 
irregular appearance of the host cell surface and the presence of knobs (k). Scale bars represent 0.5 μm. 
Reproduced from Bannister et al., Parasitol. Today, 2000, 16, 427 with permission from Elsevier. 
 
During the trophozoite stage a number of dramatic modifications to the host erythrocyte take 
place. Proteins continue to be secreted by the parasite across the parasitophorous vacuolar 
membrane to the erythrocyte cytoplasm. Destinations include the Maurer’s clefts which are 
compartments that concentrate virulence proteins for delivery to the host membrane.9 Knobs, 
self-associated clusters which represent the major adhesive proteins, distort the appearance of 
the host cell.9 The parasite also constructs an extensive exomembrane system called the 
tubovesicular network which extends from the parasite plasma membrane to the erythrocyte 
cytoplasm, and possibly to the external milieu, and is used to traffic lipids and nutrients.9 
 
Finally, during the schizont phase, further mitotic nuclear division occurs to generate between 
16 and 32 daughter merozoites (Figure 1.4B). Ingestion of almost all the host cell haemoglobin 
means that the parasite takes up the complete erythrocyte. The digestive vacuole is compacted 
into a round, single, dense mass.8 Merozoite-forming foci are spaced around the circumference 
of the parasite. There is proliferation of the rough endoplasmic reticulum and ribosomes, and 
multiplication of the mitochondrion and plastid means that a copy of each of these organelles is 
inherited by a daughter merozoite. Eventually the parasite plasma, parasitophorous vacuolar 
and the erythrocyte plasma membranes are breached as the merozoites are released into the 
bloodstream of the host at the end of this stage of the life cycle. 
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1.3. Metabolic challenges faced by the intraerythrocytic parasite 
 
1.3.1. Haemoglobin ingestion and catabolism 
 
The human erythrocyte provides a convenient niche for the malaria parasite and provides 
excellent protection from the host immune system. Apart from lacking almost any organelles, 
this blood cell provides vast quantities of haemoglobin, some of which is exploited by the 
parasite as a nutrient source.12 This also poses several metabolic challenges for the parasite that 
needs to make space for itself in the erythrocyte in order to grow. Furthermore, it needs to 
detoxify the cytotoxic iron-containing prosthetic groups of haemoglobin which are released 
following catabolism. Hence, P. falciparum has evolved an efficient pathway that catabolises 
haemoglobin to amino acids with the concomitant biocrystallisation of ferriprotoporphyrin IX 
into a remarkable structure called haemozoin.  
 
Haemoglobin degradation occurs in the acidic digestive vacuole, a lysosomal compartment 
unique to Plasmodium. Unlike most other organelles, this vacuole does not persist throughout 
the entire intraerythrocytic life cycle but instead is discarded at the end of each cycle of the 
blood stage. Although there are several competing models that attempt to explain the 
biogenesis of the digestive vacuole,11,13,14 each one relies on cytsostomal invagination of the 
double membrane between the erythrocyte and parasite cytoplasm (Figure 1.5). In this 
endocytosis-like process, haemoglobin-containing vesicles are pinched off by the cytostome and 
travel to the digestive vacuole where haemoglobin is broken down. Recent evidence suggests 
that haemoglobin catabolism probably already commences in the acidified transport vesicles.11  
 
During the semi-ordered process of haemoglobin degradation, two families of proteases play 
prominent roles. Four aspartic acid proteases called plasmepsins and three cysteine proteases 
called falcipains are found in the digestive vacuole.15,16 Digestion into smaller peptides is 
facilitated by the zinc metalloprotease falcilysin after which a dipeptidyl aminopeptidase 
generates dipeptides, some of which are exported to the cytosol for catabolism into free amino 
acids by aminopeptidases.17,18  
 
Haemoglobin degradation is necessary for parasite survival as it has been found that parasite 
development is interrupted when haemoglobin proteolysis is blocked by protease inhibitors.19 
Catabolised haemoglobin forms the main amino acid source for the parasite and the proportions 
of free amino acids which are generated by P. falciparum resemble the amino acid composition 
of globin.20,21 While 25-75% of the host cell protein may be degraded, only a small amount of 
this is utilised for parasite protein synthesis. This is typically around 16% but does not exceed 





25%.12 The majority of amino acids are simply released from the infected cell into the external 
medium. It has been suggested that the reason for this lies in the need to limit the swelling of 




Figure 1.5. Representation of haemoglobin ingestion and catabolism by P. falciparum in the host cell.  
 
1.3.2. Ferriprotoporphyrin IX detoxification and haemozoin formation 
 
Haemoglobin comprises four globular protein subunits, each of which is composed of a globin 
chain tightly associated with an iron-containing prosthetic group called haem. Hence, four haem 
groups are liberated for every molecule of haemoglobin catabolised. Upon release, haem is 
rapidly and irreversibly oxidised to its ferric form, ferriprotoporphyrin IX or Fe(III)PPIX  
(Figure 1.6), with concomitant production of hydrogen peroxide. The iron atom is coordinated 





























Figure 1.6. The structure of an oxidised haem molecule following release from a globin subunit, referred to 
as ferriprotoporphyrin IX or Fe(III)PPIX. When the axial ligand “X” is a water molecule or a hydroxide ion, 
the entity is called haematin. The former species is dominant in the digestive vacuole. 
 
Free Fe(III)PPIX is poisonous to the parasite due to its cytotoxic, pro-oxidant activity. At high 
concentrations, free Fe(III)PPIX can inhibit protein function and partition into and disrupt lipid 
bilayers.25 It can also undergo electron transfer reactions with molecular oxygen to produce 
diverse and damaging reactive oxygen species that can destroy the integrity of the cell.25 In 
mammalian cells, levels of dissociated Fe(III)PPIX are strictly regulated by haem oxygenase 
enzymes. However, the malaria parasite lacks a functional haem oxygenase and hence faces a 
unique challenge as it cannot degrade Fe(III)PPIX enzymatically.26 (Incidentally, enzymatic 
degradation of Fe(III)PPIX would also be problematic for the parasite as it would produce 
massive quantities of free iron which are equally toxic.) Instead, Fe(III)PPIX is efficiently 
biocrystallised to relatively inert and insoluble haemozoin, historically known as malaria 
pigment, within the acidic digestive vacuole. 
 
Haemozoin is a crystalline cyclic dimer of Fe(III)PPIX in which the propionate group of one 
porphyrin moiety coordinates to the iron centre of its partner and vice versa, while the second 
propionic acid group of each Fe(III)PPIX hydrogen bonds to a neighbouring dimer in the crystal 
(Figure 1.7). The synthetic counterpart of haemozoin is called β-haematin and the two species 
are chemically, spectroscopically and crystallographically identical.27  
 
It was first suspected by Fitch and Kanjananggulpan that haemozoin was probably identical to 
β-haematin, an insoluble Fe(III)PPIX precipitate first described in the 1930s.28 Subsequently, 
Slater et al. demonstrated by X-ray diffraction, infrared spectroscopy and solubilisation studies 
that haemozoin is indeed identical to β-haematin. They showed that both species possess bonds 
between the propionate group of one porphyrin and the Fe(III) centre of its neighbour.29  







Figure 1.7. The structure of haemozoin. Two hydrogen-bonded μ-propionato dimers of Fe(III)PPIX  
are represented, each of which forms the symmetrical repeating unit of the crystal. 
 
Bohle et al. further demonstrated by synchrotron X-ray diffraction that identical diffraction 
patterns are obtained from lyophilised parasitised erythrocytes and β-haematin, showing that 
haemozoin and β-haematin are identical.30,31 In 2000, Pagola et al. determined the structure of 
β-haematin from its X-ray powder diffraction pattern by Rietveld refinement.27 Eventually, the 
single crystal X-ray structure of the DMSO solvate of β-haematin was presented, providing 
irrefutable evidence of its structure (Figure 1.8).32 
 
Haemozoin formation represents the overwhelming fate of Fe(III)PPIX released in the parasite, 
accounting for at least 95% of the total iron in P. falciparum.33 Most quinoline antimalarials are 
suspected to inhibit this pathway, leading to a deleterious accumulation of Fe(III)PPIX. Amongst 
other manifestations, this is suspected to generate reactive oxygen species and destabilise the 
vacuolar membrane.25 However, the mechanism whereby Fe(III)PPIX is sequestered into 
crystalline haemozoin and, consequently, the mechanism of its inhibition by quinoline 
antimalarials, remains unclear. Theories of haemozoin formation have variously included 
protein-mediated or enzyme-catalysed mechanisms, autocatalysis and lipid-mediated 
processes.34-38 








Figure 1.8. (A) The μ-propionato dimer reported by Gildenhuys et al. as the symmetrical repeating unit of  
β-haematin as a DMSO solvate. Ellipsoids have been drawn at 50% probability. Atom colours are grey (C), 
white (H), blue (N), red (O), cyan (Fe) and yellow (S). All other hydrogen atoms as well as the included DMSO 
molecules that do not participate in hydrogen bonding have been removed for clarity. (B) SEM micrograph 
of crystals of the β-haematin DMSO solvate grown in the presence of chloroquine. The scale bar (bottom left) 
represents 20 μm. Reproduced with permission from Gildenhuys et al., J. Am. Chem. Soc., 2013, 135, 1037. 
Copyright 2013 American Chemical Society. 
 
Lipid-mediated theories of haemozoin formation have enjoyed recent success. It was first 
suggested in 1995 that phospholipids may be associated with haemozoin formation and that 
contaminating phospholipids were most likely the source of the heat-stable, protease-resistant 
“autocatalytic” behaviour of the haemozoin extracts previously observed.39,40 It was later shown 
that chloroform extracts of parasite-infected erythrocyte lysates showed approximately 70% of 
the proposed Fe(III)PPIX “polymerising activity” and this activity was chiefly attributed to 
cholesterol, neutral lipids (glycerolipids) and fatty acids.41 Fitch et al. suggested that the lipids 
act by solubilising Fe(III)PPIX to facilitate haemozoin formation.41 
 
Subsequently, Jackson et al. used fluorescence and electron microscopy to identify particles 
ranging over a few hundred nanometres in size that were in intimate association with the 
digestive vacuole and were shown to be composed of diacylglycerols and triacylglycerols 
(Figure 1.9A).42 Further evidence was provided by Coppens and Vielemeyer who discovered 
haemozoin crystals enveloped by these “neutral lipid bodies” inside the digestive vacuole of  
P. falciparum (Figure 1.9B).43 Following purification of haemozoin, Pisciotta et al. identified 
mono- and diacylglycerols as well as various polar lipids in close association with the crystals.44 
The authors proposed a “reconstituted neutral lipid blend” which was found to be an efficient 
mediator of β-haematin.44 They suggested that neutral lipid bodies are transient repositories of 
lipophilic free Fe(III)PPIX, concentrating it while promoting haemozoin formation at the surface 
where acidic conditions favour lipid-mediated biocrystallisation.44  
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Taken together, these observations have shifted the focus of the intracellular microenvironment 
of Fe(III)PPIX biocrystallisation and its concomitant inhibition by quinoline antimalarials from a 
polar aqueous to a non-polar neutral lipid environment that is able to lower the activation 




Figure 1.9. Micrographs showing the association between lipid bodies and haemozoin in P. falciparum.  
(A) Schizont-infected erythrocytes examined by confocal microscopy, with Nile Red-illuminated images on 
the right. The most intense spots of fluorescence intensity are indicated by arrow heads in the upper image. 
Scale bars represent 2 μm. Reproduced from Jackson et al., Mol. Microbiol., 2004, 54, 109 with permission 
from John Wiley & Sons. (B) Formation of haemozoin within lipid bodies (marked by black arrows) is evident 
when samples are fixed with malachite green. The scale bar represents 0.5 μm.  
Reproduced from Coppens et al., Int. J. Parasitol., 2005, 35, 597 with permission from Elsevier. 
 
Most recently, Kapishnikov et al. have applied cryogenic soft X-ray tomography and three-
dimensional electron microscopy to address the location and orientation of haemozoin within 
the digestive vacuole. They have shown that haemozoin crystals nucleate in a specific manner at 
the inner surface of the digestive vacuole, with crystallisation occurring in the aqueous rather 
than in the lipid phase. They argue that their data rule out the possibility of haemozoin crystals 
being nucleated within, or on the surfaces of, lipid nanospheres.46,47 
 
1.3.3. Lipid metabolism during the intraerythrocytic life cycle 
 
A significant feature of intraerythrocytic P. falciparum is the dramatic increase in the total lipid 
content of the infected erythrocyte over the 48-hour life cycle, despite the fact that lipid 
metabolism in the uninfected erythrocyte is almost non-existent.48-50 This reflects the parasite’s 
ability to orchestrate a vast array of lipid-dependent processes in a stage-dependent manner, 
ranging from intracellular signalling and protein trafficking to membrane biogenesis.51  
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Recently, Gulati et al. surveyed lipid species and abundances over the 48-hour intraerythrocytic 
life cycle.51 Phospholipids were the major class detected, with phosphatidylcholine and 
phosphatidylethanolamine together accounting for half of the total lipid content in the infected 
erythrocyte.51 These phospholipids mainly serve a structural role, especially as the chief 
constituents of membranes. Over the 48-hour developmental cycle, the total amount of 
phospholipid remained relatively constant.51 
 
The remaining half of the lipid content was divided between sphingolipids and glycerolipids 
(neutral lipids).51 Sphingolipid levels decreased over the course of intraerythrocytic 
development. However, the amount of sphingomyelin, the third most abundant lipid in the 
parasitised erythrocyte which aids in the biogenesis and maintenance of the tubovesicular 
network, remained static throughout the cycle. Sphingomyelin can also serve as a reservoir for 
the production of ceramides via its hydrolysis, with ceramides serving as potent second 
messengers that regulate a host of diverse processes within P. falciparum.51 
 
Intraerythrocytic parasites possess two major neutral lipid species, both of which are virtually 
non-existent in the uninfected erythrocyte and which showed a dramatic increase in abundance 
over the 48 hours.51 Diacylglycerols are potent second messengers and serve as a precursor for 
phospholipids and triacylglycerols. Triacylglycerols are themselves packaged into lipid bodies 
that may be responsible for sequestering free fatty acids.51  
 
In mammalian cells lipid bodies typically serve as highly reduced stores of oxidisable energy.43 
However, malaria parasites have little to no capacity for the oxidative degradation of fatty acids, 
implying that triacylglycerols must be used for purposes other than energy storage during 
intraerythrocytic growth.52 It is unlikely that P. falciparum uses triacylglycerols as a reservoir of 
fatty acids for phospholipid synthesis since lipid bodies are not observed in ring-stage parasites 
which themselves undergo massive membrane biogenesis.52 It has been observed that 
triacylglycerol degradation becomes active during the late schizont phase, suggesting that 
triacylglycerol metabolism facilitates merozoite maturation51 or that it is involved in parasite 
egress from the host cell.43 As described in Section 1.3.2, these lipid bodies have been observed 
in intimate contact with the digestive vacuole and haemozoin; hence, they may play a role in 
Fe(III)PPIX detoxification.42,44  
 
Finally, during intraerythrocytic development of P. falciparum, the composition of the 
erythrocyte plasma membrane is also strikingly altered.53 Since erythrocytes have a limited 
capacity for lipid synthesis and metabolism, these alterations must occur as a result of parasite-
directed metabolism of erythrocyte lipids and/or trafficking of lipids between the parasite and 
the erythrocyte membrane.53 





1.3.4. Regulation of pH within the malaria parasite 
 
The regulation of pH plays an important role in the pathophysiology of P. falciparum, both in the 
exploitation of the host erythrocyte and in the response to various antimalarials (Section 1.6.1.). 
Two proton pumps are responsible for the acidification of the digestive vacuole. These are 
located on the digestive vacuole membrane and comprise a V-type H+-ATPase and a  
H+-pyrophosphatase, the latter of which couples the hydrolysis of the phosphoanhydride bond 
of pyrophosphate to the influx of protons into the vacuole.54 These proton pumps act 
concurrently to maintain a low internal pH in the digestive vacuole.54 
 
The pH of the digestive vacuole and the cytosol in P. falciparum have been of great interest; 
however, these measurements have not been straightforward and have been the subject of 
much controversy.55 Most estimates of steady-state vacuolar and cytosolic pH values of P. 
falciparum have relied on quantitative fluorimetric techniques. Only recently have more reliable 
pH determinations in P. falciparum been achieved. These employed parasite expression of the 
ratiometric pH-dependent fluorescent protein pHluorin, which was localised to the digestive 
vacuole.56 Single-cell confocal measurements gave pH 5.18 ± 0.05 with no significant difference 
recorded between chloroquine-sensitive and chloroquine-resistant strains.56 These were 
corroborated by a thorough study involving dextran-linked, pH sensitive fluorescent dyes which 
also concluded that digestive vacuole pH does not play a primary role in chloroquine 
resistance.57 
 
Metabolic and biosynthetic activity at the trophozoite stage is particularly vigorous. The 
parasite is wholly reliant on glycolysis as its energy source and generates a substantial 
intracellular lactic acid load.58 Thus the parasite requires an effective means of extruding H+ to 
maintain its cytosolic pH. There is compelling evidence for another V-type H+-ATPase in the 
parasite’s plasma membrane which serves as the major route for the efflux of H+ ions.58 The 
same investigators measured the cytosolic pH of P. falciparum with pHluorin and recorded a 
steady-state pH of 7.15 ± 0.07 for trophozoites, again with no significant difference between 
chloroquine-sensitive and chloroquine-resistant strains.58  
 
Hydrogen peroxide released during haemoglobin degradation has been shown to inhibit the 
digestive vacuolar H+-ATPase, disrupting pH regulation in the parasite.59 Furthermore, it has 
been observed that moderate exposure to light causes irreversible acidification of the parasite 
cytosol by as much as a whole pH unit.60 The implications of these observations are important in 
the context of live-cell imaging of P. falciparum which will form an important part of this work. 
  





1.4. Antimalarial chemotherapy, resistance and drug discovery 
 
1.4.1. Current efforts to prevent and treat malaria 
 
There are a number of strategies to prevent the transmission of malaria. Eradicating mosquito 
populations and preventing mosquito bites by using insecticide-treated nets have been highly 
effective.1,2 The use of sterile male insects has emerged as an alternative vector control method 
although this has not yet been used in the field.61 Malaria vaccines, which ensure a high level of 
protection for a sustained period, are an area of intensive research.62  
 
Prophylactic drugs are able to prevent infection in travellers to malaria-endemic areas. In areas 
of chloroquine resistance, chemoprophylactics such as doxycycline and atovaquone-proguanil 
are generally well-tolerated and may be used.63 Unfortunately, the use of prophylaxis is not 
practical for residents of these areas due to the cost of the drugs as well as negative side-effects 
resulting from long-term use. Furthermore, extensive use of prophylactic drugs may encourage 
the development of drug tolerance and ultimately drug resistance in the parasite. 
 
Once infected with malaria, however, patients can expect to make a full recovery if treated 
properly. As a result, antimalarials are widely used as curative agents. The alkaloid quinine has 
been used for centuries and was the first effective drug used in the treatment of malaria. Since 
the 1940s, quinine has been replaced by alternative drugs such as chloroquine, mefloquine and 
amodiaquine, many of which are inexpensive. Unfortunately, resistance to these drugs has 
developed, or is developing rapidly, resulting in increased morbidity. 
 
Currently, the World Health Organisation recommends artemisinin-based combination 
therapies as the preferred treatment for malaria.1 These usually comprise a derivative of the 
sesquiterpene endoperoxide artemisinin in conjunction with another non-artemisinin-based 
antimalarial such as amodiaquine, mefloquine or lumefantrine. These “cocktails” are generally 
effective and well-tolerated in patients. However, resistance to artemisinins has now been 
reported in five countries in Southeast Asia.1  
 
1.4.2. A brief history of the quinoline antimalarials 
 
It is remarkable that two natural products, quinine and artemisinin (Figure 1.10), which were 
used to treat malaria for centuries before the aetiology or the pathogenesis of the disease was 
understood, remain cornerstones of contemporary antimalarial treatment. Following the 
isolation of quinine, malaria was probably the first disease treated by a pure compound.64  







Figure 1.10. Representative compounds of the most important classes of antimalarial agents.   





Malaria-like febrile illnesses have been described since the time of Hippocrates and were 
associated with marshes and swamps. It was not until 1880 that the French physician, Charles 
Louis Alphonse Laveran, discovered that the cause of malaria is a protozoan, having observed 
the parasites in a blood smear taken from a patient who had just died of malaria.65 Mosquitoes 
were incriminated as the vectors of the disease, first for avian malaria by Ronald Ross in 1897 
and then for human malaria by Giovanni Battista Grassi and others between 1898 and 1900.65  
 
Quinine occurs naturally in the bark of trees belonging to the genus Cinchona, originally found 
in the high altitudes of South America. According to one account, the Native Peruvians used it 
while working in the cold streams in Spanish-owned mines to stop shivering. This effect was 
probably the result of quinine’s direct effect on skeletal muscle and neuromuscular junctions.64 
Some physicians and Jesuit priests in Peru suspected that concoctions of the bark might be able 
to stop the shivering associated with attacks of febrile illnesses. They tried the bark of the “fever 
tree” on malarial patients and found that their feverish symptoms were miraculously relieved.64  
 
Prior to the isolation of quinine, the bark was administered as a suspension in wine or spirits to 
offset its bitterness; this recipe probably evolved into the gin and tonic drink.64 In 1820, two 
French chemists, Pierre Pelletier and Joseph Caventou, isolated the major alkaloids quinine and 
cinchonine from Cinchona bark.66 Their respective diastereomers, quinidine and cinchonine, are 
present in smaller proportions. The term quinine comes from “quina-quina”, the name which 
the Native Peruvians gave to the bark which means “medicine of medicines” or “bark of barks”.67 
Within a year, French physicians were using pure quinine to treat patients with intermittent 
fever and, from the mid-19th century to the 1940s, quinine became the standard treatment for 
such fevers throughout the world.64 Consequently, it has been described as “a drug that has 
probably benefited more people than any other in the combat of infectious disease”.68 
 
These early investigations into the chemistry of quinine coincided with a revolution in synthetic 
organic chemistry. In 1856, William Henry Perkin, a young English chemist, set out to synthesise 
quinine but instead serendipitously created mauveine, the first synthetic textile dye that did not 
wash off in water.64 The new dye industry promoted advancement in medicine as some of these 
dyes were used to stain microbes under the microscope. Paul Ehrlich (1854-1915), a German 
physician and scientist, noticed that methylene blue (Figure 1.10) was particularly effective in 
staining malaria parasites. Reasoning that the parasite might be poisoned by the uptake of the 
dye, he used this molecule to cure two patients of malaria in 1891.64  
 
Subsequently, Bayer, a leading dye company, assembled a team to develop new antimalarials 
using methylene blue as a prototype. In 1925 they developed pamaquine, an 8-aminoquinoline, 
and, later, quinacrine, an acridine derivative (Figure 1.10).69 In 1934, a compound called 





“resochin” was developed but it was thought to be too toxic. During World War II, the Japanese 
took over the Indonesian island of Java and cut off the world’s main source of quinine, the 
Cinchona plantations on the island which had been cultivated by Dutch colonials. As part of the 
war effort, American, British and Australian scientists cooperated in a large-scale attempt to 
develop new synthetic antimalarials. Interest was rekindled in resochin, which was renamed 
chloroquine.64 
 
Chloroquine has since proved to be the most effective, and arguably the most important, 
antimalarial in history. It was initially highly effective with only few adverse side-effects and 
was relatively inexpensive, making it an ideal chemotherapeutic drug. Consequently, it was the 
main antimalarial in the World Health Organisation’s Global Malaria Eradication Programme 
between the 1950s and 1960s and, although somewhat overshadowed by the widespread 
spraying of the insecticide DDT, chemoprophylaxis with chloroquine tablets or chloroquine-
medicated salt (introduced in the 1950s in Brazil) was an important supplementary component 
of eradication and control programmes.70 However, this extensive use of chloroquine probably 
contributed to the advent of resistance in P. falciparum in the 1960s. 
 
Despite challenges posed by resistance, the quinolines have formed the cornerstone of 
antimalarial chemotherapeutic development. Most of the quinolines are believed to target the 
intraerythrocytic stage of the parasite’s life cycle by inhibiting haemozoin formation, leading to 
a toxic accumulation of Fe(III)PPIX that eventually poisons the parasite (Section 1.5). 
 
1.4.3. Involvement of membrane transporters in P. falciparum resistance 
 
For several decades, chloroquine remained the gold standard for the treatment of malaria. 
Unfortunately, massive worldwide use beginning in the late 1940s was followed two decades 
later by reports of chloroquine-resistant strains of P. falciparum in Southeast Asia and South 
America. Today, chloroquine resistance has spread to the vast majority of malaria-endemic 
areas, rendering this drug increasingly ineffective. The fact that chloroquine resistance took 
over two decades to develop, despite extensive use of the drug, suggests that mutations in 
several genes of the parasite are required to produce the resistant phenotype.71 Varying clinical 
responsiveness also affects many other antimalarials such as quinine and mefloquine which are 
sometimes used as a second-line treatment for chloroquine-resistant strains. Disturbingly, 
resistance to artemisinin-combination therapies has now been reported, lending even more 
urgency to the search for novel antimalarials.71 
 
It was soon identified that chloroquine resistance was associated with an efflux of the drug in 
resistant phenotypes. Consequently, research in the resistance mechanisms has centred on 





parasite membrane transporters as they are responsible for trafficking diverse substrates in 
and out of the parasite and the host cell.72 In particular, the P. falciparum chloroquine-resistance 
transporter (PfCRT) and P. falciparum multidrug resistance transporter (PfMDR1) have been 
implicated. More recently, the multidrug resistance-associated protein (PfMRP1) has also been 
associated with changes in susceptibility to chloroquine and quinine.71 
 
In 1987 Krogstad and colleagues identified that chloroquine flows out of chloroquine-resistant 
parasites much faster than chloroquine-sensitive parasites by a route that can be blocked by 
verapamil, a general efflux pump inhibitor.73 This suggested the existence of a membrane 
protein that acts as either a channel or a carrier for chloroquine. In pioneering work reported in 
2000, PfCRT was identified as the main determinant of chloroquine resistance.74  
 
PfCRT comprises 424 amino acids and ten predicted trans-membrane domains and is localised 
in the digestive vacuole membrane (Figure 1.11).71 As mentioned above, the digestive vacuole is 
suspected to be the site of action for several antimalarials including chloroquine, quinine and 




Figure 1.11. Topology and function of PfCRT. Black arrows highlight polymorphic amino acids. The 
conserved threonine-lysine substitution at position 76, found in chloroquine-resistant parasites, is indicated 
in red. Residues that can be phosphorylated are highlighted in green. The orange arrow indicates that PfCRT 
transports a variety of quinoline drugs out of the digestive vacuole. Verapamil inhibits PfCRT-mediated drug 

















Chloroquine-resistant strains have originated in at least six different geographic regions with 
different sets of polymorphisms in the pfcrt gene of P. falciparum. All alleles feature the 
replacement of a lysine residue by a threonine residue at position 76.74 Since reduced 
chloroquine accumulation is linked with PfCRT polymorphisms in resistant strains, it is 
suspected that PfCRT controls the access of chloroquine to its target. There has been debate as 
to the nature of the natural substrate for PfCRT which is thought to be small amino acids, 
possibly those from haemoglobin catabolism.71 Recently, PfCRT has been characterised as a H+-
coupled polyspecific nutrient and drug exporter.75 However, there is a fitness cost associated 
with the mutations and chloroquine-sensitive strains eventually outcompete resistant 
phenotypes in the field.71  
 
The other transporter protein implicated in chloroquine resistance is the P. falciparum 
multidrug resistance transporter (PfMDR1, Figure 1.12). In mammalian cancer cells, drug 
resistance frequently arises from the presence of an overexpressed P-glycoprotein. This is an 
ATP-binding cassette (ABC) transporter capable of expelling a wide range of structurally and 
functionally diverse substrates, also in a verapamil-dependent manner.71 Consequently, it was 
thought that polymorphisms in the P. falciparum homologues, later termed PfMDR1 or Pgh-1, 




Figure 1.12. Topology and function of PfMDR1. Black arrows highlight polymorphic amino acids with 
altered drug responsiveness in P. falciparum. The orange arrow indicates the direction of transport of 
substrates including chloroquine, quinine, mefloquine and artemisinin from cytoplasm towards the digestive 
vacuole. Nucleotide binding domains, represented by NBD1 and NBD2, are the sites of ATP binding. 













Amplification of the gene is indeed associated with in vitro resistance to quinine, mefloquine 
and halofantrine in P. falciparum.76 However, PfMDR1 is found in the digestive vacuole 
membrane with its ATP-binding domains facing the cytoplasm (NBD1 and NBD2 in Figure 1.12), 
meaning that transport is directed inwards to the digestive vacuole.77 This counterintuitive 
observation is the opposite of mammalian cells in which P-glycoprotein-mediated export is 
directed out of the cell.77 In comparison to mammalian cells, little PfMDR1 is expressed in the 
parasite plasma membrane. While polymorphisms within PfMDR1 can contribute to resistance 
to chloroquine and related antimalarials depending on the genetic background of the parasite 
strain, the mechanism of action of this membrane transporter remains unclear.71 
 
P. falciparum multidrug resistance-associated protein (PfMRP1) was first identified in 2004 
(Figure 1.13).78 PfMRP1 has been shown to localise to the parasite plasma membrane and to 
membrane-bound vesicles during intraerythrocytic stages.79,80 Disrupting PfMRP1 expression in 
P. falciparum under normal culture conditions resulted in parasites that could not grow to a 
parasitaemia higher than 5%, possibly because of lower efficiency in removing toxic 
metabolites.80 These parasites also accumulated more radiolabelled glutathione, chloroquine 
and quinine and became more sensitive to several antimalarials, including chloroquine, quinine 
and artemisinin.80 This indicates that PfMRP1 most likely plays a role in the efflux of 




Figure 1.13. Topology and function of PfMRP1. Black arrows highlight polymorphic amino acids. The 
orange arrow indicates the direction of transport of substrates including chloroquine and quinine out of the 
parasite cytosol. Nucleotide binding domains, represented by NBD1 and NBD2, are the sites of ATP binding. 













1.4.4. Aspects of contemporary antimalarial drug discovery 
 
While improved measures in the prevention and treatment of malaria have led to decreased 
mortality in recent years, the resistance of P. falciparum to quinoline antimalarials and newer 
artemisinin-combination therapies provides an urgent stimulus to develop novel antimalarial 
chemotherapies. Typically, antimalarial drug discovery takes two forms. A screening method, in 
which hit compounds are identified, usually results in the synthesis of libraries of derivatives 
which are tested for their activity against P. falciparum in order to develop structure-activity 
relationship models. Alternatively, rational drug design requires a detailed understanding of 
both the drug target and the antimalarial pharmacophore. This latter method is particularly 
challenging. Indeed, most current antimalarial agents were not developed by rational design but 
followed the serendipitous discovery of natural products (quinine and artemisinin) or 
structural analogues of these molecules (chloroquine). 
 
Antimalarial drug discovery has been greatly aided by the development of in vitro culturing 
techniques for P. falciparum in human erythrocytes. This has become a vital method to 
determine the activities of potentially therapeutic compounds. First developed by Trager and 
Jensen in 1976, it has since been refined to optimise oxygen pressure, nutrient availability and 
temperature.82 In order to determine dose-response curves to generate a 50% inhibitory 
concentration (IC50) of a potentially therapeutic compound, parasite viability is commonly 
quantified using the lactate dehydrogenase assay which was developed by Makler and 
colleagues. This enzyme assay exploits a correlation between parasite lactate dehydrogenase 
activity and parasitaemia.83 
  
Despite these techniques, the challenges associated with antimalarial drug discovery and 
development mean that there have been no new classes of antimalarials introduced for two 
decades. This has motivated the development of improved methods for identifying active 
compounds. The construction of large compound libraries and increased knowledge of drug 
targets have encouraged parallel advances in high-throughput screening. On the one hand, 
phenotypic-based screening methods measure the effects of a compound on cell or tissue, such 
as cell viability. On the other hand, target-based approaches include screening compounds for 
their ability to inhibit β-haematin formation, for example. 
 
Determining β-haematin inhibition demands assays which are efficient and mimic biological 
environments appropriately. The first β-haematin inhibition assay was reported in 1994.84 It 
was a qualitative, acetate-based assay which exploited infrared spectroscopy to determine the 
presence of crystallised Fe(III)PPIX via characteristic peaks, i.e. 1660 cm-1 and 1207 cm-1.84 





Other investigators developed quantitative techniques using radiolabelled haematin. However, 
this is not ideal as it requires special materials and skills and is often expensive.85 
 
The acetate-based assay described above was improved when the amount of β-haematin 
formed was quantified by reacting the remaining Fe(III)PPIX with aqueous pyridine. This 
selectively forms a low-spin bis-pyridyl complex with unreacted Fe(III)PPIX but not with  
β-haematin. (Figure 1.14).86 In the presence of pyridine, the Soret band of Fe(III)PPIX increases 
in intensity which is indicative of monomerisation and shifts from 389 to 404 nm as a result of 
the change in spin state. The absorbance is thus directly proportional to the concentration of 
uncrystallised haematin. Pyridine is also likely to displace other coordinating substances, 




Figure 1.14. The low-spin bis-pyridyl complex used 
to quantify the amount of unreacted Fe(III)PPIX in 
colourimetric β-haematin inhibition assays. 
Figure 1.15. The structure of NP-40,  
the detergent used in an assay for  
β-haematin inhibition. 
 
As described in Section 1.3.2, it has been shown that lipids are implicated in haemozoin 
formation. Replacing the high concentrations of acetate with lipids as mediators of β-haematin 
formation meant that milder conditions that were more biologically-relevant could be used. 
However, lipids are not ideal for high-throughput screening approaches and so studies were 
done to find suitable, inexpensive substitutes. Detergents are surfactants that mimic the 
amphiphilic nature of lipids; that is, they are molecules with both hydrophilic and hydrophobic 
regions. Consequently, a number of detergents were screened for their capacity to mediate  
β-haematin formation and, in 2010, a detergent-mediated assay was reported in which NP-40, a 
neutral non-denaturing detergent (Figure 1.15), was determined to be the best mimic.87 NP-40 
not only generated comparable yields of β-haematin compared to a neutral lipid blend, but also 
yielded similar IC50 values for β-haematin inhibition in the presence of chloroquine and 
amodiaquine. This NP-40 detergent-mediated assay for β-haematin inhibition has formed the 
basis of several high-throughput screening efforts to find novel antimalarial chemotypes.88,89  





1.5. Interactions between the quinoline antimalarials and Fe(III)PPIX 
 
1.5.1. Recent developments in understanding haemozoin inhibition 
 
It was first proposed by Macomber and colleagues in 1967,90 and later elaborated upon by Chou 
et al. in 1980,91 that Fe(III)PPIX is the molecular drug target of various quinoline antimalarials. 
Since then, increasing evidence has shown that the interactions of these drugs with Fe(III)PPIX 
indeed lie at the heart of their antimalarial activity.92 This appears to involve inhibition of the 
incorporation of Fe(III)PPIX into haemozoin as it has been shown that these drugs inhibit  
β-haematin formation under abiotic conditions.84 This means that inhibition must occur by 
direct interaction between the drugs and Fe(III)PPIX, verifying that the haemozoin 
biocrystallisation pathway is indeed the likely target of these drugs. 
 
There are two prevailing theories of haemozoin inhibition. The first is that the quinoline 
antimalarials adsorb to the fastest-growing face of the haemozoin crystal, “capping” it and 
preventing further crystal growth. The second theory relies on the formation of stable 
complexes between the quinoline antimalarials and free Fe(III)PPIX that also prevents the 
incorporation of the metalloporphyrin into the growing crystal.  
 
Pagola et al. were the first to propose that chloroquine adsorbs to the fastest-growing faces of 
haemozoin crystals.27 The fast-growing face of the crystals exhibit grooves that expose the 
unligated porphyrin face and propionic acid side chains of Fe(III)PPIX molecules. The structure 
of the adsorbed chloroquine-haemozoin complex was subsequently proposed by Buller et al. in 
which four specific intermolecular interactions between chloroquine and Fe(III)PPIX molecules 
were identified to stabilise the complex.93 Gildenhuys et al. have recently provided kinetic 
evidence that supports the adsorption of chloroquine and quinidine onto the surface of 
haemozoin crystals.32 They found that the reduced rate of formation of β-haematin in the 
presence of low drug concentrations was consistent with a drug adsorption process. At higher 
drug concentrations, precipitation of quinoline-Fe(III)PPIX complexes caused a reduction in the 
yield of β-haematin.35 Most recently, Olafson et al. have directly imaged inhibition of β-haematin 
crystal growth by chloroquine using atomic-force microscopy.94 
 
The second proposed mechanism of inhibition by quinoline antimalarials is that of drug- 
Fe(III)PPIX complex formation. These complexes have been suggested to bind to Fe(III)PPIX in a 
form that no longer allows its incorporation into haemozoin, probably by increasing the 
solubility of the metalloporphyrin. Additionally, these complexes cause deleterious effects on  
P. falciparum. The complex between chloroquine and Fe(III)PPIX enhances the lytic effects on 





cells that have been observed with Fe(III)PPIX alone.95,96 Quinine, quinidine and chloroquine all 
form stable complexes with Fe(III)PPIX in the solution phase, lending support to this hypothesis 
(Section 1.5.2). Furthermore, the single crystal structures of Fe(III)PPIX complexes have been 
elucidated for quinine and quinidine, as well as for the related antimalarials mefloquine and 
halofantrine (Section 1.5.3).  
 
Regardless of which mechanism is responsible for the inhibition of haemozoin formation by 
these antimalarials, a recent study reported that a dose-dependent increase in free Fe(III)PPIX 
in P. falciparum was measured upon chloroquine treatment that was found to correlate with a 
decrease in parasite growth.97 Indeed, the curve representing the percentage of “free” 
Fe(III)PPIX was found to cross the parasite survival curve at approximately the IC50 of 




Figure 1.16. Fraction of total Fe(III)PPIX present as (A) “free” Fe(III)PPIX and (B) haemozoin. Asterisks 
indicate statistical significance relative to the control: *P < 0.05; **P < 0.01; ***P < 0.001, n = 3.  
“P” represents pyrimethamine and “SP” represents sulfadoxine/pyrimethamine. (C) Parasite survival curve 
(open circles, left axis) determined using the lactate dehydrogenase assay and percentage free Fe(III)PPIX 
(closed circles, right axis) as a function of chloroquine (CQ) dose. Adapted from Combrinck et al.,  
ACS Chem. Biol., 2013, 8, 133. Copyright 2013 American Chemical Society. 
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Furthermore, a single-dose treatment of quinine as well as mefloquine, amodiaquine, artesunate 
and lumefantrine, well above their IC50 concentrations, were all shown to correspond to an 
increase in free Fe(III)PPIX and a decrease in the amount of haemozoin formed.97 On the other 
hand, this was shown not to be the case for pyrimethamine and sulfadoxine which are known to 
target the folate synthesis pathway.97 This study provides direct evidence in support of the 
haemozoin inhibition hypothesis for the mechanism of action of chloroquine and other 
quinoline antimalarials, including quinine. 
 
The cytotoxic effects of free Fe(III)PPIX are likely compounded by the high concentrations of 
quinoline antimalarials that accumulate in the parasite. It has been shown that degradation of 
Fe(III)PPIX by both glutathione98 and hydrogen peroxide99 are inhibited by chloroquine, 
although this has not been established in vivo. It has consequently been proposed that these 
large concentrations of free Fe(III)PPIX associate with membranes, increasing their 
permeability and damaging the integrity of the parasite.98,99 A redistribution of Fe(III)PPIX iron 
has been detected in the cytoplasm of P. falciparum following treatment with chloroquine, in a 
region possibly corresponding to the endoplasmic reticulum.97 
 
1.5.2. Interactions of the quinoline antimalarials with Fe(III)PPIX in solution 
 
The differences between the quinoline methanol and 4-aminoquinoline antimalarials that are 
examined in this study are possibly best exemplified by their respective interactions with 
Fe(III)PPIX in solution. Despite structural similarities, the quinoline methanols and the  
4-aminoquinolines share very different modes of association with Fe(III)PPIX. 
 
Formation of a complex between the archetypal 4-aminoquinoline, chloroquine, and Fe(III)PPIX 
was first reported in the 1960s by Cohen, Phifer and Yielding.100 This observation was based on 
changes in the absorption spectrum of Fe(III)PPIX upon addition of chloroquine. In aqueous 
solution, such as the phosphate buffer used in their study, significant changes are seen in the 
shape of the Soret band of the porphyrin with only minor changes in its intensity. These can be 
interpreted to give useful information about the interaction between the two molecules. 
 
However, in mixed aqueous solution and, to a lesser extent, in pure organic solvents, the Soret 
band of Fe(III)PPIX exhibits a considerable hypochromic effect (that is, a decrease in 
absorbance) upon interaction with chloroquine, quinine and related antimalarials (Figure 
1.17).92 This hypochromic effect is not accompanied by a shift in wavelength and appears to be 
largely masked in purely aqueous medium on account of the fact that Fe(III)PPIX is essentially 
dimeric under these conditions which itself gives rise to a large hypochromic effect.92 Further 
changes in the spectrum include the apparent disappearance of the Q-band and shifts in the 





charge-transfer bands with a significant hyperchromism (that is, an increase in absorbance) at 
about 600 nm which can also be extremely valuable in detecting and monitoring the 
interactions. Indeed, in aqueous DMSO and in pure organic solvents, where Fe(III)PPIX is 




Figure 1.17. The effects of increasing concentrations of quinidine on the absorption spectrum of Fe(III)PPIX 
in 40% (v/v) DMSO in 20 mM Hepes, pH 7.5 (25°C). The black trace represents Fe(III)PPIX alone and the red 
trace indicates the final spectrum after several additions of quinidine (indicated in grey). 
 
Consequently, 40% DMSO (v/v) buffered at pH 7.5 has proved to be a useful medium for 
measuring the strength of quinoline-Fe(III)PPIX interactions and for exploring relationships 
between structure and strength of association with Fe(III)PPIX (Table 1.1).92 The solvent 
environment in 40% (v/v) DMSO comprises about 86% water (by mole fraction) and is thus still 
a reasonable approximation of pure aqueous solution. Association constants between 
Fe(III)PPIX and some of the quinoline antimalarials relevant to this study are listed in Table 1.1. 
 
Table 1.1. Association constants with Fe(III)PPIX determined from spectrophotometric titrations in 40% 
(v/v) DMSO in 20 mM Hepes, pH 7.5 (25°C). Association constants were fitted using a 1:1 binding model and 
were taken from De Villiers et al.101 
 
Compound Log K 
Quinine 4.10 ± 0.02 
Quinidine 5.02 ± 0.03 
Epiquinine 4.04 ± 0.03 
Epiquinidine 4.37 ± 0.02 























In mixed aqueous solution these association constants are almost invariably weaker than in 
pure aqueous solution, while in pure organic solvents they are weaker still.102 The fact that the 
strength of the interaction increases enormously with increasing solvent polarity indicates that 
the hydrophobic effect plays a major role in determining the stability of these complexes.102 
Measured thermodynamic parameters suggest a large loss in flexibility and a high degree of 
desolvation upon complex formation.102,103 Free energies of association are largely insensitive to 
salt concentrations, demonstrating that electrostatic interactions play only a minor role in the 
stability of these complexes under these conditions.102 
 
What evidence is there for the binding stoichiometries of these complexes in the solution state? 
Previous studies in mixed aqueous solution show that spectrophotometric titrations of quinine 
and Fe(III)PPIX conform very well to a 1:1 binding model.103 Casabianca et al. used magnetic 
susceptibility measurements to show that quinine promotes monomerisation of Fe(III)PPIX 
while chloroquine promotes the formation of its μ-oxo dimer.104 In support of the former 
conclusion, Gildenhuys et al. were able to show coordination of the alkoxide group of quinine 
and quinidine to the iron centre of Fe(III)PPIX by measuring the bond length by extended X-ray 
absorption fine structure (EXAFS) spectroscopy.105 This unequivocally confirmed that 
coordination of the quinoline methanol compounds to Fe(III)PPIX occurs in non-aqueous 
aprotic medium via their benzylic alkoxide groups. Existence of the 1:1 complexes was also 
confirmed by mass spectrometry.105 While these measurements were made in a non-aqueous 
medium, this may more closely mimic the site of haemozoin formation in P. falciparum which is 
likely to be associated with a neutral lipid environment.  
 
Meanwhile, for chloroquine, a recent comprehensive study using multiple spectroscopic 
techniques showed that it does indeed induce μ-oxo dimerisation of Fe(III)PPIX.106 It was 
confirmed that chloroquine binds to Fe(III)PPIX with a 1:2 stoichiometry with an aqueous 
association constant (log Kobs) of 13.3 ± 0.2.106 Furthermore, the interaction of chloroquine and 
the μ-oxo dimer of Fe(III)PPIX in aqueous solution was modelled using molecular dynamics 
simulations. Two models of the complex were investigated, one involving chloroquine π-stacked 
with an unligated porphyrin face of μ-oxo Fe(III)PPIX and the other in which chloroquine was 
docked between the two porphyrin rings. The feasibility of both models was tested by fitting 
predicted structures to the observed EXAFS spectrum of the CQ-(μ-oxo Fe(III)PPIX) complex in 
frozen aqueous solution. The docked model produced better agreement with experimental data, 
suggesting that this is the more likely structure in aqueous solution (Figure 1.18).107 
 







Figure 1.18. Important interactions identified between chloroquine and μ-oxo Fe(III)PPIX in the docked 
model of the CQ-(μ-oxo Fe(III)PPIX) complex include (i) an intermolecular hydrogen bond between the oxide 
bridge of μ-oxo Fe(III)PPIX and protonated quinolinium nitrogen atom of chloroquine, (ii) π-stacking 
interactions between the quinoline ring of chloroquine and porphyrin ring system of Fe(III)PPIX and (iii) 
contact between the 7-chloro substituent of chloroquine and the methyl hydrogen atoms of the porphyrin. 
Reproduced from Kuter et al., J. Inorg. Biochem., 2016, 154, 114 with permission from Elsevier. 
 
1.5.3. Crystal structures of the quinoline antimalarials with Fe(III)PPIX 
 
The first example of a crystal structure of a complex of Fe(III)PPIX with an antimalarial was that 
with the aryl methanol halofantrine reported by De Villiers et al. in 2008.101 This structure showed 
that halofantrine forms a five-coordinate complex with Fe(III)PPIX via its deprotonated hydroxyl 
group in addition to a π-stacking interaction of the phenanthrene ring over the porphyrin.101 An 
intermolecular hydrogen bond was observed between the protonated nitrogen of halofantrine 
and the propionate group of a neighbouring Fe(III)PPIX-halofantrine complex.101 
 
Using these interactions as a model, the authors attempted to rationalise the antimalarial 
activities of quinine and quinidine compared to their epimers, which are neither active 
antimalarials nor active β-haematin inhibitors. Surprisingly, all four stereoisomers exhibit 
similar association constants (Table 1.1) while, structurally, they all have the capacity to π-stack 
and coordinate to the iron centre through their oxygen atoms. Molecular mechanics modelling 
showed that the energy required to maintain a proposed conformation in which the Fe(III)PPIX 
propionate can form an intramolecular hydrogen bond to the protonated quinuclidine nitrogen 
of quinine and quinidine as well as their epimers was directly correlated to their corresponding 





IC50 values.101 This suggested that the comparative ease of forming hydrogen bonds with the 
propionate side chain of Fe(III)PPIX was important for antimalarial activity. 
 
That the quinine- and quinidine-Fe(III)PPIX complexes actually adopt this conformation with 
the proposed intramolecular hydrogen bond was subsequently confirmed by their crystal 
structures (Figure 1.19).108 It is interesting that this hydrogen bond was present despite a 




Figure 1.19. The crystal structures of the Fe(III)PPIX complexes of (A) quinine and (B) quinidine. Hydrogen 
bonds are shown as broad dashed lines (red). Solvent and hydrogen atoms not involved in bonding have been 
removed for clarity. Atom colours are grey (C), white (H), blue (N), red (O) and cyan (Fe). Reproduced with 
permission from De Villiers et al., ACS Chem. Biol., 2012, 7, 666. Copyright 2012 American Chemical Society. 
 
Single crystal X-ray diffraction confirmed that monomeric Fe(III)PPIX interacted with quinidine 
and quinine in three specific ways analogous to the interaction with halofantrine; namely, 
coordination of the alkoxide to the iron centre of Fe(III)PPIX, a π-stacking interaction between 
the quinoline ring systems of the alkaloid and the porphyrin of Fe(III)PPIX, and hydrogen 
bonding to propionate side chains on the same porphyrin (not to a neighbouring complex, as in 
the case of halofantrine).108 Most recently, the mefloquine-Fe(III)PPIX complex has also been 
crystallised confirming that alkoxide coordination is a key feature of these solid-state 
interactions.105 
 
The crystal structure of a complex between a 4-aminoquinoline antimalarial and Fe(III)PPIX has 
not yet been published. Solid-state characterisation of the precipitated CQ-Fe(III)PPIX complex 
has yielded conflicting reports of Fe(III)PPIX speciation, with solid-state NMR studies leading to 
a proposed covalent chloroquine-Fe(III)PPIX complex.109 This 1:1 stoichiometry was 
corroborated via mass spectrometry on an isolated Fe(III)PPIX adduct with a chloroquine 
analogue while a corresponding vibrational study also indicated a 1:1 stoichiometry.110,111 These 
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results contrast with those obtained from Mössbauer measurements of isolated chloroquine 
and quinine complexes with Fe(III)PPIX, respectively, where the former produced a distinctly 
different spectrum which corresponds to the μ-oxo dimer while the latter was subsequently 
shown to correspond to a 1:1 complex.112 
 
Spectroscopic evidence leaves little doubt that quinoline antimalarials are privileged scaffolds 
that are able to form stable complexes with Fe(III)PPIX in solution and in the solid-state. 
Although several crystal structures of quinoline-Fe(III)PPIX complexes are available, there is no 
guarantee that such structures resemble the species present in solution, especially given that 
these complexes tend to interact non-covalently and in a solvent-dependent manner. Hence 
solution-state and solid-state interactions must be dealt with in a complementary manner. 
 
1.5.4. Other possible mechanisms of action of the quinoline antimalarials 
 
Despite convincing evidence that the quinoline antimalarials exert their mechanism of action by 
the inhibition of haemozoin biocrystallisation, most likely as a consequence of their selective 
interactions with Fe(III)PPIX, alternative modes of action have been proposed which, although 
less likely, are mentioned here for completeness.  
 
The original observations in 1949 that quinoline and acridine antimalarial compounds interact 
with nucleic acids suggested a possible mechanism by which these agents might interfere with 
cellular processes in malarial parasites.113 At physiological pH, chloroquine and quinine are 
positively-charged cations that are able to bind to DNA, RNA and other anions.114,115 
Subsequently, a number of investigators have shown that these quinoline antimalarials inhibit 
nucleic acid synthesis in bacterial and mammalian cells.116,117 
 
It has been proposed that chloroquine might exert its antimalarial effect by intercalation with 
parasite DNA and that the activity of similar compounds might be proportional to the stability of 
their complexes with DNA.118,119 However, the chloroquine concentrations required to inhibit 
nucleic acid synthesis are much larger than those that inhibit the growth of chloroquine-
susceptible strains of P. falciparum (millimolar versus nanomolar, respectively).120 Although 
parasitised cells accumulate chloroquine several thousand-fold, even these concentrations are 
too low. Thus, for this mechanism to be important, the parasite would need to concentrate 
chloroquine a further hundred-fold in the nucleus, for which there is no evidence. Also, while 
quinine can also interact with DNA, albeit more weakly than chloroquine, mefloquine does not 
measurably bind to DNA.121,122 Furthermore, binding to DNA is greatly reduced at physiological 
salt concentrations.123 A final problem with this proposed mechanism of action is that 
chloroquine has a higher affinity for GC-rich DNA.115,116,124,125 However, the genome of  





P. falciparum is AT-rich (approximately 82%) which predicts that the affinity for chloroquine 
will be lower for the parasite genome compared to GC-rich mammalian DNA.126 All this evidence 
taken together makes it very unlikely that DNA binding accounts for the antimalarial activity of 
chloroquine. Surprisingly, this theory is still reported,127 especially in textbooks,128,129 and is 
occasionally resurrected.130-132  
 
It has also been shown that several quinoline antimalarials directly inhibit the activity of 
partially-purified haemoglobin-degrading proteases. For example, Gyang et al. partly purified an 
aspartic protease from P. falciparum and found that 33 mM chloroquine was required to inhibit 
its activity by 60%.133 Vander Jagt et al. also isolated a low-molecular weight aspartic protease 
and detected approximately 10% inhibition at 1 mM chloroquine.134 However, it is extremely 
unlikely that the concentration of chloroquine in the digestive vacuole ever reaches these levels 
which are several orders of magnitude higher than the micromolar concentrations required for 
haemozoin inhibition. It is therefore very unlikely that inhibition of the proteases described 
above is sufficient to account for the specific antimalarial activity of these drugs.  
 
Nevertheless it is worth noting that Vander Jagt et al. found that Fe(III)PPIX was a much better 
inhibitor of their partially purified aspartic protease than chloroquine and that this inhibition 
was unchanged in the presence of chloroquine.134,135 Therefore, if chloroquine indeed inhibits 
haemozoin biocrystallisation following haemoglobin catabolism, it is possible that free 
Fe(III)PPIX may accumulate to concentrations which may inhibit further proteolysis. While 
protease inhibition has been found to be reversible following removal of the inhibitor,19 the 
inhibition of parasite growth by quinoline antimalarials is irreversible.136 This observation was 
critical for concluding that the quinoline antimalarials must have more specific, irreversible 
effects on the parasite. 
  





1.6. Differential effects of the quinoline antimalarials on P. falciparum 
 
1.6.1. Physicochemical considerations and accumulation in P. falciparum 
 
There is convincing evidence that the interaction of the quinoline antimalarials with Fe(III)PPIX 
is central to their activity against P. falciparum. However, this alone is unlikely to account for 
their differences in parasite accumulation as well as differential morphological effects that are 
observed in parasites following drug treatment (Section 1.6.2). These effects may instead be 
closely related to differences in their physicochemical properties which belie the superficial 
structural similarities of the quinoline methanol and 4-aminoquinoline archetypes.  
 
Quinine and quinidine are typically described as monoprotic weak bases at physiological pH. 
Their rigid quinuclidine systems (pKa 8.58) are connected to quinoline cores via benzylic 
hydroxyl groups (Figure 1.20). All three structural motifs are important for the antimalarial 
activity of these compounds.137,138 The quinolinic pKa values of quinine and quinidine are 
approximately 4.14 and 4.42, respectively.137 Mesomeric donation of the methoxy group into the 
quinoline system increases its electron density which may encourage π-stacking interactions 




Figure 1.20. The structures of the quinoline antimalarials examined in this study. The quinoline methanol 
and 4-aminoquinoline motifs are highlighted. pKa values are taken from Warhurst et al.137 
 
Chloroquine, on the other hand, is a diprotic weak base at physiological pH. The pKa of its 
quinolinic nitrogen is higher (8.38) relative to the quinoline methanols due to mesomeric 
stabilisation of the conjugate acid by the 4-amino group.137 The tertiary amine (pKa 10.18) is 
also more basic than the corresponding quinuclidine of the quinoline methanols.137 
Consequently, chloroquine is expected to accumulate far more efficiently in the acidic digestive 
vacuole of P. falciparum due to the weak base effect, also known as pH trapping. 





Weakly-basic compounds such as the quinoline antimalarials are able to exist in both charged 
(protonated) and uncharged (unprotonated) forms. The latter (neutral) form of the molecule is 
highly membrane permeable and can diffuse rapidly across biological membranes. On the other 
hand, mono- or diprotonated forms of the molecule are substantially less membrane permeable 
and so diffuse across membranes at a much reduced rate, if at all. Therefore, if the unprotonated 
form of the drug diffuses across a membrane into the acidic digestive vacuole of P. falciparum, it 
will become protonated and thus unable to diffuse back out again.  
 
This idea was formulated by Belgian biologist Christian de Duve who discovered the lysosome 
and was later awarded the Nobel Prize in Medicine or Physiology in 1974.140 The concentration 
of weakly-basic compounds in acidic compartments is, in principle, predictable and Krogstad 
and Schlesinger proposed a model for accumulation based on the Henderson-Hasselbalch 
equation.120 This takes into account the pKa values of the molecules and the pH values of the 
cellular compartments. Assuming that protonated drugs are membrane-impermeable, it is 
possible to predict the digestive vacuolar accumulation ratio (VAR) using Equation 1.1:120 
 
                                  
       
       
 
                                 





In this equation, the pKa values refer to the weakly-basic sites of the molecule of interest while 
pHv and pHc represent the pH of the acidic digestive vacuole and the cytosol of P. falciparum, 
respectively. The pH measurements provided by Kuhn et al. were used as the limits in these 
calculations; that is, pH 7.15 ± 0.07 for the cytosol and pH 5.18 ± 0.05 for the digestive vacuole 
with no significant difference between chloroquine-sensitive and -resistant strains.55 
 
The cellular accumulation ratio (CAR) in the parasitised erythrocyte may also be calculated by 
multiplying the VAR by the fraction of the infected erythrocyte that is occupied by the digestive 
vacuole. The digestive vacuole of the parasite occupies approximately 3.25 fL (the average of 
two previous measurements)141,142 of the total erythrocyte volume which is about 75 fL.143 
 
Taking all of this into account, accumulation values for quinine, quinidine and chloroquine may 
be estimated. These are listed in Table 1.2. In the absence of additional accumulating forces, 
these calculations suggest that the quinoline methanols should accumulate approximately 
three- to six-fold in the infected erythrocyte relative to the serum concentration. Given its 
higher pKa values, chloroquine is predicted to have a higher overall cellular accumulation in the 
parasitised cell, approximately 200- to 600-fold. 





Table 1.2. Predicted vacuolar and cellular accumulations of the quinoline antimalarials 
taking into account the various assumptions listed in the text. 
 
 pKa1 pKa2 Predicted vacuolar 
accumulation ratio (VAR) 
Predicted cellular 
accumulation ratio (CAR) 
Quinine 8.58 4.12 75-130 3.4-6.0 
Quinidine 8.58 4.42 80-140 3.7-6.6 
Chloroquine 10.18 8.14 4 600-13 500 215-630 
 
It was previously thought that a consequence of this accumulation might be a drug-induced 
alkalinisation effect on the pH of the digestive vacuole. This was thought to play a role in the 
antimalarial activities of the molecules; for example, by raising the pH of the digestive vacuole 
above the optimal range for protease action.143 However, any alkalinising effects of these drugs 
were only observed at concentrations very much larger than their IC50 values, meaning that 
vacuolar alkalinisation is not their primary effect.144  
 
Despite this large predicted accumulation of chloroquine, these calculations only account for 
approximately 10% of the total amount of chloroquine that has been observed to accumulate in 
sensitive strains of P. falciparum.145,146 This “non-saturable” predicted accumulation due to the 
weak base effect is exceeded by an additional “saturable” effect.147,148 This second component 
has been suggested to be due to the binding of chloroquine to Fe(III)PPIX in the digestive 
vacuole.  
 
Convincing evidence for the two-component model of accumulation comes from the observation 
that chloroquine uptake was reduced by up to 90% in parasitised erythrocytes by interrupting 
haemoglobin degradation with a plasmepsin inhibitor, reducing the availability of 
Fe(III)PPIX.147 Furthermore, the model can account for the saturable uptake of chloroquine in 
susceptible and resistant strains in the presence and absence of verapamil (Figure 1.21).147 
Finally, erythrocyte “ghost” cells (erythrocytes no longer containing haemoglobin) loaded with 
Fe(III)PPIX also exhibited this saturable chloroquine binding in a manner dependent on the 
concentration of Fe(III)PPIX.148  







Figure 1.21. The cellular accumulation ratio (CAR) of chloroquine in P. falciparum-infected  
erythrocytes as a function of IC50, validating the two-component accumulation model of Bray et al.147  
Data from three chloroquine-sensitive strains (HB3, 3D7 and T9-96) and three chloroquine-resistance 
strains (K1, TMS5 and TMS6) are shown in the absence and presence of verapamil (VP).  
Reproduced with permission from P. G. Bray et al., Mol. Pharm., 1998, 54, 170. 
 
Although it only accounts for a small proportion of the overall accumulation, the non-saturable 
component is crucial. In the absence of weak base trapping and hence a low intravacuolar 
concentration of chloroquine, only a very small amount of the complex would form based on the 
binding constant of the complex. Therefore, in order to permit binding to Fe(III)PPIX which 
forms the majority of chloroquine accumulation, weak base trapping is required to achieve 
sufficient free drug concentrations to form a complex in the digestive vacuole.149 
 
The accumulation of the two quinoline methanol antimalarials, quinine and quinidine, in  
P. falciparum is rather different. Although a three- to six-fold cellular accumulation ratio is 
predicted on the basis of the equation above, a 300-fold cellular accumulation ratio of quinine is 
actually observed for some strains of P. falciparum (Figure 1.22).150 Sanchez et al. argue that 
non-saturable passive distribution, in accordance with the weak base effect, and saturable 
intracellular binding to Fe(III)PPIX can account only for a small fraction of this accumulation.150 
 
The results of trans-stimulation kinetic studies suggest that the unusually high accumulation of 
quinine is brought about by a carrier-mediated import system. This import system is weakened 
in parasites with reduced quinine susceptibility. This may be related to polymorphisms within 
PfCRT but not to polymorphisms within PfMDR1.151 Interestingly, a K76I mutation in PfCRT 
reversed the normal potency order of quinine and quinidine toward P. falciparum.151,152 







Figure 1.22. Time courses of [3H]-quinine accumulation. The CAR is expressed as the ratio of the 
intracellular to the extracellular quinine concentration (QNin/QNout) and as the total intracellular quinine 
concentration [QNin]. The chloroquine-sensitive HB3 strain (closed circles) is compared to the chloroquine-
resistant Dd2 strain (open circles) and uninfected erythrocytes (grey squares). Reproduced with permission 
from C. P. Sanchez et al., Mol. Microbiol., 2008, 67, 1081. 
 
Figure 1.22 demonstrates the minimal accumulation of quinine in uninfected erythrocytes (grey 
squares). While the specificity of accumulation of quinine, quinidine and chloroquine for  
P. falciparum over uninfected erythrocytes is now beyond doubt, further visual evidence has 
been provided by high-resolution electron autoradiography.  
 
In this technique, tritium (3H) is typically used as a radioactive tracer and is incorporated into a 
drug molecule. Following incubation with live cells, these are placed in contact with an 
emulsion. As ionising radiation is emitted during decay, silver ions in the emulsion become 
reduced to metallic silver grains.153 Low-energy beta particles, emitted by 3H, produce silver 
grains within a few microns of their disintegration site and so provide satisfactory resolution 
for electron autoradiography.153 Consequently, the number and distribution of these silver 
grains can be used to provide information about cellular distribution. 
 
Aikawa showed [3H]-chloroquine accumulation in the digestive vacuole in P. berghei.154 In 1996, 
Sullivan et al. reported [3H]-chloroquine and [3H]-quinidine accumulation in P. falciparum using 
electron autoradiography and found that the radiolabelled signals were associated with 
haemozoin (Figure 1.23).142 Furthermore, intracellular chloroquine-Fe(III)PPIX interactions 
have been detected by non-invasive photoacoustic spectroscopy in situ.155 
 







Figure 1.23. Evidence of chloroquine-haemozoin association in cultured P. falciparum. (A) [3H]-Chloroquine 
is located over the haemozoin crystals situated in the digestive vacuole. In this example, three silver grains 
are observed. The scale bar represents 0.5 μm. (B) The majority of [3H]-chloroquine signal is measured 
directly over the crystals. Fifty parasitized erythrocytes were scored for signal distribution. The parasite bar 
denotes grains located in the parasite but not haemozoin-associated. Data represent the mean ± SEM. 
Reproduced from D. J. Sullivan et al., Proc. Natl. Acad. Sci. USA, 1996, 93, 11865.  
 
Finally, the differences in the interactions of these two classes of drugs with biological 
membranes have been investigated. Model dipalmitoylphosphatidylcholine bilayers and 
membranes reformed from lipids extracted from uninfected human erythrocytes were studied 
using 2H- and 31P-NMR.156,157 The results showed no significant perturbation of the bilayer 
structure by chloroquine up to a molar ratio of 1:2 of drug to lipid. In contrast, quinine exhibited 
stronger interactions with the bilayers, causing significant disordering of the lipid side 
chains.156,157 Such behaviour is consistent with the penetration of quinine, rather than 
chloroquine, into the interior of the bilayers and this may contribute to the differential 
morphological effects elicited by the quinoline antimalarials on P. falciparum as described in the 
next subsection.  
 
1.6.2. Ultrastructural and morphological effects of the quinoline antimalarials  
 
As a result of the vast accumulation of these drugs in the digestive vacuole, the osmotic gradient 
between the cytosol and vacuole is predicted to increase resulting in the diffusion of water into 
the digestive vacuole with concomitant swelling and/or membrane leakiness of the vacuole. 
Indeed, swelling of the digestive vacuole following drug treatment has been described by a 
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number of investigators in chloroquine-sensitive Plasmodium species and these ultrastructural 
observations were amongst the first indications that this may be the primary site of action of 
the quinoline antimalarials.92,158-160 These and other morphological effects on P. falciparum, 
before and after drug treatment, have been recorded using different microscopies. 
 
When exposed to therapeutic plasma concentrations of chloroquine, chloroquine-sensitive  
P. falciparum show enlargement of the digestive vacuole with increased granular matrix 
material (Figure 1.24A).160 Significant clumping is seen amongst the haemozoin crystals. In 
some parasites, the digestive vacuole and plasma membrane disintegrate. Pigment granules and 
empty vesicles lie within the cytoplasm. Some nuclei become more densely stained and coarsely 
clumped with the cytoplasm showing ribosomal aggregation as well as patchy loss.160 The 
mitochondrion appears swollen and rough endoplasmic reticulum becomes difficult to 
identify.160 
 
Electron microscopy of a chloroquine-resistant strain of P. falciparum treated with chloroquine 
did not reveal the above changes and instead resembled the control cultures (Figure 1.24B).160 
Digestive vacuoles were only minimally enlarged (if at all), consistent with the mechanism of 
chloroquine efflux from the digestive vacuole of chloroquine-resistant strains.160 Other cell 
constituents appeared normal.  
 
 
Figure 1.24. Transmission electron micrographs of chloroquine-treated P. falciparum strains.  
(A) Chloroquine-sensitive strain treated with chloroquine alone (x 21 000). Marked enlargement of digestive 
vacuoles (Fv) containing pigment (P) granules and granular matrix material is present. Degenerative 
membranous changes are also seen (arrow). (B) Digestive vacuoles (Fv) in chloroquine-resistant strains 
appear compact with no evidence of swelling (x 33 000). Inset: Normal digestive vacuole (Fv) of control cells 
(x 26 000). Reproduced from Jacobs et al., Am. J. Trop. Med. Hyg., 1988, 39, 15, published by the American 
Society of Tropical Medicine and Hygiene. 
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In quinine-exposed P. falciparum parasites, there was an extensive depletion of free ribosomes 
in the cytoplasm (Figure 1.25).161 Haemozoin in digestive vacuoles was decreased or almost 
absent and mitochondria showed marked swelling with a more electron-lucent matrix.161 These 
observations are similar to those of quinine-treated parasites of P. berghei.158 In this species, the 
first observation was an increase in “the space between outer and inner parasite limiting 
membranes” (presumably the parasitophorous vacuolar and parasite plasma membranes, 
respectively). Quinine also appeared to affect the integrity of the digestive vacuole membrane, 
followed by swelling of the vacuole and a decrease in electron density of the haemozoin. 
Clumping of the ribosomes, a reduction in their number and blebbing of the nuclear membrane 




Figure 1.25. Transmission electron micrographs of quinine-treated P. falciparum parasites.  
(A) An early ring, one hour after exposure, shows the depletion of ribosomes (*) in the cytoplasm and a small 
digestive vacuole (FV). (B) A parasite, four hours after exposure, shows a swollen mitochondrion (M) and a 
digestive vacuole (FV) containing few haemozoin crystals. (MC) represents a Maurer’s cleft. (C) At eight 
hours after exposure the parasite exhibits a digestive vacuole (FV) containing abnormally few haemozoin 
crystals. Scale bars represent 200 nm. Reproduced from Sachanonta et al., Ultrastruct. Pathol., 2011, 35, 214 
with permission from Taylor & Francis. 
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Although many of the effects on the ultrastructure of P. falciparum following drug treatment are 
shared by chloroquine and quinine, there are some differences which suggest that the modes of 
action of these antimalarials may differ in other mechanistic details.  
 
It has now been extensively shown that these antimalarials modulate endocytosis and vesicle 
trafficking in the malaria parasite in different ways.162-164 Endocytosis is a fundamental process 
in eukaryotic cells and fulfils numerous functions, most notably that of macromolecular nutrient 
uptake. As described in Section 1.3.1, during its intracellular development P. falciparum ingests 
large amounts of host cytoplasm by cytostomal-mediated endocytosis. These vesicles are then 
trafficked to the digestive vacuole where catabolism of haemoglobin is accomplished.  
 
In order to investigate the effects of antimalarials on the endocytic pathway, early trophozoite 
stage cultures were incubated for eight hours with quinoline antimalarials at five times their 
IC50 values. Following release from the infected erythrocytes by saponin lysis, haemoglobin 
levels were determined by Western blots. Quinine and related antimalarials mefloquine and 
halofantrine reduced haemoglobin content significantly, showing that they inhibit parasite 
ingestion of haemoglobin by endocytosis (Figure 1.26A).162 By contrast, haemoglobin levels in 




Figure 1.26. Haemoglobin levels in drug-treated parasites. (A) Parasite cultures were untreated (Con) or 
incubated with chloroquine (CQ), amodiaquine (AQ), quinine (Q), halofantrine (H) or mefloquine (MQ).  
(B) In parallel cultures, the quinoline drugs were added in combination with two protease inhibitors. The 
intensities of the haemoglobin bands on the Western blots were normalised. Error bars indicate standard 
deviations. An asterisk (*) indicates a significant change from the results for the controls (P < 0.05). 
Reproduced from Roberts et al., Antimicrob. Agents Chemother., 2008, 52, 1840 with permission. 
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This latter finding corroborates previous observations by Famin et al.163 A previous study also 
showed that chloroquine inhibited haemoglobin digestion but had no other significant effect on 
the endocytic pathway of the parasite as assessed by electron microscopy, haemoglobin 
immunofluorescence and the distribution of fluorescent and biotinylated dextran tracers.164 
 
By contrast, protease inhibitors moderated haemoglobin perturbations, suggesting a common 
role for Fe(III)PPIX binding.162 Parasites were incubated with the quinoline antimalarials in 
combination with protease inhibitors to halt haemoglobin digestion. Predictably, these 
inhibitors increased the concentration of haemoglobin in control parasites more than three-fold 
(Figure 1.26B). Chloroquine did not significantly affect haemoglobin levels in the presence of 
protease inhibitors while a reduction in haemoglobin levels was still found in quinine-treated 
cultures, although less severe than previously observed (Figure 1.26A).164  
 
This agrees with reports that inhibition of haemoglobin digestion antagonises quinoline 
action165 and supports the notion that quinolines share Fe(III)PPIX binding as a common mode 
of action. Consequently, their differential effects on the haemoglobin endocytic pathway are 
most likely manifestations of their physicochemical differences.  
 
Finally, it was shown, following quinoline treatment, that there is an accumulation of transport 
vesicles in the parasite cytosol as identified by immunofluorescence microscopy using anti-
haemoglobin antibodies.162 While the majority of the haemoglobin colocalised with haemozoin 
in the digestive vacuole, additional fluorescent puncta representing transport vesicles were 
observed in the parasite cytoplasm.162 Enumeration of the vesicles showed that quinine caused 
a reduction in endocytic vesicle content per parasite (0.66 ± 0.09) compared to control 
parasites (1.2 ± 0.12). This proves that quinine inhibits endocytosis and, consequently, 
endocytic vesicle formation.162 On the other hand, chloroquine treatment markedly increased 
the vesicle content (6.1 ± 0.10), consistent with a disruption of normal vesicle trafficking.162 
 
1.6.3. Previous efforts to investigate protein targets of the quinoline antimalarials 
 
Enduring interest in the quinoline antimalarials, as well as unresolved details regarding their 
mechanisms of action, has resulted in several attempts to identify proteinaceous binding targets 
within uninfected erythrocytes and P. falciparum. These efforts have almost exclusively 
exploited photoaffinity labelling strategies. In this technique, a molecular probe (in this case, a 
photoreactive derivative of the quinoline antimalarial) is activated by light to form a covalent 
bond to its target.166 The advantage of this technique is that it tends to label proteins with high 
specificity.  





Typically, the photoreactive group is an aromatic azide group. When exposed to ultraviolet light, 
photodecomposition of the azide produces a highly reactive, short-lived nitrene intermediate 
that covalently labels proteins in close proximity. A common photoreactive azide group is the 
azidosalicylate moiety, highlighted in Figure 1.27, which may be additionally labelled by a 




Figure 1.27. Representative analogues of quinoline antimalarials used in protein-binding studies.  
The radiolabelled, photoreactive azidosalicylate is highlighted. 
 
Foley and colleagues synthesised a photoreactive chloroquine analogue (Figure 1.27A) that was 
comprehensively validated against P. falciparum.167 The analogue was active against a 
chloroquine-sensitive strain of P. falciparum but was less effective at killing a chloroquine-
resistant strain; these effects could be modulated using verapamil. (It is now known that these 
observations can be rationalised in terms of PfCRT-mediated efflux.) Following radiolabelling 
with Na125I, two proteins with masses of 42 kDa and 33 kDa were retrieved. Incubation with 
chloroquine competitively inhibited the photolabelling, suggesting a specific interaction.167  
 
A follow-up study found that the 42 kDa protein was present in unlabelled erythrocytes as well 
as P. falciparum-infected erythrocytes, while the 33 kDa chloroquine-binding protein was found 
exclusively in infected erythrocytes (Figure 1.28).168 Consequently, the investigators decided to 
pursue the characterisation of the 33 kDa protein. This protein was purified and identified as  
P. falciparum lactate dehydrogenase (PfLDH), one of the most ubiquitous enzymes in the 
parasite proteome.168 The enzyme was cloned and expressed in E. coli and the recombinant 
protein was used to produce an antiserum, after which immunoprecipitation using affinity-
purified anti-PfLDH antibodies confirmed the identity of the protein.168 However, the enzyme 
activity of purified PfLDH was not significantly affected by chloroquine indicating that PfLDH is 
not a direct target of the quinoline. Instead, the authors found that PfLDH was “exquisitely 
sensitive” to inhibition by free Fe(III)PPIX. Chloroquine protected against this inhibitory 
effect.168 
 







Figure 1.28. Photoaffinity labelling of chloroquine-interacting proteins. (A) Erythrocytes infected with a 
chloroquine-sensitive strain of P. falciparum were incubated with the radiolabelled, photoreactive 
chloroquine analogue and exposed to ultraviolet illumination either alone (lane a) or in the presence of 
chloroquine (lane b). Samples were subjected to SDS-Page and visualised by phosphorimage analysis.  
(B) Parasite-infected erythrocytes or uninfected erythrocytes were washed, lysed and incubated with the 
probe. They were exposed to ultraviolet illumination and subjected to SDS-Page. Lanes (a) and (b) represent 
Coomassie-blue stained profiles of lanes (c) and (d) which themselves were visualised by phosphorimage 
analysis. The 33 kDa and 42 kDa chloroquine-binding proteins are marked with arrows. Reproduced from 
Menting et al., Mol. Biochem. Parasitol., 1997, 88, 215 with permission from Elsevier. 
 
Finally, Read and colleagues determined the crystal structure of the complex between PfLDH 
and chloroquine (Figure 1.29).169 This is the first structure of a complex between chloroquine 
and an enzyme. The bound chloroquine is observed within the NADH binding pocket of the 
enzyme, occupying a position similar to that of the adenyl ring of the cofactor, indicating that 
chloroquine acts as a competitive inhibitor of NADH for this critical glycolytic enzyme.169 
Specific interactions between the drug and amino acid residues unique to the malarial form of 











Figure 1.29. Superimposed Cα traces for apo-PfLDH (blue), the chloroquine-PfLDH complex (red) and the 
ternary complex of PfLDH incorporating the NADH cofactor (green). The bound chloroquine is shown 
relative to the active site. Reproduced from Read et al., J. Biol. Chem., 1999, 274, 10213 with permission. 
  
Meanwhile, Desneves and colleagues applied the same methodology to probe for mefloquine-
binding proteins. They also synthesised a photoreactive azidosalicylate analogue that was 
subsequently radiolabelled (Figure 1.27B) and validated against mefloquine-sensitive and 
mefloquine-resistant strains of P. falciparum.170 They showed that the mefloquine analogue 
interacts specifically with apolipoprotein Al, the major protein of serum high-density 
lipoproteins. In addition, the probe was shown to interact specifically with erythrocyte 
membrane protein, stomatin (31 kDa). A further two high affinity proteins with apparent 
molecular masses of 22 kDa and 36 kDa were observed in three different strains of  
P. falciparum.170 These proteins have not subsequently been identified. 
 
More recently, Graves et al. took a different approach.171 Recognising that the heterocyclic 
quinoline ring shares common structural features with purine nucleotides and, considering that 
purine-interacting proteins represent a large proportion of the proteins in cells, they 
hypothesised that proteins that interact with purines might also interact with quinolines. As a 
result, they used a functional proteomics approach that exploited the structural similarities 
between the quinoline ring and the purine ring of adenosine triphosphate (ATP). Consequently, 
Graves et al. used a γ-phosphate-linked ATP-Sepharose affinity matrix to isolate the entire 
purine binding proteome from cell lysates in order to reduce the complexity of the protein 
mixtures.171 Several quinoline drugs were screened by displacement affinity chromatography 
against the purine binding proteome captured by the ATP-Sepharose matrix. Screening of the 





human erythrocyte purine-binding proteome identified two human proteins, aldehyde 
dehydrogenase 1 (ALDH1, 55 kDa) and quinone reductase 2 (QR2, 26 kDa). By contrast, no 
proteins were detected upon screening of the P. falciparum purine-binding proteome.171 
 
In a complementary approach, the authors passed cell lysate from a mouse, uninfected 
erythrocytes and P. falciparum sequentially over hydroxychloroquine- or primaquine-linked 
Sepharose. Consistent with the displacement affinity chromatography screen, ALDH1 and QR2 
were the only proteins recovered from the mouse and erythrocyte cell lysate. As before, no 
proteins were recovered from P. falciparum. Furthermore, the activity of QR2 was potently 
inhibited by several of the quinolines in vitro, confirming the selectivity of this target.171 
 
In an even more recent development, Lekostaj and colleagues designed and synthesised novel 
perfluorophenylazido chloroquine analogues for photolabelling studies with the deliberate 
intention of being able to extract the PfCRT protein from P. falciparum.172,173 Their probe places 
the photoreactive group at the terminal aliphatic nitrogen of chloroquine via a flexible four-
carbon ester linker and includes a convenient biotin tag (Figure 1.30A). They found that this 




Figure 1.30. (A) The biotinylated, photoreactive chloroquine analogue which was used to label PfCRT.  
(B) A cartoon showing the modelled interaction between the biotinylated, photoreactive chloroquine 
analogue and PfCRT. The authors propose that the 7-chloro-4-aminoquinoline pharmacophore binds within 
a cleft defined by three of the transmembrane helices. Reproduced from Lekostaj et al., Biochemistry, 2008, 
47, 10394 with permission from the American Chemical Society. Copyright 2008 American Chemical Society. 
 
Using reconstituted proteoliposomes harbouring partially-purified recombinant PfCRT, they 
analysed the efficiency of photolabelling in the presence of chloroquine and other drugs, 
including verapamil, and various amino acid mutations in PfCRT. They were able to define a 
single attachment site to their chloroquine analogue lying within the digestive vacuolar-
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disposed loop between putative helices 9 and 10 of PfCRT, allowing them to propose a model 
for a single chloroquine binding site in PfCRT (Figure 1.30B).173 It is surprising to note that, in a 
later work, the same group demonstrated exogenous binding of this chloroquine analogue to 
PfMDR1.174 However, they did not identify this latter protein in the photolabelling study 
described above. 
 
The results from the photoaffinity labelling studies of quinoline antimalarials described above 
are summarised in Table 1.3. Protein binding targets of the Cinchona alkaloids in P. falciparum 
have not yet been probed. Hence, these will form a key part of this study as outlined in the next 
section. 
 
Table 1.3. A summary of the results of protein affinity studies of the quinoline antimalarials. 
 
Investigator Probe  Protein(s) detected and/or identified 





Two bands from infected erythrocytes were detected, 
33 kDa and 42 kDa, the former of which was later 
identified as P. falciparum lactate dehydrogenase by 
Menting et al. (1997)168 





Several bands from uninfected erythrocytes were 
detected including an erythrocyte integral membrane 
protein stomatin (31 kDa). Two P. falciparum proteins 
of masses 22 kDa and 36 kDa were detected but not 
identified  
Graves et al. 
(2002)171 
γ-ATP-Sepharose to 
identify purine binders, 
followed by primaquine- 
and hydroxychloroquine-
labelled affinity columns 
In uninfected erythrocytes, two human proteins were 
identified: human aldehyde dehydrogenase 1 (ALDH1, 
55 kDa) and quinone reductase 2 (QR2, 26 kDa). No  
P. falciparum proteins were detected 
Lekostaj et al. 
(2008)173 
Photoreactive chloroquine 
analogue with biotin tag 









1.7. Aims and objectives of this study 
 
Malaria is the most serious and widespread parasitic disease occurring in man. The quinoline 
antimalarials, which have provided the foundation of malaria treatment for centuries, remain of 
great interest to public health. However, mechanistic details of their modes of action remain 
unresolved, particularly between the two major classes of these antimalarials. These are the 
quinoline methanols, represented in this study by the diastereomeric Cinchona alkaloids 
quinine and quinidine, and the 4-aminoquinolines, represented by chloroquine.  
 
Hence the aim of this work was to develop new tools with which to investigate the quinoline 
antimalarials and to use these tools to generate deeper insights into their mechanism of action 
against P. falciparum. The context of this research is to contribute to the development of 
antimalarial chemotherapies by elucidating novel mechanistic insights into the activities of 
these drugs on P. falciparum, the causative agent of a crippling but curable infectious disease.  
 
Consequently, the broad aims of this project were three-fold: (1) To design and synthesise novel 
fluorescent analogues of quinine, quinidine and chloroquine suitable for live-cell fluorescence 
microscopy; (2) to investigate systematically their subcellular localisation in P. falciparum; and 
(3) to identify protein binding targets, if any, of these molecules within uninfected erythrocytes 
and P. falciparum. 
 
Specific objectives relating to the aims of each chapter are given at the beginning of each 
relevant chapter. The following overarching objectives were envisaged for this work: 
 
i. To use current structure-activity models of the antimalarials quinine, quinidine and 
chloroquine with Fe(III)PPIX to design and synthesise novel fluorescent derivatives of 
these molecules suitable for live-cell imaging; 
ii. To fully characterise these novel derivatives photophysically and physicochemically, and 
to evaluate their activities against P. falciparum in vitro, in order to determine which of 
these derivatives were suitable fluorescent analogues of the parent antimalarials; 
iii. To use these analogues with confocal and super-resolution microscopy in the presence of 
fluorescent dyes and organelle-specific trackers to identify patterns of accumulation 
across the mature stages of P. falciparum; 
iv. To isolate protein binding targets of the quinoline antimalarials in uninfected 
erythrocytes and P. falciparum using matrix-based affinity chromatography and to 
identify these proteins using proteomic methods. 
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Principles of Fluorescence and Applications 






luorescence spectroscopy and microscopy form the basis of the investigations reported in 
Chapters 4 and 5 of this thesis, respectively. Hence, in order to provide a more meaningful 
discussion of the results in these chapters, theoretical aspects of fluorescence and their specific 
applications to these technologies are presented in this chapter. 
 
Fluorescence-based techniques have recently enjoyed remarkable growth across many 
disciplines, culminating in the award of the 2014 Nobel Prize in Chemistry for the development 
of super-resolution fluorescence microscopy. This recognition represents the pinnacle of a 
century-and-a-half of investigation that now permits the imaging of single proteins inside living 
cells with exquisite precision.  
 
Technologies exploiting fluorescence are characterised by rapid speeds of response, high spatial 
resolution and ultra-high sensitivity, making fluorescence the physical technique of choice for 
probing the structure and dynamics of biological systems. However, although modern 
instruments enjoy single parts-per-trillion sensitivity over large concentration ranges, the 
susceptibility of electronically-excited states to deactivation means that experiments must be 
planned carefully to avoid the pervasive effects of interference. 
F 





This chapter will describe the theoretical principles of fluorescence and their applications in 
spectroscopy and microscopy with specific relevance to this study. The historical context of 
fluorescence will be presented as well as detailed descriptions of the electronic events 
associated with fluorescence excitation and emission. Practical aspects of fluorescence 
spectroscopy will be described, noting the challenges posed by inner-filter effects. Applications 
in fluorescence microscopy will then be presented with specific reference to the diffraction limit 
and super-resolution structured-illumination microscopy (SR-SIM). Finally, various methods of 




2.2. Historical aspects of fluorescence 
 
It is an interesting reflection in the context of this study that the history of fluorescence is 
intimately linked to the alkaloid quinine. Its reputation as a famous antimalarial meant that it 
was a molecule of intense interest amongst scientists. The alkaloid fluoresces strongly in 
aqueous solutions excited by ultraviolet light, so it is not surprising that modern investigations 
in fluorescence began with the observation of a quinine solution in sunlight. 
 
Firstly, it is worth drawing attention to the origin of the term “fluorescence” which is not 
immediately clear. It is odd that the word contains “fluor” (fluorine) which is not a fluorescent 
element. In contrast, the etymologies of the related terms “phosphorescence” and 
“luminescence” are straightforward; both of these are preceded by the Greek and Latin words 
for “light”, respectively.1 Instead, the word “fluorescence” was invented by Sir George Stokes 
(1819-1903), a 19th century physicist and mathematician. 
 
Stokes’s observations of quinine sulfate in solution followed those of Sir John Herschel (1792-
1871), the famous polymath, who was the first to observe the unusual blue phenomenon at the 
surface of an acidic solution of the alkaloid in sunlight: 
 
Though perfectly transparent and colourless when held between the eye and the light … 
[the quinine sulfate solution] yet exhibits … under certain incidences of light an extremely 
vivid and beautiful celestial blue colour, which, from the circumstance of its occurrence, 
would seem to penetrate in those strata in which the light first penetrates in entering the 
liquid, and which … exert their peculiar power … only through a very small depth within 
the medium.2 





He called this phenomenon “epipolic dispersion” from the Greek word meaning “pertaining to 
the surface”.3 Herschel’s description also reveals the first indirect observation of the inner-filter 
effect (Section 2.4.2). As relatively concentrated (millimolar) solutions of quinine were used, the 
fluorescence was only observed near the surface and “only through a very small depth” because 
the sunlight was entirely absorbed by the fluorophore within the first few millimetres before 
penetrating more deeply into the solution. 
 
Later, it was Stokes who demonstrated that the phenomenon was an emission process following 
the absorption of light. In an elegant experiment, Stokes formed the solar spectrum by means of 
a prism.1 When he moved the quinine sulfate solution through the visible part of the spectrum, 
the solution simply remained transparent. But beyond the violet portion of the spectrum (that 
is, in the region corresponding to ultraviolet radiation), the solution glowed with a blue light.4 
He wrote: “It was certainly a curious sight to see the tube instantaneously light up when 
plunged into the invisible rays; it was literally darkness visible.”5 
 
Stokes initially called this phenomenon “dispersive reflexion” but in a footnote he wrote: “I do 
not like this term. I am almost inclined to coin a word, and call the appearance fluorescence, 
from fluorspar, as the analogous term opalescence is derived from the name of a mineral.”6 It is 
now known that, while calcium fluoride (the major constituent of fluorspar) is not fluorescent, 
fluorspar appears fluorescent due to the presence of small amounts of fluorescent lanthanides.4 
 
Together, these observations by Herschel and Stokes laid the foundations for a century-and-a-
half of intense development in the field of fluorescence. Edmond Becquerel (1820-1891), a 
French physicist and father of Henri Becquerel who discovered radioactivity, described the 
apparent “fluorescence” of calcium sulfide and was the first to articulate that the emitted light is 
of longer wavelength than the incident light.4 Calcium sulfide is, in fact, phosphorescent and the 
first theoretical distinction between these two processes was provided by Francis Perrin (1901-
1992) who also worked on a quantitative model of fluorescence quenching and polarised 
fluorescence.4 In 1948, Theodor Förster (1910-1974) published his quantum mechanical theory 
of dipole-dipole energy transfer (Section 2.3.5). 
 
It was around this time that quinine was again to play an important role in the history of 
fluorescence.7 During World War II, the United States Department of War was interested in 
developing fluorimetric techniques to monitor blood levels of antimalarials that were being 
tested in patients and volunteers, including quinine and chloroquine.8 A programme at the 
National Institutes of Health led to the development of the first commercial spectrofluorimeters, 
the precursors to the instruments that are now ubiquitous in analytical research laboratories. 





2.3. Characteristics of fluorescence excitation and emission 
 
2.3.1. Electronic spin states 
 
Luminescence is the emission of light by a substance that has not been heated and is thus a form 
of cold body radiation. Fluorescence and phosphorescence are alike in that they both involve 
the emission of light from an excited state brought about by the absorption of photons. 
Consequently, they are referred to as photoluminescent processes to distinguish them from 
other types of luminescence.  
 
Fluorescence is the emission of light from a singlet excited state while phosphorescence is the 
emission of light from a triplet excited state. In the former state, the electron in the excited 
orbital is paired by opposite spin to the electron in the ground state orbital (Figure 2.1). Return 
to the ground state is spin-allowed and typically occurs within nanoseconds. Emission of light 
from a triplet excited state is spin-forbidden but it is still observed as a result of spin-orbit 
coupling. As a result, transitions to the ground state from the triplet excited state are much 




Figure 2.1. An illustration of singlet and triplet electronic states. Note that the  
triplet excited state is less energetic than the corresponding singlet excited state. 
 
2.3.2. The Perrin-Jabłoński diagram 
 
The Perrin-Jabłoński diagram is a partial energy-level diagram for a photoluminescent system 
and is a useful illustration of the photophysical processes that are relevant to fluorescence 
                                                          
‡ The nomenclature “singlet” and “triplet” derive from spectroscopic multiplicity considerations. Multiplicity is defined as  
M = 2S + 1, where S represents the total spin quantum number which is the sum of the individual spins of electrons which are either 
+½ or -½ depending on their direction. In a singlet state, for example, the total spin quantum number corresponds to S = 0. 

















excitation and emission. The Polish physicist Alexander Jabłoński (1898-1950) is regarded as 
the “father” of fluorescence spectroscopy and the diagram is named after him along with Francis 
Perrin and his father, the physicist Jean Perrin (1872-1942).4  
 
The singlet ground state and first and second excited states are depicted by S0, S1 and S2, 
respectively (Figure 2.2). At each of these electronic energy levels the molecules can exist in a 
number of vibrational states depicted by 0, 1, 2, etc. and further rotational energy levels which 
are not illustrated. Transitions between states are indicated by vertical lines to indicate the 
almost instantaneous nature of light absorption or emission. Dotted lines are used to indicate 





Figure 2.2. A Perrin-Jabłoński diagram indicating energy levels and states leading to fluorescence, 
phosphorescence and non-radiative relaxation processes. Typical timescales for these events are indicated. 
 
At room temperature, thermal energy is not sufficient to populate excited vibrational states. At 
this temperature an even larger energy difference between ground and excited singlet states 
does not allow for thermal population of S1. Consequently, as absorption and emission typically 
occur from molecules in their lowest vibrational energy states, light is used to induce 
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The fluorescence process is typically governed by three important events, all of which occur on 
timescales separated by several orders of magnitude. When a photon is rapidly absorbed by a 
susceptible molecule (a femtosecond event), the molecule is excited to a higher vibrational level 
of either of the electronically-excited singlet states, S1 or S2. These higher states then rapidly 
relax to the lowest vibrational level of S1 by the slower processes of vibrational relaxation or 
internal conversion which are together measured on the picosecond scale. The excess energy is 
dissipated to solvent molecules as heat. 
 
The final process, emission of a photon and return to the ground state which typically manifests 
as fluorescence, is longer still on the order of nanoseconds. Fluorescence emission almost 
inevitably occurs from a thermally-equilibrated excited state, i.e. the lowest vibrational state of 
S1. Return to the ground state typically occurs to a higher vibrational level of S0 which then 
rapidly (10-12 s) reaches thermal equilibrium to the lowest vibrational level in the ground state. 
Consequently, the fluorescence emission spectrum is often a mirror-image of the absorbance 
spectrum of the S0→S1 transition which reflects the manifold of closely-spaced vibrational 
modes of the ground state to which the fluorophore may return. 
 
Although the entire fluorescence lifetime, from excitation to emission, is measured in billionths 
of a second, the phenomenon is a stunning manifestation of the interaction between light and 
matter which forms the foundation for the expansive fields of florescence spectroscopy and 
microscopy.9 Most fluorophores repeat this excitation and emission cycle many hundreds of 
thousands of times before the highly-reactive excited state molecule is photobleached, resulting 
in destruction of the fluorophore.9 
 
Several other excitation pathways with varying degrees of probability compete with the 
fluorescence emission process. The excited state can be dissipated non-radiatively as heat, 
either through a quenching mechanism or via energy transfer to a second molecule in another 
non-radiative process. These intermolecular deactivation processes are broadly termed 
external conversion.10  
 
Alternatively, molecules in S1 can also undergo spin conversion to the first triplet state (T1) via 
intersystem crossing. As mentioned previously, emission from the triplet state is termed 
phosphorescence and generally occurs at longer wavelengths than fluorescence. As the 
transition to the singlet state is a forbidden process which violates the spin selection rule, these 
processes exhibit rate constants much lower than those for fluorescence and may occur on a 
timescale from milliseconds to dozens of seconds. However, phosphorescence is seldom 
observed in solution as it is outcompeted by non-radiative quenching processes.  





The T1→S0 transition is favoured by spin-orbit coupling and can therefore be increased in the 
presence of heavy atoms such as bromine and iodine. The efficiency of intersystem crossing 
increases according to the fourth power of the atomic number, indicating that these interactions 
are significantly larger for heavier atoms.4 Fluorescence quenching by “heavy atom” effects are 
also explained by the rate enhancement of spin-forbidden processes due to the presence of an 
atom of high atomic number.  
 
2.3.3. Other concepts associated with fluorescence 
 
Three fundamental parameters are commonly used to describe and compare fluorophores: the 
molar absorption coefficient, the fluorescence quantum yield and the fluorescence lifetime.  
 
The molar absorption coefficient (ε) is a direct measure of the molecule’s ability to absorb light. 
Fluorophores with a large molar absorption coefficient typically have a high probability of 
fluorescence emission.  
 
The fluorescence quantum yield (Φ) or quantum efficiency is defined as the ratio of the number 
of photons emitted as fluorescence to the number of photons absorbed. The brightest 
fluorophores have fluorescence quantum yields approaching unity. Experimentally, relative 
fluorescence quantum yields can be determined by comparing a fluorophore of known 
fluorescence quantum yield to a fluorophore of unknown fluorescence quantum yield while 
keeping the experimental parameters constant. 
 
As the fluorescence quantum yield of a compound is determined by the relative rate constants 
of processes by which the lowest excited singlet state is deactivated, the fluorescence quantum 
yield is susceptible to a variety of other factors such as pH, solvent polarity and concentration. 
The most important processes to consider are the fluorescence itself (kf), intersystem crossing 
(ki), internal conversion (kic), external conversion (kec) and dissociation (kd).11 These 
relationships are expressed in Equation 2.1: 
 
                               
  





The reciprocal of the fluorescence decay rate constant (kf) is called the intrinsic lifetime of a 
fluorophore (τ0), which is defined as the lifetime of the excited state in the absence of all 
processes that compete for excited state deactivation.9 In reality, the fluorescence excited state 





lifetime is shortened by non-radiative processes resulting in a measured lifetime (τf) that is a 
combination of the intrinsic lifetime and competing non-fluorescent relaxation mechanisms. 
Because the measured lifetime is always less than the intrinsic lifetime, the fluorescence 
quantum yield never exceeds a value of unity. Thus the fluorescence quantum yield can also be 
defined in terms of lifetime values in Equation 2.2: 
 







 “Kasha’s rule”, named after the American spectroscopist Michael Kasha (1920-2013), states 
that the emission spectrum of a fluorophore is independent of the excitation wavelength. As 
previously described, despite a manifold of higher electronic and vibrational levels being 
reached upon excitation, the excess energy is quickly dissipated to the lowest vibrational level 
of the first singlet excited state (S1). This relaxation occurs irrespective of the excitation 
wavelength and, because of this rapid deactivation process, emission spectra appear to be 
independent of the excitation wavelength. 
  
This effect is illustrated by the absorption and emission spectra of the quinine dication (Figure 
2.3). Primary and secondary absorption peaks are observed at max 345 nm and 320 nm, 
respectively. The lower-energy band corresponds to a transition to the first excited singlet state 
(S0→S1) while the higher-energy band corresponds to the S0→S2 transition which rapidly 
relaxes to S1. Hence fluorescence is observed only from S1 and not from the second singlet 
excited state. Consequently, the emission spectrum is a mirror image of only the S0→S1 
absorption spectrum. This general observation is called the “mirror-image rule”.  
 
Because the energy associated with the fluorescence emission transition (S1→S0) is almost 
invariably less than that of the absorption process, the emitted photons have less energy and 
longer wavelengths. This gives rise to the “Stokes shift” which is the difference between the 
positions of the two band maxima of the absorption and emission spectra of the same electronic 
transition (Figure 2.3). An increase in the Stokes shift may also be observed due to solvent 
effects, with more polar solvents resulting in larger Stokes shifts than less polar solvents due to 
solvent-specific relaxation effects during the excited state (Section 2.3.6). 
 
 







Figure 2.3. The absorption spectrum of quinine in 0.5 M sulphuric acid and its corresponding fluorescence 
emission spectrum following excitation at 333 nm. Vertical arrows indicate electronic transitions and the 
horizontal arrows indicate a large Stokes shift between the absorption and emission maxima. 
 
2.3.4. Fluorescence quenching 
 
The intensity of fluorescence emission is susceptible to changes in pH, temperature and solvent 
polarity. Perhaps the most important measurements of changes in the intensity of fluorescence 
emission are those caused by quenching. These are decreases in fluorescence intensity arising 
from competing intermolecular processes that induce non-radiative relaxation of excited state 
electrons to the ground state. The kinetics of these deactivation processes are typically 
described using the Stern-Volmer relationship that was developed at the beginning of the 20th 
century.7 
 
While processes such as fluorescence and phosphorescence are examples of intramolecular 
deactivation processes, intermolecular deactivation processes usually fall into two groups. 
Static quenching (also referred to as contact quenching) arises from the formation of a non-
fluorescent complex between the fluorophore and the quencher that serves to limit absorption 
by reducing the population of active, excitable molecules.7 Static quenching occurs when the 
molecules form a complex in the ground state before excitation occurs. The complex has its own 







































































fluorescence emission is therefore reduced without altering the average lifetime of the excited 
state.7 
 
On the other hand, collisional (or dynamic) quenching occurs when the excited state is 
deactivated upon interaction with another non-fluorescent molecule in solution.7 Neither of the 
molecules is chemically altered in the collisional quenching process. Mechanisms for collisional 
quenching include electron transfer, spin-orbit coupling (usually in the presence of the heavier 
halogens) and intersystem crossing to the excited triplet state. Typically, higher temperatures 
and lower viscosities accelerate the quenching process as they lead to increased collisions 
between molecules and hence diminished fluorescence. A fluorophore in the excited state may 
also be quenched by a dipolar resonance energy transfer mechanism to an acceptor molecule in 
which the excited state energy can be transferred non-radiatively.  
 
2.3.5. Förster resonance energy transfer 
 
A fluorophore in the first singlet excited state can variously lose its excitation energy by 
conversion into light (fluorescence), via thermal equilibration (vibrational relaxation) or by 
formation of a non-fluorescent ground state complex with another molecule (static quenching).  
 
Yet another mechanism, first described by Theodor Förster in 1948, is a non-radiative energy 
transfer process that is regarded as a dynamic quenching mechanism because energy transfer 
occurs while the donor is in the excited state.12 Förster resonance energy transfer is a long-
range electrodynamic phenomenon that has found countless applications, particularly in 
biological systems in which its distance-dependence means that it can be used as a 
“spectroscopic ruler”.‡2 The premise of Förster’s theory is that the “donor” fluorophore can be 
treated as an oscillating dipole at a particular resonant frequency in a manner analogous to the 
behaviour of coupled oscillators. 
 
Förster resonance energy transfer occurs between a donor in its excited state and an “acceptor” 
in its ground state. (The latter molecule does not have to be capable of fluorescence.) Energy 
transfer occurs without the appearance of a photon and is the result of long-range dipole-dipole 
interactions between the donor and acceptor.7 The transfer of energy is manifested both by 
quenching of the donor fluorescence emission in the presence of the acceptor and increased (so-
called “sensitised”) fluorescence emission from the acceptor.7 
 
                                                          
‡ “FRET” is sometimes inappropriately called “fluorescence” resonance energy transfer. This is misleading because the resonance 
energy transfer associated with Förster resonance energy transfer does not necessarily involve fluorescence. 





The rate of energy transfer depends on (i) the spectral overlap of the emission spectrum of the 
donor and the absorption spectrum of the acceptor, (ii) the quantum yield of the donor, (iii) the 
relative orientation of donor and acceptor transition dipoles and (iv) the distance between the 
two molecules. This distance-dependence allows quantitative distance measurements between 
the donor and acceptor.  
 
The distance between a donor and acceptor pair (R) can be calculated from the efficiency of 
energy transfer (E) given by Equation 2.3 below: 
 
              




R0, the characteristic transfer distance for which I/I0 = 0.5 and which is known as the Förster 
distance, is given by Equation 2.4: 
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In this equation, J is a measure of the spectral overlap between the donor fluorescence emission 
and acceptor absorption, κ is a geometric factor dependent on the relative orientations of the 
donor and acceptor, n is the refractive index of the medium and ΦD is the donor fluorescence 
quantum yield. κ approaches two-thirds if the donor and acceptor are free to tumble rapidly on 
the timescale of the fluorescence emission and this value is usually used in such calculations.13 
The efficiency of Förster resonance energy transfer varies with the degree of spectral overlap 
but, most importantly, as the inverse of the sixth power of the distance separating the donor 
and acceptor. The value of the spectral overlap is calculated from Equation 2.5: 
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Here,       is the extinction coefficient of the acceptor and       is the normalised fluorescence 
intensity of the donor. Wavelengths     are expressed in centimetres. Typically the fluorescence 
intensity is measured in arbitrary units (I) and normalisation is achieved using this equation. 
 
 







It has been mentioned before that local environmental factors such as temperature, pH and 
solvent polarity have profound effects on the emission spectra of fluorophores. The effects of 
these parameters vary widely from one fluorophore to another. Solvatochromism is the shift in 
fluorescence emission maxima resulting from changes in solvent polarity. 
 
Solvent molecules surrounding the ground state fluorophore also possess dipole moments that 
can interact with the dipole moment of the fluorophore. In the ground state, these arrange to 
form an ordered distribution of solvent molecules around the fluorophore (Figure 2.4). 
Following excitation, there is a change in the dipole moment of the fluorophore that ultimately 
induces a rearrangement of surrounding solvent molecules. However, the Franck-Condon 
principle dictates that, upon excitation of a fluorophore, the molecule is excited to a higher 
electronic level far more rapidly than it takes for the fluorophore and solvent molecules to 
rearrange. As a result, there is a delay between the excitation and the re-ordering of the solvent 
molecules around the solvated fluorophore, which generally has a much larger dipole moment 




Figure 2.4. A Perrin-Jabłoński diagram indicating energy levels and states involved in solvent relaxation. 
The grey boxes indicate the alignment of the dipole moments of the fluorophore (green) and solvent 




















Vibrational relaxation (10-14 to 10-11 s)










After the fluorophore has been excited to higher vibrational levels of the first excited singlet 
state (S1), excess vibrational energy is rapidly lost to the surrounding solvent molecules as the 
fluorophore slowly relaxes to the lowest vibrational energy level of that state. Solvent molecules 
assist in lowering the energy of the excited state by rearranging around the excited 
fluorophores in a slower process termed solvent relaxation. A more polar solvent produces a 
correspondingly larger reduction in the energy level of the excited state, while a less polar 
solvent reduces the stabilisation effects of the solvent on the excited state. Consequently, a 
larger Stokes shift is seen in polar solvents while a smaller Stokes shift is observed in non-polar 
solvents.  
 
Because fluorescence lifetimes are much longer than the time required for solvent relaxation 
(on the order of picoseconds), fluorescence emission spectra are representative of the solvent-
relaxed environment in which solvent molecules are oriented around the dipole moment of the 
excited state fluorophore. However, because absorption is so rapid (on the order of 
femtoseconds), absorption spectra are less affected by solvent polarity because the ground and 













Spectrofluorimetry is most accurate at very low concentrations of the fluorophore. Under 
optically dilute or “ideal” conditions, the intensity of fluorescence                 that is 
observed is related to the intensity of the incident radiation         according to Equation 2.6: 
 




Here,            is an instrument constant dependent on geometrical and optical factors and is 
a function of the excitation and emission wavelengths,        is the molar absorption coefficient 
at the excitation wavelength, c is the concentration of the fluorophore,    is the pathlength of 
the excitation beam and       is the fluorescence quantum yield at the emission wavelength.14  
 
This direct relationship between fluorescence intensity and the concentration of the 
fluorophore allows relatively simple electronics and optics to be used in a spectrofluorimeter 
(Figure 2.5). The light source is generally a xenon lamp that illuminates equally in all directions. 
Two monochromators are usually employed, the first of which selects the excitation 
wavelength. Radiation from the excitation monochromator is split with part of the radiation 
passing to a reference photomultiplier tube and part to the sample. After fluorescence emission 
occurs from the sample in all directions, the second monochromator determines the emission 
wavelengths to be transmitted to the detector. Following dispersion by the emission 
monochromator, the light is detected using a second sensitive photocell.11,15  
 
Temperature control is required for accurate work as the intensity of fluorescence varies 
considerably over small temperature ranges. Furthermore, it is difficult to compare emission 
spectra quantitatively across instruments as the output depends not only on the fluorescence 
intensity but also on the characteristics of the lamp, transducer and monochromators. All of 
these components vary with wavelength and differ from instrument to instrument.11 
 







Figure 2.5. Schematic of a typical spectrofluorimeter. Orange rays indicate incident radiation while blue 
rays indicate fluorescence leaving the sample following excitation. 
 
Two approaches are possible for the illumination of the sample. The simplest and most common 
configuration involves excitation and emission from the centre of the cuvette, at right angles to 
one another. An alternative and less common approach is front-face illumination which obviates 
inner-filter effects.  
 
2.4.2. Inner-filter effects 
 
As shown in Equation 2.6, fluorescence intensity is a linear function of the concentration of the 
fluorophore with zero intercept under “ideal” conditions. However, these conditions are met 
only when the attenuation of light at both excitation and emission wavelengths is negligible 
over the pathlengths of interest. Absorption of excitation and/or emission radiation by a sample 































fluorescence intensity and the concentration of the fluorophore. This is called the inner-filter 
effect.  
 
Usually, the optical arrangement of a commercial spectrofluorimeter focuses the exciting light 
and collects the fluorescence emission from the centre of the cuvette (Figure 2.6). Therefore, 
when absorption at the excitation wavelength is significant, less light reaches the centre of the 
sample and thus the fluorescence of the fluorophore is reduced. This is called the primary inner-
filter effect (or pre-inner filter effect). Similarly, absorption at the emission wavelength reduces 
the emitted light that reaches the detector. This is the secondary inner-filter effect (or post-
inner-filter effect). Such effects are particularly evident in concentrated solutions. An excellent 
example is Herschel’s original observation of quinine fluorescence which was only seen to 




Figure 2.6. Illustration of inner-filter effects within a cuvette showing the attenuation of both the excitation 
radiation and the emitted fluorescence. Instrument parameters relevant to Equation 2.8 are also indicated. 
 
Various correction factors have been proposed to reduce the impact of the inner-filter effect. If 
the geometry of the instrument is such that the collected intensity comes exactly from the 
centre of the cuvette, the inner-filter effect can be estimated from Equation 2.7: 
 
             
 
       
 
 























Here, Fcorr is the corrected fluorescence intensity that would be measured in the absence of the 
inner-filter effect, Fobs is the observed (measured) fluorescence in the presence of the inner-
filter effect, dex and dem are the cuvette pathlengths in the excitation and emission direction, 
respectively, recorded in centimetres (these are typically 0.5 cm in a 1 cm pathlength cuvette), 
and Aex and Aem are the measured changes in absorbance at the excitation and emission 
wavelengths, respectively, caused by the addition of the aliquot (in a 1 cm pathlength cuvette).16 
 
In Equation 2.7 above, the fluorescence is assumed to originate exactly from the centre of the 
cuvette. This may be the case for some spectrometers, but certainly not all. A more sophisticated 
correction takes into account instrument-specific factors as well. In this case, the most common 
case of right-angle geometry is used and the excitation and emission beams are modelled as 
sharp-edged, uniform and collimated with rectangular cross-sections of known dimensions 
determined by the slit widths and heights of the excitation and emission monochromators.14  
 
This results in a relationship between Fideal and Fobs as described in the Equation 2.8:14 
 
            
          
     
          
 
          
     





Here, aex and aem are absorbances of the solution per centimetre at ex and em, respectively, and 
x1 and y1 are the distances from the edges of the beams to the cuvette wall towards the light 
source and towards the detector, respectively (Figure 2.6). The geometrical parameters Δx, x1, 
Δy and y1 are in units of centimetres. In this model, the fluorescence signal arises from 
molecules in the overlap volume of the excitation and emission beams (shown as the shaded 
square in Figure 2.6). Approximation of each of these correction factors as         and        , 
respectively, with       (approximately 0.5 cm for the typical 1 cm square cuvette), returns 
the simpler expression in Equation 2.7 above.14 
 
Deviations from these more advanced correction methods may still occur, particularly at high 
absorbance values. Thus, rather than correcting the inner-filter effects, it may be more 
appropriate to minimise them by practical considerations such as reducing the pathlength by 









2.5. Fluorescence microscopy 
 
The purpose of microscopy is insight not images. 
 
– R.W. Hamming 
 
Fluorescence is arguably at its most powerful when it is used in biological imaging. Modern 
fluorescence microscopy offers one the possibility to probe the dynamics of living cells at high 
spatial resolution and in a manner that is minimally invasive. With the vast number of 
fluorescent stains that are readily available, fluorescence microscopy also allows for the rapid 
identification of subcellular components with a high degree of specificity.  
 
An important technical consideration is the ability of the microscope to form an image in the 
focal plane with simultaneous suppression of out-of-plane emission. This is the advantage of 
confocal microscopy over traditional widefield methods, as detailed below. Meanwhile, the limit 
of spatial resolution in fluorescence microscopy is dictated by the wavelength of light that is 
used and is known as the “diffraction limit”. The German physicist Ernst Abbe (1840-1905) 
defined this limit as the ability of a lens-based optical microscope to discern only those details 
that are longer than half the wavelength of the incident light. However, this limit has been 
surpassed by a suite of super-resolution techniques that has given rise to the field of 
“nanoscopy”.  
 
2.5.1. Widefield (epifluorescence) microscopy 
 
Widefield microscopy is the most popular fluorescence microscopy technique. Although it is not 
used in this study, it is presented here for comparison with other techniques.  
 
In this configuration, excitation and observation occurs from above the specimen (hence it is 
also known as “epifluorescence” microscopy). This is in contrast to common optical 
microscopes that collect light that is transmitted through the sample.17 
 
The light source passes bright white light through a filter to produce the excitation beam 
(Figure 2.7). This is reflected by a dichroic mirror that passes the beam through the objective to 
interact with the sample. Fluorescence emission from the sample is passed back through the 
objective and the dichroic mirror transmits only the (weaker) fluorescence light. Finally, the 
fluorescence is passed through the emission filter and is captured with a detector. 
 







Figure 2.7. Schematic of a simple widefield microscope. Excitation light, after passing through the first 
optical filter, is focused on the specimen from above. Fluorescence is directed to the detector after passing 
through the emission filter that rejects reflected and scattered excitation light. 
 
The epifluorescence microscope allows efficient collection of fluorescence arising from the 
sample. Filters match the excitation light that is used to illuminate the specimen and sort the 
(much weaker) emitted light from the scattered excitation light to make up the image. Hence the 
bright fluorescence areas are observed against a dark background with high contrast. The major 
disadvantage of this form of microscopy is that it collects the image of a specimen with three-
dimensional emission of fluorescence as a two-dimensional image formed by in-focus and out-
of-focus fluorescence emission. Thus is it sometimes difficult to judge what is “in front” and 
what is “behind”. This spatial information has been lost.17 
 
2.5.2. Confocal microscopy and two-photon excitation 
 
Confocal microscopy offers a different principle for forming sharp images. While the excitation 
of out-of-focus fluorophores by the incident beam is not avoided, an optical configuration of the 
instrument allows the rejection of their emission by means of a confocal pinhole that provides 




















principle allows the rendering of sharp images due to a dramatically-improved signal-to-noise 
ratio.  
 
A schematic of a typical confocal microscope is shown in Figure 2.8. Because a higher intensity 
of photons is required for excitation in comparison to widefield microscopes, lasers are 
employed. The beam enters the microscope and passes through the excitation filter and a 
dichroic mirror. Next, two scanning mirrors (not indicated in Figure 2.8) move the beam in a 
raster across the sample. Fluorescence emission then passes back through the objective and is 
de-scanned by reflecting off both of the scanning mirrors. The light is then reflected off the 
dichroic mirror. Importantly, only in-focus light is allowed to proceed through the pinhole and 





Figure 2.8. Schematic of a typical confocal microscope showing the beam geometry that allows rejection of 
photons emitted from outside the focal plane. The sold lines indicate in-focus photons that pass through the 

























The great advantage of confocal microscopy is the ability to adjust the focal plane. This enables 
one to scan the object at different z-levels so that cross-sections at various depths can be 
obtained. These two-dimensional sections can then be reconstructed to form a three-
dimensional image of the object. The disadvantage of the confocal microscope is the need to use 
high intensity lasers for excitation and to illuminate the sample with a large volume of light, not 
only within the focal plane. As a result this increases the possibility of photobleaching and 
phototoxicity, especially when imaging live cells.17  
 
This problem can be circumvented to some extent by utilising a two-photon excitation source. 
This takes advantage of a phenomenon that brings an electronic system to an excited state by 
the absorption of two photons simultaneously, the total energy of which corresponds to the 
energy of the required transition (Figure 2.9). For such summation of energies, these quanta 
should appear together in the right place at the right time and their simultaneous absorption 
should occur in a single event which is typically very rare. To increase this probability, a high 
photon flux is needed. In order to excite a dye that absorbs at 350 nm, a two-photon laser 
should emit at a wavelength of approximately 700 nm.17 
 
 
Figure 2.9. Energy scheme for a two-photon up-conversion process. 
 
The major advantage of this technique, in contrast to single-photon excitation in which the 
emission changes linearly with the intensity of the excitation light, is that the fluorescence 
emission of two-photon excitation varies with the square of the excitation intensity. This 
quadratic relationship between excitation and emission allows the excitation power to be 
focused to a very small volume without observing emission outside this volume, achieving high 
spatial resolution.17 Above and below the focal point, the photon density is not sufficiently high 
for two photons to pass at the same instant within the absorption cross-section of a single 
fluorophore. Only at the focal point is this density adequately high that two photons will be 
















dyes such as Hoechst or DAPI that require ultraviolet excitation. This high-energy radiation is 
damaging to cells. A two-photon excitation system minimises this damage. 
 
2.5.3. The diffraction limit and the advent of super-resolution microscopy 
 
Towards the end of the 19th century, Ernst Abbe (1873)18 and Lord Rayleigh (1896)19 found 
that light of wavelength  , travelling in a medium with refractive index n and converging with 









Consequently, widefield and confocal microscopes are constrained by this “diffraction limit”. 
When light is focused by the objective of a microscope, the notion of light “rays” converging to 
an infinitely sharp focal point does not occur. Instead, the light forms a blurry focal “spot” with a 
finite size due to diffraction. 
 
A single point emitter such as a fluorescent molecule therefore appears as a blurry “smudge” 
with a finite size when imaged through a microscope. The intensity profile of this smudge 
defines the point spread function of the microscope and has approximately the same width as 
the focal “spot” defined above. Consequently, two identical emitters separated by a distance less 
than the width of the point spread function will appear as a single object and are thus 
unresolvable from one another.20  
 
Practically, this means that for green light of wavelength 500 nm passing through a microscope 
objective with a high numerical aperture (1.2-1.5), the Abbe limit is about 200 nm 
perpendicular to the direction of light propagation (laterally) and about 500 nm parallel to the 
direction of the light propagation (axially, or in the z-direction). These dimensions may be small 
compared to most cells (1-100 μm) but not viruses (100 nm) or proteins (10 nm). Structures as 
small as these are unresolvable by light microscopy.  
 
Typically, electron microscopes have been used to overcome these resolution problems but they 
cannot be used for imaging live cells. Furthermore, electron microscopy typically requires 
                                                          
‡ In this equation, the term        is sometimes abbreviated to “NA” which represents the numerical aperture of the objective. This 
quantity characterises the light-gathering ability of the objective. 





extensive sample preparation and suffers from a lack of contrast in biological samples, making 
the identification of subcellular components extremely challenging. 
 
For almost a century-and-a-half it was believed this limit of resolution could not be surpassed. 
However, a number of different techniques have subsequently been developed that overcome 
this limit. These technologies, with a resolving power exceeding the diffraction limit, are 
collectively known as super-resolution (SR) microscopy. 
 
Stimulated emission depletion (STED) microscopy was developed and demonstrated by Stefan 
Hell in the 1990s. This method creates super-resolution images by the selective deactivation of 
fluorophores, minimising the area of illumination of the focal point and thus increasing the 
resolution. Two laser sources are used; one excites the fluorophores while the other quenches 
all the fluorophores except those surrounding the nanometre-sized region of interest. 
Quenching occurs by forcing these outer fluorophores into higher vibrational levels of the 
ground state without emission of fluorescence (“stimulated depletion”). The energy of the 
second laser is therefore lower than the excitation energy and is generally in the far-red region. 
However, the high intensities required for STED microscopy mean that photobleaching is 
problematic when working with live cells. Special fluorophores are typically required. 
 
Eric Betzig and W. E. Moerner, who were awarded the 2014 Nobel Prize in Chemistry jointly 
with Hell, separately laid the foundations for a second way of performing super-resolution 
microscopy. Their method relies on photoswitchable fluorophores that alternate between “on” 
(fluorescent) and “off” (dark) states. Typically, only a few of these molecules are “on” during a 
single image acquisition. The center of each “spot” can be found by fitting the observed emission 
profile to a known geometrical function. Superimposing these partial fluorescent 
representations yields a dense, super-resolved image; essentially, this is a pointillist 
representation of the coordinates of all the localised molecules. The two most popular 
variations on this theme are photoactivated localisation microscopy (PALM) and stochastic 
optical reconstruction microscopy (STORM).  
 
2.5.4. Super-resolution structured-illumination microscopy (SR-SIM) 
 
A different kind of super-resolution technology, structured-illumination microscopy (SIM), is 
based upon the idea of patterning the excitation light. By allowing the patterned light (usually a 
fine grid) to interfere with the structures in the sample, a characteristic pattern is produced. By 
rotating the grid between the acquisition of each image set and transforming the images into 





frequency space, additional spatial information may be retrieved. The reverse Fourier 
transform returns the reconstructed super-resolution image. 
 
This process is best understood in terms of the moiré effect. If two fine patterns are 
superimposed multiplicatively, a beat pattern (moiré fringes) will appear in their product 
(Figure 2.10). In SIM, one of the patterns being superimposed is the unknown sample structure 
(specifically, the unknown spatial distribution of the fluorescent dye) and the other pattern is a 
purposely-structured excitation light intensity.21 As the amount of light emitted from a point is 
proportional to the product of the dye intensity and the local excitation light intensity, the 
observed emission image is the product of the two patterns and will thus contain moiré fringes. 
As the moiré fringes contain information about the unknown structure and, because the 





Figure 2.10. A demonstration of moiré fringes, observed here as vertical stripes  
occurring in the region of overlap between two sets of parallel lines. 
 
In reciprocal space, low-resolution information resides close to the origin while higher-
resolution information resides further away. In a conventional microscope hindered by 
diffraction, the set of low-resolution information it can detect defines a circular “observable 
region” of reciprocal space (Figure 2.11.1).21 
 
Consider the Fourier transform of an illumination light structure that consists of a sinusoidal 
stripe pattern. This has only three non-zero points – one at the origin and the other two offset 
from the origin but contained within the circle defining the observable region (Figure 2.11.2).21 
If the sample is illuminated with the patterned light, moiré fringes will appear which represent 
information that has changed position in space. The observable region not only contains the 
usual information that itself resides there but information originating in the two offset regions 





as well (Figure 2.11.3). From a sequence of such images with different orientations and phases 
of the pattern, it is possible to recover information from an area twice the size of the normally 




Figure 2.11. A series of diagrams to explain the resolution enhancement possible by SIM.21   
See the text for details. 
 
Hence SIM is capable of doubling the conventional diffraction-limited resolution to 100 nm 
laterally and 300 nm axially. Furthermore, the technique does not rely on special photophysical 
properties of the fluorophores but purely on the optics of the microscope. Therefore any 
fluorescent probe used in a typical fluorescence microscope is compatible with SIM. It is 
regarded as a widefield technique as it does not make use of the confocal pinhole to reject out-
of-focus emission light. 
 
2.5.5. Quantitative image analysis 
 
Beware of determining and declaring your opinion suddenly on any subject; for 
imagination often gets the start of judgement, and makes people believe they see things 
which better observations will convince them could not be seen: therefore assert nothing 
till after repeated experiments and examinations in all lights and in all positions. When you 
employ a microscope shake off all prejudice, nor harbour any favourite opinions.  
 
– Advice of an 18th century microscopist 
 
One of the most common applications of fluorescence microscopy is to compare the subcellular 
distributions of two fluorescent molecules. Often the goal is to probe the localisation of a 
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fluorescently-tagged substrate and thus the second fluorophore is usually a commercially-
available tracker dye that is specific for a subcellular region or organelle.  
 
“Colocalisation” is a term that has received much criticism but appears ubiquitously in the 
literature. The term refers to the general spatial overlap between two (or more) different 
fluorescence signals; however, even super-resolution images cannot identify the physical 
apposition of two molecules merely by comparing their fluorescence signals. Hence the term 
“codistribution” may be preferred in which it is asked whether the molecules tend to associate 
with the same structures.22 This, in turn, may be thought of as a combination of “co-occurrence” 
(the spatial overlap of probes in a fluorescence image) and “correlation” (distribution in 
proportion to one another within and between structures).22 Although it may be helpful to bear 
these nuances in mind, in this text “colocalisation” will be used to retain consistency with the 
rest of the literature. 
 
Qualitative methods of image analysis rely on a comparison of separate fluorescence channels. 
Typically, images are displayed in different channels using pseudo-colouring (usually green and 
red) and regions of overlap are identified in a dual-channel image (in this case, regions of 
overlap would appear yellow). Quantitative methods, on the other hand, involve global 
statistical analysis of the pixel intensity distribution and are called intensity correlation 
coefficient-based analyses. This involves statistical analysis of the correlation of the intensity 
values of the pixels in the dual-channel image and is usually done using correlation coefficients 
that measure the strength of the linear relationship between two values. 
 
2.5.5.1. Scatterplots and the Pearson correlation coefficient. A simple way of measuring the 
dependency of pixels in dual-coloured images is to plot the pixel intensity values of the two 
images against one another and to display the result in a pixel distribution diagram, also called a 
scatterplot or “cytofluorogram”. If the intensities of both pixel distributions are proportional to 
one another and if detection has been carried out in the linear range, the resulting scatterplot 
should form a dot cloud in the shape of a line, the slope of which reflects the relative (unique) 
stoichiometry of both fluorophores. The spread of this distribution with respect to a fitted line, 
calculated by linear regression, may be estimated by calculating the Pearson correlation 
coefficient. 
 
The Pearson correlation coefficient is a standard procedure in pattern recognition for matching 
one image with another and is used to describe the degree of overlap between two patterns. It 
provides information about the similarity of shape without regard to the average intensity of 
the signals. In the case of pixel scatterplots, the Pearson correlation coefficient quantifies the 





spread of the dot cloud relative to the median line. Values may range from 1 (complete 
correlation) to -1 (negative correlation), while a value of zero indicates no correlation and 
results from a random distribution of pixels. A hypothetical data set, illustrating cases of 









Figure 2.12. Scatterplots for a hypothetical data set, showing positive colocalisation between the red and 
green data sets (left) but negative colocalisation between the red and blue data sets (right). Calculated 
Pearson correlation coefficients are 0.830 and -0.455, respectively. 
 
The Pearson correlation coefficient may be calculated from Equation 2.10: 
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Here, Ai and Bi represent the intensities of pixel i of channels A and B of a dual-colour image, 
respectively, while a and b are the mean intensities of the two channels, respectively. In this 
equation, the average intensity values are subtracted from the original intensity values and 
hence the value of this coefficient ranges from -1 to 1.  
 
Pearson correlation coefficients are highly dependent on noise, heterogeneity and variations in 
fluorescence intensity. Evaluation of colocalisation using the Pearson correlation coefficient 
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exclusively should be avoided. However, scatterplots and the Pearson correlation coefficient 
provide a useful first estimate of colocalisation.23 
 
2.5.5.2. The Manders overlap coefficient. When the average intensity values of the pixels are not 
subtracted from the original intensity values in the Equation 2.10, a new coefficient may be 
defined (Equation 2.11). This is known as the Manders overlap coefficient (rM).24 
 
   
∑       
√∑   







This new coefficient ranges from zero (no overlap) to one (full colocalisation). The product in 
the numerator brings in a non-zero value only when the pixel intensities Ai or Bi belong to a 
pixel of one of the colocalising objects (Ai > 0 and Bi > 0). In other words, each added product is 
zero when one of the pixel values is zero (no fluorescence signal). Thus the numerator is 
proportional to the number of colocalising objects. In the same way, the denominator is 
proportional to the total number of (colocalising and not colocalising) objects in both 
components of an image.24 
 
A major advantage of the Manders overlap coefficient over the Pearson correlation coefficient is 
that is it not sensitive to differences in signal intensities between the components of an image 
caused by different labelling with fluorophores, photobleaching or changes in gain settings 
during acquisition. A disadvantage of the Manders overlap coefficient is that the result of the 
calculation may be ambiguous because the ratio of the number of objects in both components 
plays a strong role.24 
 
2.5.5.3. The Manders colocalisation coefficients. To cancel out the large effect played by the 
number of objects, the Manders overlap coefficient may be divided into two new coefficients, 
known as the “split” coefficients:24 
 
  




Here, k1 and k2 are respectively defined by the equations below: 
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Using these coefficients, the degree of colocalisation is expressed as two separate parameters. In 
these equations, k1 and k2 depend on the sum of the products of the intensities of A and B. 
Therefore k1 is sensitive to differences in intensity of the signal from B while, analogously, k2 
depends linearly on the intensity of A.24 In the case of perfect colocalisation, k1 will approach   
and k2 will reach 1/ , where   is the slope of the mean line in the cytofluorogram (related but 
not equal to the stoichiometry of the two molecules).  
 
However, if one channel is corrupted by noise or background, the denominator of the 
corresponding coefficient will increase and consequently its value will decrease. Looking at 
both coefficients is therefore useful to identify the source of the problem if the overlap 
coefficient is close to zero.24 
 
Based on the split overlap coefficients, two final coefficients are defined that are not dependent 
on the intensities of the signals. These are referred to as the Manders colocalisation coefficients 
(different from the Manders overlap coefficient defined above) and are defined below:24 
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Here, Ai,coloc = Ai if Bi > 0 and Bi,coloc = Bi if Ai > 0. Again, M1 and M2 can take any values between 
zero and one where the latter indicates complete colocalisation. The sum of the intensities of 
colocalising pixels from one channel is divided by the integrated density, i.e. a pixel from A is 
colocalised with B if it has a non-zero intensity counterpart in B. M1 and M2 have therefore been 





defined so that colocalisation can be determined even when the signal intensities of the two 
components differ strongly.  
 
A summary of the Pearson correlation coefficient and various Manders coefficients (overlap, 
split and colocalisation) is presented in Table 2.1.25 Taken together, they are most useful when 
compared over several sets of images. The Pearson correlation coefficient (rP) provides a value 
for the correlation between the intensity distributions of the components, but the overlap of the 
signals is better represented by the Manders overlap coefficient (rM). In cases where there are 
an equal number of objects in each component of an image, the overlap coefficient exactly 
reflects the fraction of colocalising objects in the images. When the numbers of objects in the 
two components of the image differ significantly, the Manders colocalisation coefficients M1 and 
M2 should be used. M1 and M2 have been shown to be sensitive for uniform and non-uniform 
background and crosstalk, providing confidence that the result of these calculations reflects the 
biological reality of the image.24 
 
Table 2.1. A summary of the colocalisation coefficients used in this study.25 
 
Coefficient Interpretation Values indicating 
colocalisation 




rP describes the correlation 
between the intensity 
distributions of two channels 
From 0.5 to 1.0 From -1.0 to 0.5 
Manders overlap 
coefficient, rM 
rM indicates an actual overlap of 
the signals and is considered to 
represent the true degree of 
colocalisation 
From 0.6 to 1.0 From 0 to 0.6 
Manders split 
coefficients, k1 and k2 
k1 and k2 divide colocalisation 
into two separate parameters, 
allowing determination of the 
contribution of each channel to 
the areas of colocalisation 
Any close values, 
such as 0.5 and 0.6 
or 0.8 and 0.9 
Any distant values, 
such as 0.5 and 0.9 
or 0.2 and 0.7 
Manders colocalisation 
coefficients, M1 and M2 
M1 and M2 describe the 
contributions of the two 
channels to the pixels of interest 
More than 0.5 Less than 0.5 
 
  





2.5.5.4. Van Steensel’s cross-correlation coefficient. A different approach, described by Van 
Steensel and co-workers, helps to distinguish between positive correlation and partial 
colocalisation. The latter might arise from the occasional overlap of randomly-distributed 
objects.26  
 
The authors applied a cross-correlation analysis by shifting one image pixel-by-pixel in the x-
direction relative to the other image (Figure 2.13). For each shifted set, they calculated the 
respective Pearson correlation coefficient (rP). Finally, the retrieved values of the Pearson 




Figure 2.13. An illustration of Van Steensel’s cross-correlation analysis. Three different scenarios contain 
overlapping (A), mutually exclusive (B) and non-correlated (C) blue and orange elements. 
 
In a true colocalisation situation, the correlation is lost after the displacement. Consequently 
there is a peak in the Pearson correlation coefficient at δx=0 and the trace exhibits a bell-shaped 
























that are mutually excluded from one another show a dip at δx=0 as shifting either image over a 
small distance leads to an increase in the amount of overlap. For objects that are partially 
overlapping or those which are randomly-distributed with respect to each other, a small shift 
has no effect on the amount of overlap. 
 
Van Steensel’s cross-correlation analysis works well for signals that are located in punctate 
clusters. While this cross-correlation function allows ready discrimination between the 
different colocalisation situations, its major drawback is that it is only valuable for small, 
isotropic particles as it may vary depending on the orientation of the objects relative to the shift 
axis. 
 
2.5.6. A brief overview of fluorescence reporters 
 
As described above, fluorescence is an invaluable tool for probing biology at many levels, from 
cellular dynamics to complete organisms. Originally, fluorescence was observed from small 
organic dyes attached to antibodies which display high specificity for the protein of interest. 
However, antibody targeting of intracellular proteins normally requires cell fixation and 
permeabilisation which perturbs the biological system and may introduce artefacts.  
 
Later, fluorophores were developed to recognise directly organelles, nucleic acids and ions in 
living cells. Over the past few decades, fluorescent proteins have enabled non-invasive imaging 
of reporter gene expression, protein trafficking and dynamic biochemical signals. Meanwhile, 
semiconductor nanocrystals (quantum dots) have been developed with superior brightness and 
photostability compared to previous fluorophores, but their use in cells and tissues remains 
challenging.27 
 
Despite these advances, organic dyes remain the most common fluorescence reporters. The 
benefits of these dyes are that they are usually inexpensive, readily available and are often small 
compared to their substrates. Many possess superior photostability and brightness, but most 
important is their versatility. There is immense variation in their chemical, photophysical and 
spectroscopic properties meaning that their use can be adapted to almost any system. 
Unsurprisingly, a one-size-fits-all or “ideal” fluorescent dye does not exist so compromises have 
to be made depending on the role of the fluorescent reporter and the system in question. 
Microscopy, and especially live-cell imaging, is usually more challenging than spectroscopic 
studies in a cuvette. These considerations were kept in mind for the selection of an appropriate 
reporter fluorophore, as described in Chapter 3. 
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The Design and Synthesis of Novel  






or centuries, quinoline-based molecules have formed the cornerstone of chemotherapeutic 
resources to tackle the scourge of malaria. Given the prevalent use of these drugs, it is 
surprising that crucial details of the mechanism of action of these antimalarials against the most 
virulent malaria parasite, Plasmodium falciparum, remain elusive. While recent work has 
provided some clarity into the mode of action of the prototypical 4-aminoquinoline 
chloroquine,1 its quinoline methanol counterparts, the diastereomeric Cinchona alkaloids 
quinine and quinidine, remain less well understood.  
 
It has been extensively demonstrated that these antimalarials accumulate in the acidic digestive 
vacuole of the malaria parasite P. falciparum and that this property is a key aspect of their 
efficacies (Section 1.6.1).2,3 However, their propensities to associate with other subcellular 
compartments have not been thoroughly evaluated. It was anticipated that a systematic survey 
of their subcellular localisation within P. falciparum would reveal deeper insights into their 
mechanism of action and might suggest potential secondary targets within the parasite to 
account for their potencies, particularly in the case of the Cinchona alkaloids. 
 
F 





Although fluorescence microscopy is an ideal tool with which to probe subcellular distributions 
of suitable molecules, various limitations described below suggest that the intrinsic 
fluorescence of the quinoline antimalarials cannot be exploited directly; hence, it was necessary 
to design and synthesise derivatives of these drugs labelled with an extrinsic fluorophore. As 
intimate association with Fe(III)PPIX is an important property of these antimalarials, structure-
activity relationships of these interactions were evaluated to decide where suitable 
modifications to the parent compounds should be made. For the quinoline methanols, a number 
of fluorescent analogues were prepared in order to vary the length of the spacer chain between 
the quinoline core and the extrinsic fluorophore. By contrast, only a single novel fluorescent 
derivative of chloroquine was prepared.  
 
In this chapter, design aspects relating to the synthesis of these novel fluorescent antimalarials 
will first be presented. The necessity of incorporating an extrinsic fluorophore into the parent 
quinolines and the choices of fluorophores will be defended. Structure-activity relationships 
between these antimalarials and Fe(III)PPIX will be presented, justifying the sites identified for 
covalent modification. For both classes of antimalarials, retrosynthetic analyses will be 
presented and key synthetic intermediates identified. Finally, appropriate mechanistic details 
relating to methods of synthesis will be discussed and relevant details pertaining to 
spectroscopic characterisation will be given. Photophysical and physicochemical 
characterisation of these fluorescent derivatives are described in Chapter 4. 
 
Thus the specific objectives relating to design aspects described in this chapter were:  
i. To identify a suitable reporter fluorophore and to evaluate current structure-activity 
models of the two classes of quinoline antimalarials in order to propose suitable sites of 
covalent modification to retain key physicochemical properties of the parent molecules; 
ii. To propose the structures of suitable derivatives followed by appropriate retrosynthetic 
and forward analyses to generate efficient syntheses of these derivatives; 
 
With these considerations in mind, the synthetic objectives described in this chapter were: 
iii. To derivatise the quinoline methanol antimalarials via a thiol-ene ‘click’ reaction in order 
to provide convenient access to functionalised derivatives of the Cinchona alkaloids; 
iv. To prepare various fluorescent derivatives of these alkaloids by varying the length of the 
spacer chain, requiring the application of various coupling methodologies; 
v. To prepare a novel synthetic derivative of chloroquine via N-desethylation of chloroquine 
as an important intermediate; 
vi. To fully characterise these novel fluorescent derivatives and their intermediates using a 
range of spectroscopic and analytical techniques. 





3.2. Design aspects of novel fluorescent quinoline antimalarials  
  
3.2.1. Identification of NBD as a suitable extrinsic fluorophore 
 
The intrinsic fluorescence of the Cinchona alkaloids conferred by the 6-methoxyquinoline 
heterocycle is well established and has led to the use of quinine as a common fluorescence 
standard.4 This inherent fluorescence also provides an intuitive starting point for fluorescence 
microscopy. Although a previous study successfully utilised the intrinsic fluorescence of quinine 
to investigate its distribution within P. falciparum,5 in our hands it was not possible to observe 
any localisation using either widefield or confocal microscopy without causing significant 
photodamage to the cells, thus limiting the utility of this method. 
 
There are several reasons that might account for this. Firstly, quinine has a poor extinction 
coefficient at its absorbance maximum which lies in the ultraviolet region of the spectrum, 
making this an undesirable combination for the direct excitation of live cells. Two-photon 
excitation also proved to be inefficient. Furthermore, fluorescence emission from quinine may 
be quenched by strongly-absorbing chromophores such as Fe(III)PPIX which is an important 
metabolic species in P. falciparum.  
 
Most importantly, and somewhat surprisingly, quinine fluorescence is quenched in polar aprotic 
solvents with ET(30) values between 40-50 kcal/mol (Figure 3.1). It is not obvious what 
photophysical properties might account for this unexpected behaviour. These solvents have 
ET(30) values similar to those of phospholipid bilayers (49-50 kcal/mol)6 as well as neutral lipid 
components (45 ± 4 kcal/mol for the synthetic neutral lipid blend described in Section 1.3.2),7 
both of which are essential and important subcellular components of P. falciparum. Hence, the 
value of quinine autofluorescence to evaluate thoroughly the subcellular localisation of the 
molecule is limited. By contrast, the 7-chloro-4-aminoquinoline heterocycle of chloroquine is 
only minimally fluorescent due to quenching caused by the chlorine atom, a manifestation of the 
internal heavy-atom effect (Section 2.3.2). This renders its autofluorescence unsuitable for live-
cell microscopy as well. 
 
Taken together, these obstacles suggested the attachment of an extrinsic fluorophore to these 
antimalarials. The Cinchona alkaloids have not yet been modified to incorporate an extrinsic 
fluorophore suitable for live-cell imaging. While several fluorescently-labelled derivatives of 
chloroquine have previously been prepared, it was anticipated that an improved design, more 
closely related to the physicochemical properties of the parent molecule, could be proposed. 
 








Figure 3.1. Relative fluorescence emission intensities of quinine in eight common solvents. 20 μM solutions 
of quinine were excited at 333 nm at 25°C. Emission intensities were calculated relative to water  
(20 mM Hepes, pH 7.5) which was set at 100%. ET(30) values taken from Reichardt.8 Red points indicate 
polar aprotic solvents in which quinine fluorescence is quenched. The grey shaded region indicates the 
approximate range of ET(30) values over which the quinine fluorescence is quenched corresponding to 
polarity values of phospholipid bilayers6 and neutral lipid bodies.7 
 
With the recent growth of fluorescence microscopy, dozens of small-molecule fluorophores are 
now commercially available. 7-Nitrobenz-2-oxa-1,3-diazole (NBD, Figure 3.2) was selected as a 
suitable fluorescence reporter for several reasons. It is one of the smallest fluorophores and was 
thus expected to cause the least perturbation of biological activity upon conjugation to the 
drugs.9 Although the fluorophore exhibits solvatochromism, typical excitation and emission 
maxima in aqueous media are approximately 470 nm and 540 nm, respectively. Hence these 
bands overlap only minimally with the prominent Soret region of Fe(III)PPIX. The NBD 
fluorophore also has a secondary excitation maximum at 350 nm. While the fluorescence of NBD 
is stable over a biologically-relevant pH range,9 it is enhanced in non-aqueous environments 
which directly compensates for the quenching of native alkaloid fluorescence in these regions. 
 
Finally, NBD was favoured for its modest aqueous fluorescence quantum yield. As the weakly-
basic quinoline antimalarials in this study have been measured to accumulate several hundred- 
or thousand-fold in the digestive vacuole of P. falciparum (Section 1.6.1), this photophysical 
feature of the fluorophore was deliberately selected to avoid the fluorescence from this 
compartment overwhelming weaker signals from elsewhere within the cell.  
 















































Figure 3.2. The structure and conventional numbering of the 7-nitrobenz-2-oxa-1,3-diazole (NBD)  
fluorophore when substituted by an amine at the 4-position.  
 
NBD has been used extensively as an attachment to biomolecules, especially for the preparation 
of NBD-labelled lipids.10,11 Given these applications, the fluorophore is readily available as an 
inexpensive 4-chloro derivative (NBD-Cl). An electron-withdrawing nitro group situated para to 
the chlorine atom makes this derivative susceptible to nucleophilic aromatic substitution. This 
suggested that it might be useful to introduce a terminal amine functionality into the quinoline 
antimalarials, a feature that was later judged to be a crucial consideration in the design of the 
novel fluorescent derivatives. 
 
3.2.2. Retention of key physicochemical features of the parent molecules 
 
The three quinoline antimalarials investigated in this study, quinine, quinidine and chloroquine, 
all associate appreciably with Fe(III)PPIX and this is presumed to be important for their 
activities. Consequently, retaining this strong association was deemed likely to assist in the 
retention of the biological activities of fluorescent derivatives of the parent molecules. This was 
to be an important factor in the evaluation of these compounds as suitable analogues of the 
parent molecules, as described in Chapter 4. 
 
The solution-state interactions of the quinoline methanol antimalarials, quinine and quinidine, 
with Fe(III)PPIX have been extensively evaluated and were described in Section 1.5.2.12 Most 
recently, it has been shown that coordination to the iron centre of Fe(III)PPIX via their benzylic 
alkoxide group is a key interaction.13 This is also an important interaction in the solid state as 
identified by single-crystal analysis of the complexes between these alkaloids and Fe(III)PPIX.14 
This study also confirmed the importance of several other interactions. As described in Section 
1.5.3, the electron-rich quinoline ring system has been shown to π-stack with the porphyrin ring 
of Fe(III)PPIX. The weakly-basic tertiary nitrogen is important for accumulation and for forming 
a salt bridge with one of the carboxylate groups of Fe(III)PPIX.14 Additionally, the rigid 
quinuclidyl group is necessary for biological activity as its replacement with a less rigid tertiary 





amine led to an increase in its IC50 value against P. falciparum.15 Thus, functionalising the vinyl 
group of these alkaloids was an obvious choice since this was unlikely to interfere with 
Fe(III)PPIX association and hence the activity of their NBD-labelled derivatives.  
 
Proposed derivatives of the Cinchona alkaloids, with retention of the key physicochemical 
interactions described above, are depicted in Scheme 3.1. These diastereomers have a crucial 
and opposite configurational attachment to the rigid bicyclic quinuclidine template, resulting in 
the different topologies indicated in the scheme. A single fluorescent derivative of quinine was 
proposed while several fluorescent derivatives of quinidine allowed the length of the spacer 




Scheme 3.1. Key aspects of the structure-activity relationships between Fe(III)PPIX and the Cinchona 
alkaloids quinine (1) and quinidine (2), emphasising topological differences arising from their 
stereochemical configurations. Proposed NBD-labelled fluorescent derivatives (3-6) are shown in which key 
characteristics of the parent molecules are retained. Incorporation of the NBD fluorophore in the fluorescent 
derivatives is indicated by thickened black bond widths. 





As terminal double bonds are amenable to thiol-ene ‘click’ reactions, which are favoured for 
their efficacy, versatility and green chemistry properties, the introduction of a thioether linker 
was considered to be a crucial part of the design of fluorescent derivatives. As mentioned in 
Section 3.2.1, the introduction of a terminal amine functionality would provide a useful handle 
for the direct attachment of the NBD fluorophore or for the introduction of NBD-labelled alkyl 
chains of various lengths.  
 
Finally, although these novel derivatives were prepared as new tools for investigations into 
malaria parasite biology for this study, quinine and quinidine have also been used as a muscle 
relaxant and as a cardiac depressant, respectively, and so it was anticipated that these new 
compounds might also be useful probes in applications beyond malaria research.16 
 
By comparison, the interaction of the prototypical 4-aminoquinoline chloroquine with 
Fe(III)PPIX is fundamentally different from that of the quinoline methanols. Whereas the 
interaction between the quinoline methanols and Fe(III)PPIX is monomeric, chloroquine 
induces μ-oxo dimerisation of the porphyrin (Section 1.5.2). Hence, this drug contains a number 
of physicochemical motifs that are distinct from those of the quinoline methanols. 
 
The quinoline ring of chloroquine is less electron-rich than the corresponding heterocycle of the 
quinoline methanols due to the deactivating effect of the chlorine atom as a result of its 
electron-withdrawing inductive effect. This promotes π-stacking with the π-excessive 
porphyrin. It has also been found that halogen-hydrogen interactions with Fe(III)PPIX are 
favoured by electronegative substituents such as chlorine (Scheme 3.2).17 On the other hand, the 
electron-releasing 4-amino group increases the pKa of the quinolinium ion, improving its 
capacity as a hydrogen-bond donor for strong binding to the μ-oxo bridge of the Fe(III)PPIX 
dimer.15 Crucially, chloroquine also contains a basic aliphatic tertiary amine which is important 
for accumulation in the acidic digestive vacuole of P. falciparum. 
 
Consequently, chloroquine has no obvious sites suitable for synthetic modification. The diethyl 
side chains offer the best opportunity for modification as these are situated furthest away from 
the quinoline core of the molecule. Thus, in order to introduce an additional primary amine 
functionality for facile attachment of the NBD fluorophore by nucleophilic aromatic 
substitution, a suitable N-dealkylated key intermediate was identified by retrosynthetic analysis 
as detailed later in this chapter (Section 3.4.1). 
 
  





Unlike the Cinchona alkaloids, fluorescent analogues of chloroquine have previously been 
prepared and evaluated.18-20 Indeed, one such derivative has already incorporated an extrinsic 
NBD fluorophore connected by a lengthy (six-carbon) linker chain.18 We anticipated that a more 
suitable analogue of the parent molecule would require a shorter linker chain and this was 




Scheme 3.2. Key aspects of the structure-activity relationships between chloroquine (7) and Fe(III)PPIX are 
indicated, leading to a proposed novel NBD-labelled fluorescent derivative (8) which exhibits retention of the 
key characteristics of the parent molecule. Incorporation of the NBD fluorophore is indicated by thickened 










3.3. Synthesis of novel fluorescent quinoline methanol antimalarials 
 
3.3.1. Retrosynthetic analysis and forward synthesis  
 
First, an overview of the considerations relating to the synthesis and characterisation of the 
Cinchona alkaloid derivatives will be presented in the following two sections before 
commencing a discussion of the synthesis in detail (covered in Sections 3.3.3-3.3.6). In order to 
prepare the novel fluorescent quinoline methanols presented in Scheme 3.2, a retrosynthetic 
analysis of the target compounds (3-6) was conducted as depicted in Scheme 3.3. Disconnection 
of the N-C bond between the spacer chain and the fluorophore generated terminal amine-
containing alkaloids that were identified as appropriate key intermediates (9, 10). Subsequent 




Scheme 3.3. Retrosynthetic analysis reveals key intermediates 9 and 10  
which provide access to a host of fluorescent derivatives of the Cinchona alkaloids.  





The full synthesis of the fluorescent derivatives of the Cinchona alkaloids is detailed below in 
Scheme 3.4. A regioselective thiol-ene ‘click’ reaction was chosen involving a bifunctional amino 
thiol in order to introduce an additional amine functional group to the alkaloids via a short 
thioether spacer, opening up the possibility of a variety of derivatives easily obtainable from the 
starting alkaloids. In this respect, there was a single report of such a modification of the vinyl 
group of quinine using a photoinitiated radical reaction.21 For this reaction, it was necessary to 
use an N-Boc-protected amine instead of a primary amine directly but the extra protection step 
was mitigated by the short reaction time required for complete reduction and facile purification 
steps of this ‘click’ reaction. Subsequent cleavage of the N-Boc groups of 11 and 12 yielded the 
primary amines 9 and 10 which provided convenient handles for direct attachment of the NBD 
fluorophore via nucleophilic aromatic substitution of its 4-chloro derivative. As a result, the 
NBD-labelled alkaloids 3 and 4 with the shortest spacer chains were prepared over three steps 




Scheme 3.4. The forward synthesis of two novel ‘short-chain’ fluorescent derivatives 3 and 4  
of the quinoline methanol antimalarials quinine (1) and quinidine (2), respectively. 





In order to vary the length of the spacer chain, NBD-labelled succinimidyl ester amino acids 
were prepared as depicted in Scheme 3.5. The latter were generated from nucleophilic aromatic 
substitution reactions of the NBD 4-chloro derivative with amino acids of different chain lengths 
(two versions) after which a DCC-mediated Steglich esterification introduced the succinimidyl 




Scheme 3.5. The synthesis of intermediate- and long-chain fluorescent derivatives 5 and 6 of quinidine (2). 
This required the preparation of two NBD-labelled amino acids and their respective succinimidyl esters. 
 
3.3.2. General considerations for NMR characterisation of modified alkaloids 
 
Since quinine was first isolated in 1820, the alkaloid and its diastereomer, quinidine, have been 
of great interest to organic chemists. In 1853, Louis Pasteur exploited the unique 
stereochemical properties of these molecules as agents for chiral resolution. Today, these 
alkaloids are commonly found as chiral auxiliaries in catalytic asymmetric synthesis and as 
chiral selectors in stereoselective stationary phases. Despite the intense interest in these 
alkaloids, the first stereoselective total synthesis of quinine was only accomplished in 2001.22  
 
The general structures of quinine and quinidine are characterised by an aromatic quinoline ring 
connected to an aliphatic quinuclidine bicyclic system through a chiral hydroxymethine carbon 





linkage (Figure 3.3). The vinyl and methoxy substituents appear at C-18 of the quinuclidine ring 
and at C-6 of the quinoline ring, respectively. These alkaloids possess four chiral carbon centres 
of which two have the same absolute configuration in both alkaloids, i.e. (13S,18R). The other 
two chiral centres give rise to the diastereomeric relationship; (10R,11S) and (10S,11R) for 
quinine and quinidine, respectively. 
 
Consequently, the 1H and 13C NMR spectra of the Cinchona alkaloids are relatively complex. The 
carbon atoms of the four quinuclidine ring methylene groups are all prochiral and hence their 
hydrogen atoms are diastereotopic and magnetically non-equivalent in their 1H NMR spectra. 
Additional considerations for the NMR analysis of these alkaloids and their derivatives are 




Figure 3.3. General considerations for the characterisation of quinine (1) using NMR spectroscopy. 
 







Figure 3.4. 1H and 13C NMR spectra of quinine (1) recorded in CDCl3 at 400 MHz and 100 MHz, respectively. 
Assignments were confirmed using two-dimensional correlation NMR spectroscopy. Diastereotopic proton 
signals and their corresponding carbon atoms are labelled in orange. The spectra of quinidine (2) are almost 
identical except for small differences in the chemical shifts of the aliphatic proton signals. The numbering 
refers to the structure given in Figure 3.3. 
 
By contrast, the NMR properties of the NBD fluorophore are much simpler. The proton signals 
corresponding to H-a and H-b appear in the 1H NMR as an AB doublet pair (J = 9 Hz) due to 
vicinal coupling (Figure 3.5). The proton signal for H-a is more shielded than the one for H-b 
owing to delocalisation of the amine lone pair into the six-membered ring. There are four 
quaternary carbon centres (indicated by ● in Figure 3.5) that relax very slowly and are typically 



























































Figure 3.5. Resonance structures of the NBD fluorophore when conjugated to an amine. Shielding by the 
lone pair of the amine results in a 2 ppm difference in chemical shift between the signals for H-a and H-b. 
 
3.3.3. Modifying the Cinchona alkaloids with the thiol-ene ‘click’ reaction 
 
The term ‘click’ chemistry was introduced by K. B. Sharpless in 2001 to describe reactions that 
generate heteroatom-linked systems with high efficiency under a variety of mild conditions by 
joining small units together.23,24 Such reactions also display characteristics such as being wide in 
scope, high-yielding and stereoselective. They usually require readily-available starting 
materials and employ simple reaction conditions that should be insensitive to atmospheric 
oxygen and trace amounts of water. Furthermore, such reactions should take place in no 
solvent, or one that is benign or easily removed, and generate only inoffensive by-products that 
can be removed non-chromatographically.23,24 
 
One such example is the radical-mediated reduction of an alkene by a thiol which has become 
known as the “thiol-ene” reaction. Many examples exist which proceed with near-quantitative 
formation of the corresponding thioether in a regioselective fashion.25 A wide-range of alkenes 
and thiols can be used. The mechanism of the thiol-ene reduction is depicted in Scheme 3.6 and 
follows a typical three-step radical sequence. The reaction is initiated by irradiating the thiol in 
the presence of a photoinitiator, which generates the thiyl radical (RS·) and other byproducts. A 
common, inexpensive photoinitiator is 2,2-dimethoxy-2-phenylacetophenone (DMPA), which is 
cleaved homolytically upon radiation with low-energy ultraviolet light. Propagation is a two-
step process involving the direct addition of the thiyl radical at the less hindered (less 
substituted) carbon of the double bond so as to form the more substituted and more stable 
radical intermediate in what qualifies as an anti-Markovnikov addition. Hydrogen transfer from 
the thiol to this radical then generates the desired addition product with formation of a thiyl 
radical for further propagation.23 Termination, which leads to incomplete conversion of the 
starting material, can result via radical homo-coupling such as the formation of a disulfide from 
two thiyl radicals. 
 







Scheme 3.6. The mechanism of the thiol-ene ‘click’ reaction.  
 
Prior to this work quinine was reported as a substrate for the thiol-ene ‘click’ reaction using 3-
mercaptopropyltriethoxysilane as reagent in which investigators recorded a high yield for 
conversion (98%) using DMPA as a radical initator.21 While no chromatographic purification 
was required, a lengthy reaction time of 27 hours was reported. In order to generate key amino 
sulfide intermediates 9 and 10, it was hoped to ‘click’ quinine with the bifunctional thiol-amine 
cysteamine directly (Scheme 3.7). However, thin-layer chromatography (TLC) revealed no or 
negligible reaction, even when the amounts of the reagents and the photoinitiator were 




Scheme 3.7. A first direct attempt at the thiol-ene ‘click’ reaction was unsuccessful as judged by TLC. 
 





Consequently, a number of model systems were exploited to probe the reaction conditions and 
these are further listed in Table 3.1. Firstly, a “proof-of-concept” reaction between styrene, the 
simplest UV-active alkene, and 1-butanethiol, a prototypical thiol, was explored. Fortunately, 
this appeared to be successful as evidenced by spot-to-spot conversion from the reagent 
(styrene) to the putative product on the TLC plate. A subsequent experiment using quinine itself 
and 1-butanethiol was also judged by TLC to be successful, suggesting that the problem in the 
reaction in Scheme 3.7 lay with the specific character of the thiol. This view was supported by a 
simple qualitative experiment between quinine and the thiol-containing amino acid L-cysteine, 
which did not proceed to any appreciable extent either.  
 
Table 3.1. Systematic investigation into the conditions required for the thiol-ene ‘click’ reaction. Reactions 
were performed at ambient conditions in CHCl3. The reaction flask was illuminated at 368 nm for one hour. 
 
Entry Alkene Thiol Photoinitiator Success of reaction  
as evaluated by TLC 
1 Quinine (1 eq) Cysteamine (1 eq) DMPA (10 eq) No reaction 
2 Quinine (1 eq) Cysteamine (10 eq) DMPA (1 eq) No reaction 
3 Quinine (10 eq) Cysteamine (1 eq) DMPA (1 eq) No reaction 
4 Styrene (1 eq) 1-Butanethiol (1 eq) DMPA (1 eq) Complete reaction 
5 Quinine (1 eq) 1-Butanethiol (1 eq) DMPA (1 eq) Complete reaction 
6 Quinine (1 eq) L-Cysteine (1 eq) DMPA (1 eq) No reaction 
7 Quinine (1 eq) N-Boc-cysteamine (1 eq) DMPA (1 eq) Incomplete reaction 
8 Quinine (1 eq) N-Boc-cysteamine (6 eq) DMPA (1 eq) Complete reaction 
 
As it is well-known that primary amines undergo facile one-electron oxidation involving the N-
lone pair to form an aminium radical cation under the influence of ultraviolet light, this was 
suspected to have been the complicating factor with cysteamine.26 Hence, it was decided to 
carry out the reaction using N-Boc-cysteamine instead, with the amino group protected as a 
carbamate. It was anticipated that this would also improve the solubility of the thiol, which 
might facilitate the reaction, as cysteamine is poorly soluble in CHCl3. Upon reacting N-Boc-
cysteamine with quinine under thiol-ene conditions, TLC indicated that the thiol reagent was 
completely consumed, corroborating the view that the primary amino group was the problem. 
By increasing the number of equivalents of the thiol it was possible to achieve complete reaction 
of the alkaloid. 
 
As mentioned above, Cinchona alkaloids are well known for their fluorescent properties but this 
also makes these molecules susceptible to photodestruction when exposed to ultraviolet 





radiation due to constant population of the 6-methoxyquinoline excited state. As a result, the 
ultraviolet radiation required for radical photoinitiation during the thiol-ene ‘click’ reaction 
( max 368 nm) can damage the methoxyquinoline ring in the substrate and the product ( max 333 
nm) if the illumination time of the reaction is not carefully monitored. Hence, this was 
investigated using 1H NMR spectroscopy.  
 
A trial thiol-ene reaction was conducted on a small scale with quinidine (2) as the limiting 
reagent (20 mg, 0.062 mmol) in CDCl3 (2.5 mL). 0.35 mL aliquots were removed at 0, 2, 5, 10 
and 30 minutes and diluted using CDCl3. These were transferred to NMR tubes and their spectra 
recorded. Disappearance of the signals for the vinyl protons H-19 suggested that the thiol-ene 
reaction was complete after just five minutes (Figure 3.6). However, it was ultimately decided to 
expose the reaction to ten minutes’ illumination to ensure complete reaction, as 
photodestruction of the heterocycle was only evident after 30 minutes. 
 
Although introducing a primary amine directly into the alkaloid would have been more useful 
for our purposes, the versatility and rapid reaction time of these optimised reaction conditions 
mitigated the extra deprotection step that was required to liberate the primary amine. 




Scheme 3.8. A series of reactions showcasing the versatility of the thiol-ene ‘click’ reaction  
applied to various Cinchona alkaloids. 
 
  







Figure 3.6. A time-lapse experiment using 1H NMR spectroscopy to determine the optimum illumination 
time required for the photoinitiated thiol-ene ‘click’ reaction. Spectra were recorded in CDCl3 (300 MHz)  
(A) before illumination, i.e. at zero minutes, (B) after two minutes’ illumination and (C) after five minutes’ 
illumination. The proton signals corresponding to the disappearance of the H-19 multiplet (approx. 6 ppm) 


















Hence the desired amine derivatives 11 and 12 of quinine and quinidine, respectively, were 
generated. Cinchonine (17), another Cinchona alkaloid related to quinidine, was also found to 
be a suitable substrate for amine derivatisation yielding 18. It was also possible to introduce a 
primary hydroxyl group by using 2-mercaptoethanol as the thiol in the click reaction, 
generating the expected target and thus proving that the problem with the initial reaction 
conditions lay with the primary amine.  
 
All three derivatised alkaloids were obtained in high yields (> 85%) by acid-base extraction and 
crystallisation from aqueous alcohol. Analytical purity was confirmed by elemental analysis. The 
presence of trace water in the reaction did not appear to affect the outcome of the reactions. 
Thus these reactions fulfil the criteria necessary for a successful ‘click’ reaction.23  
 
As these thiol-ene derivatives are novel versions of the parent alkaloids, their optical properties 
were an important aspect of their characterisation. Specific rotations were measured in ethanol 
at the same concentrations for the parent alkaloids and their derivatives (Table 3.2). A 
correlation between the polarisation of light induced by each parent alkaloid and its derivatised 
product was observed, indicating retention of absolute stereochemistry in the product.  
 
Table 3.2. Specific rotations measured for the parent alkaloids and their thiol-ene derivatives 
measured using the D-line of a sodium lamp (λ = 589 nm) in ethanol at 20°C. 
 
Compound Specific rotation, [α]D20 Conditions (g/100 mL) 
1 (Quinine) -80° c. 0.515 
11 -83° c. 0.797 
2 (Quinidine) +136° c. 0.515 
12 +138° c. 0.797 
17 (Cinchonine) +107° c. 0.468 
18 +111° c. 0.749 
 
3.3.4. N-Boc deprotection and substitution of the NBD fluorophore 
 
In order to render the amine-derivatised alkaloids 11 and 12 suitable for nucleophilic aromatic 
substitution reactions, the N-Boc protecting group needed to be removed. This was achieved 
using an excess of trifluoroacetic acid (TFA) in CH2Cl2 in which the mixture was stirred in an ice-
bath for two hours to allow the reaction to proceed in a controlled manner, after which it was 
allowed to warm to room temperature. Surprisingly, the trifluoroacetate product was amenable 
to column chromatography, albeit using high concentrations of methanol in the mobile phase 





(25% MeOH:CH2Cl2). These trifluoroacetate salts 9 and 10 were obtained in moderate yields 
(40-50%).  
 
N-Boc deprotection follows a four-step mechanism represented in Scheme 3.9. Protonation of 
the t-butyl carbamate of the N-Boc protecting group (i) is followed by loss of the t-butyl cation 
which gives carbamic acid as an intermediate (ii). The t-butyl cation is quenched or 
deprotonated to give isobutylene. Decarboxylation of the acid generates the free amine (iii) and 
subsequent protonation of the amine under acidic conditions generates the trifluoroacetate salt 




Scheme 3.9. The general mechanism for the TFA-mediated deprotection of N-Boc-protected amines. 
TFA and the trifluoroacetate anion are depicted in blue. 
 
In the absence of a basic work-up, N-Boc deprotection of an amine generates a trifluoroacetate 
salt. Although it was possible to liberate the free base by dissolving the salts in MeOH and 
stirring with K2CO3, followed by filtration and rotary evaporation, some difficulties were 
encountered with the isolation of the free base. Hence, in order to continue using the salts in 
subsequent reactions, it was necessary to calculate the stoichiometry of the trifluoroacetate 
anion(s) associated with these molecules. 
 
The pKa values of the quinoline, quinuclidine and terminal amines of 9 and 10 are predicted to 
be 4.06, 8.85 and 9.78, respectively (MarvinSketch 14.8.25.0, ChemAxon Ltd, 2014). Since the 
pKa of trifluoroacetic acid is 0.23, it was reasonable to expect that all three nitrogen atoms 
would be protonated, resulting in the coordination of three trifluoroacetate ions. This was 
confirmed by determining the molecular weights of 9 and 10 independently using two different 
techniques; namely, 1H NMR and UV-Vis spectroscopy. 
 
For the 1H NMR study, 6-methoxyquinoline was used as an internal standard. The masses of two 
samples of 9 and 10 were accurately determined and the material transferred to vials 
containing accurately-determined masses of the internal standard. The mixture was then 





dissolved in deuterated methanol (CD3OD), transferred to an NMR tube and the 1H NMR 
spectrum was recorded (300 MHz). The ratios of the integrals of aromatic and methoxy proton 
signals generated by the two compounds allowed the calculation of their molecular weights. 
 
In the UV-Vis spectroscopy study, solutions containing accurately-determined masses of the salt 
were prepared in methanol. The molar absorption coefficient of the starting alkaloids is well 
known ( max 333 nm; ε   5 000 M-1 cm-1 in EtOH) and the salts 9 and 10 exhibit the same 
absorption profile. As it is unlikely that chemical derivatisation of the vinyl group affects the 
chromophoric quinoline ring, it was reasonable to use the molar absorption coefficients of the 
starting alkaloids to calculate the concentrations of the salt solutions from the Beer-Lambert 
law. From this, the molecular weights of 9 and 10 could then be computed. 
 
Two independent samples were examined for each molecule using each technique and, in both 
cases, the results were consistent and reproducible. The average molecular weight was 
determined to be 742 ± 8 g/mol, while the calculated molecular weight with three molecules of 
trifluoroacetate coordinated was predicted to be 743.64 g/mol. Thus the results corresponded 
to 9 and 10 each associating with three equivalents of trifluoroacetate, as initially expected. 
 
With these salts in hand, the 4-chloro derivative of the NBD fluorophore could be linked to the 
derivatised alkaloid via nucleophilic aromatic substitution. Thus, the salts 9 and 10 were stirred 
in methanol at room temperature and three equivalents of N,N-diisopropylethylamine (Hünig’s 
base), a moderately strong, non-nucleophilic base suitable for liberating the free amines, were 
added. Subsequently, the mixture was heated in the presence of NBD-chloride with an excess of 
sodium bicarbonate to neutralise the HCl released.28  
 
The mechanism of this nucleophilic aromatic substitution (SNAr) reaction is depicted in Scheme 
3.10. It commences with the nucleophilic addition (AN) of the liberated primary amine to the 
NBD heterocycle at the position of the chlorine. This is the slow, rate-determining step which 
forms a high-energy intermediate called a Meisenheimer complex. This anionic intermediate is 
resonance-stabilised by the electron-withdrawing nitro group that is situated para to the 
leaving group. This is followed by a rapid elimination step (E) to generate the NBD-labelled 
alkaloid, which effectively “switches on” the fluorescence of the NBD group as it removes the 
internal heavy-atom fluorescence quenching effect of the chlorine atom, making this reaction 
convenient to follow on the TLC plate. 
 







Scheme 3.10. The general mechanism for the nucleophilic aromatic substitution (SNAr) reaction  
of the NBD 4-chloro derivative and a primary amine. 
 
Column chromatography followed by recrystallisation in aqueous methanol yielded the ‘short-
chain’ NBD-labelled alkaloids 3 and 4 in 26% and 27% yield, respectively. This resulted in a 
10% overall yield for each compound over three steps.  
 
By way of illustration, the 1H NMR spectrum of NBD-labelled quinidine 4 is shown in Figure 3.7. 
The characteristic AB doublet pair due to the NBD signals H-a and H-b (6.5 ppm and 8.5 ppm, 
respectively, both with J = 8.9 Hz), as well as the doublet associated with the new secondary aryl 




Figure 3.7. 1H NMR spectrum of NBD-labelled quinidine (4) acquired in DMSO-d6 (400 MHz). Important 
hydrogen atoms on the NBD fluorophore are displayed in orange and correspond to the proton signals in the 
enlarged boxes. H-10, which connects the quinoline and quinuclidine ring systems, is visible as a 
characteristic doublet (approx. 6 ppm) which confirms the integrity of the alkaloid core. 
H-b (d)
J = 8.9 Hz
H-a (d)
J = 8.9 Hz
H-23 (d)
J = 4.0 Hz
H-10 (d)
J = 2.3 Hz





3.3.5. Preparation and substitution of NBD-labelled amino acid succinimidyl 
esters to vary the length of the spacer chain 
 
With the amine derivatives 8 and 9 of the alkaloids in hand and, in order to probe the effect of 
varying the length of the spacer chain between the quinoline core and the NBD fluorophore, it 
was necessary to derivatise the NBD fluorophore to make it suitable for amide linkage to the 
derivatised alkaloids.  
 
A bifunctional linear amino acid with a variable tether provided an ideal linker between alkaloid 
and fluorophore in which it was elected to vary the tether length as six carbon atoms (6-
aminohexanoic acid) and as twelve carbon atoms (12-aminododecanoic acid). In each case the 
amino group of the amino acid was coupled to the NBD fluorophore using the same reaction 
conditions for the nucleophilic aromatic substitution as described above. Following an acidic 
work-up to remove unreacted amino acid, recrystallisation in aqueous methanol generated the 




Scheme 3.11. The preparation of two NBD-labelled amino acids with different chain lengths. 
 
The NBD-labelled amino acids 13 and 14 were characterised by NMR spectroscopy. However, 
the signals corresponding to the quaternary carbons in the NBD heterocycle were not clearly 
visible in the 13C NMR spectrum (Figure 3.8A). Consequently, a spin-relaxation agent was used 
in order to visualise these poorly-relaxing nuclei by improving the sensitivity of the spectrum. 
Chromium(III) acetylacetonate, Cr(acac)3, is an octahedral complex with three unpaired 
electrons that is typically used as a spin-relaxation agent. As the magnetogyric ratio of an 
unpaired electron is about 1 000 times larger than that of a proton, carbon will relax much 
faster in the presence of Cr(acac)3 (Figure 3.8B). Although only a small mass of compound was 
available for this analysis, compounding the problem as the signal-to-noise ratio in these 
spectra was already low, addition of Cr(acac)3 permitted assignment of the quaternary signals. 
 







Figure 3.8. 13C NMR spectra of NBD-labelled amino acid 13 in the absence (A) and presence (B) 
of spin-relaxation agent Cr(acac)3. Spectra were collected in CDCl3 (400 MHz). 
 
Linking these NBD-labelled amino acids 13 and 14 to the amine-derivatised alkaloids required 
the formation of an amide bond. In its simplest form, this involves direct condensation between 
an amine and a carboxylic acid, a reaction that requires high temperatures that are not always 
compatible with diverse functionalities. Instead, activating the hydroxyl moiety in the carboxylic 
acid by transforming it into a good leaving group allows for amine attack at a lower activation 
energy and hence milder reaction conditions may be used.30-32 The premier methodology is 
based on activating the acid towards nucleophilic acyl substitution (SNAc) using amide coupling 
agents such as the carbodiimides DCC or EDC. This is also the easiest methodology as activation 
















It is now possible 
to assign these 
signals in the 
presence of 
Cr(acac)3





Alternatively, one may activate the carboxylic acid via prior activation and then follow it with a 
nucleophilic acyl substitution reaction. There are various possibilities of which the simplest, in 
principle, is the activation of the carboxylic acid by conversion to its corresponding acid halide. 
A mixed anhydride methodology may be employed whereby a second carboxylic moiety is 
coupled onto the carboxylic acid; however, regioselectivity of the appropriate carbon centre 
may present a challenge when using this methodology. A variation on this method exploits 
chloroformates. In the presence of a base, the reaction between a carboxylate and a 
chloroformate yields a mixed carbonic anhydride which reacts rapidly with amines to form 
amides. 
 
In this project, it was elected to exploit an active ester methodology by activating the carboxylic 
acid with the excellent leaving group, N-hydroxysuccinimide (NHS). A nucleophilic acyl 
substitution reaction then links the amine to the acyl centre of the active ester via an amide 
bond (Scheme 3.12). NHS esters are highly reactive and easily prepared. They react cleanly and 
rapidly and do not have the purification problems associated with carbodiimides or the 




Scheme 3.12. Nucleophilic acyl substitution (SNAc) of a succinimidyl ester by a primary amine  
to generate an amide bond. 
 
It was first necessary to activate the NBD-labelled amino acids by esterification of the carboxylic 
acids with NHS. Two different methods were briefly screened.  
 
The Yamaguchi esterification was first reported in 1979 and allows the mild synthesis of highly 
functionalised esters.33 The carboxylic acid and 2,4,6-trichlorobenzoyl chloride form a mixed 
anhydride, which is then attacked regioselectively by 4-dimethylaminopyridine (DMAP) at the 
less hindered and more electrophilic carbon of the anhydride, producing acyl-substituted 
DMAP. This electrophilic centre is then intercepted by the hydroxyl group of the NHS to form 
the ester. Carrying out this reaction according to Scheme 3.13 generated the NBD-labelled 
succinimidyl ester 16 in a modest yield (43%) following column chromatography. 







Scheme 3.13. Preparation of NBD-labelled succinimidyl ester 15 under Yamaguchi esterification conditions. 
 
The second method that was screened was a Steglich esterification using DCC as the coupling 
reagent facilitated by catalytic amounts of DMAP.34 Applying the Steglich conditions improved 
the yield of the NHS-labelled NBD-substituted esters which were prepared according to Scheme 
3.14 with optimised reaction conditions indicated. The lability of the succinimidyl groups made 
isolation by column chromatography challenging in which the yield of 15 was markedly better 




Scheme 3.14. The preparation of NBD-labelled succinimidyl esters under Steglich esterification conditions. 
 
This esterification reaction was first described by Steglich in 1978.34 The carboxylic acid reacts 
with DCC to form an O-acylurea that is then substituted by DMAP to form the reactive N-acyl 
pyridinium transfer agent that reacts with the hydroxyl group of the alcohol. The presence of 
DMAP is crucial as, without it, O-rearrangement of the O-acylurea intermediate to an N-acylurea 
“dead end” product competes with interception by the poorly nucleophilic alcohol. These ideas 
are depicted in the mechanism shown in Scheme 3.15, the first step of which involves proton 
transfer of the carboxyl proton to the basic imide nitrogen. This facilitates reaction of both 
partners by increasing both the nucleophilicity and electrophilicity of the carboxylate and imide, 










Scheme 3.15. The general mechanism of the DCC-mediated Steglich esterification  
and the role of DMAP as an acyl transfer agent in this esterification. 
 
For characterisation of the NBD-labelled NHS esters, infrared spectroscopy was valuable. In 
Figure 3.9, the 4-chloro derivative of NBD (A) is contrasted with its amino acid substitute 13 (B) 
and NHS-labelled ester 15 (C). The spectra revealed two imide carbonyl stretches at 1785 cm-1 
and 1815 cm-1, and one at 1730 cm-1 for the succinimidyl ester carbonyl group. 
 







Figure 3.9. Infrared spectra of the NBD 4-chloro derivative (A), the NBD-labelled amino acid 13 (B)  
and the NBD-labelled succinimidyl ester 15 (C). In (C), stretching vibrations of the carbonyl group of the 
amino acid (orange) and the imide bonds (red) indicate successful activation of the carboxylic acid. 
 
These NBD-labelled succinimidyl esters were then reacted with the primary amine quinidine 
substrate 10 in CH2Cl2 (Scheme 3.16) in which DIPEA (3 eq) was first added to neutralise the 
trifluoroacetate salt and to liberate the primary amine. To ensure that the reaction progressed 
in a controlled manner the neutralization reaction was first conducted at -78°C. Thereafter, the 
succinimidyl ester was added and the reaction allowed to warm slowly to room temperature 
over about four hours. This protocol resulted in higher overall yields and, following an aqueous 
work-up, the products were isolated by column chromatography in yields of 29% and 68% for 5 


















Scheme 3.16. The preparation of two NBD-labelled quinidine molecules 5 and 6 with  
varying lengths of the spacer chain between the quinoline core and the NDB fluorophore. 
 
Figure 3.10 shows the 1H NMR spectrum of the NBD-labelled quinidine derivative of 
intermediate chain-length (5) in which characteristic signals arising from the quinoline and 
NBD motifs are labelled. The new -NH signal (H-23), indicating formation of the amide bond, is 
observed as a broad singlet at approximately 5.5 ppm. Furthermore, the carbonyl group of the 
amide (C-i) was observed by HMBC to correlate to H-22, H-ii and H-iii, confirming the successful 
tethering of the two precursor molecules. 
 
 







Figure 3.10. 1H and 13C NMR spectra of the NBD-labelled quinidine derivative of intermediate chain-length 
(5) in DMSO-d6 (400 MHz). Signals relating the NBD fluorophore are indicated in orange while those 
corresponding to the quinoline core are shown in blue. Signals in pink indicate those corresponding to  












J = 8.8 Hz
H-23
























3.3.6. Preparation of a quinine derivative incorporating the bimane fluorophore 
 
In order to increase the scope of the fluorophore-labelled alkaloid preparations, another small 
bicyclic heterocyclic fluorophore was identified: 1,5-diazabicyclo[3.3.0]octa-3,6-diene-2,8-dione 
or “bimane” (bi, two; manus, hand). Bimane fluoresces in the blue region of the visible spectrum 
and is typically available as its bromine derivative, monobromobimane (mBBr), which is 




Figure 3.11. The structure of monobromobimane (mBBr) indicating its susceptibility to SN2 reactions. 
 
The synthesis and fluorescent properties of this family of heterocycles was first described by 
Kosower et al. in a series of articles from the early 1980s.35,36 Bimane has suitable photophysical 
properties for live-cell microscopy and, like NBD, a major advantage is its small size. Its 
absorption maximum is located at 385 nm and it fluoresces in the blue region of the visible 
spectrum (460 nm). Hence, unlike NBD, it may be used in conjunction with other green-emitting 
cellular markers or dyes.  
 
In order to prepare an additional bimane-labelled alkaloid, mBBr was reacted with the primary 
amine derivative of quinine (9) in dry CH2Cl2 (Scheme 3.17). As dry Et3N is easier to distil than 
DIPEA, given the lower boiling point of the former, several equivalents of this base were added 
to neutralise the trifluoroacetate salt 9 and liberate the primary amine. Following addition of 
mBBr, the SN2 reaction proceeded with stirring at room temperature overnight (18 hours). 
Scrupulous care was taken to ensure that water was eliminated from the system in order to 
avoid hydrolysis of the alkyl-bromide bond prior to substitution by the amine.  
 
 







Scheme 3.17. The synthesis of a bimane-labelled fluorescent derivative of quinine (19). 
 
Column chromatography yielded the quinine-bimane conjugate (19) as a pale-yellow solid in 
32% yield. A portion of the 13C NMR spectrum is presented in Figure 3.12 with assignments of 
the sp2-hybridised carbon signals. Infrared spectra provided additional evidence of 
incorporation of the bimane group into the quinoline scaffold (Figure 3.13).  
 
  







Figure 3.12. A portion of the 13C NMR spectrum of the quinine-bimane conjugate (19) in CDCl3 (100 MHz). 
Signals corresponding to bimane are labelled in orange while those corresponding to the quinoline core are 
labelled in blue. Quaternary carbons are indicated in the structure with filled circles at the carbon atom and 






















Figure 3.13. Infrared spectra of quinine intermediate 9 (A), monobromobimane (B) and quinine-bimane 
conjugate 19 (C). Dashed lines show two stretching vibrations common amongst all three molecules. More 
importantly, the carbonyl stretches of the bimane functional group are indicated in orange in (B) and 
















3.4. Synthesis of a novel fluorescently-tagged chloroquine derivative 
 
3.4.1. Synthetic planning and N-desethylation of chloroquine 
 
The prototypical 4-aminoquinoline, chloroquine, possesses three amino functionalities. The 4-
amino nitrogen was considered to be insufficiently nucleophilic to partake in nucleophilic 
aromatic substitution with the fluorophore in view of resonance donation into the pyridine ring. 
Although the quinoline sp2 ring nitrogen is DMAP-like and thus quite nucleophilic due to the 
aforementioned resonance effect of the 4-amino substituent, any substitution activity would 
only serve to act as a transfer site as in the case of DMAP. The remaining nitrogen in the side 
chain is a much stronger basic tertiary amine that is important for accumulation of the drug in 
the digestive vacuole of P. falciparum and, as such, was an unsuitable point of attachment for an 
extrinsic fluorophore. 
 
Thus, in order to exploit similar methodology as used above, it was deemed necessary to 
introduce an additional aliphatic amine functionality into the molecules as a connection site for 
the fluorophore, and for this it was investigated whether one of the terminal ethyl groups 
connected to the tertiary amine could be selectively removed. Fortunately, there is precedent 
for this modification as there has been much interest in the N-dealkylated derivative of 
chloroquine (known as desethylchloroquine) as it is the major human metabolite of the 
antimalarial.37 This led to the identification of 8 as a target for fluorophore attachment as 
proposed in Scheme 3.2 previously.  
 
The synthesis thinking for accessing 8 is illustrated by way of a retrosynthetic analysis shown in 
Scheme 3.18 in which disconnection of the fluorophore produced the key intermediate primary 
amine 23. Subsequent disconnection of a C-N bond on the tertiary amine generated 
desethylchloroquine (21). Importantly, the synthetic chemistry required to generate this N-
dealkylated derivative of chloroquine was already available.37 
 






Scheme 3.18. Retrosynthetic analysis of the target compound 8 via key intermediate 23 
and desethylchloroquine 21. 
 
The forward synthesis of the novel fluorescent derivative of chloroquine 8 is depicted in 
Scheme 3.19. First, an overview of the reactions involved follows: In the first step, selective N-
dealkylation of chloroquine was achieved via formation of a chloroformate ester 20 followed by 
subsequent reduction by zinc in acetic acid to give 21.37,38 The latter was then condensed with 
N-Boc-glycinal under reductive amination conditions using NaBH3CN to generate N-Boc-
protected amine 22. This was followed by N-Boc deprotection of 22 to generate primary amine 
23, which could then be used in a nucleophilic aromatic substitution reaction with the 4-chloro 
derivative of the NBD fluorophore, using similar conditions to those described for preparing the 
fluorescently-labelled alkaloids above, to afford the NBD-labelled chloroquine derivative 8. 
 
 







Scheme 3.19. The forward synthesis of NBD-labelled chloroquine derivative 8.  
 
The various steps of the synthesis of the NBD-labelled chloroquine derivative will now be 
described in detail. The first step involved desethylation of chloroquine via a chloroformate 
which was generated using sodium hydride and 2,2,2-trichloroethyl chloroformate in refluxing 
THF. Work-up and subsequent purification yielded two quinoline derivatives that could not be 
separated by column chromatography. Combined analysis via 1H NMR, infrared spectroscopy 
and mass spectrometry suggested that this mixture comprised the desired carbamate 20 and 
pyrrolidine 20’ (Scheme 3.19). Integration of peaks in the 1H NMR spectrum suggested that 20 
and 20’ were present in approximate proportions of 2:1 respectively. This was also reflected in 
the relative intensities of the ion peaks in the mass spectrum. In the infrared spectrum, a 
prominent stretching band at 1715 cm-1 was observed for the carbamate while, in the mass 
spectrum, major peaks corresponding to the molecular weights of these two products were 
observed.  
 
The formation of the two products 20 and 20’ may be rationalised as follows. Treatment of 
chloroquine with sodium hydride deprotonates the relatively acidic aromatic secondary 4-
amino group, while the tertiary amine of the side chain becomes N-acylated by the 
chloroformate to afford a charged carbamate intermediate (depicted in square brackets in 
Scheme 3.20 below). One may speculate about the order of these chemical events in which it 





makes sense that the N-acylation proceeds faster than the deprotonation. The amino anion can 
then reduce the energy of the molecule in two ways, either by a β-elimination on a relatively 
unhindered ethyl group (red arrows), or alternatively acting as a nucleophile at the α-
methylene in the chain (blue arrows), the latter being dictated primarily by the distance 
between the two centres in the bond-forming step. While the former process affords the desired 
desethyl product 20 as its protected trichloroethyl carbamate, the latter affords pyrrolidine 20’ 




Scheme 3.20. Preparation of carbamate 20 and pyrrolidine 20’ via a charged carbamate intermediate. In 
the second line of the scheme, the formation of 20 and 20’ are indicated by red and blue arrows, respectively. 
 
Treating the mixture of 20 and 20’ with zinc dust in acetic acid at room temperature, followed 
by column chromatography, gave the target compound desethylchloroquine (21) in 41% yield 
over the two steps.37 Integration of the aliphatic proton signals of 21 using 1H NMR 
spectroscopy confirmed that one of the diethyl groups had been removed. The decrease in 
intensity of the corresponding carbon signal in the 13C spectrum confirmed the same. In 
addition, a broad singlet at approximately 4 ppm was exchanged upon washing with D2O, 
confirming the presence of an additional secondary amine (Figure 3.14). Finally, the infrared 
spectrum of desethylchloroquine was indistinguishable from the infrared spectrum of the 
starting material. 







Figure 3.14. A comparison of the 1H NMR spectra of chloroquine 7 (A), desethylchloroquine 21 (B) 
and desethylchloroquine 21 with D2O wash to confirm amine signals (C).  
All spectra were acquired in CDCl3 at 400 MHz. 
 
3.4.2. N-Alkylation, N-Boc deprotection and fluorophore substitution 
 
With desethylchloroquine 21 in hand, an additional (protected) amine was introduced by N-
alkylation of the secondary aliphatic amine using reductive amination with N-Boc-glycinal, 
which could be prepared by LiAlH4 reduction of a Weinreb amide as shown in Scheme 3.21. TLC 
analysis of the latter suggested that the crude product (99% yield) was sufficiently pure for use 
in the subsequent N-alkylation reaction. The 1H NMR spectrum in CDCl3 revealed a singlet at 
approximately 9.7 ppm corresponding to the aldehyde hydrogen (indicated in red in  
Scheme 3.21) which was not present in the starting material. Concomitant disappearance of the 
methyl and methoxy signals corresponding to the reduction of the Weinreb amide starting 
material was also observed. 
-NH (d)
J = 7.3 Hz
















Scheme 3.21. Reduction of a Weinreb amide to form N-Boc-glycinal. The hydrogen atom (red) was detected 
in the 1H NMR spectrum (CDCl3, 300 MHz) at approximately 9.7 ppm. 
 
Weinreb amides are N-methoxy-N-methylamides that are readily reduced with hydrides to 
afford aldehydes. This conversion proceeds through a stable lithium-chelated intermediate 




Scheme 3.22. Mechanism of the Weinreb amide reduction which forms N-Boc-glycinal  
via a lithium-chelated intermediate. 
 
The N-alkylation reaction between desethylchloroquine 21 and N-Boc-glycinal was conducted 
in the presence of a catalytic amount of acetic acid, as shown in Scheme 3.23.18 Quenching of the 




Scheme 3.23. N-alkylation of desethylchloroquine 21 to afford reductively N-alkylated 22. 
  





The 1H and 13C NMR spectra of 22 are depicted in Figure 3.15. A new singlet integrating for 9H 
at approximately 1.5 ppm corresponds to introduction of the t-butyl group, as well as a new C=O 
signal in the 13C NMR spectrum (approximately 155 ppm). HMBC analysis confirmed the 3J 
correlation relationship between the proton and carbon signals labelled 13, 14 and 16 
(highlighted in pink). The new amine signal at approximately 5 ppm corresponds to the 
incorporation of the carbamate and is shown relative to the 4-amino group adjacent to the 




Figure 3.15. 1H and 13C NMR spectra of 22 (400 MHz and 100 MHz, CDCl3) highlighting the aliphatic proton 
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The general mechanism for the reductive amination in question proceeds via an intermediate 
iminium ion as depicted in a generalised form in Scheme 3.24. The iminium salt is formed when 
a secondary aliphatic amine reacts with an aldehyde under acid-catalysed conditions to produce 
a hydroxylamine intermediate. Proton transfer followed by elimination of water generates the 
iminium salt. Sodium cyanoborohydride (NaBH3CN) was used as a mild reducing agent. Owing 
to the presence of the electron-withdrawing cyanide substituent group, it is less reactive than 
sodium borohydride and more stable in methanol. 
 
 
Scheme 3.24. General mechanism for acid-catalysed reductive alkylation via iminium salt formation. 
 
In order to liberate the primary amine of compound 22 to render it suitable for nucleophilic 
aromatic substitution, it was necessary to cleave the N-Boc protecting group. This proceeded as 
described above for the Cinchona alkaloids, using an excess of TFA in CH2Cl2 to furnish the tris-
trifluoroacetate salt of 23 (Scheme 3.25). Unlike its alkaloid counterparts, it was not possible to 
retrieve this salt from the stationary phase of the chromatographic column. This is probably due 
to the more polar nature of the chloroquine derivatives as a result of the higher pKa values of its 
nitrogen atoms compared to those of the alkaloids. Hence, for characterisation purposes, a base 
extraction with 1 M NaOH and CH2Cl2 was employed followed by column chromatography, 
requiring the presence of 5% Et3N in the 100% MeOH mobile phase, to afford the free base of 
23 in 60% yield. Removal of the N-Boc protecting group in 23 was evident on TLC with 
concomitant disappearance of the carbamate and t-butyl signals in the NMR and infrared 
spectra.  
 







Scheme 3.25. N-Boc deprotection of 22 and subsequent base extraction yielded the free base of 23. 
 
For coupling purposes though, a similar methodology as described for the incorporation of the 
NBD fluorophore into the Cinchona alkaloids described previously was adopted using Hünig’s 
base for deprotonation of the salt (of 23) in which the latter was deemed pure enough via 1H 
NMR for proceeding with reaction with the NBD fluorophore. Hence, as illustrated in Scheme 
3.26, three equivalents of Hünig’s base were added to liberate the amines from their salts, this 
time at room temperature, and this was followed by heating with NBD-chloride in methanol as 
solvent, with an excess of sodium bicarbonate to neutralise the HCl formed. Column 




Scheme 3.26. Neutralisation of the tris-trifluoroacetate salt 23 and SNAr with NBD-Cl to generate 
fluorescent chloroquine derivative 8. Incorporation of the NBD fluorophore is indicated in the dashed box. 
 
The 1H and 13C NMR spectra of the NBD-labelled chloroquine 8 are shown in Figure 3.16. 
Characteristic signals relating to the quinoline heterocycle are labelled in blue. The AB doublet 
pair due to the NBD signals H-a and H-b is highlighted in orange at 6.5 ppm and 8.5 ppm, 
respectively (J = 9.5 Hz). Surprisingly, the signal corresponding to the 4-amino hydrogen was 
not observed. Quaternary signals arising from the NBD heterocycle in the 13C NMR spectrum 
were also observed, also highlighted in orange. The identity of product 8 was further 
corroborated using HRMS. 
 







Figure 3.16. 1H NMR spectrum of NBD-labelled chloroquine 8 in DMSO-d6 (400 MHz). Proton signals 
relating to the hydrogen atoms in the NBD fluorophore are displayed in orange while those corresponding to 
the quinoline ring are shown in blue. Two-dimensional NMR correlation analysis proved covalent 
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3.5. Summary and conclusions  
 
This chapter describes the design and synthesis of a series of novel fluorescent antimalarials. 
Specifically, five fluorescent derivatives of the Cinchona alkaloids were prepared as 
representative probes for the class of quinoline methanol antimalarials; two were derivatives of 
quinine and three were derivatives of its diastereomer, quinidine. Three of these were ‘short-
chain’ derivatives containing a minimum number of atoms between the pharmacophore and the 
fluorophore (3, 4 and 19 in Figure 3.17). The length of the spacer chain was varied by preparing 
quinidine derivatives with an intermediate (5) and longer (6) chain length. All derivatives were 
linked to the small green-emitting NBD fluorophore except for one which was linked to the 
blue-emitting bimane fluorophore (19). A single novel NBD-labelled chloroquine derivative was 




Figure 3.17. The suite of six novel fluorescent antimalarials prepared in this chapter.  
Fluorophores are highlighted in colour. 
  





Design aspects of these novel fluorescent derivatives were described above. Briefly, in order to 
retain the distinctive interactions of the parent molecules with their putative target in  
P. falciparum, Fe(III)PPIX, it was important to preserve key physicochemical properties of the 
parent molecules as elucidated by recent structure-activity relationship studies. Retention of 
these properties was evident in all proposed derivatives. The primary choice of fluorophore, 7-
nitrobenz-2-oxa-1,3-diazole (NBD), was explained. 
 
A retrosynthetic analysis of the target quinoline methanols was provided, identifying a key 
intermediate containing a primary amine functionality. Versatile and convenient derivatisation 
of the parent alkaloids was enabled by a regioselective radical-mediated thiol-ene ‘click’ 
reduction. Following N-Boc deprotection of these reduced derivatives, the NBD fluorophore was 
attached by means of a nucleophilic aromatic substitution to generate two ‘short-chain’ 
derivatives (3, 4). In order to vary the length of the spacer chain between the quinoline core and 
the fluorophore, NBD-labelled amino acids and their corresponding succinimidyl esters were 
prepared in order to facilitate amide bond formation between the two molecules (5, 6). In 
addition, a final novel derivative was prepared using the blue-emitting bimane fluorophore 
(19). Together, these are the first derivatives of the Cinchona alkaloids that have been prepared 
for live-cell fluorescence microscopy. 
 
For comparison purposes, an analogous single novel derivative of chloroquine was prepared. 
Retrosynthetic analysis of this derivative suggested utilising its N-dealkylated analogue, 
desethylchloroquine, as a key intermediate. N-Alkylation of this intermediate with N-Boc-
glycinal, prepared from the reduction of a Weinreb amide, enabled introduction of an additional 
amine functionality in the molecule which, following N-Boc deprotection, was reacted with NBD 
in a manner similar to the quinoline methanols to form a novel fluorescent probe 8. 
 
All six novel fluorescent derivatives were characterised using a full range of spectroscopic and 
analytical techniques. Photophysical characterisation of these derivatives, and hence their 
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Photophysical and Physicochemical 
Characterisation of  






he intimate mechanistic details describing the action of the quinoline antimalarials against 
the most virulent malaria parasite, Plasmodium falciparum, remain unclear. Furthermore, 
the two major classes of these antimalarials, the quinoline methanols and 4-aminoquinolines, 
generate differential ultrastructural and morphological effects on the parasite.1-3 Thus, in order 
to generate deeper insights into the mechanism of action of these two classes of antimalarials, 
six novel fluorescent derivatives of these drugs were designed and synthesised for the purpose 
of live-cell imaging studies (Chapter 3). 
 
Although these novel derivatives were expected to possess suitable photophysical properties 
for fluorescence microscopy, it was necessary to characterise and evaluate these derivatives 
thoroughly to ensure that key physicochemical properties of the parent drugs were retained. As 
the solution-state interactions of these quinoline antimalarials with Fe(III)PPIX have been well-
characterised with respect to their binding modes and strengths of association,4,5 these were 
used as benchmarks to determine whether the fluorescent derivatives were suitable analogues 
of the parent molecules. These derivatives were also evaluated for their activities against β-
haematin formation and, crucially, against P. falciparum in vitro. 
T 





This chapter first describes the photophysical characterisation of the six novel fluorescent 
derivatives prepared in Chapter 3. Their absorption and fluorescence spectra are discussed as 
well as other photophysical aspects such as fluorescence quantum yields, solvatochromism, 
Förster resonance energy transfer and stability. Thereafter, the derivatives are directly 
compared to their parent compounds by evaluating their physicochemical interactions with 
Fe(III)PPIX. As described in Section 1.5.2, the solution-state interactions between the two 
classes of quinoline antimalarials with Fe(III)PPIX are fundamentally different. The quinoline 
methanols, represented in this work by the diastereomeric alkaloids quinine and quinidine, 
bind to Fe(III)PPIX with a 1:1 stoichiometry.4 On the other hand, chloroquine, which represents 
the 4-aminoquinolines, induces μ-oxo dimerisation of Fe(III)PPIX in aqueous solution.5 
 
To further determine which fluorescent derivatives were the most suitable analogues of their 
parent compounds, their aqueous solubilities and diffusion coefficients were measured and 
these observations were rationalised. The activities of the novel fluorescent derivatives were 
measured against β-haematin formation using a biomimetic detergent-mediated assay. Most 
importantly, their in vitro activities against P. falciparum were evaluated. Taken together, these 
measurements were used to decide which of the fluorescently-labelled derivatives prepared in 
Chapter 3 were most suitable for live-cell microscopy studies. 
 
Thus the specific objectives described in this chapter were:  
 
i. To fully characterise the photophysical properties of the six novel fluorescent derivatives 
prepared in Chapter 3 by interpreting their absorption and fluorescence spectra and 
establishing relevant photophysical aspects; 
ii. To evaluate the physicochemical behaviour of these fluorescent derivatives by measuring 
their binding stoichiometries and association constants with Fe(III)PPIX and comparing 
these directly to the parent quinoline antimalarials; 
iii. To measure the activities of these derivatives against β-haematin formation and the 
malaria parasite, P. falciparum, in vitro; 
iv. To determine which of these six fluorescent derivatives are the most suitable analogues of 









4.2. Photophysical evaluation of novel fluorescent derivatives  
 
4.2.1. Absorption and fluorescence emission spectra 
 
As described in Chapter 3, six novel fluorescent derivatives of the antimalarials quinine, 
quinidine and chloroquine were designed, synthesised and characterised. NBD was identified as 
a suitable reporter fluorophore and hence this dye was incorporated in most of these 
derivatives (Figure 4.1). A single NBD-labelled derivative of quinine was prepared (3) while 
three derivatives of its diastereomer, quinidine, were synthesised with varying chain lengths 
between the quinoline core and the reporter fluorophore and classified as short- (4), 
intermediate- (5) or long-chain (6) derivatives. In addition, another derivative of quinine with 
an alternative reporter fluorophore, bimane, was prepared (19). Finally, a novel NBD-labelled 




Figure 4.1. The suite of six fluorescent derivatives of the quinoline antimalarials prepared in this study.  
 
The absorption and fluorescence profiles of these novel fluorescent derivatives were measured 
in ethanol. Table 4.1 lists the absorption maxima ( max) and molar absorption coefficients (ε) at 
those wavelengths for each compound, as well as their fluorescence emission maxima following 
excitation at their absorption maxima.  





Table 4.1. Absorption maxima (λmax) and molar absorption coefficients (ε) at those wavelengths of novel 
fluorescent derivatives measured in ethanol, as well as their corresponding fluorescence emission maxima. 
 
Fluorescent derivative λmax, nm (ε, M-1 cm-1) Fluorescence emission  
maximum at λmax, nm 
Quinine-NBD (3) 335 (11 500), 465 (18 500) 545 (excitation at 465 nm) 
Quinidine-NBD (4) 335 (11 000), 465 (17 000) 545 (excitation at 465 nm) 
Quinidine-HexNBD (5) 335 (10 500), 465 (15 500) 530 (excitation at 465 nm) 
Quinidine-DodecNBD (6) 335 (6 000), 465 (10 000) 530 (excitation at 465 nm) 
Quinine-Bimane (19) 335 (10 000), 385 (8 500) 455 (excitation at 385 nm) 
Chloroquine-NBD (8) 330 (18 000), 465 (15 000) 370, 520 (excitation at 330 nm);  
530 (excitation at 465 nm) 
 
All fluorescent derivatives possess two absorption maxima. The shorter-wavelength band at 
330-335 nm corresponds to the absorption band of the quinoline core and also, in the case of 
the NBD-labelled derivatives, to the secondary absorption band of the NBD fluorophore. The 
longer-wavelength band corresponds to the absorption maximum of the extrinsic fluorophore. 
Generally, the NBD-labelled derivatives are characterised by strong absorption bands (ε > 10 
000 M-1 cm-1) except for the longest-chain quinidine derivative (6). The bimane derivative of 
quinine (19) has the lowest molar absorption coefficient at its primary absorption band and 
thus was expected to be less bright compared to the NBD-labelled derivatives.  
 
Fluorescence emission was recorded following excitation at both absorption maxima. All 
compounds exhibited a single emission maximum in ethanol (that is, no fluorescence emission 
was observed from the quinoline core) except in the case of the NBD-labelled chloroquine (8) 
for which fluorescence emission following excitation at 330 nm resulted in a strong band in the 
ultraviolet range centred at 370 nm. 
 
Despite their stereochemical differences, quinine and quinidine are photophysically identical. 
Primary and secondary absorption bands are observed at approximately 335 nm and 320 nm 
(Figure 4.2A) and correspond to electronic transitions to the first and second excited singlet 
states, respectively. The alkaloids exhibit fluorescence maxima at approximately 383 nm in 
their free base or monocationic species. While the dicationic forms of these alkaloids fluoresce 
more brightly at longer wavelengths (approximately 460 nm), this species is unlikely to be 
physiologically significant. Taking the lower limit of the pH of the acidic digestive vacuole of  
P. falciparum (Section 1.3.4)6 and incorporating a pKa value of 4.42 for the quinolinic nitrogen,7 
the Henderson-Hasselbalch equation predicts that this species is not likely to be present at 
more than 17% of the drug concentration in the digestive vacuole of the parasite. 







Figure 4.2. The absorption and fluorescence emission spectra of (A) quinine, (B) NBD-labelled 6-
aminohexanoic acid and (C) the NBD-labelled quinine derivative (3). Absorption spectra (blue) and 
fluorescence emission spectra (black) were recorded in ethanol. The dashed black line indicates fluorescence 
emission from excitation at 335 nm and the solid black line indicates an emission spectrum following 
excitation at 485 nm. The weak emission peak at approximately 380 nm in (C) is evidence for Förster 

























































































































































































The NBD fluorophore, on the other hand, has a primary absorption band at approximately 460 
nm and a secondary absorption band centred at 350 nm (Figure 4.2B). The molar absorption 
coefficient of the former band is particularly high (ε ≈ 20 000 M-1 cm-1). As this coefficient is 
related to the brightness of a dye, NBD fluorescence is more suitable for microscopy compared 
to the autofluorescence of the Cinchona alkaloids (ε ≈ 5 000 M-1 cm-1). Excitation of either band 
of the NBD fluorophore generates fluorescence in the green region of the visible spectrum 
(approximately 545 nm in ethanol) but this fluorescence is always greater following excitation 
of the primary absorption band. The NBD fluorophore is strongly solvatochromic and thus its 
emission maximum and intensity depend on the solvent.  
 
The NBD-labelled alkaloids all display similar photophysical properties and are exemplified in 
this discussion by the NBD-labelled quinine derivative (3, Figure 4.2C). Its absorption spectrum 
is essentially the sum of the absorption spectra of its constituent chromophores. Consequently, 
the secondary absorption band in the ultraviolet region exhibits the structure of the alkaloid 
absorption band but with a higher molar absorption coefficient than either of the starting 
materials. Whilst either band can be excited to generate fluorescence, a brighter emission 
profile is always observed from direct excitation of the NBD fluorophore. The very weak 
emission peak at approximately 380 nm is evidence for efficient Förster resonance energy 
transfer from the quinoline core to the NBD fluorophore (Section 4.2.3). 
 
The absorption and emission spectra of the bimane derivative of quinine (19) are depicted in 
Figure 4.3. Again, the absorption spectrum of this derivative resembles the sum of the 
absorption spectra of its two constituent chromophores. The absorption band of quinine is 
preserved ( max 333 nm) while a secondary, broader absorption band corresponding to the 
bimane fluorophore ( max 383 nm) overlaps closely with the emission maximum of quinine. 
Excitation of either band results in fluorescence emission in the blue region (approximately 460 
nm) although the fluorescence intensity arising from excitation at the absorption maximum of 
quinine ( max 333 nm) is greater. Once again, a weak emission peak at approximately 380 nm is 
evidence that much of the energy from excitation of the quinoline core is transferred non-
radiatively to the bimane fluorophore via a Förster resonance energy transfer mechanism. 
 
In the case of the NBD-labelled chloroquine derivative (8, Figure 4.4), the high molar extinction 
coefficient of the 4-amino-7-chloroquinoline heterocycle means that the ultraviolet absorption 
band ( max 330 nm) is more strongly absorbing than the primary absorption band of the NBD 
fluorophore ( max 465 nm). It is somewhat surprising that the primary fluorescence emission 
band results from excitation of the quinoline directly with its fluorescence maximum in the 
ultraviolet region (approximately 385 nm) while fluorescence arising from direct excitation of 





the NBD fluorophore is very much weaker. This is counterintuitive as one might expect reduced 
quinoline fluorescence as a result of spin-orbit coupling of the chlorine atom. Nevertheless, it is 
possible that an intramolecular arrangement might bring the NBD fluorophore in close 
proximity to the chlorine atom thus reducing the intensity of its fluorescence. In contrast to the 
derivatives described above, the significant emission of fluorescence from the quinoline core 
suggests that Förster resonance energy transfer between the quinoline core and the NBD 




Figure 4.3. The absorption and fluorescence emission spectra of the quinine-bimane conjugate (19) in 
ethanol. The dashed black line indicates fluorescence emission arising from excitation at 335 nm and the 




Figure 4.4. The absorption and fluorescence emission spectra of the NBD-labelled chloroquine derivative (8) 
in ethanol. The dashed black line indicates fluorescence emission arising from excitation at 335 nm and the 
solid black line indicates the emission spectrum following excitation at 480 nm. 

























































































































As described in Section 2.3.3, the fluorescence quantum yield (Φ) of a fluorophore is defined as 
the ratio of the number of photons emitted as fluorescence to the number of photons absorbed. 
Bright fluorophores are efficient fluorescence emitters and thus have quantum yields 
approaching unity. Relative fluorescence quantum yields may be determined experimentally by 
comparing a fluorophore of known fluorescence quantum yield to a fluorophore of unknown 
fluorescence quantum yield while keeping the experimental parameters constant.  
 
Fluorescence quantum yields were measured in both organic and mixed aqueous solvents. 
These were ethanol and 40% (v/v) DMSO in 20 mM Hepes, pH 7.5 (Table 4.2). The latter solvent 
was used in anticipation of subsequent binding studies. Quinine was used as the reference 
fluorophore for which a fluorescence quantum yield of Φ = 0.546 in 0.5 M sulfuric acid has been 
measured.8 While the NBD fluorophore has a high fluorescence quantum yield in ethanol (Φ ≈ 
0.2), its fluorescence is much weaker in mixed aqueous solution (Φ ≈ 0.04) and is weaker still in 
pure aqueous solution. The opposite is observed for the parent alkaloids quinine and quinidine 
which have much larger fluorescence quantum yields in aqueous solution compared to ethanol.  
 
Consequently, the NBD-labelled alkaloids are all relatively bright in ethanol but less so in the 
mixed aqueous medium. The intermediate- (5) and long-chain (6) derivatives are brighter 
compared to their short-chain counterparts (3, 4) in both solvents, possibly because of the 
formation of an hydrophobic environment facilitated by intramolecular folding arrangements 
accessible to derivatives with longer chain lengths. While the bimane derivative (19) is not very 
bright in ethanol, it is reasonably bright in aqueous solution. Of all the derivatives, the NBD-
labelled chloroquine (8) exhibited the lowest quantum yield in both organic and mixed aqueous 
media, most likely due to the internal heavy-atom quenching effect of the chlorine substituent. 
 
Table 4.2. Fluorescence quantum yields evaluated relative to quinine in 0.5 M sulfuric acid (Φ = 0.546).8 
Two independent measurements were made and uncertainties represent standard errors of the mean. 
 
Compound Fluorescence quantum 
yield (Φ) in ethanol 
Fluorescence quantum yield (Φ) in  
40% (v/v) DMSO in 20 mM Hepes, pH 7.5 
Quinine/quinidine 0.064 ± 0.002 0.242 ± 0.012 
Quinine-NBD (3) 0.111 ± 0.002 0.018 ± 0.003 
Quinidine-NBD (4) 0.086 ± 0.008 0.017 ± 0.002 
Quinidine-HexNBD (5) 0.227 ± 0.040 0.039 ± 0.002 
Quinidine-DodecNBD (6) 0.391 ± 0.027 0.033 ± 0.003 
Quinine-Bimane (19) 0.049 ± 0.006 0.018 ± 0.002 
Chloroquine 0.003 ± 0.001 0.018 ± 0.003 
Chloroquine-NBD (8) 0.004 ± 0.001 0.017 ± 0.004 





4.2.2. Solvent effects on NBD-labelled derivatives 
 
Solvent molecules assist in lowering the energy of the excited state by rearranging around the 
excited fluorophores in a process termed solvent relaxation. This may affect the absorption and 
fluorescence profiles of the molecules. Solvatochromism is the shift in the fluorescence emission 
maximum resulting from changes in solvent polarity (Section 2.3.6). A more polar solvent 
produces a larger reduction in the energy level of the excited state while a less polar solvent 
reduces the stabilisation effects of the solvent; consequently, a larger Stokes shift is seen in 
more polar solvents compared to less polar solvents.  
 
The fluorescence emission spectrum of the NBD fluorophore is susceptible to this 
solvatochromic shift. For the NBD-labelled quinidine derivative, a shift in the fluorescence 
emission maximum from approximately 525 nm to 550 nm was observed across ten common 
solvents. Plotting the emission maximum against solvent polarity, as measured by the solvent 
polarity parameter ET(30), produced an excellent linear correlation (R2 = 0.980, Figure 4.5). 





Figure 4.5. The relationship between the fluorescence emission maximum of the NBD fluorophore  
and solvent polarity in ten common solvents. ET(30) values taken from Reichardt.9 The short-chain NBD-
labelled quinidine derivative (4) was excited at 480 nm at a concentration of 20 μM at 25°C. 
 
The intensity of fluorescence emission was also measured across a variety of different solvents. 
Again, this generated a good correlation with the ET(30) solvent polarity parameter (R2 = 0.906, 














































Figure 4.6). As expected, the fluorescence of the NBD fluorophore was brightest in non-polar 
environments but was fairly weak in aqueous solution. Hence, association of these derivatives 
with cellular components with ET(30) values similar to those of phospholipid bilayers (49-50 
kcal/mol)10 and neutral lipid components (45 ± 4 kcal/mol for the synthetic neutral lipid blend 
described in Section 1.3.2)11 should be easily detectable. On the other hand, their modest 
aqueous fluorescence quantum yield means that the signal arising from the digestive vacuole – 
their preferred site of accumulation – will not overwhelm the detector of the microscope at the 




Figure 4.6. The relationship between fluorescence intensity and solvent polarity for eleven common solvents. 
ET(30) values taken from Reichardt.9 The short-chain NBD-labelled quinidine derivative (4) was excited at 
480 nm at a concentration of 20 μM at 25°C. 
 
Despite the rapid nature of the absorption process, solvent-dependent effects may still be 
observed in absorption spectra. Absorption spectra for the NBD-labelled quinine derivative 
were compared between ethanol and 20 mM Hepes, pH 7.5, for which there is an ET(30) 
difference of approximately 11.2 kcal/mol. For the NBD-labelled quinine derivative (3), a 
hypochromic shift of approximately of 2 500 M-1 cm-1 with an increase in solvent polarity, was 
observed for the ultraviolet absorption band (Figure 4.7). A bathochromic shift of 
approximately 15 nm (460 to 475 nm) was detected for the primary absorption band, again 
with an increase in solvent polarity.  
 
















































Figure 4.7. Solvent-dependent shifts in the absorption spectra of the NBD-labelled  
quinine derivative (3) in two different solvents. 
 
4.2.3. Förster resonance energy transfer  
 
Förster resonance energy transfer is a long-range electrodynamic phenomenon that results 
from dipole-dipole interactions between two fluorophores. As described in Section 2.3.5, the 
rate of energy transfer depends on the spectral overlap of the emission spectrum of the donor 
and the absorption spectrum of the acceptor, the quantum yield of the donor (ΦD), the relative 
orientation of donor and acceptor transition dipoles (κ) and the distance between the two 
fluorophores (R). The important equations associated with quantifying these parameters are 
reprinted in this section for convenience: 
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In Equation 4.1, J is a measure of the spectral overlap between the donor fluorescence emission 
and acceptor absorption while R0, the characteristic Förster distance for which energy transfer 
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is 50% efficient, is given by Equation 4.2. If the distance between a donor and acceptor pair is 
known, the efficiency of energy transfer (E) given by Equation 4.3 can be calculated. 
 
There are three donor-acceptor pairs amongst the six fluorescent derivatives prepared in this 
work. The 6-methoxyquinoline core of the quinine and quinidine alkaloids may function as a 
donor fluorophore with either the NBD or bimane fluorophores as the acceptor. In the case of 
the NBD-labelled chloroquine derivative (8), the 4-amino-7-chloroquinoline core of chloroquine 
is the donor and the NBD fluorophore is the acceptor. In these calculations, the donor 
fluorophores will be exemplified by the substituted quinoline rings of quinine and chloroquine. 
 
In order to determine the potentials of these donor-acceptor pairs for non-radiative energy 
transfer via Förster resonance energy transfer, the spectral overlap J for each donor-acceptor 
pair was calculated using Equation 4.1. From these values, the characteristic Förster distance 
for each donor-acceptor pair was calculated from Equation 4.2. In order to be biologically 
relevant, absorption and fluorescence emission spectra were collected in 20 mM Hepes at pH 
7.5. For the orientation factor κ a value of 0.67 was used as it was assumed that both probes can 
undergo unrestricted isotropic motion. A value of 1.33, the refractive index of aqueous solution, 
was used for n.  
 
The results of these calculations are listed in Table 4.3. The Förster distance R0 is the largest for 
the quinine-NBD donor-acceptor pair indicating that energy transfer is most efficient between 
this pair of fluorophores. In contrast, the overlap integral J and R0 are smaller for the quinine-
bimane pair. This is likely a result of the smaller molar extinction coefficient of bimane at its 
 max. While the overlap integral J of the chloroquine-NBD pair is larger than the overlap integral 
of the quinine-bimane pair, its R0 value is much smaller than the other two pairs. This is because 
the donor (chloroquine) has a very weak fluorescence quantum yield due to the internal heavy-
atom effect previously mentioned. 
 
Table 4.3. Calculated overlap integrals (J) and characteristic Förster distances (R0)  
for the three donor-acceptor pairs described in this work in 20 mM Hepes, pH 7.5. 
 
 Donor Acceptor Overlap integral 
J, M-1 cm-1 nm4 
Characteristic 
Förster distance R0 
Efficiency of energy 
transfer (R = 13 Å) 
1 Quinine NBD 1.55 x 10-14 28.7 Å 99% 
2 Quinine Bimane 9.59 x 10-15 16.1 Å 78% 
3 Chloroquine NBD 1.11 x 10-14 11.5 Å 33% 
 





A model of the short-chain NBD-labelled quinine derivative (3) was energy-minimised using the 
Marvin Sketch software package (Version 14.8.25.0, ChemAxon Ltd, 2014). The minimum 
distance measured between the two fluorophores (R = 13 Å) was used in Equation 4.3 to 
determine an approximate efficiency of energy transfer (Table 4.3). As this distance is very 
much smaller than the Förster distance between the quinine-NBD donor-acceptor pair, this 
fluorophore pair exhibited the greatest efficiency of energy transfer (99%). This efficiency was 
also reasonably high for the quinine-bimane pair (78%) but much lower for the chloroquine-
NBD pair (33%).  
 
These calculations rationalise the profiles of the fluorescence emission spectra of the 
fluorescently-labelled derivatives. For the NBD-labelled alkaloids (Figure 4.2C), there is a very 
small emission peak arising from the quinoline core in the ultraviolet region suggesting that 
Förster resonance energy transfer is very efficient (almost 100%). For the quinine-bimane 
derivative (Figure 4.3), this band is more pronounced suggesting that energy transfer is less 
efficient (approximately 80%). Finally, for the chloroquine-NBD pair (Figure 4.4), excitation of 
the quinoline core generates fluorescence that is very much greater than the fluorescence 
emitted by the NBD fluorophore, suggesting that Förster resonance energy transfer between 
these two fluorophores is much less favoured in accordance with predicted behaviour. 
 
4.2.4. Sensitivity of NBD-labelled derivatives to light and temperature 
 
Exposure of fluorescent molecules to ambient light leads to constant population of the excited 
state which may eventually result in photobleaching and loss of fluorescence. In the presence of 
solvent, the enhanced reactivity of the excited-state can lead to reactions with the solvent. Thus, 
in order to probe the propensities of the NBD-labelled alkaloids to photo- and thermal 
degradation, a quantitative stability study was conducted. 
 
The intermediate-chain NBD-labelled quinidine derivative (5) was selected as a representative 
molecule. Approximately 1 mg of this derivative was weighed out in several glass vials which 
was either left as a solid or dissolved in acetonitrile and subjected to the conditions listed in 
Table 4.4. This included storage in a freezer (-4°C), in an oven (70°C) or on the laboratory 
benchtop at ambient temperature (23°C). Two sets of the latter samples were prepared, one 
which was exposed to ambient light and one which was not. After three months at these 
conditions, quantitative analysis was performed using HPLC.  
 
No decomposition of the samples stored in the freezer or in the dark on the benchtop, either in 
the solid phase or in solution, was recorded (Table 4.4). While some decomposition was 





observed at the high temperature of the oven (16%) or upon exposure to light on the benchtop 
(9%), the combination of ambient light in the solution phase caused the most degradation 
(96%). The results indicate that it is important to protect the NBD-labelled derivatives from 
light, especially when they are in the solution state.  
 
Table 4.4. Decomposition of the intermediate-chain NBD-labelled quinidine derivative (5)  
after three months as a solid or solution and exposed to various conditions. 
 
Entry Temperature Exposure to 
ambient light 
Decomposition in  
the solid state 
Decomposition in  
the solution state 
1 -4°C No 0% 0% 
2 23°C No 0% 0% 
3 23°C Yes 9% 96% 
4 70°C No 16% N/A 
  





4.3. Physicochemical evaluation of novel fluorescent derivatives 
 
4.3.1. Binding stoichiometries and association constants of complexes with 
Fe(III)PPIX 
  
A common feature amongst the quinoline antimalarials is the thermodynamic stabilities of their 
complexes with Fe(III)PPIX. Since it was first proposed that Fe(III)PPIX is the molecular target 
of various quinoline antimalarials,12,13 increasing evidence has shown that the interactions of 
these drugs with Fe(III)PPIX are central to their antimalarial activity.4 This direct interaction 
appears to involve inhibition of the incorporation of Fe(III)PPIX into haemozoin, either by 
adsorption of the drug onto the surface of the crystal and inhibiting further biocrystallation14 or 
by sequestering free Fe(III)PPPIX via complexation and thus making the porphyrin unavailable 
for biocrystallisation.15 Accumulation of free Fe(III)PPIX following drug treatment has been 
observed for chloroquine and quinine, verifying that the haemozoin biocrystallisation pathway 
is indeed the likely target of these drugs within P. falciparum (Section 1.5.1).16 
 
As the binding stoichiometries and association constants with Fe(III)PPIX in solution of the 
three quinoline antimalarials in this study have been thoroughly characterised (Section 1.5.2),4,5 
these measurements were used as benchmarks to determine whether the fluorescently-labelled 
derivatives prepared in the previous chapter were suitable analogues of the parent molecules. 
As Fe(III)PPIX exhibits complex speciation in solution, it was elected to use a mixed aqueous 
solution of 40% DMSO (v/v) in 20 mM Hepes, pH 7.5, in which Fe(III)PPIX is predominantly 
monomeric, to simplify the comparison.17 This also allowed direct comparison of results with 
previous measurements.18,19 
 
In order to determine the binding stoichiometries of these complexes, the method of continuous 
variation, also known as Job’s method, was employed.20 In this approach, two equimolar stock 
solutions of Fe(III)PPIX and quinoline are mixed in a manner such that the total concentration 
of the two components is kept constant while the Fe(III)PPIX to quinoline ratio varies from 
sample to sample. The absorbance is plotted as a function of the mole fraction of Fe(III)PPIX.  
 
As stoichiometric ratios give rise to the greatest deviation in absorbance from the expected 
absorbance of Fe(III)PPIX, the position corresponding to the ratio of the complex is observed at 
the intersection of two lines fitted to the points originating from either side of the mole fraction 
scale. For example, a point of intersection corresponding to a 0.5 mole fraction of Fe(III)PPIX 
suggests a complex of 1:1 composition while an intersection corresponding to a mole fraction of 
0.67 indicates a complex with a 2:1 ratio of Fe(III)PPIX to quinoline compound.  





In these experiments, it is important to ensure (i) that the system conforms to the Beer-Lambert 
law, (ii) that a single complex predominates under the conditions of the experiment, (iii) that 
the total concentration of Fe(III)PPIX plus quinoline compound is kept constant and (iv) that pH 
is maintained constant.20 
 
A typical Job plot obtained from these experiments is depicted in Figure 4.8. In this case, the 
stoichiometry of the complex between Fe(III)PPIX and quinine was measured. The dashed red 
line indicates the absorbance of Fe(III)PPIX alone at 400 nm. Blue lines represent regression 
analyses through the two sets of circular data points. In this example, the intersection of the two 





Figure 4.8. Example of a typical Job plot to determine the stoichiometry of the Fe(III)PPIX-quinoline 
complexes; in this case, quinine was used. The dashed red line represents the absorbance of Fe(III)PPIX at 
400 nm in the absence of a binding partner. Blue lines represent the lines of best fit through the two sets of 
circular data points. The intersection of the two blue lines corresponds to a Fe(III)PPIX mole fraction of 0.5 
and hence to a 1:1 binding stoichiometry. 
 
These measurements were made for the fluorescently-labelled derivatives as well as the parent 
quinoline antimalarials. The results are tabulated in Table 4.5. As expected, the parent alkaloids 
quinine and quinidine formed complexes with Fe(III)PPIX with an unambiguous 1:1 ratio.18,19 
Their NBD-labelled derivatives retained the same clear binding stoichiometry, except for the 
longest-chain quinidine derivative (6) which could not be measured due to insolubility at the 

















necessary concentrations and the quinine-bimane derivative (19) for which a point of 
intersection of 0.455 ± 0.009 was observed. Nevertheless, a 1:1 binding ratio for this derivative 
is still likely as any other stoichiometric ratio corresponding to this mole fraction of Fe(III)PPIX 
would lead to an unusual, and hence unlikely, aggregation state of the two components.  
 
Table 4.5. Stoichiometries and association constants (log K) for complexes of the quinoline antimalarials 
and their fluorescently-labelled derivatives with Fe(III)PPIX determined via Job’s method and 
spectrophotometric titrations, respectively. Experiments were conducted in 40% (v/v) DMSO in 20 mM 
Hepes, pH 7.5, at 25°C. Measurements were performed in triplicate and uncertainties represent standard 
errors of the mean. ND = Not determined due to insolubility at the required concentrations. 
 
Entry Compound Point of intersection 
from Job plot 
Stoichiometry of  
Fe(III)PPIX to quinoline  
Log K 
1 Quinine (1) 0.499 ± 0.019 1 : 1  4.49 ± 0.03 
2 Quinine-NBD (3) 0.480 ± 0.009 1 : 1  4.92 ± 0.02 
3 Quinine-Bimane (19) 0.455 ± 0.009 1 : 1  4.26 ± 0.02 
4 Quinidine (2) 0.499 ± 0.007 1 : 1  4.95 ± 0.06 
5 Quinidine-NBD (4) 0.471 ± 0.009 1 : 1  5.22 ± 0.07 
6 Quinidine-HexNBD (5) 0.539 ± 0.019 1 : 1  5.17 ± 0.03 
7 Quinidine-DodecNBD (6) ND ND ND 
8 Chloroquine (7) 0.686 ± 0.003 2 : 1  10.11 ± 0.04 
9 Chloroquine-NBD (8) 0.606 ± 0.009 2 : 1  10.56 ± 0.09 
 
An unambiguous ratio of 2:1 was obtained for the Fe(III)PPIX-chloroquine complex, in 
agreement with experimental observations in aqueous solution.5 Although the stoichiometry of 
the Fe(III)PPIX complex with the NBD-labelled chloroquine derivative (8) was less definitive 
(0.606 ± 0.009), this most likely corresponds to a 2:1 ratio for the reasons given above.  
 
Having determined the stoichiometries of the Fe(III)PPIX-quinoline complexes, the strength of 
this interaction was measured by spectrophotometric titration. In the mixed aqueous system of 
40% DMSO (v/v) in 20 mM Hepes at pH 7.5, the strong quenching of the Soret band was used to 
determine association constants in accordance with methods used previously (Section 1.5.2).18 
All spectrophotometric titration data were fitted over the entire spectrum using the HypSpec 
software package (Version 1.1.33, HyperQuad, 2008). The association constants (log K) fitted 
using the binding ratios determined from the Job plots are listed in the final column of Table 4.5. 
A representative example of a spectrophotometric titration of quinidine with Fe(III)PPIX is 
shown in Figure 4.9.  







Figure 4.9. Spectrophotometric changes observed upon the addition of quinidine to Fe(III)PPIX in 40% 
DMSO (v/v) in 20 mM Hepes, pH 7.5, at 25°C. The initial spectrum with no compound added is shown as a 
continuous black line and the final spectrum is shown as a black dashed line. Intermediate spectra are 
coloured. The direction of change at 400 nm is indicated by an arrow and an isosbestic point is indicated by 
an asterisk. All spectra are corrected for dilution. Inset: Absorbance values at 400 nm fitted to a 1:1 
association model using non-linear least squares fitting are represented by a continuous blue line. 
 
Fe(III)PPIX has previously been shown to bind more strongly to quinidine than to quinine, 
corroborating the current measurements.18,19 As described earlier (Section 1.5.3), it has been 
shown in the solid state that there are three cooperative interactions responsible for the 
association between Fe(III)PPIX and the Cinchona alkaloids.21 This three-point binding mode of 
the alkaloids to Fe(III)PPIX comprises π-π stacking interactions, coordination to the iron centre 
of Fe(III)PPIX and a charge-assisted intramolecular hydrogen bond between the Fe(III)PPIX 
propionate group and the hydrogen of the (protonated) quinuclidine nitrogen of the alkaloid.21 
These observations corroborate previous computational predictions.22 Molecular mechanics 
modelling revealed that quinine and quinidine possess low-energy conformers that facilitate the 
formation of this charge-assisted hydrogen bond. Indeed, quinidine exhibits a lower strain 
energy of complex formation than quinine as a result of the “pre-organisation” afforded by its 



































absolute stereochemistry.22 This might explain its more favourable association constant and 
hence superior activity against P. falciparum compared to quinine.7 
 
The NBD-labelled derivatives of the Cinchona alkaloids all exhibit somewhat stronger binding to 
Fe(III)PPIX compared to the parent compounds. For example, log K values of 4.49 ± 0.03 and 
4.92 ± 0.02 were found for quinine and its NBD-labelled derivative (3), respectively. It is likely 
that the three cooperative interactions with Fe(III)PPIX described above are retained by the 
NBD-labelled derivatives but with enhancement of the π-stacking effect facilitated by the 
heteroaromatic NBD fluorophore. Once again, the association constant for the longest-chain 
quinidine derivative (6) could not be measured due to its insolubility at the necessary 
concentrations indicating its unsuitability for live-cell imaging studies. The association constant 
for the quinine-bimane derivative (19) was somewhat reduced (log K = 4.26 ± 0.01) compared 
to quinine itself.  
 
For chloroquine, the binding model was adjusted to account for complex formation with a 2:1 
ratio of Fe(III)PPIX to chloroquine. In this case, the binding of the NBD-labelled derivative was 
also somewhat stronger (log K 10.56 ± 0.09) compared to chloroquine on its own (log K 10.11 ± 
0.04), most likely because of enhanced π-stacking interactions due to the NBD fluorophore. 
 
In order to verify the speciation of Fe(III)PPIX in the complex with the NBD-labelled 
chloroquine, magnetic circular dichroism spectra were collected. This technique offers better 
resolution than conventional absorption spectroscopy and thus can indicate, unambiguously, 
the species of Fe(III)PPIX present. It has been definitively shown that chloroquine induces μ-oxo 
dimerisation of Fe(III)PPIX.5 This complex exhibits a characteristic magnetic circular dichroism 
spectrum (Figure 4.10A).5 A magnetic circular dichroism spectrum obtained for the complex 
between Fe(III)PPIX and the NBD-labelled chloroquine closely resembles this spectrum (Figure 
4.10B). This “fingerprint” technique shows that the NBD-labelled chloroquine derivative very 
likely also induces μ-oxo dimerisation of Fe(III)PPIX, corroborating the 2:1 stoichiometric 
measurements and similar association constants obtained. 
 







Figure 4.10. Magnetic circular dichroism  spectra of (A) the Fe(III)PPIX-chloroquine complex and  
(B) the complex between Fe(III)PPIX and the NBD-labelled chloroquine derivative. The spectra resemble 
closely those previously reported for the Fe(III)PPIX-chloroquine μ-oxo dimer complex.2 
 
All of the novel fluorescent derivatives retained the binding stoichiometry and reasonably 
similar association constants to their parent compounds with Fe(III)PPIX, their likely target 
within the malaria parasite, except for the long-chain NBD-labelled quinidine derivative (6) for 
which the necessary measurements could not be performed. These results suggest that, with the 
exception of 6, the derivatives are largely unaffected by the tethering of the fluorescent tag. 
These results also vindicate the design choice in Chapter 3 to functionalise the vinyl group of the 
Cinchona alkaloids as covalently modifying this part of the parent molecule does not appear to 
impact binding with Fe(III)PPIX. Similarly, for chloroquine, introducing a fourth amino 
functionality by selective N-dealkylation of a terminal diethyl group does not affect the capacity 
of the labelled derivative to induce μ-oxo dimerisation of Fe(III)PPIX. 
 
4.3.2. Solubility, aggregation and quenching studies of NBD-labelled derivatives  
 
As described previously, several NBD-labelled derivatives of quinidine were prepared by 
varying the length of the spacer chain between the alkaloid core and the reporter NBD 
fluorophore to generate derivatives of short (4), intermediate (5) and long (6) chain lengths. 
These three derivatives possess similar photophysical properties to one another (Table 4.1) 
although the latter two derivatives possess a higher fluorescence quantum yield than the short-
chain derivative (Table 4.2). However, only the short- (4) and intermediate-chain (5) 
derivatives were shown to retain their binding stoichiometries and association constants upon 
complexation with Fe(III)PPIX. These properties could not be measured for the long-chain 
quinidine derivative (6) due to the insolubility of this derivative at the necessary 
concentrations. Thus, to distinguish between these derivatives in order to determine the most 
suitable analogue, further physicochemical properties were probed. 











































To determine the aqueous solubility ranges of the NBD-labelled alkaloids compared to their 
parent alkaloids, a turbidimetric solubility assay was employed. In this assay, absorbance was 
measured at 620 nm to detect light scattering arising from insolubility. (The quinolines 
themselves do not absorb at this wavelength.) Table 4.6 demonstrates that the parent alkaloids 
quinine and quinidine are soluble in aqueous solution (pH 7.5) at concentrations greater than 
200 μM. However, their NBD-labelled derivatives are all less soluble in aqueous solution. While 
the short-chain derivatives (3, 4) are soluble between 150-200 μM, the longer chain derivatives 
are even less soluble. The long-chain derivative (6) was particularly insoluble, accounting for 
the difficulties associated with measuring its stoichiometry or association constant with 
Fe(III)PPIX, even in the presence of 40% (v/v) DMSO. 
 
Table 4.6. The aqueous solubility ranges of the Cinchona alkaloids and their  
NBD-labelled derivatives measured by turbidimetry in 20 mM Hepes, pH 7.5. 
 
Entry Compound Solubility range 
1 Quinine (1) > 200 μM 
2 Quinine-NBD (3) 150-200 μM 
3 Quinidine (2) > 200 μM 
4 Quinidine-NBD (4) 150-200 μM 
5 Quinidine-HexNBD (5) 100-150 μM 
6 Quinidine-DodecNBD (6) 20-40 μM 
 
The reduced solubility of the NBD-labelled derivatives indicates an increased hydrophobicity 
which most likely results from the incorporation of the heteroaromatic NBD fluorophore. This 
hydrophobicity may encourage aggregation of these derivatives in aqueous solution which 
would be detrimental to live-cell imaging studies. Hence, diffusion measurements were 
conducted to determine whether there was evidence of aggregation as a result of reduced 
aqueous solubility.  
 
To measure the diffusion coefficients of the NBD-labelled quinidine derivatives, a diffusion cell 
method was used in which a concentrated solution of the alkaloid was loaded into a lower 
chamber of the apparatus and allowed to diffuse into the corresponding upper chamber at 
ambient temperature.23 The upper chamber was then isolated, its absorbance measured and the 
concentration of the diffused molecule determined. Diffusion constants were calculated from 
Equation 4.4 which is derived from Fick’s laws of diffusion.23 In this expression, D is the 
diffusion coefficient (m2 s-1), h is the height of the diffusing column (m), t is the length of time 
(s), c0 the initial concentration (M) and c the final concentration in the upper well (M). 















The hydrodynamic radius of the molecule R, which is the apparent radius of the solvated 
molecule, can be calculated from its diffusion coefficient using the Stokes-Einstein equation 
(Equation 4.5). In this expression, k is the Boltzmann constant (J K-1), T is the absolute 









Diffusion coefficients were determined for quinidine and its NBD-labelled derivatives in both 
aqueous solution and 40% DMSO (v/v) in 20 mM Hepes, pH 7.5 (Table 4.7). In aqueous solution, 
the diffusion coefficients of the short- (4) and intermediate-chain (5) NBD-labelled derivatives 
were much smaller than the diffusion coefficient of the parent alkaloid quinidine, reflecting the 
reduced hydrophilicity of these derivatives. Their corresponding hydrodynamic radii were 
much larger to reflect their slower rates of diffusion; this was particularly large for the 
intermediate-chain derivative (102 Å) compared to the short-chain derivative (20 Å). The large 
hydrodynamic radius of the former molecule suggests aggregation in aqueous solution.  
 
Table 4.7 Diffusion parameters for quinidine and its NBD-labelled derivatives measured in aqueous and 
mixed aqueous solutions. ND = Not determined due to insolubility at the required concentrations. 
 
Entry Compound Diffusion coefficient D and 
hydrodynamic radius R  
in 20 mM Hepes, pH 7.5 
Diffusion coefficient D and 
hydrodynamic radius R  
in 40% DMSO (v/v) in  
20 mM Hepes at pH 7.5 
1 Quinidine 10.5 x 10-10 m2 s-1 (2.37 Å) 2.87 x 10-10 m2 s-1 (3.55 Å) 
2 Quinidine-NBD (3) 1.27 x 10-10 m2 s-1 (19.5 Å) 1.59 x 10-10 m2 s-1 (6.41 Å) 
3 Quinidine-HexNBD (4) 0.245 x 10-10 m2 s-1 (101.7 Å) 1.58 x 10-10 m2 s-1 (6.44 Å) 
4 Quinidine-DodecNBD (5) ND ND 
 
In mixed aqueous solution, the hydrodynamic radii of the short- (4) and intermediate-chain (5) 
NBD-labelled derivatives were very much smaller than in aqueous solution at approximately 6.5 





It is most likely that DMSO prevents aggregation due to its capacity as an efficient hydrogen-
bond acceptor and its lower dielectric constant. In both systems, the diffusion coefficients for 
the long-chain NBD-labelled quinidine derivative (6) could not be measured due to insolubility 
at the required concentrations, indicating again the unsuitability of this derivative for live 
imaging studies. 
 
To investigate whether these diffusion coefficients were indeed evidence of aggregation rather 
than increased molecular volume, especially in the case of the intermediate-chain derivative (5), 
an empirical relationship was exploited that relates the logarithm of the diffusion coefficient 
(log D) to molar volume (log Vm). A deviation from this relationship is evidence of aggregation.25  
 
The molar volume is calculated by dividing the molar mass of a substance by its density, which 
was predicted using the ChemSketch software package (Version 12.01, Advanced Chemistry 
Development Inc., 2010). Although this relationship holds strongly for polycyclic aromatic 
organic molecules, it can also be used to estimate the degree of aggregation of more complex 
organic molecules.25 Hence a number of known diffusion coefficients of polycyclic aromatic 
organic molecules (filled circles) were incorporated into the plot (Figure 4.11) along with the 
values from Table 4.7 (unfilled circles).25,26 The linear regression fitted to this data set 
(excluding the point in blue) is indicated by the red line and shows a very good correlation 




Figure 4.11. Plot of the dependence of log D on log Vm at 298 K (R2 = 0.949). Regression analysis excluded 
the point indicated in blue. Previously-measured values are indicated by filled circles25,26 while unfilled 
circles represent values measured in this work and listed in Table 4.7. The blue point corresponds to the 
intermediate-chain NBD-labelled quinidine derivative (5) in aqueous solution (20 mM Hepes, pH 7.5).  















All the values measured in this work, which are represented by unfilled circles in Figure 4.11 
but exclude the point in blue, obey the relationship between log D on log Vm at 298 K. This 
suggests that the NBD-labelled derivatives do not display behaviour associated with 
aggregation in aqueous solution, the only exception of which is the intermediate-chain NBD-
labelled quinidine derivative (5) whose values fall far outside the regression line (indicated by 
the blue point in Figure 4.11). This deviation suggests that the molecular weight of this complex 
is far larger than expected, consistent with behaviour arising from aggregation. These 
observations also show that the short-chain NBD-labelled derivatives (3, 4) are more closely 
related to the physicochemical properties of the parent molecules and are therefore more 
suitable analogues of the parent alkaloids. 
 
To probe the nature of the aggregation phenomenon exhibited by the intermediate-chain NBD-
labelled quinidine derivative (5), its fluorescence emission spectrum was monitored in the 
presence of Fe(III)PPIX. Fe(III)PPIX is a strongly-absorbing chromophore and so exerts a 
substantial inner-filter effect on fluorescence spectra in which the exciting radiation and/or 
fluorescence emission is attenuated, giving a lower signal than expected (Section 2.4.2). 
Furthermore, Fe(III)PPIX quenches fluorescence due to spin-orbit coupling of the heavy Fe(III) 
atom, especially with molecules with which it associates such as the intermediate-chain NBD-
labelled derivative (5, Log K = 5.17 ± 0.03 from Table 4.5). 
 
An example of the conspicuous inner-filter effect caused by Fe(III)PPIX is demonstrated by 
measuring the fluorescence emission of NBD-labelled 6-aminohexanoic acid which may be 
excited at either 465 nm or 350 nm to generate fluorescence at  max 545 nm. (The absorption 
and fluorescence spectra of this molecule were depicted above in Figure 4.2B.) This molecule 
has been measured to interact negligibly with Fe(III)PPIX and so one would not, initially, expect 
a decrease in its fluorescence emission in the presence of Fe(III)PPIX. However, attenuation of 
the fluorescence signal following excitation at both wavelengths is observed (represented by 
filled circles in Figure 4.12). This apparent quenching may be corrected by applying the inner-
filter factor that was presented in Equation 2.8 which takes into account the attenuation of the 
signal as a result of the strong absorption spectrum of Fe(III)PPIX. Consequently, there is no 
actual quenching of the fluorescence emission that takes place (unfilled circles in Figure 4.12).  
  







Figure 4.12. An illustration of the inner-filter effect when Fe(III)PPIX is titrated with NBD-labelled  
6-aminohexanoic acid (20 μM) in 20 mM Hepes, pH 7.5. Filled circles indicate attenuation of fluorescence in 
the presence of Fe(III)PPIX when excited at two different wavelengths, while unfilled circles indicate the 
correction applied by Equation 2.8. This reveals that there is no actual attenuation of the fluorescence signal 
caused by Fe(III)PPIX quenching. In both cases emission was monitored at 545 nm. 
 
In the case of quenching studies with the intermediate-chain NBD-labelled quinidine derivative 
(5) in the presence of Fe(III)PPIX, all fluorescence spectra were corrected for the inner-filter 
effect. It is worth pointing out that the aqueous absorption and emission spectra of this 
derivative (Figure 4.13) are somewhat different from its spectra in ethanol (Figure 4.2C) in 
which this molecule did not display an appreciable fluorescence emission at 385 nm. However, 
in the aqueous environment emission is observed at 385 nm, most likely due to reduced 
efficiency of Förster resonance energy transfer. Hence, fluorescence may be monitored at this 
emission wavelength to generate additional insights into its local chemical environment.  
 
Upon titrating Fe(III)PPIX into an aqueous solution of the intermediate-chain NBD-labelled 
quinidine derivative (5) and monitoring the fluorescence emission at both excitation and 
emission wavelengths, two different fluorescence emission profiles were observed (Figure 
4.14). Fluorescence emission following excitation at the wavelength corresponding to the NBD 
fluorophore (485 nm) indicates a rapidly diminishing fluorescence profile, while fluorescence 
emission following excitation at the wavelength corresponding to the quinoline core (335 nm) 
shows that fluorescence is quenched more gradually. This differential quenching profile 
suggests the presence of different chemical environments inhabited by the two fluorophores of 
the intermediate-chain quinidine derivative (5). 
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Figure 4.13. The absorption and fluorescence emission spectra of the intermediate-chain NBD-labelled 
quinidine derivative (5) in 20 mM Hepes, pH 7.5. The dashed black line indicates fluorescence emission 
arising from excitation at 335 nm while the solid black line indicates the emission spectrum following 
excitation at 480 nm. The red asterisk indicates stray light from second-order excitation that occurs at 




Figure 4.14. Quenching behaviour of the intermediate-chain NBD-labelled derivative (5) in 20 mM Hepes 
pH 7.5 after the addition of Fe(III)PPIX. Excitation at 485 and 335 nm were monitored at 550 and 385 nm, 
respectively. Data points were corrected for the inner-filter effect by applying Equation 2.8. 
 
The differential quenching effect of the intermediate-chain NBD-labelled quinidine derivative 
(5) may be qualitatively explained by an equilibrium process. As diffusion measurements 
suggest that this molecule aggregates in solution, it is not unreasonable to expect that these 
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molecules are packed to form micelles in which hydrophilic groups are in contact with the 
surrounding solvent while hydrophobic groups are sequestered together in the micelle centre 
(Figure 4.15A). In the case of the intermediate-chain NBD-labelled quinidine derivative (5), the 
quinidine groups, which are monocationic at pH 7.5, are exposed to the aqueous medium on 
account of their hydrophilic character (represented in blue in Figure 4.15). On the other hand, 
the NBD fluorophore is hydrophobic in character and prefers the interior of the micelle 




Figure 4.15. A qualitative equilibrium model rationalising the differential quenching observed for the 
quinoline and NBD fluorophores of the intermediate-chain NBD-labelled quinidine derivative (5) in aqueous 
solution in the presence of Fe(III)PPIX. The quinoline and NBD fluorophores are represented in blue and 
orange, respectively. Water molecules are also indicated. Addition of Fe(III)PPIX gives rise to three different 
arrangements of Fe(III)PPIX (B-D) in relation to the micelle (A). Addition of a large amount of Fe(III)PPIX 
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In the absence of Fe(III)PPIX, the intermediate-chain NBD-labelled quinidine derivative (5) 
likely forms the micelle arrangement represented in Figure 4.15A. Upon addition of a small 
amount of Fe(III)PPIX, some quenching of the quinoline may be observed on account of the 1:1 
association of the quinoline with Fe(III)PPIX (Figure 4.15B). On the other hand, due to its 
amphipathic nature, Fe(III)PPIX may prefer to partition within the micelle and hence a small 
amount of Fe(III)PPIX may quench a larger number of the NBD fluorophores simultaneously 
(Figure 4.15C). This gives rise to the differential quenching profile observed in Figure 4.14 
where the NBD fluorescence appears to be disproportionately quenched at low concentrations 
of Fe(III)PPIX compared to the quinoline. After a large amount of Fe(III)PPIX is added (n 
equivalents), complete quenching of both the quinoline and NBD fluorophores is observed. This 
occurs because all of the quinoline groups have been quenched in a 1:1 manner and Fe(III)PPIX 
has also partitioned within the micelle (Figure 4.15D), quenching all the NBD fluorescence. 
 
As live-cell microscopy is conducted in an aqueous medium, these observations suggest that the 
intermediate-chain NBD-labelled quinidine derivative (5) is a less suitable analogue of the 
parent molecule compared to its short-chain derivative (4). However, in order to conclude 
definitively which of the derivatives is the most suitable analogue of the parent molecule, it was 
necessary to test these derivatives against β-haematin inhibition and, most importantly,  
P. falciparum, as described in the subsequent section. 
  





4.4. Evaluation of the activities of novel fluorescent derivatives 
 
The mechanism of haemozoin formation in the malaria parasite implicates neutral lipid bodies 
as sites of nucleation and crystal growth (Section 1.3.2).27-29 However, the relatively high cost of 
lipids and the handling times required to prepare a suitable lipid blend are not amenable to 
initial laboratory screening. Instead, an assay to monitor synthetic haemozoin (β-haematin) 
formation based on the low-cost, commercially-available detergent NP-40 has been developed 
(Section 1.4.4).30,31 This detergent acts as a surrogate for neutral lipid droplets to promote 
crystallisation under physiologically-relevant conditions. β-Haematin inhibition is quantified by 
means of the colourimetric pyridine-ferrichrome method in which pyridine forms a low-spin 
complex with Fe(III)PPIX but not with β-haematin.32 Monitoring the absorbance at the Soret 
band of the pyridine-Fe(III)PPIX complex (405 nm) provides a rapid quantification of β-
haematin inhibition. 
 
The parent quinoline antimalarials as well as their fluorescent derivatives were tested using 
this assay, the results of which are listed in Table 4.8. These are presented as IC50 values, i.e. the 
concentration of compound needed to inhibit β-haematin formation by 50%. Representative 
examples of sigmoidal dose-response curves obtained for quinine, its bimane-labelled 
derivative (19) and the monobromobimane starting material (Figure 3.11) are presented in 
Figure 4.16.  
 
IC50 values of 52.3 ± 1.3 μM and 24.7 ± 0.6 μM were obtained for quinine and quinidine, 
respectively. The result is consistent with previous assays in which quinidine is a more potent 
β-haematin inhibitor than quinine.19 Chloroquine (22.0 ± 0.8 μM) was found to have similar 
activity to quinidine.  
 
Significantly, all fluorescent derivatives were found to be more active than their parent 
compounds. The NBD-labelled derivative of quinine (3) was a more potent β-haematin inhibitor 
than its bimane analogue (19). Both of these derivatives were more active than quinine itself. 
The short-chain derivative of quinidine (4) was the most active of all the tested compounds (5.2 
± 0.07 μM), although only slightly more active that its intermediate-chain counterpart (5) at 6.5 
± 0.1 μM. The long-chain derivative of quinidine was the least active of the three NBD-labelled 
quinidine derivatives (6) most likely because of its poor aqueous solubility; however, it was still 
more active than its parent compound. The NBD-labelled chloroquine (8) was also more active 
than its parent antimalarial with an IC50 value of almost half that of chloroquine. 
 
 





Table 4.8. 50% inhibitory activities (IC50) of quinoline antimalarials and their fluorescently-labelled 
derivatives measured using the NP-40 detergent-mediated assay for β-haematin inhibition and an in vitro 
assay against P. falciparum. Measurements were performed in triplicate and uncertainties represent 
standard errors of the mean. 
 
Entry Compound β-Haematin 
inhibition IC50, μM 
P. falciparum IC50, 
nM (NF54 strain) 
P. falciparum IC50, 
nM (Dd2 strain) 
1 Quinine  52.3 ± 1.3  62 ± ND // 
2 Quinine-NBD (3) 12.1 ± 0.01  100 ± 2 // 
3 Quinine-Bimane (19) 30.4 ± 1.6 721 ± 17 // 
4 Quinidine  24.7 ± 0.6  43 ± 7 // 
5 Quinidine-NBD (4) 5.2 ± 0.07  109 ± 4 // 
6 Quinidine-HexNBD (5) 6.5 ± 0.1  190 ± 30 // 
7 Quinidine-DodecNBD (6) 12.1 ± 2.2  39 ± 18 // 
8 Chloroquine  22.0 ± 0.8  14 ± 3 179 ± 14 




Figure 4.16. Representative examples of sigmoidal dose-response curves obtained using the NP-40 
detergent-mediated assay for quinine (red) and quinine-bimane derivative (blue), both of which showed 
activity against β-haematin formation. Monobromobimane (black) was inactive. 
 
Compounds were also tested for antiplasmodial activity in vitro against P. falciparum and 
quantified via the lactate dehydrogenase method developed by Makler et al.33 The results are 
also reported as IC50 values in Table 4.8. For the parent alkaloids and their fluorescent 
derivatives, activity was only tested against the chloroquine-sensitive NF54 strain. Quinidine 
was again found to be a more potent antimalarial than quinine, corroborating previous 



















observations.7 Intriguingly, the opposite relationship was observed between their respective 
short-chain derivatives whereby the NBD-labelled quinidine derivative (4, 109 ± 4 nM) was less 
active than the NBD-labelled quinine derivative (3, 100 ± 2 nM). In contrast to the results for β-
haematin formation, both of these derivatives were only about half as potent as their parent 
alkaloids. The long-chain NBD-labelled quinidine derivative (6) was the most potent of all three 
NBD-labelled quinidine derivatives. Presumably its enhanced lipophilicity allows it to cross 
bilayers or embed itself in biological membranes more efficiently, increasing its potency against 
P. falciparum. 
 
Despite favourable physicochemical interactions with Fe(III)PPIX and its capacity to inhibit β-
haematin formation, the bimane-labelled quinine derivative (19) was found to be much less 
active against P. falciparum (721 ± 17 nM). This indicates that this derivative is not, in fact, a 
suitable analogue of its parent alkaloid. Hence the short-chain NBD-labelled quinine derivative 
(3) is a more suitable fluorescent analogue of quinine than its bimane-labelled counterpart 
(19). While further work will be needed to ascertain the reason(s) for the reduced activity of 
the quinine-bimane conjugate (19) against P. falciparum, one does not expect the trends of the 
NP-40 assay to directly parallel the results of the biological testing. While the conditions of the 
β-haematin formation assay closely mimic biological conditions, other factors such as 
lipophilicity become important when considering, for example, permeability through 
membranes in a biological system.  
 
Chloroquine and its NBD-labelled derivatives were tested against the chloroquine-sensitive and 
chloroquine-resistant NF54 and Dd2 strains, respectively (Table 4.8). The NBD-labelled 
chloroquine derivative (8) exhibited improved activity compared to its parent compound in 
both strains. In the resistant Dd2 strain, a two-fold reduction in the activity of the chloroquine 
derivative was observed compared to a 12-fold reduction in the activity of its parent. The large 
increase in the IC50 value of chloroquine against this strain is genuine evidence of resistance 
while, on the other hand, the small two-fold change in the IC50 value of the fluorescent 
derivative shows that its activity against the resistant strain was, in fact, largely retained. This is 
consistent with previous observations that modifications to the chloroquine side-chain are 









4.5. Summary and conclusions  
 
Six novel fluorescent derivatives of the quinoline antimalarials were synthesised as described in 
Chapter 3 and as depicted in Figure 4.1. The broad aim of this chapter was to evaluate these 
derivatives using a suite of photophysical and physicochemical techniques in order to 
determine which of these derivatives were the most suitable analogues of the parent 
antimalarials for use in live-cell microscopy. The most important component of this evaluation 
was the measurement of their biological activities against P. falciparum. 
 
Photophysical characterisation indicated that the NBD-labelled derivatives possess a lower-
energy absorption band ( max approximately 480 nm) corresponding to the primary absorption 
band of the NBD fluorophore and a higher-energy band in the ultraviolet region corresponding 
to the superposition of the secondary absorption band of the NBD fluorophore and the 
absorption band of the quinoline core. Fluorescence emission following excitation at either of 
these wavelengths was observed at approximately 540 nm. This fluorescence exhibited a small 
solvatochromic shift from 525-550 nm over ten common solvents which showed excellent 
correlation with the ET(30) polarity parameter (R2 = 0.980). Fluorescence emission of the NBD-
labelled derivatives was enhanced in non-polar media but modest in aqueous solution, 
suggesting that this fluorophore was particularly suitable for evaluating the association of these 
derivatives with non-aqueous or lipid components of P. falciparum.  
 
Fluorescence quantum yields of all derivatives were higher in ethanol than in mixed aqueous 
solution, except for the NBD-labelled chloroquine derivative (8) for which the aqueous 
fluorescence quantum yield was higher than in ethanol. While substantial fluorescence was 
observed from the 4-amino-7-chloroquinoline heterocycle (approximately 380 nm), the 
corresponding fluorescence from the 6-methoxyquinoline heterocycle was greatly diminished 
in the bimane-labelled quinine derivative (19) and was absent in the NBD-labelled alkaloids (3-
6). This suggests that non-radiative energy transfer between the two fluorophores in the latter 
cases may be efficiently facilitated by a Förster resonance energy transfer mechanism. This 
observation was rationalised by quantitative predictions of spectral overlap and evaluation of 
the characteristic Förster distances R0 between the donor-acceptor pairs. 
 
As the binding stoichiometries and association constants of these antimalarials with Fe(III)PPIX 
have been well characterised,4,5 these measurements were used as benchmarks to determine 
whether the fluorescently-labelled derivatives had retained key physicochemical properties 
that were likely to be important for their in vitro activities. Spectrophotometric titrations 
revealed that a 1:1 binding stoichiometry to Fe(III)PPIX was conserved for the NBD-labelled 





alkaloids, vindicating the design choice to functionalise the vinyl group of these molecules. The 
strength of association with Fe(III)PPIX was also retained, albeit slightly enhanced in the NBD-
labelled derivatives and most likely due to improved π-stacking interactions with the 
heterocyclic NBD fluorophore. Unfortunately these values could not be measured for the long-
chain NBD-labelled alkaloid (6) as suitably high concentrations could not be reached. A 2:1 
binding stoichiometry to chloroquine and its NBD-labelled derivative (8) was observed and μ-
oxo dimerisation of Fe(III)PPIX in aqueous solution was confirmed by magnetic circular 
dichroism, indicating that addition of the NBD fluorophore does not affect the capacity of this 
derivative to induce μ-oxo dimerisation of Fe(III)PPIX. 
 
In order to evaluate further the physicochemical properties of the three NBD-labelled quinidine 
derivatives with varying chain lengths (4-6), their aqueous solubilities and diffusion coefficients 
were measured. Their aqueous solubilities were reduced compared to the parent molecules, 
most likely as a result of the incorporation of the hydrophobic NBD fluorophore. The long-chain 
NBD-labelled quinidine derivative (6) was particularly insoluble, indicating its unsuitability for 
microscopy. Furthermore, the intermediate-chain quinidine derivative (5) aggregates in 
aqueous solution. This may result from micelle formation in which the hydrophobic fluorophore 
is screened from the aqueous milieu, also indicating the unsuitability of this derivative. 
 
A detergent-mediated assay indicated that all of these derivatives retained their abilities to 
inhibit β-haematin formation and, indeed, were more active β-haematin inhibitors than the 
drugs. Crucially, the NBD-labelled derivatives were all active against the chloroquine-sensitive 
NF54 strain of P. falciparum with IC50 values in the nanomolar range. Surprisingly, the bimane-
labelled derivative of quinine (19) was much less active against this strain (IC50 > 700 nM) 
indicating that, despite an otherwise-favourable physicochemical profile, it was unsuitable as an 
analogue of quinine. The NBD-labelled chloroquine derivative (8) was active against the NF54 
strain and somewhat less active against the chloroquine-resistant Dd2 strain. The two-fold 
reduction in the activity of this derivative compared to the 12-fold reduction in the activity of 
chloroquine in the resistant strain is consistent with previous observations that modifying the 
chloroquine side-chain may overcome mechanisms of resistance in resistant strains.  
 
Taken together, these results indicate that the short-chain NBD-labelled alkaloids (3, 4) are the 
most suitable analogues of quinine and quinidine, respectively, by virtue of the retention of 
their interactions with Fe(III)PPIX and their potent activities against β-haematin formation in  
P. falciparum. For the same reasons, the NBD-labelled chloroquine derivative (8) is a suitable 
analogue of its parent molecule. Hence, these novel fluorescent derivatives were exploited in 
live-cell fluorescence microscopy studies of P. falciparum as described in Chapter 5. 
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Live-Cell Fluorescence Microscopy of Novel 






lthough quinoline-based drugs are regarded by many as the archetypal antimalarials, the 
intimate details of their mechanism of action against Plasmodium falciparum remain 
unclear. While most investigations have focused on the inhibition of haemozoin formation as 
their primary target and hence on the accumulation of these drugs within the digestive vacuole, 
these molecules may exert additional effects on the parasite. For example, the ultrastructure of 
several organelles in addition to the digestive vacuole is altered following drug treatment 
(Section 1.6.2).1,2 Furthermore, quinine (representing the quinoline methanols) and chloroquine 
(representing the 4-aminoquinolines) generate differential morphological effects on the 
parasite.3,4 While these effects may merely reflect the physicochemical differences between 
these two classes of antimalarials, they also suggest possible secondary targets within  
P. falciparum. 
 
Investigating the subcellular localisation of these antimalarials in P. falciparum, with emphasis 
on organelles other than the digestive vacuole, may reveal deeper insights into their mode(s) of 
action. Hence, novel fluorescent derivatives representing the two major classes of these 
quinoline drugs were designed and synthesised (Chapter 3). These fluorescent derivatives were 
thoroughly evaluated in order to determine which of these were the most suitable analogues of 
A 





the parent compounds (Chapter 4). These experiments identified the short-chain NBD-labelled 
derivatives of quinine and quinidine (3 and 4, respectively) and the NBD-labelled chloroquine 
derivative (8) as suitable analogues of their parent antimalarials. These analogues were 
therefore exploited in the live imaging studies described in this chapter. 
 
Several challenges associated with live imaging of the malaria parasite, notably its sensitivity to 
light and the restrictions posed by the diffraction limit of light, will be discussed. Several 
commercially-available tracker dyes used to co-stain organelles and other subcellular 
structures in this work will be described. Using confocal microscopy, a comprehensive survey of 
the accumulation and distribution of these analogues in P. falciparum-infected erythrocytes will 
be presented. Accumulation relative to co-illuminated organelles including the nucleus, 
endoplasmic reticulum (ER), mitochondrion and membranes will be illustrated. Quantitative 
colocalisation analysis was used to add rigour to these qualitative observations and a time-lapse 
study to investigate accumulation of the NBD-labelled quinine analogue across the 48-hour 
intraerythrocytic life cycle of the parasite was also conducted.  
 
In order to address some of the limitations associated with the small size of the parasite, super-
resolution structured-illumination microscopy (SR-SIM), which offers a two-fold improvement 
in resolution over confocal imaging, was employed. Once again, the colocalisation of the 
analogues was investigated relative to the ER, mitochondrion and membranes using the lipid-
specific stains LysoTracker and Nile Red. Observations regarding the prevalence and size 
distribution of haemozoin-associated neutral lipid bodies in the presence and absence of drug 
treatment will be presented. Finally, a critical discussion of all the major points arising from the 
live-cell imaging experiments in this chapter will be given. 
 
Thus the specific objectives described in this chapter were:  
 
i. To establish conditions suitable for live-cell imaging of P. falciparum; 
ii. To observe accumulation of the novel fluorescent analogues of the quinoline antimalarials 
within P. falciparum-infected erythrocytes; 
iii. To investigate general patterns of distribution, qualitatively and quantitatively, of these 
analogues relative to tracker dyes for organelles such as the nucleus, ER, mitochondrion 
and membranous structures using both confocal and super-resolution microscopies; 
iv. To generate new insights into the stage-specificity and size distribution of neutral lipid 
bodies in P. falciparum in the presence and absence of the NBD-labelled analogues; 
  





5.2. General considerations for live-cell imaging of P. falciparum  
 
5.2.1. Photosensitivity and endogenous fluorescence 
 
While live-cell fluorescence microscopy provides exceptional insights into structural and 
functional details of the intraerythrocytic malaria parasite, an important consideration for  
P. falciparum is that the parasite is extremely light-sensitive.5 Moderate exposure to light causes 
irreversible acidification of the parasite cytosol by as much as a whole pH unit, probably due to 




Figure 5.1. An illustration of the susceptibility of P. falciparum to photodamage via rupture of the  
digestive vacuole upon strong illumination. Panel A represents an infected erythrocyte stained with 
LysoSensor Blue DND-192 (“Lysosensor”) which colocalises with a weak autofluorescence arising from the 
cell (“Auto”). In Panel B, after 40 exposures at five-second intervals, both the autofluorescence and 
LysoSensor staining are found throughout the cytosol, indicating its acidification. Scale bars represent 2 μm. 
Reproduced from Wissing et al., J. Biol. Chem., 2002, 277, 37747 with permission from the American Society 
of Biochemistry and Molecular Biology. 
 
The authors hypothesise that the digestive vacuole membrane is highly susceptible to 
photodamage as a result of ferriprotoporphyrin IX, Fe(III)PPIX, which acts as a photosensitiser. 
A rapid increase in hydroxyl radicals is observed during irradiation.5 These are believed to be 
produced by a Fenton reaction with hydrogen peroxide which is produced during autoxidation 
of Fe(II)PPIX to Fe(III)PPIX, catalysed in turn by ferrous iron, viz. 
 
Fe2+ + H2O2 → Fe3+ + HO
● + HO- 
A B





The hydroxyl radicals result in peroxidation of polyunsaturated fatty acids which are enriched 
in the digestive vacuole membrane, resulting in disruption of the membrane and acidification of 
the cytosol.5 Furthermore, hydrogen peroxide released during haemoglobin degradation has 
been shown to inhibit the digestive vacuolar H+-ATPase directly (Section 1.3.4), disrupting pH 
regulation in the parasite by loss of the pH gradient rather than by loss of integrity of the 
digestive vacuole membrane.6 This has been confirmed by ultrastructural studies.6 
 
In order to reduce artefacts arising from photodamage of P. falciparum in this work, exposure of 
cells to light was kept at a minimum. Nevertheless, exposure to high-energy illumination was 
sometimes unavoidable, particularly in confocal microscopy for which high excitation energies 
are often required. Thus, in order to ensure that irreversible acidification of the parasite had not 
occurred over the course of an experiment, the autofluorescence of the digestive vacuole was 
monitored before and after each acquisition to ensure that membrane integrity had been 
maintained. 
 
Autofluorescence in P. falciparum arises from the haemozoin pigment and is also observed from 
its synthetic equivalent, β-haematin (Figure 5.2).7 Both species of crystalline Fe(III)PPIX exhibit 
a solid-state exciton fluorescence characterised by excitation and emission maxima of 555 and 
577 nm, respectively.7 This excitation maximum corresponds to the Q-band in the absorption 
spectrum which represents the lowest-energy singlet state of the material. The quantum yield of 
this autofluorescence is very low which makes it unsuitable for extensive imaging, but this is in 
fact advantageous as the signal is unlikely to interfere with the fluorescence of the much 




Figure 5.2. Haemozoin autofluorescence (red) originating from the digestive vacuole of P. falciparum, 
detected following excitation with the 561 nm laser and emission from the 575-630 nm filter. This 
autofluorescence colocalises with the signal from LysoTracker Yellow (false-coloured blue) which is specific 
for the digestive vacuole of the parasite. The scale bar represents 5 μm.  
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5.2.2. Stage-dependent sensitivity of P. falciparum to quinoline antimalarials 
 
Although the intraerythrocytic life cycle of P. falciparum may be conveniently divided into the 
ring, trophozoite and schizont stages based on morphology and metabolism (Section 1.2.2.), 
considerable variation is demonstrated amongst these stages in their sensitivities to the 
quinoline antimalarials. In order to address this, Yayon et al. monitored the effects of clinically-
relevant doses of chloroquine on P. falciparum by three different techniques and found that the 
trophozoite and schizont-stage were considerably more sensitive to chloroquine than ring-stage 
parasites.8 Furthermore, chloroquine sensitivity decreased as nuclear division neared 
completion.8 These findings were identical in chloroquine-sensitive and -resistant strains.8  
 
The authors commented that this stage-specificity in chloroquine sensitivity may be related to 
changes exhibited by later-stage parasites with respect to the rate of uptake of the drug, the 
presence of intracellular factors, changes in the chloroquine receptor site or changes in a 
metabolic process that is specifically inhibited by the drug.8 These comments from over three 
decades ago are insightful in the light of recent work which confirms the primary role of 
chloroquine as a haemozoin inhibitor and shows that a concomitant dose-dependent increase in 
free Fe(III)PPIX is correlated with a decrease in parasite growth.9 
 
For quinine, stage-specific experiments indicated that its primary mode of action is exerted on 
mature-stage parasites, producing 80% growth inhibition in schizonts within two hours of drug 
exposure and 100% growth inhibition of trophozoites over the same period.10 More recently, a 
flow cytometry-based approach for assessing the stages of the parasite life cycle showed that 
quinine and chloroquine both cause parasite death during the trophozoite stage.11 Wilson et al. 
found it unlikely that either of these drugs exert additional antimalarial efficacy through 
inhibition of merozoite invasion, ring development or schizont rupture.11 (It should be noted 
here that a single study found that ring-stage parasites are more susceptible to chloroquine 
than trophozoites, and that chloroquine in therapeutic concentrations prevented the 
transformation of rings to trophozoites.12) 
 
Consequently, in this work, only trophozoite- or schizont-stage parasites were examined as 
these stages of the intraerythrocytic life cycle are most sensitive to the quinoline antimalarials 
under investigation. Furthermore, this period is characterised by intense metabolic activity and 
parasite growth, alleviating some of the problems associated with the small size of the cells and 
the practical challenges posed by resolution. 
 
 





5.2.3. Overcoming the challenges of resolution for imaging P. falciparum 
 
Erythrocytes are already amongst the smallest of mammalian cells; P. falciparum is smaller still. 
Depending on the stage of its intraerythrocytic life cycle, the parasite varies in size from 1 μm to 
6 μm. Consequently, organelles such as the nucleus and digestive vacuole are even smaller and 
make the quantification of signals from these structures using widefield or confocal microscopy 
challenging.  
 
Furthermore, large amounts of haemoglobin and free Fe(III)PPIX within the infected host cell 
and P. falciparum present further complicating factors.13 Fe(III)PPIX is highly photoactive and 
may interfere with fluorescence excitation and emission signals. While isolating the parasites 
from the host cell via detergent lysis may provide some relief, this practice introduces problems 
of its own and most likely perturbs the natural metabolic processes of the parasite. 
 
Despite its obvious value in providing high-resolution images, electron microscopy is limited in 
its usefulness for investigating P. falciparum for several reasons. Firstly, membrane 
preservation in parasites is generally poor following sample preparation and this creates 
problems with identifying organelles in micrograph sections. Furthermore, serial sectioning is 
laborious, making it difficult to analyse the large number of cells necessary to obtain an overall 
picture of an organism’s organisation. Imaging live cells, on the other hand, offers the possibility 
of observing organelle morphology dynamically with minimal perturbation. However, light 
microscopy suffers from the so-called “diffraction limit” and traditional microscopy is 
fundamentally limited in its ability to resolve small cellular structures (Section 2.5.3). 
 
Thus, in order to overcome these limitations, a “super-resolution” technique was employed in 
the latter part of this work. Super-resolution structured-illumination microscopy (SR-SIM) is 
the simplest but also the most versatile of these techniques, offering an improvement in 
confocal resolution of up to two-fold without any special fluorophores or unusual sample 
preparation. This technique uses patterned illumination to reveal new information about the 
sample and was described fully in Section 2.5.4.  
 
A comparison between widefield (epifluorescence) imaging and SR-SIM is shown in Figure 5.3. 
The resolution enhancement in the lower panel is clearly visible. Colocalisation, in which the 
fluorescent molecules exhibit spatial overlap due to association with the same cellular 
structures, is clearly visible between the red and the green channels and manifests as yellow in 
the merged images. These channels represent LysoTracker Red, which illuminates the 
membranes of acidic compartments, and the NBD-labelled quinine derivative, respectively. 





Neither channel colocalises with the blue signal which represents the nucleus. Preliminary 
qualitative analysis of Figure 5.3 reveals a preference of the red and green signals for the region 




Figure 5.3. A comparison of widefield and SR-SIM imaging modalities. The upper panel represents a three-
colour experiment in widefield mode. The lower panel represents the same experiment using SR-SIM with a 
concomitant improvement in resolution. Colocalisation between the red and green channels is visible as 
yellow in the merged images. Haemozoin is labelled “Hz”. Scale bars represent 5 μm. 
 
In order to ensure that multicolour imaging using SR-SIM is reliable, especially for colocalisation 
analysis, it was necessary to ensure that all fluorescence channels were properly aligned. Hence, 
the microscope software was carefully calibrated with a channel alignment algorithm for the 
correction of lateral and axial drift and for chromatic aberration between the different 
fluorescent channels. For this purpose, multicolour fluorescent beads supplied by the 
microscope manufacturer were used. The results of the channel alignment algorithm are seen in 
Figure 5.4. The multicolour beads appear as three separate objects before the alignment; after 
the alignment algorithm, all three colours overlap precisely with one another. The coefficients 
obtained from this channel alignment algorithm were then applied to every image set post-
acquisition to ensure correct alignment of the fluorescence channels. 
DIC
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Figure 5.4. An illustration of the alignment of fluorescence channels before and after the alignment 
algorithm using multicoloured fluorescent beads. Scale bars represent 0.25 μm but the insets  
represent a four-fold magnification of the single bead in the small white box. 
 
All images were acquired over a range of 2 μm which is approximately the thickness of an 
erythrocyte. This “z-stack” comprises a number of slices approximately 0.1 μm thick in the axial 
(vertical) direction. Unless otherwise stated, all images presented in this chapter are maximum 
intensity projections of this acquired stack. Care was taken to evaluate each image stack on its 
own merits but, usually, maximum intensity projections were high-contrast, fair 
representations of the three-dimensional organisation of the cells. 
 
5.2.4. Commercially-available tracker dyes used in this work 
 
Several commercially-available tracker dyes were used to co-illuminate cellular compartments 
or subcellular structures in P. falciparum. As described below, these dyes have all been used 
previously in live imaging of the parasite hence justifying their use in this work. The chemical 
structures of these trackers are illustrated in Figure 5.5.14 
 
Hoechst 33342, hereafter referred to as “Hoechst”, is a cell-permeable bis-benzimidazole dye 
that is widely used to stain DNA in live or fixed cells. In P. falciparum, this gives a useful 
indication of the developmental stages of the asexual parasite. This dye binds to the minor 
groove of double-stranded DNA with AT-rich regions appearing the most fluorescent14 and thus 
is particularly well suited to this study as the genome of P. falciparum is AT-rich (82%).15 
Although Hoechst is excited in the ultraviolet region, in this study it was mostly used in 













Figure 5.5. The chemical structures of the commercially-available tracker dyes used in this study.  
The sulfonylurea drug glibenclamide is shown in the dashed box in its derivatised amide form. 
 
ER-Tracker Red (Figure 5.5) is a cell-permeable stain that comprises glibenclamide, a 
sulfonylurea antidiabetic drug, covalently tethered to a BODIPY (boron-dipyrromethane) 
reporter dye. The manufacturer indicates that glibenclamide binds to the sulfonylurea receptors 
of ATP-sensitive K+ channels which are prominent on the ER.14 However, quinine has also been 
found to inhibit the binding of a [3H]-glibenclamide derivative to the inner mitochondrial 
membrane, most likely by binding to its sulfonylurea receptors.16 Hence the NBD-labelled 
quinine analogue in this work may compete with ER-Tracker Red for binding to these 
sulfonylurea receptors. Furthermore, as sulfonylurea receptors may be present on other 
organelles such as the mitochondrion, non-specific staining may also be observed. Although the 
localisation of ER-Tracker to the ER has previously been verified in P. falciparum,17 for super-
resolution imaging in the latter part of this work care was taken to compare the signal received 
from the ER-Tracker to the expected morphology of the ER as previously described. This is 
discussed further in Section 5.4.1.  
 
MitoTracker Deep Red (Figure 5.5) is a far-red carbocyanine dye that passively diffuses across 
membranes and accumulates in active mitochondria. Its chloromethyl moiety reacts with thiol-





containing cysteine residues in the mitochondria.14 Thereafter, if the membrane potential in the 
mitochondrion is lost, the dye is still covalently bound in place. Hence, in order to generate 
reliable signals from this tracker dye which may be confounded by drug treatment, parasites 
were incubated first with MitoTracker to ensure covalent accumulation of the dye prior to 
treatment with the NBD-labelled analogues. MitoTracker Deep Red has previously been used to 
illuminate mitochondria in P. falciparum in combination with the SYBR nuclear dye to develop a 
medium-throughput flow cytometry-based assay to determine death-inducing compounds.18  
 
LysoTracker Red (Figure 5.5) is an acidotropic dye that illuminates acidic organelles in live cells, 
such as the digestive vacuole in P. falciparum. The dye consists of an N,N-dimethylethylamine 
motif which, like ER-Tracker Red, is linked to a BODIPY reporter dye.14 The fluorophore and 
weak base are together only partially protonated at neutral pH and the dye is thus freely 
permeable to cell membranes. The weakly basic amine selectively accumulates in low pH 
compartments due to the weak base effect.14 LysoTracker Red has previously been used for 
distinguishing the digestive vacuole of the parasite.19 
 
Finally, Nile Red (Figure 5.5) is a lipophilic dye that has been well-characterised and is 
commonly used to illuminate lipids in cells.20 It is highly solvatochromic in non-polar 
environments but is almost entirely quenched in water.20 Nile Red has previously been used to 
identify neutral lipid bodies within P. falciparum which have been implicated in haemozoin 
formation (Section 1.3.2).21 An advantage of Nile Red is that it has very broad excitation and 
emission spectra, allowing one to distinguish between different chemical environments as 
described below. A disadvantage of this property is that cross-talk is frequently observed when 
Nile Red is used in conjunction with other green dyes for which high-energy excitation is 
required.  
 
When excited using a 561 nm laser and monitored for fluorescence in the red region of the 
visible spectrum (650-710 nm), Nile Red emits a signal that corresponds to fluorescence from a 
phospholipid-rich environment.20 However, if the dye is excited with the same laser but 
emission is monitored at lower wavelengths (575-630 nm), the resulting signal corresponds to 
an environment characterised by uncharged or neutral lipids. Thus neutral lipid bodies in  
P. falciparum may be clearly identified using these settings (indicated by white arrows in Figure 
5.6).20 However, if Nile Red is excited with a high-energy laser at 488 nm and emission is 
measured between 500-550 nm, wavelengths typically used for the detection of fluorophores 
emitting in the green region of the visible spectrum, cross-talk in the green channel from low-
wavelength emission of Nile Red may be detected. This problem may be circumvented by using 
a narrower filter for green fluorescence to exclude this interfering signal. Recording emission 





from 500-520 nm, for example, eliminates the cross-talk but also reduces the amount of light 




Figure 5.6. An erythrocyte infected with a mature P. falciparum parasite and the staining pattern of Nile 
Red at various excitation and emission wavelengths. Blue represents the haemozoin autofluorescence 
previously described. Neutral lipid bodies are indicated by white arrows. Nile Red cross-talk from these 
neutral lipid bodies may be detected in what is typically the “green” region. The final panel represents 
excitation at 488 nm and the collection of green fluorescence over a reduced range (500-520 nm). With these 
collection parameters, the cross-talk corresponding to the neutral lipid bodies is no longer visible in the 
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5.3. Distribution of novel fluorescent analogues in P. falciparum 
 
5.3.1. Detection of novel fluorescent analogues in infected erythrocytes 
 
Confocal fluorescence microscopy was used for the initial examination of erythrocytes infected 
with the chloroquine-sensitive NF54 strain of P. falciparum. Infected erythrocytes were 
resuspended in Ringer’s solution and incubated at 37°C for imaging.22 Infected erythrocytes 
were readily identified under transmitted light by the haemozoin pigment. Detection of the 
novel NBD-labelled analogues within these cells was systematically investigated. 
 
Figure 5.7 illustrates selective accumulation of the NBD-labelled analogues of quinine and 
quinidine in infected erythrocytes. Although these analogues were observed to distribute 
throughout the parasite, there was a discernible structure to these patterns which was likely to 
correspond to accumulation within different organelles. For example, the diffuse signal 
corresponding to the parasite’s cytosol might indicate accumulation in the ER while, on the 
other hand, the tube-like structures that are seemingly in contact with the parasite plasma 
membrane may correspond to the mitochondrion (indicated by white arrows in Panels A and B 
in Figure 5.7). These analogues show a preference for localisation near the haemozoin (“Hz”) 
which most likely indicates accumulation within the digestive vacuole.  
 
For the NBD-labelled quinidine analogue, some cytoplasmic or plasma membrane staining in 
the infected host cell is observed (Panel B in Figure 5.7). This was present to a lesser extent in 
erythrocytes incubated with the NBD-labelled quinine analogue but was not observed at all in 
uninfected erythrocytes. Indeed, no accumulation of any of the NBD-labelled analogues, 
including the chloroquine analogue, was observed in uninfected erythrocytes (Panel C in Figure 
5.7). Although there are some differences in the host cell plasma membrane composition 
between infected and uninfected erythrocytes,23 this alone is probably not responsible for the 
selectivity of the analogues for the plasma membrane of infected host cells. It is possible that 
macromolecular remodelling of the host cell membrane, possibly through proteins exported to 
the host cell from P. falciparum, may provide additional binding sites on the surface of the host 
cell for these analogues.24 
 
The reversibility of accumulation and specificity of binding of these analogues in P. falciparum 
was investigated via competition experiments. There was negligible attenuation of the green 
signal when imaging medium containing the NBD-labelled analogues was removed and replaced 
with fresh medium containing no analogue or an equivalent amount of the parent antimalarial, 
suggesting that accumulation of the analogues within P. falciparum was irreversible or non-





specific. This was confirmed when cells, after initial loading with the parent quinoline, were 
washed in fresh medium and then incubated with the respective NBD-labelled analogue. Typical 
accumulation patterns of the NBD-labelled analogues were still observed, suggesting that the 
association was non-specific or that they had displaced the parent antimalarials despite the fact 
that the reverse did not occur. This is probably indicative of non-specific binding of the 
analogues. This is unsurprising given their enhanced lipophilicities over the parent compounds 




Figure 5.7. Panels A and B represent P. falciparum-infected erythrocytes incubated with the NBD-labelled 
analogues of quinine and quinidine, respectively. White arrows indicate patterns of accumulation in close 
association with the parasite plasma membrane and resembling the morphology of the mitochondrion.  
In Panel B, cytoplasmic or plasma membrane staining of the infected host cell is observed. Panel C represents 
an uninfected erythrocyte variously incubated with all fluorescent analogues, including the NBD-labelled 















Figure 5.8 indicates a z-stack over a vertical displacement of approximately 2 μm. In the upper 
two layers, corresponding to the plane of the host cell, binding of the quinidine analogue to the 
erythrocyte membrane is evident. Punctate clusters in the host cell cytosol likely correspond to 
parasite-derived transport vesicles. As one moves deeper through the infected cell and through 
the various planes of the parasite, more structural detail within the parasite is visible. 
Accumulation patterns within the parasite are similar to those described above with the most 
prominent signal arising from the region corresponding to the digestive vacuole. There is a 
reduction in green signal at the site of the haemozoin itself; this is to be expected as it is unlikely 




Figure 5.8. A z-stack over an axial displacement of approximately 2 μm. Staining of the host cell membrane 
and cytosol is evident in the upper two layers. Regions of accumulation of the quinidine analogue 
corresponding to various structures within the parasite can be seen in all layers. Scale bars represent 5 μm. 
 
Selective accumulation in infected erythrocytes, almost entirely within P. falciparum, was also 
observed for the NBD-labelled chloroquine analogue (Figure 5.9). Accumulation was most 
significant around the haemozoin and hence within the digestive vacuole of the parasite. This is 

















Figure 5.9. The distribution of the NBD-labelled chloroquine analogue in P. falciparum. The regions of 
brightest fluorescence from this analogue were closely associated with haemozoin (“Hz”) and hence the 
digestive vacuole as indicated by white arrows. Scale bars represent 5 μm. 
 
Generally, the signal observed from the NBD-labelled chloroquine was weaker than the signal 
from the NBD-alkaloids. While this may be due to the lower quantum yield of the chloroquine 
analogue (Table 4.2), it may also indicate enhanced accumulation of this analogue in aqueous 
compartments such as the digestive vacuole. This is not surprising as the chloroquine analogue 
is more hydrophilic than its alkaloid counterparts. Indeed, chloroquine may be expected to 
accumulate over a hundred-fold in the digestive vacuole compared to the alkaloids (Section 
1.6.1). Furthermore, the NBD fluorescence is weakest in aqueous medium compared to non-
polar environments (Figure 4.6). This was deliberately chosen to avoid the signal from this 
compartment overwhelming signals from elsewhere in the cell.  
 
Alternatively, the weaker signal of the chloroquine analogue might also be explained by the fact 
that it binds more strongly to Fe(III)PPIX compared to the alkaloid analogues. Consequently, its 
fluorescence is more readily quenched via the heavy-atom effect. Hence, any fluorescence signal 
observed from the chloroquine analogue originates from molecules which are not complexed to 
Fe(III)PPIX. Indeed, at doses of the NBD-labelled chloroquine analogue close to its IC50 value  
(< 50 nM), negligible signal was observed suggesting that all accumulated analogue within  












Taken together, these observations support the hypothesis that Fe(III)PPIX is the molecular 
target of chloroquine within P. falciparum and hence that haemozoin inhibition is its primary 
mode of the action against the parasite. While quinine and quinidine are also likely to share this 
target and mechanism of action, localisation studies suggest additional effects against the 
parasite insofar as their fluorescent analogues are suitable representations of the parent 
antimalarials.  
 
Although not shown here, the other NBD-labelled derivatives of quinidine that were prepared in 
Chapter 3 (that is, those with varying chain lengths between the quinoline core and the NBD 
fluorophore) also accumulated selectively within P. falciparum. However, following the process 
of evaluation as described in Chapter 4, these fluorescent derivatives were not considered 
suitable analogues of the parent molecules and hence their localisation was not considered in 
detail. Nevertheless, these derivatives might yet prove to be useful tools in the future as 
membrane-specific probes due to their hydrophobic character and are mentioned here for 
completeness. 
 
It was also shown in Chapter 3 that the bimane-labelled quinine derivative was not a suitable 
analogue of the parent alkaloid. This was primarily because its activity against the parasite was 
significantly reduced (IC50 > 700 nM) compared to quinine (IC50 ≈ 60 nM). Despite this, cells 
were incubated with this derivative but no signal was detected in P. falciparum-infected 
erythrocytes. This suggests two possible explanations which may be related to its reduced 
activity in vitro. Either this derivative does not accumulate within infected erythrocytes, which 
may explain its reduced activity against P. falciparum, or its fluorescence is completely 
quenched within the infected erythrocyte even at the high concentrations required for imaging 
(300 nM).  
 
Intriguingly, at the excitation and emission settings at which fluorescence from the bimane-
labelled quinine derivative was expected, an endogenous signal was observed originating from 
the digestive vacuole. This most likely corresponds to autofluorescence originating from the 
haemozoin as it was present even in control (untreated) cells. It was detected following 
irradiation with a two-photon laser at approximately 750 nm (corresponding to an excitation 
wavelength of 375 nm) with emission between 415-500 nm. This autofluorescence is more 
prominent than the autofluorescence previously discussed above in Section 5.2.1.17 
Furthermore, this new endogenous signal is compatible with other dyes such as LysoTracker 
and Nile Red which would typically overwhelm the characteristic autofluorescence arising from 
haemozoin in the red region. This previously-unreported autofluorescence signal is depicted in 
Figure 5.10. 







Figure 5.10. Erythrocytes infected with P. falciparum. A strong haemozoin autofluorescence (blue) 
corresponded to two-photon excitation at 750 nm and emission between 415-500 nm observed in (A) 
untreated cells and also cells treated with (B) LysoTracker Red and (C) Nile Red. Scale bars represent 5 μm. 
 
This new autofluorescence phenomenon may correspond to the autofluorescence reported by 
Bohórquez et al. which these investigators observed from a “non-acidic compartment adjacent 
to the digestive vacuole”.19 They claimed to detect the autofluorescence of quinine following 
excitation at 405 nm with emission from 410-455 nm. Their images are reproduced in Panel A 
of Figure 5.11. These excitation and emission wavelengths are a surprising choice as the 
absorption maximum of quinine is centred in the ultraviolet region at approximately 335 nm. 
Indeed, its molar extinction coefficient at 405 nm is negligible (Figure 4.2A). Furthermore, 


















Bohórquez et al. (Figure 4.2A). Although it is possible that some of the dicationic species of 
quinine, which does fluoresce between 410-455 nm, may be present in the parasite, the authors 
specifically claimed that the alkaloid accumulated in a non-acidic compartment. It is very 
unlikely that the monocationic species would predominate in non-acidic conditions. They 
inferred the non-acidic nature of this compartment from the fact that the autofluorescence 
signal did not colocalise with LysoTracker Red (Panel B in Figure 5.11).  
 
It is more likely that the autofluorescence signal arises from haemozoin autofluorescence rather 
than quinine. The authors do not present any untreated cells in their work, in which the quinine 
autofluorescence signal would be absent, to support their claim. Indeed, as described in Section 
3.2.1, the autofluorescence of quinine could not be detected to any appreciable extent using 




Figure 5.11. Panel A represents a P. falciparum trophozoite (3D7 strain) incubated with quinine (blue).  
A white arrow points to haemozoin crystals in the digestive vacuole. The authors claim that “quinine 
overlapped with haemozoin … and thus localised to the food vacuole”. The scale bar represents 5 μm.  
Panel B represents a reconstruction of a P. falciparum parasite indicating the different regions in space 
occupied by quinine (blue), LysoTracker Red (red) and a nuclear stain in green. Reproduced with minor 
modifications from E. B. Bohórquez et al., Malaria J., 2012, 11, 350. Licensed by BioMed Central Ltd. 2012. 





Besides the digestive vacuole, P. falciparum possesses several organelles that also play 
important roles during the intraerythrocytic cycle such as the endoplasmic reticulum (ER), the 
mitochondrion and the plastid (apicoplast). Unlike the digestive vacuole, these organelles 
persist in all stages of the intraerythrocytic cycle of P. falciparum and cannot be formed de novo. 
Furthermore, these organelles are becoming increasingly important as targets for drugs. For 
example, the clinically-relevant antimalarial atovaquone is a P. falciparum mitochondrial 
electron transport inhibitor. Consequently, the ER and the mitochondrion were examined in 
conjunction with the NBD-labelled analogues of the quinoline antimalarials. As described in 
Section 5.2.4, these organelles were illuminated using ER-Tracker Red and MitoTracker Deep 
Red, respectively.  
 
When incubated with ER-Tracker Red and Hoechst, infected erythrocytes displayed a diffuse, 
featureless red signal that appeared to represent the parasite cytosol but did not overlap with 
the highly-localised blue nuclear dye (Figure 5.12). The signal representing ER-Tracker 
colocalised broadly with the NBD-labelled analogues of quinine and quinidine. While suitable 
images in the presence of the NBD-labelled chloroquine analogue were more challenging to 
obtain, broad colocalisation was also observed between this analogue and the ER-Tracker. In 
contrast, overlap in signals was not observed between the green and blue channels, providing a 
first indication that the NBD-labelled quinolines do not localise to the nuclear compartment(s) 
of the parasite. 
 
It was found that incubating the cells with both ER-Tracker and the NBD-labelled analogues 
simultaneously resulted in a weak signal from the tracker dye. This situation was improved by 
treating the cells first with the ER-Tracker and then, after some time, the drug analogues. This 
suggests competitive binding which was not unexpected given that quinine binds to the 
sulfonylurea receptors which are prominent on the ER.16 That similar “competition” was noted 
for all three drug analogues may be as a result of structural similarities amongst the three 
quinoline antimalarials. Indeed, this observation serves as further evidence that the ER is an 
important site of accumulation of these drugs. 
 
On the other hand, the signal obtained from MitoTracker Deep Red corresponded to a more 
localised, tube-like structure within the parasite (Figure 5.13). This structure was typically 
found in close juxtaposition with the parasite plasma membrane and colocalised with regions of 
high signal intensity from all three NBD-labelled analogues, indicating that there was some 
extent of colocalisation between the mitochondrion and these analogues.  







Figure 5.12. P. falciparum-infected erythrocytes incubated with (A) quinine and (B) quinidine analogues 
(green) and co-stained with ER-Tracker Red (red) and Hoechst (blue). Broad colocalisation was observed 




Figure 5.13. P. falciparum-infected erythrocytes incubated with (A) quinine and (B) chloroquine analogues 
(green) in addition to MitoTracker Deep Red (red). Although diffuse signals were observed for the drug 
analogues, a highly localised signal was observed for MitoTracker which colocalised with prominent green 


















The ER and mitochondrion have previously been implicated in ultrastructural studies of drug-
treated P. falciparum. In quinine-exposed P. falciparum, mitochondria showed marked swelling 
with a more electron-lucent matrix.2 In P. falciparum treated with chloroquine, the 
mitochondrion also appeared swollen.1 It was also noted that the ER became difficult to identify 
following treatment with chloroquine.1 The “disintegration” of the ER may also explain why it 
was difficult to acquire suitable images dual-stained with the chloroquine analogue and ER-
Tracker. Indeed, images of cells acquired with the tracker dyes on their own and without 
analogue treatment provided better signal corresponding to ER-Tracker. These colocalisation 
observations may also be related to the remark by Combrinck et al. that liberated Fe(III)PPIX in 
chloroquine-treated parasites was observed in a region outside the digestive vacuole, possibly 
corresponding to be the ER.9  
 
It is tantalising to imagine that accumulation of the quinoline antimalarials in either of these 
organelles may interfere with essential metabolic processes of P. falciparum. However, it may 
not be entirely surprising that the NBD-labelled analogues accumulate in the ER of the parasite. 
It is well-established that lipophilic xenobiotics tend to accumulate in the ER, where many of the 
enzymes responsible for their catabolism reside.25 Xenobiotics refer to foreign molecules not 
normally produced in an organism or expected to be found there, or substances that are present 
in much higher concentrations than usual.25 These definitions both apply to the NBD-labelled 
drug analogues. It is thus difficult to distinguish whether the quinoline antimalarials play a 
specifically-disruptive metabolic role within the ER or whether their accumulation there is 
simply the consequence of a natural detoxification system that cells have developed to deal with 
foreign substances.  
 
5.3.2. Quantitative colocalisation analysis 
 
As demonstrated above, qualitative image analysis is useful for identifying patterns of signal 
distribution in a small number of cells, especially relative to other subcellular structures such as 
haemozoin or co-stained organelles. It is also useful for giving a first impression of the extent of 
signal overlap. However, qualitative analysis is inherently subjective and becomes impractical 
as the number of images becomes large. Thus, analysing images quantitatively to measure the 
amount of overlap between different signals is more efficient and less subjective. Quantitative 
analysis is particularly helpful in distinguishing between the distributions of closely-related 
fluorophores such as the diastereomeric NBD-labelled alkaloids.  
 
As described in Section 2.5.5, quantitative methods involve global statistical analysis of the pixel 
intensity distribution. Correlations between the intensity values of the pixels in a dual-channel 





image are examined and this is done using a variety of coefficients that measure the strength of 
the relationship between these two values. For the colocalisation analysis described below, “Just 
Another Colocalisation Plugin” (JACoP) for ImageJ (Version 1.48) was used.26  
 
As many of the colocalisation coefficients defined in Section 2.5.5 are sensitive to background 
noise, it is useful to define a threshold or cut-off value below which pixel intensities are 
discarded. However, deciding which pixels count as signal and which pixels count as noise by 
visual estimation is tedious and subjective. Instead, a robust way to determine thresholds has 
been proposed by Costes et al.27 On a cytofluorogram, the expected location of pixels 
representing noise is close to the origin and takes the shape of a formless cloud. When isolated, 
this population has a Pearson correlation coefficient of zero. Appropriate thresholds will 
therefore have been determined when all pixels carrying intensities below the thresholds have 
a Pearson correlation coefficient equal to or below zero.27 These values are computed 
incrementally, avoiding user input. The only drawback is that automatic thresholding is limited 
to images with a good signal-to-noise ratio. In the case of poor signal-to-noise ratio, the cloud 
formed by pixels contributing to noise encompasses part of the cloud formed by pixels 
contributing to the fluorescence signal.27 
 
Table 5.1 presents the correlation coefficients computed by quantitative analysis of at least ten 
different single-cell images for each pair of channels. The Pearson correlation coefficient was 
calculated with and without the automatic thresholding algorithm. All other coefficients were 
calculated with the automatically-generated threshold values taken into account. The signal of 
the NBD-labelled quinine analogue was directly compared to that of LysoTracker Red and 
Hoechst. In order to compare the NBD-labelled alkaloids against one another, the signal of the 
NBD-labelled quinidine analogue was also analysed against LysoTracker Red. As one would not 
expect LysoTracker Red (which labels the membranes of acidic compartments) to colocalise 
with Hoechst (which represents the nucleus), these correlation coefficients served as negative 
controls. To aid interpretation of Table 5.1, a sample dataset is provided in Figure 5.14.  
 
In the absence of automatic thresholding, the Pearson correlation coefficient shows that there is 
good overlap between the signals of the NBD-labelled alkaloids and LysoTracker Red (rP > 0.5) 
but that the overlap between either of these signals with Hoechst is poor (rP < 0.5). According to 
Figure 5.14, this is an accurate reflection of qualitative impressions of the images, i.e. the signals 
from the NBD-labelled alkaloids share very many more pixels with LysoTracker than with 
Hoechst. When automatic thresholding is applied, the negative correlations are somewhat 
stronger (rP < 0) but the positive correlations become weaker. This reflects pixels of noise in the 
images which are discarded by the thresholding algorithm. The Pearson coefficients determined 





in the presence of automatic thresholding are more reliable but they make the case of positive 
colocalisation more ambiguous. 
 
Table 5.1. Quantitative colocalisation analysis of at least ten different single-cell images per dataset 
generated a range of correlation coefficients in the presence or absence of automatic thresholding. Average 
values are given and uncertainties represent standard errors of the mean, except in the case of Van Steensel’s 
cross-correlation coefficient (CCF) for which the values are the modes of the datasets. 
 
  No thresholds Automatic thresholds applied Van Steensel’s CCF 
Channel 1 Channel 2 rP rP rM |k1 – k2| M1 M2 Min. δx Max. δx 























































Figure 5.14. Panel A represents an erythrocyte infected with P. falciparum and treated with LysoTracker 
Red (red), NBD-labelled quinine (green) and Hoechst (blue). Panel B represents the merged image where 
yellow indicates areas of overlap. Cytofluorograms show first estimates of colocalisation between red and 











If the average intensity values of the pixels are not subtracted from the original intensity values 
(Section 2.5.5), the Manders overlap coefficient (rM) can be generated which ranges from zero to 
one. The advantage of this coefficient is that it is less sensitive to differences in signal intensity 
between channels that might arise from labelling with different fluorophores, photobleaching 
and differences in gain settings during image acquisitions.26 All of these factors are relevant to 
the images in question. In the case of the Manders overlap coefficient, there is a stronger 
correlation obtained between the red and green channels (rM >> 0.5). However, it is surprising 
that a positive correlation is also observed for the blue signals with either the red or green 
channels (rM > 0.6). While the Manders overlap coefficient is regarded as more reliable than the 
Pearson correlation coefficient, it is not good practice to rely on these two coefficients alone; 
hence, other colocalisation coefficients were evaluated as well. 
 
As described in Section 2.5.5, the extent of colocalisation may be further examined by “splitting” 
the Manders overlap coefficient into two separate parameters (k) to determine the 
contributions of either signal to the extent of colocalisation. In the case of good colocalisation k1 
will approach α (the line of best fit through the cytofluorogram). This is indeed the case for the 
dataset in Figure 5.14 in which k1 = 0.683 for the red-green channel combination. The mean 
slope of the cytofluorogram is α   0.657, which is close to the value of k1, suggesting very good 
colocalisation. Because k1 is sensitive to differences in intensity from channel B, and vice versa, 
the difference between these split coefficients (|k1 – k2|) gives a further indication of 
colocalisation as it is typically small for true colocalisation. This is the case for the red and green 
channel pairs in Table 5.1 (|k1 – k2| ≈ 0.1). This relationship also shows that there is an equal 
contribution to colocalisation from both channels. In contrast, this value is high for the red-blue 
channels (|k1 – k2| > 0.3) indicating an absence of colocalisation.  
 
The Manders colocalisation coefficients M1 and M2 both approach unity in the case of the red-
green channels, suggesting excellent colocalisation between these channels. These values are 
much lower (M1, M2 < 0.5) for the green-blue and red-blue channel combinations which, when 
taken in conjunction with the other coefficients above, show conclusively that there is no 
colocalisation between these channels. 
 
Finally, van Steensel’s cross-correlation coefficient (CCF) can be used as an alternative approach 
to distinguish between positive correlation and partial colocalisation. The images are shifted 
pixel-by-pixel in the x-direction relative to one image and for each shifted set the Pearson 
correlation coefficient is calculated (Section 2.5.5). In a true colocalisation scenario, the 
correlation is lost after the displacement and is reflected by small δx values for the NBD-labelled 
alkaloids compared to LysoTracker Red (δx = 0 and δx = -1). In the case of the blue dye, a larger 





Pearson correlation coefficient is obtained only after the shift process (δx = 10 and δx = 11). In 
this case, an improvement in colocalisation is achieved only after shifting the images relative to 
one another, suggesting that they were not colocalised to begin with.  
 
These various colocalisation coefficients show that, in general, colocalisation of the quinidine 
analogue with LysoTracker Red is higher than with the quinine analogue. None of these three 
signals overlap significantly with the nucleus. The implications of these observations are 
discussed critically in Section 5.5. Further verification of these quantitative colocalisation 
results may be obtained by considering a three-dimensional rendering of a sample image set. 
Although the qualitative analysis above has been performed on images acquired by confocal 
microscopy, better three-dimensional renderings may be constructed from super-resolution 
datasets as the axial slices are much thinner (z   0.1 μm) hence there is less interpolation 
required. In Figure 5.15, which is a three-dimensional rendering of the data set acquired in 
Figure 5.3, it can be seen that red and green regions are closely apposed and often overlap, 
especially on the surface of the parasite. The blue signal does not overlap with either the red or 
green signals. The “hole” or absence of signal in the top right-hand corner corresponds to the 
haemozoin in this schizont-stage parasite. Some binding of the analogue can also be seen in the 




Figure 5.15. Two different views of a three-dimensional rendering of the schizont in Figure 5.3 incubated 
with LysoTracker Red (red), Hoechst (blue) and the NBD-labelled quinine analogue (green).  
 





To understand better the spatial distribution of the NBD-labelled analogues relative to the ER 
and mitochondrion, quantitative analysis was carried out between the confocal image pairs in 
the presence of these trackers. Because the quinine and quinidine analogues have very similar 
distributions (Table 5.1), these analogues were pooled when considering their colocalisation 
relative to the ER. Additionally, because suitable images of NBD-labelled chloroquine and ER-
Tracker could not be obtained, these were not included in the quantitative analysis. All 
coefficients in Table 5.2 were obtained in the presence of automatically-determined threshold 
values. 
 
The Pearson correlation coefficient (rP) is high in the case of the NBD-labelled analogues and 
ER-Tracker, but it is lower in the case of MitoTracker. This reflects initial qualitative 
impressions of the images in which the ER-Tracker is generally diffuse, overlapping with the 
entire signal from the NBD-labelled analogues (Figure 5.12). On the other hand, the MitoTracker 
dye is more tightly localised relative to the green signal and this is reflected by a lower Pearson 
correlation coefficient as there are large areas of green signal that do not correspond to a signal 
in the red channel (Figure 5.13). The more reliable Manders overlap coefficient (rM) indicates 
excellent overlap (rM > 0.8) for all three channels which is somewhat surprising given that the 
fraction of overlap between the green and red channels differs between the ER and 
mitochondrial signals. 
 
Table 5.2. Quantitative colocalisation analysis of at least five different single-cell images per dataset 
generated a range of correlation coefficients in the presence of automatic thresholding. Average values are 
given and uncertainties represent standard errors of the mean, except in the case of Van Steensel’s cross-
correlation coefficient (CCF) for which the values are the modes of the datasets. 
 
  Automatic thresholds applied Van Steensel’s CCF 
Channel 1 Channel 2 rP rM |k1 – k2| M1 M2 Min. δx Max. δx 
NBD-labelled 
alkaloid 






































The difference between the “split” k coefficients between green and red channel pairs is once 
again small and indicates a positive colocalisation between all dye pairs. The Manders 





coefficients are most useful where there are clear structural features in the images;26 hence, in 
the case of a very diffuse signal such as ER-Tracker, the value is fairly low (M2 ≈ 0.5). These 
same coefficients are very high for the NBD-labelled probes when compared with Mito-Tracker 
(M2 > 0.5), showing excellent colocalisation. Van Steensel’s CCF also shows that these results 
represent a true colocalisation situation as the magnitude of the Pearson correlation coefficient 
does not improve after shifting the channels relative to one another; on the other hand, the 
Pearson correlation coefficient can be minimised by shifting the channels further away from 
one another in the x-direction (min. δx = 20 or -20).  
 
Some of the coefficients presented in Table 5.2 have large uncertainties compared to those in 
Table 5.1. This is probably due to noise in these signals, particularly from the ER-Tracker for 
which the signal was weak and relatively featureless. Nevertheless, these results corroborate 
the qualitative observations that there is broad overlap between the ER and the NBD-labelled 
alkaloids, and between the mitochondrion and the NBD-labelled analogues. 
 
5.3.3. NBD-labelled quinine distribution over the life cycle of P. falciparum 
 
P. falciparum undergoes a 48-hour life cycle of asexual replication in human erythrocytes which 
causes the clinical symptoms of malaria. This cycle commences when extracellular merozoites 
invade erythrocytes. Upon entry into the erythrocyte, ring-stage parasites actively modify the 
host cell and begin ingesting the abundant haemoglobin from the erythrocyte (Section 1.2.3). To 
avoid the toxic effects of Fe(III)PPIX, this molecule is biocrystallised to haemozoin within the 
parasite’s digestive vacuole. The mechanism of this biocrystallisation process is still unclear but 
neutral lipid bodies28 and, more recently, phospholipid membranes29,30 have been implicated in 
its formation (Section 1.3.2). After almost complete consumption of the erythrocyte cytoplasm, 
trophozoites undergo a series of nuclear divisions to form multinucleated schizonts. These 
eventually form many daughter merozoites which burst out of the remnant host cell and invade 
fresh erythrocytes.  
 
Despite diminished use due to decreased efficacy and undesirable side effects, quinine remains 
the frontline drug for severe malaria and malaria in pregnancy.31 Due to its clinical relevance, 
the accumulation of its NBD-labelled analogue over the course of the intraerythrocytic life cycle 
was monitored at six time points (Figure 5.16). Besides live-cell fluorescence imaging, slides of 
fixed cells were prepared in which parasitised erythrocytes were detected using a Giemsa stain 
to tell most reliably the size and extent of the nucleus and thus the life cycle stage of the 
parasite. As mentioned in Section 5.2.4, Nile Red can be monitored using different emission 
filters to differentiate between phospholipid and neutral lipid structures within P. falciparum. 






Figure 5.16. Time-lapse experiment of P. falciparum. Giemsa-stained slides of fixed cells and fluorescence 
channels of live cells were recorded at six time intervals. At each time point, parasites were incubated with 






















































































































































The earliest time point that was investigated was the mid-ring stage approximately 12 h into the 
intraerythrocytic life cycle (Figure 5.16A). At this stage, parasites were small (1-2 μm) and were 
often in close proximity to the plasma membrane of the host cell following invasion. The nucleus 
(blue) was elongated and was found alongside the plasma membrane of the host cell. Nile Red 
revealed large amounts of phospholipid (red) but no emission in the region corresponding to 
neutral lipid (gold). The pattern of red emission resembled the pattern of fluorescence from the 
quinine analogue (green) resulting in large overlap between these signals. 
 
At approximately 18 h, similar features were observed but the parasite had positioned itself in 
the centre of the erythrocyte (Figure 5.16B). There was still prominent overlap between the 
phospholipid region of Nile Red (red) and the NBD-labelled quinine (green). The nucleus was 
rounder in shape and fluorescence from both red and green channels was reduced in the region 
corresponding to the nucleus (blue). 
 
After the first day of the P. falciparum life cycle (24 h), haemozoin was detectable both in the 
Giemsa-stained slides and in the transmitted light channel of the fluorescence microscope 
(indicated by a white arrow in Figure 5.16C). The appearance of haemozoin corresponded to the 
formation of a small digestive vacuole. However, at this stage there was still no indication of 
neutral lipid bodies, consistent with other studies that implicate these structures only later in 
the parasite life cycle.32 The appearance of more structure in the red channels, corresponding to 
phospholipid regions, indicated the development of organelles such as the ER and a juvenile 
mitochondrion. Overlap with the green channel was still prominent, especially near the 
haemozoin and hence indicative of association with the young digestive vacuole. 
 
Upon maturation of the trophozoite at approximately 36 h, the parasite increased at least two-
fold in size (Figure 5.16D). Extensive haemoglobin catabolism was evident from the large 
haemozoin pigment and individual clumps of crystals were discernible, especially in the 
Giemsa-stained slide. Also prominent was the appearance of a spherical neutral lipid body 
(approximately 0.5 μm in diameter) indicated by a white star in Figure 5.16D. There was some 
evidence of overlap between the quinine analogue and the neutral lipid body but not an 
increase in signal as might be expected from accumulation within this neutral lipid environment 
and in which the brightness of the NBD fluorophore is enhanced.  
 
At this time point, the signals of the phospholipid region of Nile Red and the quinine analogue 
still overlapped extensively. Maturation of organelles corresponded to distinct shapes with their 
signals. The tube-like structure which appeared adjacent to the plasma membrane was likely to 
be the mitochondrion (Figure 5.16D). This structure also appeared faintly in the neutral lipid 





region of the Nile Red spectrum. A significant amount of green signal was seen in the region 
corresponding to the digestive vacuole which may be significant given that this is also the 
period in the life cycle in which quinine has been found to be most active against P. falciparum 
(Section 5.2.2). 
 
At 42 h, corresponding to the late trophozoite or early schizont stage, the nucleus was enlarged 
and irregular. In most cells examined, several nuclei were often present indicating that the 
parasite had commenced nuclear division (Figure 5.16E). The parasite took up almost the entire 
erythrocyte and the haemozoin pigment was very prominent. The number and size of neutral 
lipid bodies increased. In this example, one lipid body showed partial colocalisation with the 
NBD-labelled quinine analogue. There was still extensive overlap between the phospholipid 
region of Nile Red and the quinine analogue while the signal from Hoechst (nucleus) was clearly 
excluded from both channels. Once again, a small circular structure was faintly visible in the 
neutral lipid region of the Nile Red signal which corresponded to a similar signal in the 
phospholipid and NBD-labelled quinine channels. 
 
At 48 h, corresponding to the late schizont phase of the intraerythrocytic life cycle, many 
daughter merozoites, each with its own nucleus, were almost fully formed (Figure 5.16F). At 
this stage, the haemozoin was usually found in the centre of the host cell and often in intimate 
association with several neutral lipid bodies. In this example, the lipid bodies displayed little if 
any colocalisation with the NBD-labelled quinine. Nevertheless, there was high lipid content in 
this mature cell and this phospholipid emission overlapped strongly with the quinine analogue. 
Eventually the host cell burst, releasing many merozoites each of which took some of the 
quinine analogue fluorescence with them (not shown).  
 
Although quinine is known to be most active in mature-stage parasites (Section 5.2.2),10,11 these 
data show that quinine accumulates in all stages of the intraerythrocytic P. falciparum life cycle. 
At all six points of this time-lapse experiment, the quinine analogue showed an affinity for 
membranous regions within the parasite by overlapping with the Nile Red emission 
corresponding to phospholipid signal. This corroborates the quantitative measurements in 
which the quinine analogue localised strongly with LysoTracker Red. Despite this, the quinine 
analogue did not readily associate with the neutral lipid bodies even though the quinine 
analogue is somewhat lipophilic due to its tethered fluorescent tag. Hence it is more likely that 









5.4. Colocalisation studies with super-resolution microscopy 
 
5.4.1. Colocalisation of NBD-labelled analogues with the ER and mitochondrion 
 
In order to overcome the limitations of resolution and to generate deeper insights into the 
localisation and distribution of the NBD-labelled analogues of the quinoline antimalarials in  
P. falciparum, super-resolution structured-illumination microscopy (SR-SIM) was employed. 
This modality offers a two-fold enhancement in resolution compared to confocal microscopy 
(Section 2.5.4). Importantly, it is a live-cell imaging technique and does not require special 
sample preparation or fluorophores. Imaging conditions are also less harsh, preserving the 
integrity of the cells. As SR-SIM has not previously been used to investigate drug localisation in 
P. falciparum, the tracker dyes used to co-stain organelles were first validated in the absence of 
the NBD-labelled analogues. These images were compared to images obtained in previous 
studies in which their morphologies were fully characterised using organelle-specific 
fluorescent proteins.  
 
In the case of the ER and the mitochondrion, van Dooren et al. have produced transfected lines 
of P. falciparum that allow specific illumination of these organelles.33 For the ER, they used an 
ER-specific marker PfBiP to encode a fluorescent fusion protein BIP(s)–GFP–SDEL.33 This 
comprised the BiP signal sequence (BiP)s followed by a green fluorescent protein (GFP) 
reporter and finally the SDEL motif of PfBiP which was postulated to mediate retention of BiP in 
the ER. They confirmed the localisation of this construct using immunofluorescence, 
demonstrating that it is retained in the ER and that it reliably depicts the structure of the 
organelle.33 In a separate experiment, they prepared a double transfectant line in which both 
mitochondrial and apicoplast proteins were tagged with the fluorescent proteins eYFP and 
dsRed, respectively.33  
 
In early intraerythrocytic parasites, the ER has a simple morphology and comprises a crescent 
shape that subsequently develops into a ring of fluorescence, presumably around the nuclear 
envelope, from which extensions emerge into the cytosol (Panel A in Figure 5.17).33 Van Dooren 
et al. reported occasional “horn-like” extensions emerging from the nuclear envelope which 
often extend around the digestive vacuole.33 Whether this indicates trafficking of substrates 
between these organelles still remains to be seen. In later stages, the ER appears to branch 
extensively through the cytosol, creating a complicated network. These changes in morphology 
probably reflect the increase in the number of functions of the ER as the parasite becomes more 
metabolically active. 
 





Panel B in Figure 5.17 represents SR-SIM images of ER-Tracker Red (red) and Hoechst (blue). 
There are various similarities to the images of Van Dooren et al. such as the ER encircling the 
nucleus and even the presence of the “horn-like” structures making contact with the digestive 
vacuole, indicated by white arrows in both panels. Thus it may be concluded that ER-Tracker 




Figure 5.17. Comparison of ER morphology in P. falciparum using (A) fluorescent proteins and (B) ER-
Tracker Red. Panel A represents confocal images of a GFP-labelled protein that is specifically localised to the 
ER.33 Panel B represents SR-SIM images of ER-Tracker Red (red) and Hoechst (blue). Scale bars represent 5 
μm. Panel A is reproduced with permission from G. G. van Dooren et al., Mol. Microbiol., 2005, 57, 405. 
 
Figure 5.18 depicts several SR-SIM images of ER-Tracker Red in the presence of the three NBD-
labelled antimalarials. It is immediately clear that there is an improvement in signal from the 
ER-Tracker in the confocal studies which was previously diffuse and featureless. In Figure 5.18, 
the structure of the ER is complex and becomes more reticulate in more mature cells. All three 
NBD-labelled analogues showed colocalisation with at least some regions of the ER. The regions 
with most prominent colocalisation between red and green channels are indicated with white 
arrows in Figure 5.18. In the case of the NBD-labelled alkaloids, staining of the plasma 
membrane of the host erythrocyte was also frequently observed. This is particularly evident in 















Figure 5.18. Erythrocytes infected with mature P. falciparum and incubated with ER-Tracker Red (red) and 
the NBD-labelled analogues (green). Yellow indicates regions of overlap with areas of most intense overlap 
indicated by a white arrow. Scale bars represent 5 μm. 
 
The signal for the NBD-labelled chloroquine analogue is very weak and, once transformed by 
the SR-SIM post-acquisition processing algorithm, it emerges as discrete punctate clusters. It is 
not possible to say whether this punctate clustering reflects the actual distribution of this 
molecule within P. falciparum or whether it is merely an artefact of SR-SIM processing. The ER 
is often closely juxtaposed with the haemozoin, and hence the digestive vacuole, and these 
regions were occasionally observed to colocalise with the analogues (Figure 5.18A). In almost 














each case, there is signal corresponding to the analogues that does not colocalise with the ER-
Tracker. This could refer to alternative sites of localisation such as the mitochondrion, or 
accumulation within the digestive vacuole as is likely the case in Figure 5.18B. 
 
The mitochondrion of P. falciparum presents a different morphological profile from the ER. 
Ultrastructural studies have identified the mitochondrion as a single crescent-shaped organelle 
in merozoites that branches out to form a tubular structure in trophozoites, before segregating 
along with the nucleus into daughter merozoites.33 In mature parasites it frequently appears to 
fuse upon itself and is often seen in close association with the plasma membrane (Panel A in 
Figure 5.19, white arrows).33 A similar profile was also observed for the SR-SIM images of the 
mitochondrion acquired using MitoTracker Deep Red, validating the use of this organelle 
indicator (Panel B in Figure 5.19). Panel C in Figure 5.19 represents a particularly clear confocal 
image of MitoTracker (blue) and LysoTracker Red (red) showing the morphology of a branched 




Figure 5.19. Comparison of mitochondrial morphology in P. falciparum. Panel A represents confocal images 
of eYFP-labelled mitochondrial protein CS(I) (green). The apicoplast protein ACP(1) has been tagged with 
fluorescent protein dsRed (red). In some panels, Hoechst (blue) has been added as a co-stain. Panel B 
represents SR-SIM images of ER-Tracker Red (red) and Hoechst (blue). Panel C represents a confocal image 
of MitoTracker Deep Red (blue) and LysoTracker Red (red). Scale bars represent 5 μm. Panel A is reproduced 
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Although the apicoplast was not investigated in this study, it is mentioned here for 
completeness. Van Dooren et al. noted that the apicoplast (indicated in red in Panel A of Figure 
5.19) is a small, cylindrical structure which lengthens during the trophozoite stage.33 Electron 
microscopy studies revealed a close association between the apicoplast and mitochondrion at 
various stages during the intraerythrocytic cycle. This has been postulated to allow transfer of 
metabolites between these two organelles.33  
 
Figure 5.20 shows SR-SIM images of MitoTracker Deep Red in the presence of the three NBD-
labelled quinoline analogues. Regions of colocalisation were mostly in close association with the 
plasma membrane of the parasite and sometimes with the haemozoin-containing digestive 
vacuole (white arrows in Figure 5.20). Once again, an apparently punctate distribution of the 
NBD-labelled chloroquine derivative probably results from a weak signal from this fluorophore. 
As was the case in Figure 5.20, there are often regions of green fluorescence from the analogues 
that do not overlap with the MitoTracker dye, suggesting accumulation within other subcellular 
compartments such as the ER or the digestive vacuole (Figure 5.20A). For that matter, there are 
also regions illuminated by MitoTracker that do not overlap with signal from the analogues, 











Figure 5.20. Erythrocytes infected with mature P. falciparum and incubated with MitoTracker Deep Red 
(red) and the NBD-labelled analogues (green). Yellow indicates regions of overlap. Areas of most intense 
overlap are indicated with a white arrow. Scale bars represent 5 μm. 
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5.4.2. Colocalisation studies with lipid probes LysoTracker Red and Nile Red 
 
To further investigate the affinity of the fluorescent analogues of the quinoline antimalarials for 
lipid and membranous structures within P. falciparum, infected erythrocytes were stained with 
either LysoTracker Red or Nile Red and examined using SR-SIM.  
 
LysoTracker Red, which comprises a weakly basic aminoalkyl chain tethered to a BODIPY 
reporter, stains the membranes of acidic organelles. When infected erythrocytes were stained 
with this dye, the regions of greatest fluorescence intensity corresponded to the parasite 
digestive vacuole (white arrows in Panel A, Figure 5.21). Some punctate structures, possibly 
acidic transport vesicles, were also illuminated. LysoTracker Red also weakly stained the 
parasite plasma membrane, presumably because the cytoplasmic pH of P. falciparum is 
somewhat lower than that of the host cell. Occasional cross-talk in the green channel was 
observed due to photo-conversion of LysoTracker Red to a green fluorescent molecule,34 but 




Figure 5.21. Erythrocytes infected with P. falciparum and illuminated by (A) LysoTracker Red or  
(B) Nile Red and co-stained with Hoechst (blue). Haemozoin is labelled “Hz”. Scale bars represent 5 μm. 
 
Nile Red (Panel B in Figure 5.21) stains membranes brightly. It revealed the membrane network 
within P. falciparum in which the digestive vacuole and parasite plasma membranes were often 
















vesicle-like structures within the erythrocyte cytosol (white arrows in Figure 5.21B). As 
described in Section 5.2.4, Nile Red is useful for differentiating between structures of 
phospholipid and neutral lipid composition, especially neutral lipid bodies in very mature 
parasites, but this property comes at the cost of its broad excitation and emission spectra which 
make co-staining with other dyes challenging.  
 
As colocalisation between LysoTracker Red and the analogues of quinine and quinidine was 
discussed quantitatively above (Section 5.3.2), observations will now focus on colocalisation 
between this lipid dye and the NBD-labelled chloroquine analogue. 
 
Figure 5.22 illustrates once again the selective accumulation of the chloroquine analogue within 
infected erythrocytes. Panel A shows two erythrocytes alongside one another, infected (left) and 
uninfected (right). Fluorescence corresponding to the chloroquine analogue was only detected 
from the infected erythrocyte and specifically from P. falciparum. Closer inspection of this cell 
reveals partial colocalisation of the chloroquine analogue with LysoTracker Red but not with 
Hoechst. The green signal that does not colocalise with the LysoTracker Red probably arises 
from accumulation in the aqueous compartment of the digestive vacuole rather than from the 
membranes, an observation which was previously difficult to resolve using the confocal 
microscope. This indicates a preference of the chloroquine analogue for hydrophilic 
environments rather than for membranes which is probably a fundamental difference between 
this class of antimalarial and the quinoline methanols. Although some colocalisation seems to be 
present between LysoTracker Red, chloroquine and the Hoechst dye, this is probably a 
misleading result from the maximum intensity projection which has placed these organelles “on 
top” of one another in the two-dimensional representation. 
 
Panel B of Figure 5.22 represents a magnified region of Panel A. The green signal corresponding 
to the chloroquine analogue appears to be grouped into two distinct patterns. One part of the 
signal is closely associated with the haemozoin, which presumably indicates accumulation 
within the digestive vacuole (“DV”), while the other originates from the other side of the cell and 
appears to be in close association with the plasma membrane. This signal, coupled with its 
distinctive worm-like shape and apposition to the parasite plasma membrane, is highly 
suggestive of accumulation within the mitochondrion. That LysoTracker Red stains the 
mitochondrion might be explained by the pH gradient maintained between the intermembrane 
space and the matrix of this organelle. Studies on mammalian mitochondria have found that the 
difference in pH between these two compartments of the mitochondrion may be as much as a 
whole pH unit, which is probably sufficient to account for the accumulation of the LysoTracker 
Red dye within this organelle.35 







Figure 5.22. Panel A shows infected (left) and uninfected (right) erythrocytes alongside one another. Green 
fluorescence is detected from P. falciparum only. Some colocalisation with LysoTracker Red is observed. 
Panel B represents a magnification of the boxed region in Panel A and indicates two main regions of green 
fluorescence corresponding to the chloroquine analogue. One region is clearly haemozoin-associated and is 
likely to represent the digestive vacuole (“DV”) while the other region appears to represent what one might 
expect for accumulation within the mitochondrion. Scale bars represent 5 μm. 
 
Both lipid dyes often revealed small vesicle-like structures within the host cell and sometimes in 
neighbouring uninfected erythrocytes. These are illustrated in Figure 5.23 which represents the 
same erythrocytes as those in Figure 5.22. In Panel B of Figure 5.23, the contrast was enhanced 
to reveal all staining features of LysoTracker Red as indicated by white arrowheads. These 
vesicle-like structures have recently been characterised and it is now known that they are 
exported from P. falciparum and may enter other erythrocytes, even uninfected ones. That they 
are illuminated with LysoTracker Red does not necessarily mean that they are very acidic in 
nature, as they exhibit about the same intensity of fluorescence as the plasma membranes of 
infected and uninfected erythrocytes. It has recently been determined that these structures, so-










called “exosome-like vesicles”, enable direct communication between parasites within a 
population and are even capable of delivering genes.36 Communication via these exosome-like 




Figure 5.23. Panel A shows infected (left) and uninfected (right) erythrocytes side-by-side that are stained 
with LysoTracker Red. There are many extra-parasitic vesicles, some of which are indicated by white 
arrowheads. In Panel B, the same image has been converted to greyscale to enhance the contrast. Blue 
indicates empty pixels. The scale bar represents 5 μm. 
 
Infected erythrocytes treated with the chloroquine analogue were also incubated with Nile Red. 
This time, the intimate association between membranous components of P. falciparum and the 
chloroquine analogue is more obvious in the mature trophozoite represented in Figure 5.24. In 
this image sequence, the chloroquine analogue exhibits an affinity for the parasite plasma 
membrane (“PPM”) and, especially, the internal membrane of the digestive vacuole (“DV”). The 
two prominent lipid bodies, indicated by white arrowheads, probably do not correspond to 
signal from the chloroquine derivative but instead represent cross-talk from Nile Red due to the 
high excitation energies used to excite the former fluorophore. However, it is difficult to say 
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where the signal arising from the lipid bodies “starts” and where the signal from the 
chloroquine analogue “ends”; hence, there might be some overlap between the spatial 




Figure 5.24. An infected erythrocyte stained with Nile Red (red) which clearly indicates the parasite plasma 
membrane (“PPM”) and the digestive vacuole (“DV”) in the presence of the NBD-labelled chloroquine 
analogue (green). White arrowheads indicate two neutral lipid bodies, the signals of which likely originate 
from the Nile Red dye. Scale bars represent 5 μm. 
 
Figure 5.24 presents intriguing evidence in light of recent work by Kapishnikov et al. which 
shows that haemozoin crystals nucleate at the inner surface of the digestive vacuole with 
biocrystallisation occurring in the aqueous rather than in the lipid phase.29,30 With respect to the 
inhibition of haemozoin formation, Figure 5.24 suggests that this may occur from adsorption of 
chloroquine to haemozoin crystals positioned in or adjacent to the inner membrane of the 
digestive vacuole. One might usually expect the signal from the analogue to be quenched in this 
case; however, as the chloroquine analogue is present at much higher levels than its IC50 value, 













Intimate association between the alkaloid analogues with membranous structures of acidic 
compartments has been shown via quantitative analysis with LysoTracker Red (Section 5.3.2) 
and a similar affinity of the chloroquine analogue for phospholipid components is demonstrated 
in Figure 5.24 above. The discussion will now turn to colocalisation of the fluorescent analogues 
with neutral lipid components. For these experiments, the analogues were administered in 
somewhat higher concentrations than usual (2 μM compared to 300 nM) to generate sufficient 
signal such that lower excitation energies could be used to ensure that there was no cross-talk 
from the Nile Red channel in the full green collection range (500-550 nm). It was not possible to 
eliminate cross-talk in the presence of the NBD-labelled chloroquine derivative; hence, these 
colocalisation studies were only performed with the analogues of quinine and quinidine. Figure 
5.25 illustrates two representative images of infected cells at different stages of the 




Figure 5.25. P. falciparum-infected erythrocytes stained with a high concentration of the NBD-labelled 
quinidine analogue (green) to eliminate any cross-talk from the Nile Red dye (red). Neutral lipid bodies are 
indicated by white asterisks. The arrow in Panel A refers to colocalisation within a densely-reticulated 
structure, possibly the ER or the mitochondrion. The arrow in Panel B indicates a lipid body-like structure 
that does not match the intensity profile of a typical neutral lipid body. Scale bars represent 2 μm. 
 
Panel A in Figure 5.25 represents a schizont. This is indicated by nuclear division that has 
occurred at the periphery of the cell in the compartments not illuminated by any signal. Four 
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spherical neutral lipid bodies are evident and are indicated by white asterisks. These vary in 
size from 0.3 μm to 0.7 μm and appear to be in intimate association with the haemozoin, 
although one cannot tell whether they are placed within or outside the digestive vacuole. These 
neutral lipid bodies do not show colocalisation with the quinidine analogue, except for the large 
lipid body on the right-hand side for which partial colocalisation may be observed. There is 
broad colocalisation between the quinidine analogue and Nile Red across the rest of the cell, 
especially within a densely-reticulated structure in the lower half of the cell (indicated by a 
white arrow) which represents the ER or the mitochondrion, or both. 
 
On the other hand, Panel B in Figure 5.25 represents a mature trophozoite. The white arrow 
indicates a region of intense colocalisation of the two dyes which, although resembling a 
haemozoin-associated lipid body, does not match the spherical shape or the deep fluorescence 
profile typical of neutral lipid bodies. Furthermore, as will be discussed below, neutral lipid 
bodies are only observed in later trophozoites and schizonts.32 Thus this structure is more likely 
to be one of the organelles in which colocalisation was previously observed and thus may be the 
ER or the mitochondrion. As this structure lies in close association with the digestive vacuole, it 
may be the former. Additionally, there is a region of NBD-labelled quinidine accumulation at the 
top of the cell that is clearly haemozoin-associated but does not overlap with the Nile Red. This 
is most likely evidence of accumulation of the quinidine analogue within the digestive vacuole. 
 
Of all the cells examined (n = 15), approximately half of the neutral lipid bodies that were 
identified colocalised only partially with the quinine and quinidine analogues such as the 
example in Figure 5.25A. For the other half of the neutral lipid bodies identified, no 
colocalisation was observed. Thus it is unlikely that the quinoline methanol antimalarials exert 
a significant portion of their mechanism of action via accumulating within neutral lipid bodies; 
nevertheless, it is still possible that partial accumulation on the surface of the lipid body may be 
sufficient to exert an important biological effect.  
 
It is interesting that the NBD-labelled alkaloids do not merely sequester within the lipid bodies 
on account of their high lipophilicities compared to the parent compounds. It has previously 
been hypothesised that these lipid bodies may sequester free Fe(III)PPIX to promote haemozoin 
biocrystallisation,28 but this was not observed as any such sequestration would result in 
quenching of the Nile Red signal as has previously been shown in synthetic lipid bodies.37 Such 
quenching does not appear to occur endogenously as the Nile Red signal from these bodies is 
always deeply intense and shows no evidence of internal quenching. However, that does not 
rule out accumulation of Fe(III)PPIX, or the Fe(III)PPIX-quinoline complex, on the surface of the 
neutral lipid bodies where fluorescence quenching would render these species unobservable. 





In order to investigate whether the NBD-labelled alkaloids exert any effects on the population 
or size distribution of haemozoin-associated neutral lipid bodies, cells were examined in the 
absence and presence of the alkaloid analogues and the number of neutral lipid bodies per cell 
was enumerated. In each case, the cells were classed according to their developmental stage. 
The size of haemozoin-associated lipid bodies, if present, were recorded. To facilitate this 
process, the mature stages of intraerythrocytic development were divided into six stages based 
on morphological considerations (Table 5.3). It was thought that identifying specific 
morphological features for developmental classification was a more reliable system than using 
time points which may vary owing to imperfect synchronisation. Neutral lipid bodies were 
assumed to be spherical and classified as small (< 0.5 μm), medium (0.5-1 μm) or large (> 1 μm). 
In total, 51 cells were examined. 29 of these were untreated while the remaining 22 were 
treated with either of the NBD-labelled alkaloids.  
 
Table 5.3. Classification of cells over six stages from early trophozoite to late schizont. 
 
Stage Size of cell relative  
to host erythrocyte 
Presence of  
haemozoin 
Appearance and  
number of nuclei 
Early trophozoite Small and spherical Light brown pigment  
visible 
1, inside cytoplasm  
(not on edge of cell) 
Mid-trophozoite Medium-sized and spherical Clump of pigment 1, enlarged 
Late trophozoite Enlarged; not necessarily 
spherical 
Large clump(s) of pigment 1 or 2, irregularly-shaped 
Early schizont Irregular shape Large clump(s) of pigment 2-5, irregularly-shaped 
Mid-schizont Irregular shape; parasite fills 
most of the host cell 
Large clump(s) of pigment > 5, mostly oval in shape 
Late schizont Parasite fills the entire host cell; 
about to burst 
Large clump(s) of pigment >> 5, all round or oval  
in shape 
 
Neutral lipid bodies were only found in late trophozoite-stage parasites as has been previously 
observed.32 The vast majority of these were digestive vacuole-associated; of the 84 neutral lipid 
bodies examined, only 15 (18%) were not in clear proximity to the haemozoin. Figure 5.26 
illustrates the average number and size distribution of haemozoin-associated lipid bodies per 
cell from late trophozoites to late schizonts. In untreated cells, small to medium-sized lipid 
bodies were the most common. Medium-sized lipid bodies occurred more frequently in treated 
cells. This trend may be rationalised if the NBD-labelled alkaloids are considered to behave in a 
detergent-like manner, with the charged quinoline group at one end tethered to a hydrophobic 
fluorophore at the other end which may encourage the aggregation of smaller lipid bodies. 







Figure 5.26. The average number and size distribution of haemozoin-associated neutral lipid bodies per cell 
across all phases of the life cycle of P. falciparum in the absence or presence of the NBD-labelled alkaloids. 
Neutral lipid bodies were classified as small (< 0.5 μm), medium (0.5-1 μm) or large (> 1 μm). 
 
Figure 5.27 depicts the average number and size distribution of haemozoin-associated neutral 
lipid bodies per cell across the four major stages in which they appear. Similar trends are 
observed for both untreated and treated cells. There is an increase in the average number of 
lipid bodies per cell from the late trophozoite phase, peaking in the mid-schizont phase. 




Figure 5.27. The average number and size distribution of haemozoin-associated neutral lipid bodies  
per cell across the four life cycle stages of P. falciparum in which they appear  
in the absence or presence of the NBD-labelled alkaloids.  





This increase in the average number of lipid bodies from the trophozoite to the schizont stage 
corresponds to the increase in diacylglycerol and triacylglycerol seen over the final 16 hours of 
the parasite’s life cycle.38 In particular, this profile matches closely the abundance profile of 
triacylglycerol in P. falciparum which peaks in the early- to mid-schizont phase but diminishes 
just before host cell rupture.38 
 
Figure 5.28 illustrates the average number of neutral lipid bodies per cell as a fraction of the 
total. This indicates that the small lipid bodies form a smaller proportion of the total in the later-
stage parasites while the proportion of medium-sized lipid bodies increases as the parasite 
matures. This suggests that aggregation of smaller lipid bodies may be responsible for the 
decrease in number of lipid bodies reported in the late schizont phase. The final few hours of 
the P. falciparum life cycle are characterised by an increase in diacylglycerol abundance,38 
suggesting that hydrolysis of triacylglycerol to diacylglycerol may be related to such aggregation 




Figure 5.28. The size distribution of haemozoin-associated neutral lipid bodies in untreated cells,  
measured across the late phases of the life cycle of P. falciparum in which they appear. 
 
A drawback of this study is the high concentrations of the NBD-labelled alkaloids that were used 
to increase their fluorescence signal in order to eliminate cross-talk from the Nile Red (2.0 μM). 
It is undesirable to use such high concentrations as it has been found that micromolar levels of 
lysosomotropic compounds induce apoptotic hallmarks. This has led investigators to establish a 
programmed cell death pathway for P. falciparum, analogous to mammalian apoptosis.39,40 It has 
been found that micromolar levels of chloroquine (> 3 μM) resulted in the permeabilisation of 





the digestive vacuole membrane with an abrupt and rapid redistribution of calcium ions.39,40 
However, there was no visible rupture of the digestive vacuole membrane by transmission 
electron microscopy.40 Digestive vacuole permeabilisation is trigged by any lysosomotropic 
compound, suggesting that the NBD-labelled alkaloids may have the same effect. However, it is 
unlikely that neutral lipid metabolism was deleteriously affected over the short exposure time 
of the high concentrations of these analogues to the cells (1-2 hours). The investigators claim 
that digestive vacuole permeabilisation and other apoptotic indicators only occur 









5.5. Critical discussion of live-cell microscopy observations  
 
For decades it has been believed that the prototypical quinoline antimalarials, quinine and 
chloroquine, exert their mechanism of action on P. falciparum by inhibiting haemozoin 
biocrystallisation. Not only do these molecules interact directly with Fe(III)PPIX42 and probably 
with haemozoin itself,43 but they have been shown to inhibit the formation of β-haematin.44 
Most recently, it has been shown that treatment of P. falciparum with both chloroquine and 
quinine leads to a decrease in haemozoin formation and a concomitant increase in free 
Fe(III)PPIX, lending support to this hypothesis.9  
 
Such inhibition requires large quantities of the inhibitor to be present in the digestive vacuole of 
the parasite, the main site of haemoglobin catabolism and haemozoin biocrystallisation. While 
mechanisms of accumulation due to a “non-saturable” weak base effect and “saturable” 
Fe(III)PPIX binding have been described in Section 1.6.1, visual evidence of accumulation in the 
digestive vacuole has been provided by autoradiography of tritiated chloroquine and 
quinidine45 and the detection of chloroquine derivatives using fluorescence microscopy.46,47 
Additional evidence supporting haemozoin inhibition as the primary mechanism of action of 
these quinoline antimalarials has now been provided by the detailed live-cell studies described 
herein.  
 
Mature-stage P. falciparum were treated with the novel fluorescent analogues of quinine, 
quinidine and chloroquine that were synthesised earlier in this work. These analogues 
accumulated selectively in infected erythrocytes and almost entirely in the parasite, although 
some staining of the host cell cytoplasm or plasma membrane by the alkaloid analogues was 
observed. The analogues of quinine and quinidine were distributed more diffusely throughout 
the parasite than the chloroquine analogue which was prominently localised to fewer regions 
within the parasite. Significantly, all three analogues accumulated near the haemozoin in a 
region corresponding to the digestive vacuole (Figures 5.7 and 5.9). This was particularly 
notable for the chloroquine analogue for which super-resolution imaging revealed areas of 
intense accumulation near the haemozoin (Figure 5.22). These observations are in accordance 
with expectations for haemozoin formation as the mechanism of action of these antimalarials. 
The observations also account for the swelling of the digestive vacuole that is evident in 
ultrastructural studies.1,2 Additionally, this is the first time that visual evidence of accumulation 
within P. falciparum of a labelled quinine derivative has been provided.  
 
Treatment with the fluorescent analogues at their respective IC50 values generated no 
detectable signal. This was most likely due to fluorescent quenching by the putative target of 





these molecules, Fe(III)PPIX, further supporting haemozoin inhibition as their mechanism of 
action. As a result, cells were treated with concentrations of probes at several times their IC50 
values to generate a detectable signal. It should be noted that the fluorescence emission of the 
NBD reporter fluorophore is at least 15-fold brighter in environments corresponding to the 
polarities of neutral lipid and phospholipid, respectively, compared to aqueous solution (Figure 
4.6). Hence, the fact that prominent signals were detected from the aqueous interior of the 
digestive vacuole shows that this is a site of significant accumulation of the analogues.  
 
The NBD-labelled analogues of quinine and quinidine exhibited colocalisation with LysoTracker 
Red, a dye which partitions into the membranes of acidic organelles, but not with the nuclear 
stain, Hoechst. This was corroborated by quantitative measurements which showed that these 
analogues have a strong affinity for membranous structures, especially the quinidine analogue. 
Whether this is related to their relative lipophilicities may be examined by comparing the acid 
dissociation constants and partition coefficients of the parent alkaloids (Table 5.4). Considering 
that these alkaloids are diastereomers of one another, these values are very similar. Although 
quinidine is less hydrophobic than quinine in its uncharged form or at a neutral pH, it is more 
lipophilic at an acidic pH (log D = 0.40 compared to log D = 0.30 for quinine) which may explain 
why it is more likely to colocalise to a greater extent with LysoTracker. This observation may 
also be related to the fact that quinidine is more active against the malaria parasite in vitro than 
its diastereomer quinine (Table 4.8), although it should be noted that the activities of the two 
analogues of these alkaloids against P. falciparum were very similar to one another. 
 
Table 5.4. Acid dissociation constants (pKa) and partition coefficients of the  
diastereomeric alkaloids quinine and quinidine cited from Warhurst et al.48 
 
 pKa1 pKa2 Log P Log D (pH 7.4) Log D (pH 5.2) 
Quinine 8.58 4.12 3.17 1.97 0.30 
Quinidine 8.58 4.42 2.84 1.66 0.40 
 
Quantitative analysis of the NBD-labelled alkaloids supports qualitative observations that all 
three analogues do not accumulate in the nucleus of the P. falciparum. It is still widely reported 
that these quinolines disrupt DNA replication by intercalating with the nucleic acid base pairs, a 
mechanism which requires high concentrations of drug in the nucleus and for which there is 
little evidence (Section 1.5.4).49-51 It has now been possible to show, using qualitative and 
quantitative image analysis of these fluorescent analogues, that an absence of accumulation of 





these analogues in the nucleus makes this mode of action of the quinoline antimalarials 
extremely unlikely. 
 
With respect to other organelles, it is very likely that the quinoline antimalarials associate with 
the ER of the parasite. Although confocal imaging of ER-Tracker Red gave a featureless signal 
throughout the cytoplasm of P. falciparum which broadly colocalised with the alkaloid 
analogues, super-resolution microscopy indicated clear colocalisation of all three analogues 
with the ER marker (Figure 5.18). In addition, the signal of this marker was attenuated if 
administered simultaneously with the analogues, suggesting competitive binding to the 
sulfonylurea receptors on the surface of the ER to which ER-Tracker and quinine are known to 
bind.16 This provides further evidence for an interaction between the drug analogues and this 
organelle. Furthermore, these observations corroborate a previous ultrastructural study of P. 
falciparum which noted disintegration of the ER following treatment with chloroquine.1 This 
may be enhanced by the lytic effect of Fe(III)PPIX which was observed to localise to a region 
corresponding to the ER following chloroquine treatment.9 Indeed, the ER is implicated in 
phospholipid biosynthesis, calcium storage and trafficking of proteins in P. falciparum and has 
been shown to lie in close proximity to the digestive vacuole, an observation which was 
corroborated by the imaging described herein (Figure 5.18A).33 Consequently, association of the 
quinoline antimalarials with the ER, either in their native form or as a complex with Fe(III)PPIX, 
may disrupt crucial metabolic processes within the ER or interrupt intracellular transport 
between this compartment and the digestive vacuole. 
 
It is also possible that the quinoline antimalarials localise to the mitochondrion of P. falciparum 
(Figure 5.20). The organelle signal provided by MitoTracker Deep Red was clear and 
represented the tube-like structure described by previous morphological studies.33 However, 
colocalisation with this organelle was less clear than in the case of the ER. Despite this, 
colocalisation with all three NBD-labelled analogues was supported by quantitative analysis. 
The intermembrane space in the mitochondrion might account for accumulation of the 
quinoline antimalarials due to the weak base effect, which may also explain labelling of the 
mitochondrion by LysoTracker Red. Accumulation of the analogues is consistent with the 
swelling of the mitochondrion that is observed by electron microscopy after treatment with 
both quinine and chloroquine.1,2 It is thought that the mitochondrion may associate with the 
plasma membrane of P. falciparum to serve as a conduit for plasma membrane phospholipids.33 
Given the lipophilic nature of the quinoline antimalarials, especially the Cinchona alkaloids, it is 
possible that high concentrations of these drugs may interfere with this aspect of lipid 
metabolism. The mitochondrion has also been implicated in a programmed cell death pathway 





after treatment with high concentrations of lysosomotropic molecules;41 hence, it would not be 
surprising if this were due in part to an accumulation of the quinoline antimalarials there. 
 
To investigate the affinity of the quinoline analogues for lipid components within P. falciparum, 
cells were co-stained with either LysoTracker Red or Nile Red and investigated with SR-SIM. 
There is evidence that haemozoin formation is mediated by neutral lipid bodies or phospholipid 
membranes (Section 1.3.2).21,28-30 Pisciotta et al. have suggested that neutral lipid bodies 
provide transient repositories of free Fe(III)PPIX, concentrating the metalloporphyrin while 
promoting haemozoin formation at the surface where the acidic conditions of the digestive 
vacuole favour lipid-mediated biocrystallisation.28 If this hypothesis is correct, it is plausible 
that the quinoline antimalarials might themselves accumulate in the neutral lipid bodies and 
sequester free Fe(III)PPIX by complexation, reducing the availability of Fe(III)PPIX for 
biocrystallisation. However, quenching of the Nile Red-labelled lipid bodies, which would be 
expected in the case of Fe(III)PPIX sequestration in these bodies, was not observed.37 
Furthermore, only very partial colocalisation, if any, between neutral lipid bodies and the NBD-
labelled alkaloids was observed in mature parasites. Despite being implicated in haemozoin 
formation, neutral lipid bodies are only observed from the late trophozoite stage, well after 
biocrystallisation has commenced. It is, however, possible that Fe(III)PPIX accumulates in lipid 
bodies in earlier stages of the life cycle to promote haemozoin biocrystallisation, quenching the 
signal from Nile Red and hence preventing their detection in these early stages.  
 
Phospholipid components have also been implicated in haemozoin formation and hence are of 
interest in elucidating the mechanism of action of the quinoline antimalarials. Kapishnikov et al. 
recently reported that haemozoin nucleation occurs at the inner membrane of the digestive 
vacuole, with biocrystallisation occurring in the aqueous rather than the lipid phase.29 The 
authors argue that their data rule out the possibility of haemozoin crystals being nucleated 
within, or on the surfaces of, lipid nanospheres.29 This is supported by a striking observation in 
Figure 5.24 in which the chloroquine analogue was closely associated with the inner membrane 
of the digestive vacuole as well as the parasite plasma membrane. Close association of this 
analogue with the inner surface of the digestive vacuole membrane suggests an affinity for this 
membrane or even for adsorption to haemozoin, as these crystals have previously been shown 
to line the inner membrane of the digestive vacuole.29 Adsorption to haemozoin as a mechanism 
of action for chloroquine is somewhat more plausible, stoichiometrically and chemically, than 
sequestration of Fe(III)PPIX in solution or in neutral lipid bodies. Alternatively, differential 
association with phospholipid membranes may also be responsible for the differential 
morphological effects exhibited by these antimalarials.3,4  
 





There are several limitations to the fluorescence microscopy approach carried out in this work. 
Although live-cell imaging conditions imply that P. falciparum has been imaged with as few 
disturbances to its natural metabolic processes as possible, all three analogues of the quinoline 
antimalarials have been labelled by a hydrophobic fluorophore that is structurally-distinct from 
the parent molecules. Hopefully, the incorporation of this smallest-possible organic fluorophore 
has been mitigated by thorough evaluation against the parent antimalarials as carried out in 
Chapter 4. Nevertheless, the presence of the fluorophore reduces its aqueous solubility (Table 
4.6), increasing its hydrophobicity and this may be responsible for the striking preference of the 
analogues for membranous and lipid components demonstrated above. Furthermore, these 
labelled probes are quenched upon complexation with Fe(III)PPIX and possibly by haemozoin 
as well. Despite the utility of fluorescence exhibited in this chapter, alternative techniques or 
fluorophores to probe solution- or solid-state interactions of these quinoline antimalarials with 
Fe(III)PPIX will be required. 
 
  





5.6. Summary and conclusions  
 
Live-cell fluorescence microscopy provides exceptional insights into structural and functional 
minutiae of intraerythrocytic P. falciparum. Although ultrastructural studies provide excellent 
resolution, these samples suffer from extensive preparation procedures and poor contrast. Most 
especially, structural and functional information cannot easily be related to one another. Light 
microscopy, on the other hand, lends itself to live-cell studies with minimal sample preparation, 
allowing the acquisition of reliable and dynamic information about the system at hand.  
 
In this chapter, the novel fluorescent analogues of the quinoline antimalarials that were 
prepared in Chapter 3, and subsequently validated in Chapter 4, were investigated using live-
cell imaging methods. Although P. falciparum presents a number of challenges for light 
microscopy, especially the photosensitivity of the cells and their small size, these may be 
overcome to generate valuable insights. In this work a number of commercially-available 
tracker dyes were selected to co-stain structures within live parasites. 
 
The NBD-labelled derivatives of quinine, quinidine and chloroquine that were identified as 
suitable analogues of their parent antimalarials were all found to accumulate selectively within 
P. falciparum-infected erythrocytes. No accumulation was observed in uninfected erythrocytes. 
All three analogues, but especially the NBD-labelled chloroquine analogue, were frequently 
found in close association with the haemozoin pigment and hence with the digestive vacuole. 
This is consistent with its well-established primary mode of action as a haemozoin inhibitor. In 
addition to digestive vacuole accumulation, the analogues of quinine and quinidine were more 
diffusely spread throughout the cell and were also observed to accumulate in the plasma 
membranes of the parasite and the host cell.  
 
By contrast, the bimane-labelled derivative of quinine was not observed at all, suggesting a 
quenching effect or a lack of accumulation within P. falciparum that may be responsible for its 
diminished activity against the parasite. Intriguingly, a bright autofluorescence signal 
corresponding to the haemozoin was detected in the blue region of the visible spectrum where 
such fluorescence has not previously been observed. This is likely to correspond to the 
supposed autofluorescence of quinine as claimed in previous work by Bohórquez et al.19 
 
Quantitative colocalisation analysis indicated excellent correlation between the distributions of 
the two NBD-labelled alkaloids and LysoTracker Red, confirming the qualitative observations 
that these molecules show preferential accumulation in membranous structures within the 
parasite. Quinidine showed superior colocalisation with LysoTracker Red, indicating a high 





affinity for membranes, which may be partly responsible for its more potent activity against  
P. falciparum compared to its diastereomer quinine. A negative correlation was found between 
all three of these signals and Hoechst, representing the parasite nucleus, indicating that it is 
extremely unlikely that these molecules exert their action by interfering with DNA replication as 
is still occasionally reported.  
 
All three NBD-labelled quinoline antimalarials exhibited colocalisation with the ER and the 
mitochondrion following co-staining with the organelle-specific dyes ER-Tracker Red and 
MitoTracker Deep Red, respectively. Furthermore, the signal of the ER-Tracker Red was 
attenuated if the NBD-labelled quinolines and the dyes were administered simultaneously, 
suggesting competition for binding sites or changes in organelle morphology as a result of drug-
treatment. This corroborates previous ultrastructural studies of P. falciparum which implicate 
both of these organelles in the mechanism of action of the quinoline antimalarials, as previous 
investigators have reported swelling of the mitochondrion and disintegration of the ER 
following treatment with these drugs.1,2 Using super-resolution structured-illumination 
microscopy (SR-SIM), convincing colocalisation was again observed between all three NBD-
labelled analogues and the ER and mitochondrion, but with much greater precision. It was again 
shown that the NBD-labelled chloroquine analogue possesses a strong affinity for the digestive 
vacuole, a characteristic shared by the NBD-labelled alkaloids in addition to their accumulation 
within membranous structures.  
 
These NBD-labelled alkaloids did not accumulate significantly within haemozoin-associated 
neutral lipid bodies. Although the size distribution of these lipid bodies shifted from small to 
medium size after treatment (< 0.5 μm to 0.5-1.0 μm), and the average number of neutral lipid 
bodies per cell decreased after treatment, in both cases the mid-schizont phase of the life cycle 
exhibited the highest number of neutral lipid bodies per cell, corroborating previous studies32 
and matching the abundance profiles of neutral lipids during this stage of the life cycle.38 
 
Taken together, these results support haemozoin inhibition through accumulation in the 
digestive vacuole as the primary mechanism of action of these quinoline antimalarials. 
Secondary effects due to association with the ER, mitochondrion and phospholipid membranes 
may cause deleterious metabolic disruption to the parasite. Whether these regions of 
accumulation within the parasite are the result of binding of these quinoline antimalarials to 
specific protein targets within P. falciparum is investigated in the subsequent chapter. 
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Affinity Detection and Identification of 






here is considerable evidence to suggest that the quinoline antimalarials quinine, quinidine 
and chloroquine interact with the haemozoin biocrystallisation pathway in P. falciparum 
by inhibiting the incorporation of Fe(III)PPIX into the growing crystal (Section 1.5).1-3 In spite of 
this, ultrastructural investigations suggest that organelles other than the digestive vacuole may 
be implicated in the mode of action of these antimalarials.4,5 It has also been shown that quinine 
and chloroquine exhibit morphological effects on the parasite that are seemingly unrelated to 
their roles as haemozoin inhibitors (Section 1.6.2).6,7 Intriguingly, these two drugs, representing 
the two major structural classes of the quinoline antimalarials, were found to modulate 
endocytosis in a differential manner.6,7 These observations suggest that these drugs may have 
secondary targets against the parasite in addition to their primary role as haemozoin inhibitors. 
 
Previous investigations to determine whether these molecules have additional targets against  
P. falciparum have exploited photoaffinity-labelling strategies (Section 1.6.3). While this tends 
to label proteins with high specificity, it requires covalent modification of the drug in order to 
introduce photoreactive and radiolabelled components for binding to the target and for 
detection, respectively. Many of these derivatives modified the quinoline heterocycle directly 
which is likely to be an essential part of the pharmacophore and hence may interfere with 
T 





important binding interactions.8,9 Although a single matrix-based affinity chromatography study 
has been carried out, these investigators were unable to identify any protein binding targets of 
quinoline antimalarials in P. falciparum.10 A reason for this might be that a hydroxychloroquine-
labelled matrix was used as a substitute for chloroquine itself.10 With respect to the quinoline 
methanol antimalarials, alkaloid-labelled matrices have not yet been exploited in affinity 
chromatography studies to probe the binding targets of these molecules in P. falciparum.  
 
Hence, this chapter describes a thorough investigation into the binding targets of the quinoline 
antimalarials in uninfected human erythrocytes and P. falciparum using a chemical proteomics 
approach. Using a matrix-based affinity detection methodology, agarose beads linked to quinine, 
quinidine and chloroquine were prepared using the novel derivatives of these drugs described 
in Chapter 3 of this work. These matrices were used to probe the erythrocyte and P. falciparum 
proteomes for binding targets of these antimalarials. In the latter case, this was followed by 
mass spectrometric analysis of these sub-proteomes in conjunction with SDS-Page to identify 
protein targets. 
 
Thus the specific objectives described in this chapter were:  
 
i. To prepare cell lysate from uninfected human erythrocytes and P. falciparum trophozoites 
in a manner suitable for use in these experiments; 
ii. To prepare quinoline antimalarial-labelled affinity matrices using the novel derivatives of 
the quinoline antimalarials prepared in Chapter 3; 
iii. To use these drug-labelled matrices to extract quinoline antimalarial-binding proteins in 
uninfected erythrocytes and to detect these via SDS-Page; 
iv. To use these drug-labelled matrices to capture drug-binding sub-proteomes of quinoline 
antimalarial binding targets from P. falciparum and to identify target proteins, if any, 
using SDS-Page and mass spectrometry. 
  





6.2. Background to the techniques employed in this chapter  
 
It is surprising that approximately 18% of approved drugs have a poorly-defined mechanism of 
action and that as many as 7% do not have a well-defined primary target.11 Despite recent work 
that directly implicates chloroquine, quinine and quinidine as haemozoin inhibitors,1-3 the 
online database DrugBank describes the mechanism of action of these prototypical 
antimalarials as “not well understood”.12  
 
Drug target identification methods typically include affinity-based methods and phenotypic 
methods. In the former approach, direct binding of the drug to its target(s) is probed while, in 
phenotypic methods, targets are inferred from physiological or biochemical responses induced 
by the drugs.13 Affinity-based target identification methods are typically divided into matrix-
based and matrix-free affinity detection methods.13 Matrix-based affinity methods usually take 
the form of affinity chromatography where the “pull-down” of a target protein is achieved by 
covalently attaching the small molecule to a solid support such as a bead or a capturable group 
such as biotin. On the other hand, matrix-free affinity detection relies on labelling methods such 
as the incorporation of a radioisotope or a photoreactive/fluorescent label into the ligand of 
interest.13 A critically significant point is that both of these methods are limited to molecules 
containing derivitisable functionalities. These methods require that the binding of the ligand to 
its target, and hence the biological activity of the ligand, is not affected by the modification. 
 
6.2.1. Affinity chromatography as a matrix-based affinity detection method 
 
Affinity chromatography is used to separate complex mixtures by exploiting specific receptor-
ligand interactions. This is done by immobilising the ligand on an insoluble matrix (stationary 
phase) and exposing the matrix to a mixture containing the putative receptor (mobile phase). 
The protein target may be recovered from the stationary phase by displacement with a mobile 
phase containing a high concentration of the unbound ligand or by elution under denaturing 
conditions. In this work, the ligands of interest were small-molecule drugs and the receptors, if 
any, were expected to be proteins. 
 
Matrix-based affinity chromatography typically requires at least three conditions: (1) the ligand 
must contain a reactive functionality, (2) the biological activity and binding specificity of the 
small molecule should not be affected by derivatisation and (3) the matrix must not hinder 
binding of the target protein to the drug. The primary limitation of this method is usually the 
synthetic chemistry required to derivatise the ligand to make it amenable to covalent linkage to 
the solid support, especially in the case of complex natural products. Usually, structure-activity 





relationship studies are carried out to identify functional groups that are dispensable for ligand 
activity which are then used as points of attachment to the affinity scaffold. 
 
This matrix is then exposed to all the possible binding targets. This is usually a complex mixture 
such as cell lysate or protein extract. This is followed by extensive washing to remove non-
specific binding partners. Retained proteins are then eluted under denaturing conditions that 
disrupt intermolecular interactions (“solid-phase elution”, Figure 6.1A) or with an excess of free 
ligand (“competition elution”, Figure 6.1B). Proteins may then be separated and identified by 
SDS-Page or by mass spectrometry directly. Often there are many more non-specific binders 
than actual targets and so negative control experiments using an inactive analogue or a non-




Figure 6.1. Detection of protein targets using matrix-based affinity chromatography.  
A ligand (red pentagon) is tethered to a matrix (black circle) and incubated with protein extract. After  
non-binding proteins have been removed by a series of washing steps, any ligand-bound proteins are eluted 
using (A) denaturing buffer conditions or (B) an excess of free ligand and then investigated by SDS-Page.  
To minimise the identification of non-specific binders, the proteins that are obtained with an inactive ligand 
analogue or non-specific matrix is also determined (C) and the two outcomes are compared.13  
  










6.2.2. Preparation of biological material for affinity experiments 
 
Evidence has shown that the trophozoite and schizont stages of P. falciparum are most sensitive 
to the quinoline antimalarials investigated in this work (Section 5.2.2).14-16 Hence, mature 
cultures of P. falciparum were harvested for this study. The workflow for the preparation of 
parasite material for these experiments is illustrated in Figure 6.2. During cell lysis, samples 
were placed on ice to maintain their integrity, protease inhibitors were used to prevent 




Figure 6.2. Workflow to prepare material from P. falciparum for this study. 
 
In order to liberate the trophozoite from the erythrocyte, the infected cultures were lysed using 
saponin. The resultant pellet was washed several times to remove extraneous erythrocyte 
material but especially excess haemoglobin which might obscure detection of proteins of lower 
abundance. Saponin-lysed parasites were then stored for several days at -80°C. Subsequent 
thawing of this sample ruptured the parasitophorous vacuolar and plasma membranes of the 
parasite. However, the tougher digestive vacuole membranes remained intact as evidenced by 
the small assemblies of haemozoin crystals. In order to lyse this membrane, a freeze-thaw cycle 
was commenced over several days. Digestive vacuole lysis was judged to be complete when a 
wet mount showed no distinct shapes under high magnification. 
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Ultracentrifugation was performed to separate soluble proteins from the membrane-associated 
insoluble fraction. Afterwards, the soluble fraction was concentrated via ultrafiltration using  
3 kDa molecular weight cut-off tubes. The membrane fraction was resuspended with a 
minimum volume of 1% (w/v) CHAPS detergent and triturated to promote mixing. Finally, the 
protein concentrations of all fractions were quantified using the Bradford assay. This assay 
measures the binding of Coomassie Brilliant Blue G-250 dye to proteins.17 Under acidic 
conditions, the dye is predominantly in the doubly-protonated red cationic form ( max 470 nm); 
however, when the dye binds to protein, it is converted to a stable unprotonated blue form ( max 
595 nm). Hence, measuring the absorbance at this latter wavelength is used to determine the 
protein concentration with the use of a standard curve.18 In this assay, bovine serum albumin 
was used for calibration purposes.  
 
Material from uninfected human erythrocytes was also prepared. These cells were lysed at 4°C 
for an hour in the presence of a buffer previously formulated by Graves et al.10 To promote cell 
lysis, this buffer contained 0.1% CHAPS detergent. Centrifugation of lysed material permitted 
insoluble residue to be removed. Lysate was quantified using the Bradford protein assay. 
 
6.2.3. Separation of bound proteins by SDS-Page and detection by staining 
 
Electrophoresis refers to the movement of charged molecules in response to an electric field, 
resulting in their separation. When electrophoresis is performed in polyacrylamide, the gel 
serves as a size-exclusion sieve during separation; hence, smaller proteins travel faster than 
larger proteins. In this work a discontinuous buffer system was used in which the gel is divided 
into a large-pore “stacking gel” above a smaller-pore “resolving gel”. In this system, proteins 
first migrate quickly through the stacking gel and are slowed down as they enter the resolving 
gel. As they slow down, the proteins stack on top of one another to form a tight band which 
improves resolution. Discontinuous systems also have glycinate and chloride ions in the 
electrophoresis buffer which sandwich the proteins as they migrate through the gel, tightening 
the bands even more.19 
 
SDS-Page, the most popular format of electrophoresis, incorporates the detergent sodium 
dodecyl sulfate (SDS) into the discontinuous buffer system. When proteins are separated in the 
presence of SDS, they are fully denatured and dissociate from one another. SDS binds non-
covalently to proteins in a manner that imparts (i) an overall negative charge on the proteins, 
(ii) a similar mass-to-charge ratio for all proteins and (iii) a long rod-like shape on the proteins 
instead of their complex tertiary confirmations.19 Consequently, the rate at which SDS-bound 





proteins migrate in a gel depends predominantly on their sizes, enabling molecular weight 
estimation. 
 
Following electrophoresis, detection of the protein bands is carried out by staining the gel. The 
most popular stain is the Coomassie Brilliant Blue series of anionic dyes but this stain is only 
moderately sensitive. For example, the detection limit of Coomassie Brilliant Blue R-250 is  
36-47 ng protein/mm2.19 However, silver-based stains have a much lower detection limit of 
approximately 0.1 ng protein/mm2.20 Furthermore, staining a gel first with Coomassie Brilliant 
Blue, followed by de-staining and subsequent treatment with a silver stain enhances sensitivity 
four-fold allowing extremely low-abundance proteins to be identified (0.025 ng/mm2).20 
 
6.2.4. Mass spectrometry-based proteomics 
 
Once a sample has been identified for mass spectrometric analysis, the proteins must be 
enzymatically cleaved into smaller fragments. These may be “in-solution” or “in-gel” digestions 
depending on whether the source is a protein mixture or a band from a protein electrophoresis 
gel, respectively. In both cases, digestion is preceded by several modifications to the proteins. 
Proteins are usually reduced and cysteine residues are thiomethylated.21 They are then digested 
by a suitable protease such as trypsin. Following the removal of residual components from the 
digestion, liquid chromatography separates out the trypsin-digested peptides by 
hydrophobicity. These peptides are then delivered to a tandem mass spectrometer. In this work, 
peptides were eluted onto an electrospray ionisation source where they were nebulised in 
small, highly-charged droplets.22 The first spectrometer separates peptides according to their 
mass-to-charge ratio (m/z). Ions of a particular m/z ratio are then selected and fragmentation 
occurs, after which the resulting fragment ions are separated and then detected in a second 
stage of mass spectrometry. Following detection of these fragment ions, the resultant spectra 









6.3. Affinity chromatography and identification of binding targets  
 
6.3.1. Preparation of the quinoline antimalarial-labelled stationary phase 
 
As described in Section 6.2.1 above, affinity chromatography requires the small molecule ligand 
to be attached to a stationary phase. In this study, N-hydroxysuccinimide-activated Sepharose 4 
Fast Flow (GE Healthcare) was selected as a suitable scaffold (Figure 6.3). This is a highly cross-
linked agarose matrix containing pre-activated N-hydroxysuccinimide (NHS) end-groups which 
form stable amide bonds when reacted with amine-containing ligands. This activated scaffold 
was anticipated to be compatible with the derivatives of the quinoline antimalarials prepared 




Figure 6.3. Sepharose 4 Fast Flow beads activated with an N-hydroxysuccinimide (NHS) leaving group 
indicated in the dashed box. The spacer chain is indicated in brackets.23  
 
The identity of the spacer chain between the bead and the activated end-group is important as 
there should be enough space for binding to take place. A short spacer chain may generate steric 
hindrance which will obstruct the ligand-target interaction. On the other hand, if the spacer 
chain is too hydrophobic, different linkers may interact with one another or promote unspecific 
target binding with macromolecules.24 For these reasons, an optimal chemical spacer should be 
mildly hydrophilic and lengthy enough to avoid steric hindrance. This was judged to be the case 
for the spacer chain depicted in Figure 6.3.  
 
The ligands used in this work were the primary amine-containing derivatives of quinine, 
quinidine and chloroquine prepared in Chapter 3. These derivatives were prepared by taking 
into account the structure-activity relationships of the parent molecules with Fe(III)PPIX. 
Hence, key structural motifs were retained, an approach that was validated in Chapter 4. These 
derivatives lend themselves to a facile coupling reaction with NHS-activated beads through 
nucleophilic acyl substitution (SNAc) as illustrated in Figure 6.4. This results in the departure of 
the NHS group and the formation of an amide bond between the quinoline pharmacophore and 
the matrix. 







Figure 6.4. The coupling reaction to the beads via nucleophilic acyl substitution (SNAc) of the  
N-hydroxysuccinimidyl ester, exemplified by the chloroquine derivative prepared in Chapter 3. 
 
A workflow for preparing the drug-labelled beads is presented in Figure 6.5. Briefly, the beads 
were washed with 1 mM HCl to remove the isopropanol solution in which they were supplied. 
Thereafter, the beads were incubated with a solution comprising the number of moles of the 
derivatised drug necessary for the desired loading capacity, dissolved in 100 mM Hepes at pH 
8.3. This was rotated at room temperature for one hour after which the beads were washed 
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In order to quantify the amount of ligand that had coupled to the beads, the washings were 
collected, made up to a known volume and quantified by spectrophotometry. Thereafter, the 
beads were incubated in “blocking solution” comprising 100 mM Tris at pH 8.5. As the structure 
of Tris contains a primary amine (aminomethane) linked to three hydroxymethyl groups, the 
amine reacted with the remaining NHS-activated end-groups to give “Tris-blocked” end-groups 
that were hydrophilic in nature. After this step, the beads were alternately washed with high 
and low pH buffers and were stored in 20% aqueous ethanol to avoid microbial contamination. 
 
Depending on the sizes of the ligand and the putative target(s), it is important to avoid over-
loading the derivatised ligand onto the beads as this may result in steric hindrance between the 
binding targets. It has previously been reported that 3 μmol ligand/mL matrix is an optimal 
concentration.24 The manufacturer’s specifications indicate that there are 19.5 μmol/mL NHS 
binding sites available on the NHS-activated Sepharose 4 Fast Flow beads.23 Hence, incubating  
1 mL of beads with 19.5 μmol ligand results in 100% loading capacity. Differences in loading 
capacity can be seen in Figure 6.6A below, where 100% loading results in overloading of the 
matrix and hence encourages non-specific interactions, probably due to auto-aggregation of 
proteins as a result of hydrophobic interactions. When only 3 μmol/mL ligand was applied to 
the beads, spectrophotometry indicated that almost all of this ligand (> 95%) was linked to the 
framework within an hour. The lane corresponding to this loading capacity in Figure 6.6A 
showed a better elution profile where only those proteins that are likely to interact directly with 
the ligand were retained. 
 
In order to establish an appropriate buffer system for the affinity chromatography experiments, 
samples of chloroquine-labelled beads (loaded at 3 μmol chloroquine/mL) were exposed to the 
soluble fraction recovered from P. falciparum lysate in the presence of two different buffers. 
Protein binders were removed by solid-phase elution (Figure 6.6B). One sample was prepared 
in the presence of a Tris-based buffer at pH 8.3 while the other was a Hepes-based buffer 
previously used by Graves et al. at pH 7.5.10 The latter buffer contained 0.1% CHAPS detergent. 
Despite this, it can be seen from Figure 6.6B that elution profiles for both buffers are very 
similar. Hence, binding interactions do not appear to be affected by the presence of the small 
amount of detergent in the affinity buffer which might have been suspected to weaken 
intermolecular interactions. Hence, this buffer was used for subsequent affinity 
chromatography experiments and is hereafter referred to as “affinity buffer”. 
 







Figure 6.6. SDS-Page (14% acrylamide) visualised with a silver stain. In both panels, beads were exposed to 
the soluble fraction recovered from P. falciparum. Bound proteins were removed by solid-phase elution. 
Panel A demonstrates the difference between two different loading capacities of quinine-labelled beads.  
3 μmol/mL corresponds to 15% of the available loading capacity and 19.5 μmol/mL corresponds to a fully-
loaded matrix (100%). In the latter case, non-specific binding is evident as a result of overloading of the 
beads. Panel B demonstrates beads labelled with chloroquine (3 μmol/mL) that were washed extensively 
with either a Tris-based buffer or “affinity buffer”. Both elution profiles are almost identical; hence, binding 
was not affected by the presence of a small amount of detergent (0.1% CHAPS) in the affinity buffer.  
 
6.3.2. Matrix-based affinity chromatography of uninfected human erythrocytes 
 
Matrix-based affinity chromatography was conducted in microcentrifuge tubes. An aliquot of 
labelled beads was equilibrated in affinity buffer. To this was added a suitable amount of cell 
lysate from uninfected human erythrocytes and the mixture was gently rocked at 4°C for half an 
hour. Afterwards, the mixture was centrifuged to separate the beads from non-specific binders 



































times to ensure that all non-specifically bound proteins were removed. At this stage, solid-phase 
elution was carried out to compare the binding proteomes of all three of the drug-labelled beads 
as well as the “blocked” Tris-labelled beads. Hence, sample application buffer was added 
directly to the microfuge tubes. Following dry-boiling and centrifugation, the supernatants of 
the four samples were separated on SDS-Page and stained.  
 
Figure 6.7 indicates the erythrocyte binding proteomes of the labelled beads after solid-phase 
elution. The elution profiles show that chloroquine retained the most material. Despite not 
being labelled with a drug, the Tris-labelled beads still retained protein material indicating non-
specific binding of proteins either to the Tris motif, to the spacer or to the beads themselves. 
These bands are mostly also present in the lanes corresponding to the drug-labelled beads as 
well, suggesting that these bands arise from the binding of proteins to the beads themselves. 




Figure 6.7. SDS-Page (14% acrylamide) treated with a silver stain. Labelled beads were exposed to human 
erythrocyte lysate after which they were thoroughly washed with affinity buffer. Bound proteins were 
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An alternative approach to solid-phase elution is competition elution which is carried out by 
incubating the beads with a high concentration of the free ligand after they have been exposed 
to a protein mixture. Rather than eluting all the proteins bound to the beads, competition 
elution removes only those proteins which interact specifically with the free ligand and hence 
are competed off the ligand-labelled beads. Thus, a high concentration of free ligand was added 
to the tubes and this mixture was incubated at 4°C for a further 20 minutes. Following 
centrifugation, sample application buffer was added to the supernatants. These were dry-boiled 
and proteins were separated by SDS-Page and stained.  
 
Figure 6.8 indicates the major bands eluted from chloroquine- and Tris-labelled beads after two 
consecutive elutions with a high concentration of chloroquine (5 mM). The elution profiles were 
identical for both the first and second elutions, indicating that not all chloroquine-binding 




Figure 6.8. SDS-Page (12% acrylamide) treated with silver stain. Chloroquine- and Tris-labelled beads were 
exposed to erythrocyte lysate. Two consecutive competition elutions were performed using a high 
concentration of free chloroquine (5 mM). Three major bands were identified and their approximate 
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The several dominant bands that eluted corresponded to three molecular weights. Two bands, 
of approximately 41 and 58 kDa, were specific for the chloroquine-labelled beads. However, 
these bands did not present themselves tightly on the gel suggesting that other proteins with 
similar molecular weights may be present, possibly isoforms of these proteins. The third band 
corresponded to a non-specific binding protein which also eluted from the Tris-labelled beads 
in the presence of chloroquine (72 kDa).  
 
The 58 kDa protein that was specifically eluted from the chloroquine-labelled beads 
corresponds closely to a 55 kDa protein isolated by Graves et al.10 Those investigators identified 
this protein as human aldehyde dehydrogenase 1 (ALDH1) after screening the human 
erythrocyte purine-binding proteome by using γ-ATP-linked Sepharose affinity matrix. ALDH1 
was also captured on hydroxychloroquine-labelled beads by screening uninfected erythrocyte 
lysate directly. The mouse homologue of this protein was also detected by passing lysate from a 
mouse over the same beads. However, in vitro assays of ALDH1 in the presence of chloroquine 
revealed that it was a weak inhibitor of ALDH1 at physiological levels of NAD+, indicating that 
ALDH1 was unlikely to be a direct target of chloroquine unless chloroquine accumulates to high 
levels in the tissues, which is unlikely in the case of the unparasitised erythrocyte.10 However, 
ALDH1 may be involved in the side-effects observed for chloroquine, such as retinopathy which 
results from an accumulation of retinaldehyde in the retina.10 
 
As several incubations with the free drug were required to competitively elute all of the binding 
proteins from the beads, it was decided to pool the elutions and concentrate them by 
ultrafiltration using microfuge tubes with a low molecular weight cut-off (3 kDa). Hence, this 
would allow more sensitive detection of all binding proteins.  
 
Figure 6.9 represents such a competition elution experiment performed for all the labelled 
beads. Fractions were combined and concentrated after three competitive elutions. It can be 
seen that there are several more chloroquine-specific binding partners than originally 
illustrated by Figure 6.8. The major bands from the chloroquine-labelled beads were still 
present at approximately 74, 58 and 43 kDa which almost certainly correspond to the 72, 58 
and 41 kDa proteins observed in Figure 6.8. These bands are also indicated with red arrows in 
the inset in Figure 6.9.  
 
Once again, Tris-labelled beads were eluted with a high concentration of the corresponding free 
ligand to identify non-specific binders corresponding to that ligand. Indeed, a non-specific band 
corresponding to all the labelled beads across all six lanes was observed at 74 kDa, although this 
was less clear for the Tris-labelled beads eluted with quinidine. The band at 61 kDa appears to 





be specific for the drug-labelled beads, although there may be a trace of this band in the 
corresponding Tris-labelled lanes. This 61 kDa band does not correspond to the dominant band 
previously observed at approximately 58 kDa in the lane corresponding to the chloroquine-
labelled beads. Instead, there is a cluster of bands around this molecular weight suggesting a 




Figure 6.9. SDS-Page (12% acrylamide) treated with silver stain. Competition elution of labelled beads 
reveals specific and non-specific binding interactions after exposure to human erythrocyte lysate. The inset 
represents elution of the chloroquine-labelled beads (second lane from the left). The three bands indicated by 
the molecular weights in red correspond to the dominant bands identified previously in Figure 6.8. 
 
Higher molecular-weight bands were also observed from chloroquine- and quinidine-labelled 
beads (87 and 94 kDa, respectively), but not for the quinine-labelled beads. Bands 
corresponding to a higher molecular weight were not observed. Conversely, another tight 
cluster of bands of lower molecular weight corresponding to the chloroquine-labelled beads 
centred at around 43 kDa. Finally, a low molecular weight band at approximately 25 kDa was 












Competition elution of labelled beads exposed to erythrocyte lysate
Chloroquine Tris Quinine Tris Quinidine Tris
















to identify these specifically-eluting proteins in order to determine whether they play a 
mechanistic role in the action of these quinoline antimalarials. 
 
6.3.3. Matrix-based affinity chromatography of P. falciparum 
 
As material isolated from P. falciparum was in somewhat limited supply, the limit of detection of 
binding targets that could be revealed by staining on SDS-Page was determined. In a typical 
affinity experiment, approximately 40 μg of protein isolated from P. falciparum was loaded onto 
the labelled beads. The average protein abundance in P. falciparum is approximately 200 ppm.25 
Assuming that all of this “average” protein is successfully retained on the beads and then eluted, 
8 ng of this protein will be retrieved. If this material is spread over a band with dimensions 0.5 
mm x 10 mm on SDS-Page, the band will have a local concentration of 1.6 ng protein/mm2. The 
detection limit of silver staining is 0.1 ng/mm2. Double staining, on the other hand, increases 
sensitivity to 25 pg/mm2. These limits are 16- and 64-fold above the concentration of this 
“average” protein, respectively.  
 
This implies that proteins with abundances higher than 3 ppm may be detected on a gel by 
double staining. Of the approximately 5 000 proteins in P. falciparum proteome, more than 80% 
have abundances greater than 3 ppm.25 However, proteins which are known targets of small 
molecules tend to have abundances very much higher than this. For example, atovaquone 
disrupts mitochondrial electron transport by inhibiting the cytochrome bc1 complex26 while 
pyrimethamine inhibits bifunctional dihydrofolate reductase-thymidylate synthase. Plasmepsin 
is a putative target for halofantrine.27 These three proteins have abundances of 90, 765 and 242 
ppm, respectively.25 Hence, the small amount of P. falciparum lysate available was not 
considered to be a limiting factor in these experiments.  
 
Labelled beads were exposed to both the soluble and membrane fractions of lysate recovered 
from mature P. falciparum cultures. After incubation, the labelled beads were eluted with an 
excess of the respective free ligand. As before, for each drug-labelled bead a corresponding Tris-
labelled fraction was eluted with the same concentration of free ligand to determine any non-
specific binders. For each fraction, three competitive elutions were performed. These were 
pooled and concentrated by ultrafiltration.  
 
Figure 6.10 depicts a silver-stained gel of samples after competition elution of the membrane 
fraction recovered from P. falciparum lysate. There are several faint bands in the lanes 
corresponding to the drug-labelled beads between 72-180 kDa; however, the gel reveals a 
prominent band in the high molecular weight region above 180 kDa (indicated by an arrow on 





the right-hand side of the gel). As this band lies above the highest marker in the molecular 
weight ladder (180 kDa), an approximate molecular weight for this band could not be 
calculated. The band appears to be specific for the drug-labelled beads compared to Tris-
labelled beads eluted with chloroquine (central lane in Figure 6.10). The same band was also 
detected in the drug-labelled lanes incubated with the soluble fraction recovered from the  




Figure 6.10. SDS-Page (15% acrylamide) treated with a silver stain. Beads were incubated with the 
membrane fraction recovered from P. falciparum. Lanes represent samples following three successive 
competitive elutions of labelled beads with an excess of free ligand and subsequent concentration.  
A high molecular weight band was observed for the drug-labelled lanes as indicated by the black arrow. 
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In order to further investigate this prominent band, the same samples were separated using a 
gel with a lower concentration of acrylamide to emphasise the higher molecular weight bands. 
The gel was first stained with Coomassie Brilliant Blue, followed by silver staining, to give the 
highest sensitivity of detection. In Figure 6.11, the same high molecular weight band as before 
was observed in the lanes corresponding to the drug-labelled beads. A faint band corresponding 
to the same molecular weight was also identified in the Tris-labelled lane eluted with 
chloroquine. This suggested that it was likely that some of this protein had been retained non-





Figure 6.11. SDS-Page (8% acrylamide) treated with Coomassie Brilliant Blue followed by silver staining.  
A prominent band in the region 200-250 kDa is indicated by the black arrow. 
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Although an accurate molecular weight could not be determined, this band was estimated to lie 
in the molecular weight range 200-250 kDa. In order to identify a possible protein 
corresponding to this band, all proteins in the P. falciparum proteome within this molecular 
weight range were listed (Table 6.1).25,28 All proteins in this range have abundances greater 
than 5 ppm, almost double the limit of detection afforded by double staining. Many of the 
proteins in this molecular weight range are so-called “hypothetical proteins” meaning that their 
functions cannot be readily assigned. Only a few proteins in this molecular weight range have 
had their functions characterised while several of these proteins have only putative functions 
which have been assumed from their gene sequences.  
 
Table 6.1. List of proteins from the P. falciparum proteome with molecular weights between 200-250 kDa. 
 
PaxDb ID Protein name Abundance Molecular weight 
MAL7P1.102 Hypothetical protein, conserved 37 ppm 206 kDa 
PF11_0091 Hypothetical protein 6 ppm 207 kDa 
PFF1260c Hypothetical protein, conserved 5 ppm 210 kDa 
PFL1530w Asparagine-rich protein, putative 28 ppm 213 kDa 
PFL1865w Hypothetical protein, conserved 21 ppm 213 kDa 
PfMRP1 Multidrug resistance-associated protein (ABC transporter) 11 ppm 214 kDa 
PF11_0317 Structural maintenance of chromosome protein, putative 168 ppm 215 kDa 
PFB0540w Hypothetical protein 14 ppm 215 kDa 
PFC0325c Hypothetical protein, conserved 21 ppm 216 kDa 
PF07_0016 Hypothetical protein, conserved 9 ppm 218 kDa 
PF07_0115 Cation-transporting ATPase 32 ppm 225 kDa 
PFL1800w Hypothetical protein, conserved 23 ppm 231 kDa 
PFL2335w Hypothetical protein, conserved 42 ppm 231 kDa 
PFL0930w Clathrin heavy chain, putative 292 ppm 233 kDa 
PFF0410w Hypothetical protein, conserved 29 ppm 233 kDa 
M26-32-14 Hypothetical protein, conserved 12 ppm 235 kDa 
PFI0250c Hypothetical protein, conserved 9 ppm 235 kDa 
PF14_0454 Hypothetical protein 14 ppm 238 kDa 
MAL7P1.171 Hypothetical protein 22 ppm 244 kDa 
MAL7P1.109 Hypothetical protein, conserved 15 ppm 246 kDa 
PF10_0320 Leucine-rich repeat protein 8, LRR8 9 ppm 247 kDa 
PfRON2 Hypothetical protein 17 ppm 249 kDa 
 
Only three proteins in this molecular weight range have been characterised; namely, multidrug 
resistance-associated protein (PfMRP1, 214 kDa), a cation-transporting ATPase (225 kDa) and 





leucine-rich repeat protein 8 (247 kDa). The 225 kDa cation-transporting ATPase may be 
involved in binding to small molecules such as the quinoline antimalarials which are cations at 
physiological pH. On the other hand, leucine-rich repeat motifs are frequently involved in the 
formation of protein-protein interactions and hence are unlikely to interact with the quinoline 
antimalarials. A more likely candidate for this protein is PfMRP1. This protein has been 
associated with decreased susceptibility to antimalarials including chloroquine and quinine 
(Section 1.4.3).29 The fact that it is a membrane-associated transporter explains why it was 
prominently observed in the membrane fraction recovered from P. falciparum compared to the 
corresponding soluble fraction. 
 
In order to identify this protein, these samples were analysed using mass spectrometry-based 
proteomics. To increase the number of hits while limiting the amount of interference that might 
be generated from gel bands, samples from each set of labelled beads from both soluble and 
membrane fractions were pooled and analysed in-solution. Following digestion, separation and 
tandem mass spectrometry, peptide fragments were screened against databases for H. sapiens 
and P. falciparum.  
 
When screened against the human proteome, no hits in the range 200-250 kDa were retrieved. 
Indeed, no hits were expected from H. sapiens as there were no bands corresponding to this 
molecular weight range detected from affinity chromatography of the erythrocyte lysate (Figure 
6.9). When screened against the P. falciparum proteome, several proteins across a broad 
molecular weight range were identified. Table 6.2 lists only those proteins that were present in 
all the samples as reflected by the gel in Figure 6.11. These are listed in order of decreasing 
probability of identification. 
 
Table 6.2. List of P. falciparum proteins identified across all labelled beads, 
 in order of decreasing probability. 
 
Entry Protein name Molecular weight 
1 Multidrug resistance-associated protein (PfMRP1) 214 kDa 
2 Hypothetical protein 21 kDa 
3 Hypothetical protein 12 kDa 
4 Hypothetical protein 349 kDa 
5 Fructose-bisphosphate aldolase 42 kDa 
6 Hypothetical protein 12 kDa 
7 Hypothetical protein 103 kDa 
 
 





Once again, many of the proteins identified in this list are hypothetical proteins. Only two of 
these proteins have been characterised. The first is fructose-bisphosphate aldolase, an enzyme 
important in glycolysis. This has a much lower molecular weight (42 kDa) than the observed 
band (200-250 kDa). Furthermore, this is one of the most abundant proteins in the P. falciparum 
proteome (> 8 000 ppm) and hence is more likely to be a contaminant. Thus, the only protein in 
the molecular weight range corresponding to the 200-250 kDa gel bands in Figure 6.11 is 
PfMRP1 (214 kDa). This was also the protein with the highest probability of identification, 
suggesting it is extremely likely that this was the protein competitively eluted from the 
chloroquine-, quinine- and quinidine-labelled beads and in much lower quantity from the Tris-
labelled beads. 
 
As described in Section 1.4.3, PfMRP1 is one of many ATP-binding cassette transporters in  
P. falciparum. Although only identified just over a decade ago,30 it has subsequently been shown 
to localise to the parasite plasma membrane and to membrane-bound vesicles during the 
intraerythrocytic stages.31,32 Disrupting PfMRP1 expression in P. falciparum under normal 
culture conditions resulted in parasites that could not grow to a parasitaemia higher than 5%, 
possibly because of lower efficiency in removing toxic metabolites.32 These parasites also 
accumulated more radiolabelled glutathione, chloroquine and quinine and became more 
sensitive to several antimalarials, including chloroquine, quinine and artemisinin.32 This 
indicates that PfMRP1 most likely plays a role in the efflux of glutathione, chloroquine and 
quinine from the parasite.34 Expression of PfMRP1 also increased in the presence of chloroquine 
and mefloquine.33 Although PfMRP1 is expressed in all stages of the life cycle, Noguiera et al. 
showed that this expression peaks at the late trophozoite and early schizont stages.33 
Interestingly, this is exactly when the quinoline antimalarials have been shown to be most 
potent against the parasite (Section 5.2.2).14-16  
 
PfMRP1 has not previously been identified to bind directly to these drugs. Although 
photoaffinity-based techniques label substrates with high specificity and have previously been 
exploited to probe for binding targets of these drugs in P. falciparum, the rapid nature of 
photolabelling means that it labels substrates promiscuously; that is, molecules in higher 
abundance are more likely to be labelled. This may explain why the photoreactive derivative of 
chloroquine designed by Foley et al. detected lactate dehydrogenase enzyme (PfLDH) as it is an 
extremely abundant protein in P. falciparum (> 9 000 ppm).8,25 The activity of this enzyme was 
later shown not to be significantly affected by the presence of chloroquine.  
 
PfMRP1 is a low abundance protein in the P. falciparum proteome (11 ppm).25 Hence, the 
matrix-based study of Graves et al. may not have been sensitive enough to detect this protein.10 





Alternatively, these authors’ use of a hydroxychloroquine-labelled matrix as a substitute for 
chloroquine itself might also have contributed to a reduced specificity of the matrix for PfMRP1. 
 
It is probably unsurprising that other membrane transporters associated with the quinoline 
antimalarials, such as PfCRT and PfMDR1, were not detected at all in this study which only 
investigated a chloroquine-sensitive strain of P. falciparum. PfCRT associates more strongly 
with the quinoline antimalarials in resistant strains in which polymorphic mutations allow 
these drugs to bind more readily to the transporter.29 PfMDR1, on the other hand, is typically 
expressed at low levels in sensitive strains. Amplification in resistant strains is one of its key 
characteristics.29 As PfMRP1 is itself a low abundance protein in sensitive strains, this means 
PfMRP1 must bind these quinoline antimalarials in a strong and specific manner.29 That the 
drug-labelled beads in this study were selective for PfMRP1 is evidence of a dynamic binding 
process between these ligands and the protein receptor. The fact that only a single, dominant 
band was detected on SDS-Page, coupled with the relatively small number of proteins retrieved 
from in-solution proteomic analysis, suggests that these matrix-based scaffolds were exquisitely 









6.4. Summary and conclusions  
 
Although chloroquine, quinine and quinidine are generally accepted to function primarily as 
haemozoin inhibitors, these quinoline antimalarials exert other effects on P. falciparum which 
may not be related to this primary role. For example, quinine and chloroquine appear to 
modulate endocytosis in a differential manner.6 This suggests that these antimalarials may have 
alternative targets within the parasite. Thus the aim of this chapter was to isolate and identify 
protein binding targets, if any, of the quinoline antimalarials in uninfected erythrocytes and  
P. falciparum using chemical proteomics.  
 
Biological material from both uninfected human erythrocytes and P. falciparum trophozoites 
was prepared in a manner suitable for use in these experiments. Quinoline antimalarial-labelled 
matrices were prepared by reacting N-hydroxysuccinimide-activated beads with the primary 
amine-containing derivatives prepared in Chapter 3 of this work. A deliberate reduction in 
coupling capacity of these matrices (3 μmol/mL) prevented overloading of the beads.  
 
These drug-labelled matrices were used to capture quinoline antimalarial-binding proteins in 
uninfected erythrocytes. Binding sub-proteomes were separated and visualised using SDS-Page. 
Two dominant, specific human binding targets were detected for chloroquine (41 kDa and  
58 kDa). The latter corresponds closely in molecular weight to that of human aldehyde 
dehydrogenase 1 (ALDH1), a 55 kDa protein that was previously isolated by Graves et al. using 
hydroxychloroquine-labelled beads.10 A host of less dominant bands were detected for 
chloroquine with fewer bands generally observed for the alkaloids, but a specific band at 
approximately 61 kDa was detected for all three quinoline antimalarials. Further work will be 
required to identify these bands. 
 
The drug-labelled matrices were also used to extract quinoline antimalarial-binding proteins 
from P. falciparum. SDS-Page revealed a single band between 200-250 kDa that was prominent 
in the membrane-associated fraction recovered from the parasite. Screening the P. falciparum 
proteome in this molecular weight range suggested that PfMRP1 might be a suitable candidate 
(214 kDa). This was confirmed by in-solution proteomics that identified PfMRP1 as the only 
protein in the appropriate molecular weight range across samples from all the labelled beads. 
No human proteins in this molecular weight range were identified. This is an intriguing result as 
PfMRP1 has been implicated in resistance mechanisms of chloroquine and quinine.  
  







1. J. M. Combrinck, T. E. Mabotha, K. K. Ncokazi, M. A. Ambele, D. Taylor, P. J. Smith, H. C. 
Hoppe and T. J. Egan, ACS Chem. Biol., 2013, 8, 133.  
2. J. Gildenhuys, T. le Roux, T. J. Egan and K. A. de Villiers, J. Am. Chem. Soc., 2013, 135, 1037.  
3. T. J. Egan and K. K. Ncokazi, J. Inorg. Biochem., 2004, 98, 144.  
4. G. H. Jacobs, A. Oduola, D. E. Kyle, W. K. Milhous, S. K. Martin and M. Aikawa, Am. J. Trop. 
Med. Hyg., 1988, 39, 87.  
5. N. Sachanonta, K. Chotivanich, U. Chaisri, G. D. H. Turner, D. J. P. Ferguson, N. P. J. Day and 
E. Pongponratn, Ultrastruct. Pathol., 2011, 35, 214.  
6. L. Roberts, T. J. Egan, K. A. Joiner and H. C. Hoppe, Antimicrob. Agents Chemother., 2008, 
52, 1840.  
7. O. Famin and H. Ginsburg, Biochem. Pharmacol., 2002, 63, 393.  
8. M. Foley, L. W. Deady, K. Ng, A. F. Cowman and L. Tilley, J. Biol. Chem., 1994, 269, 6955.  
9. J. Desneves, G. Thorn, A. Berman, D. Galatis, N. La Greca, J. Sinding, M. Foley, L. W. Deady, 
A. F. Cowman and L. Tilley, Mol. Biochem. Parasitol., 1996, 82, 181.  
10. P. R. Graves, J. J. Kwiek, P. Fadden, R. Ray, K. Hardeman, A. M. Coley, M. Foley and T. A. J. 
Haystead, Mol. Pharm., 2002, 62, 1364.  
11. E. Gregori-Puigjané, V. Setola, J. Hert, B. A. Crews, J. J. Irwin, E. Lounkine, L. Marnett, B. L. 
Roth and B. K. Shoichet, Proc. Natl. Acad. Sci. USA, 2012, 109, 11178. 
12. DrugBank, http://www.drugbank.ca (accessed July 2016). 
13. G. C. Terstappen, C. Schülpen, R. Raggiaschi and G. Gaviraghi, Nat. Rev. Drug Discov., 2007, 
6, 891. 
14. A. Yayon, J. A. Vande Waa, M. Yayon, T. G. Geary and J. B. Jensen, J. Protozool., 1983, 30, 
642.  
15. T. S. Skinner, L. S. Manning, W. A. Johnston and T. M. E. Davis, Int. J. Parasitol., 1996, 26, 
519.  
16. D. W. Wilson, C. Langer, C. D. Goodman, G. I. McFadden and J. G. Beeson, Antimicrob. Agents 
Chemother., 2013, 57, 1455.  
17. M. M. Bradford, Anal. Biochem., 1976, 72, 248. 
18. Quick Start Bradford Protein Assay Instruction Manual, Bio-Rad Laboratories, Inc. 
19. A Guide to Polyacrylamide Gel Electrophoresis and Detection, Bio-Rad Laboratories, Inc. 
20. ProteoSilver Plus Silver Stain Kit Technical Bulletin, Sigma-Aldrich. 
21. R. Aebersold and M. Mann, Nature, 2003, 422, 198. 
22. U. Rix and G. Superti-Furga, Nat. Chem. Biol., 2009, 5, 616. 
23. Affinity Chromatography: Principles and Methods, Amersham Biosciences, 2002.  





24. D. Guiffant, D. Tribouillard, F. Gug, H. Galons, L. Meijer, M. Blondel and S. Bach, Biotechnol. 
J., 2007, 2, 68. 
25. PaxDB, http://pax-db.org (accessed August 2016). 
26. A. L. Baggish and D. R. Hill, Antimicrob. Agents Chemother., 2002, 46, 1163. 
27. R. Friedman and A. Caflisch, ChemMedChem, 2009, 4, 1317. 
28. D. Tao, C. Ubaida-Mohien, D. K. Mathias, J. G. King, R. Pastrana-Mena, A. Tripathi, I. 
Goldowitz, D. R. Graham, E. Moss, M. Marti and R. R. Dinglasan, Mol. Cell. Proteomics, 2014, 
13, 2705. 
29. C. P. Sanchez, A. Dave, W. D. Stein and M. Lanzer, Int. J. Parasitol., 2010, 40, 1109.  
30. A. Klokouzas, T. Tiffert, D. van Schalkwyk, C. Wu, H. W. van Veen, M. A. Barrand and S. B. 
Hladky, Biochem. Biophys. Res. Commun., 2004, 321, 197. 
31. R. A. Kavishe, J. M. W. van den Heuvel, M. van de Vegte-Bolmer, A. J. F. Luty, F. G. M. Russel 
and J. B. Koenderink, Malaria J., 2009, 8, 205. 
32. D. K. Raj, J. Mu, H. Jiang, J. Kabat, S. Singh, M. Sullivan, M. P. Fay, T. F. McCutchan and X. Su, 
J. Biol. Chem., 2009, 284, 7686. 
33. F. Nogueira, D. Lopes, A. C. Alves and V. E. do Rosário, J. Cell Anim. Biol., 2008, 2, 10.  

















7.1. Overall conclusions 
 
alaria is the most serious parasitic disease occurring in man and places an intolerable 
burden on global health. Quinoline-based antimalarials have provided the foundation of 
malaria treatment for centuries and remain of great interest. Despite recent challenges posed by 
resistance, these antimalarials continue to be used widely, especially in cases of severe malaria 
and malaria in pregnancy.1 In addition, the quinoline motif persists as an important template in 
drug discovery.2,3 However, the mechanistic details of the modes of action of these antimalarials 
against the intraerythrocytic cycle of the most virulent malaria parasite, Plasmodium falciparum, 
remain incompletely resolved. Hence the broad aim of this work was to develop new tools with 
which to investigate these antimalarials, and to use these tools to generate deeper insights into 
their mechanism of action against P. falciparum. In this work, the two major classes of these 
antimalarials, the quinoline methanols and 4-aminoquinolines, were represented by the 
diastereomeric Cinchona alkaloids, quinine and quinidine, and chloroquine, respectively.  
 
Recent evidence continues to support the inhibition of haemozoin biocrystallisation as a 
primary mode of action of these quinoline antimalarials.4,5 Accordingly, most studies have 
focused on the parasite digestive vacuole as the sole site of action of these drugs. However, 
ultrastructural analyses implicate other regions of the parasitic cell following treatment with 
M 





these drugs.6-8 In addition, previous work to identify protein binding targets of these 
antimalarials suggests that alternative modes of action against P. falciparum may exist.9,10 
Hence, in order to conduct a systematic investigation into the localisation of these antimalarials 
within P. falciparum, fluorescently-labelled derivatives were prepared from which the most 
suitable analogues for microscopy were selected. These were then imaged in P. falciparum using 
live-cell confocal and super-resolution microscopy. Finally, in a chemical proteomics approach, 
agarose beads were functionalised with the drugs and these were used to identify protein 
binding targets of these antimalarials in P. falciparum. These ideas are depicted in Figure 7.1. 
 
 
Figure 7.1. A summary of the two major approaches taken in this study.  
Dashed boxes represent the regions of synthetic modification of the parent compounds. 
 
For the preparation of fluorescent derivatives, NBD was selected as a suitable reporter on 
account of its appropriate photophysical properties and small size. Structure-activity 
relationships between Fe(III)PPIX and the quinoline antimalarials were evaluated which 
suggested that the vinyl group of the alkaloids and the N-diethyl side chain of chloroquine were 
suitable sites for structural modification (dashed boxes in Figure 7.1). A general synthetic 
strategy was the introduction of an additional amino group for attachment of the NBD 
fluorophore via nucleophilic aromatic substitution. For the alkaloids, this was enabled by a 





regioselective radical-mediated thiol-ene click reduction which provided facile access to 
derivatives in high yield. Additional derivatives were prepared in which the length of the spacer 
chain between the quinoline core and the fluorophore was varied by preparing NBD-labelled 
amino acids and their corresponding succinimidyl esters. In contrast, only a single fluorescent 
derivative of chloroquine was prepared for which an N-dealkylated analogue of the drug was 
exploited as a key intermediate. 
 
In order to determine which of these derivatives were the most suitable analogues of the parent 
antimalarials for live-cell imaging, their physicochemical interactions with Fe(III)PPIX were 
evaluated. Spectrophotometric titrations revealed that distinctive features of association were 
retained for most NBD-labelled alkaloids, vindicating the design choice to functionalise the vinyl 
group. Aqueous solubility and diffusion measurements suggested that the most suitable 
analogues of the alkaloids were those in which the chain length between the quinoline core and 
the reporter fluorophore was the shortest. Longer-chain derivatives were either insufficiently 
soluble or exhibited behaviour analogous to micelles, excluding these derivatives from use in 
microscopy studies. Crucially, all derivatives exhibited low to moderate nanomolar activities 
against a chloroquine-sensitive strain of P. falciparum. These results confirmed that the labelled 
alkaloids with the shortest spacer chain were the most suitable analogues of the quinoline 
methanol antimalarials. Indeed, these are the first derivatives of these antimalarials suitable for 
live-cell imaging that have been prepared. For chloroquine and its NBD-labelled derivative,  
μ-oxo dimerisation of Fe(III)PPIX and activity against P. falciparum were conserved, indicating 
the suitability of this derivative as a representative 4-aminoquinoline for microscopy.  
 
Live-cell imaging demonstrated selective accumulation of these fluorescently-labelled 
analogues within P. falciparum-infected erythrocytes. The chloroquine analogue was invariably 
found in close association with the haemozoin and hence the region corresponding to the 
digestive vacuole. This is in accordance with its established role as a haemozoin inhibitor, 
corroborating previous imaging studies11,12 and vindicating the approach taken in this work. 
Analogues of the quinoline methanols were also found near the haemozoin although this did not 
always correspond to the regions of most intense fluorescence. Intriguingly, an 
autofluorescence signal that had been previously reported to originate from quinine was 
instead found to correspond to the haemozoin in untreated cells. This casts doubt on the claim 
made by earlier investigators that quinine localises to a non-acidic compartment adjacent to the 
digestive vacuole.13 Instead, the analogues of quinine and quinidine were found to have an 
affinity for membranous structures within the parasitic cell. Quantitative analysis of cells co-
stained with the lipophilic dye LysoTracker Red demonstrated extensive colocalisation between 
these two signals, indicating a preference for phospholipid bilayers of acidic organelles. The 





distribution of the quinidine analogue colocalised with membranes to a larger extent than its 
quinine counterpart which may explain the more potent activity of quinidine against P. 
falciparum. Significantly, qualitative and quantitative analysis revealed that the analogues of the 
alkaloids did not accumulate in the nucleus. This makes the persistent claims that these 
molecules disrupt DNA replication in P. falciparum very unlikely.  
 
In order to overcome the resolution limitations of the confocal microscope, a super-resolution 
technique (SR-SIM) was employed. Extensive colocalisation was observed between analogues of 
all three quinoline antimalarials and the ER. Colocalisation between these analogues and the 
mitochondrion was also evident but less conclusive. These observations are consistent with 
ultrastructural studies in which swelling of the mitochondrion and disintegration of the ER 
following drug treatment were observed.6,7 Furthermore, a shared receptor between the 
quinine analogue and ER-Tracker Red on the surface of the ER gave rise to behaviour consistent 
with competitive binding between these two ligands, strengthening the case for colocalisation 
with this organelle.14  
 
Whether the regions of accumulation in P. falciparum corresponded to binding of these 
antimalarials to protein targets within the parasite was investigated using chemical proteomics. 
Drug-labelled matrices captured quinoline antimalarial-binding proteins in human erythrocytes 
and P. falciparum. In uninfected erythrocytes, two dominant binding targets were detected for 
chloroquine, one of which corresponded closely in molecular weight to that of human aldehyde 
dehydrogenase 1 (ALDH1, 55 kDa) which was previously isolated using hydroxychloroquine-
labelled beads.15 In P. falciparum, SDS-Page revealed a prominent band between 200-250 kDa 
from the membrane-associated fraction. Proteomics analysis revealed that this band 
corresponded to P. falciparum multidrug resistance-associated protein (PfMRP1, 214 kDa). This 
is intriguing as PfMRP1 has been implicated in resistance mechanisms of chloroquine and 
quinine.16 Disrupting this gene makes cells more susceptible to these drugs, indicating that this 
protein plays a role in transport and hence must bind these substrates.17 That PfMRP1 was 
detected in binding sub-proteomes corresponding to all drug-labelled matrices shows that 
PfMRP1 dynamically binds to all three of the quinoline antimalarials investigated in this study.  
 
PfMRP1 has previously been shown to localise to the parasite plasma membrane.17 The 
analogues of all three quinoline antimalarials illuminated this membrane, suggesting that 
binding to PfMRP1 might be partly responsible for this localisation pattern. It is believed that 
this protein extrudes these drugs from the parasite cytoplasm to the parasitophorous vacuolar 
lumen.17 Hence PfMRP1 is likely to have a high affinity for the quinoline antimalarials as this 
protein is found in relatively low abundance and, furthermore, the quinoline antimalarials are 





unlikely to be present in high concentrations in the parasite cytoplasm. That PfMRP1 is a low-
abundance protein but was still identified by affinity chromatography strengthens the findings 
that additional protein targets in P. falciparum were not detected. Thus it is likely that these 
antimalarials do not bind appreciably to protein targets within organelles such as the ER, the 
digestive vacuole and the mitochondrion, despite evidence of accumulation of the fluorescent 
analogues within or on the surface of these organelles. Although quinine has been shown to 
bind to the surface of mammalian sulfonylurea receptors which are prominent on the ER and 
mitochondrial membranes,14 these receptors were not detected in any of the affinity 
experiments performed in this work.  
 
Besides Fe(III)PPIX and the single protein PfMRP1, what other targets could possibly play a role 
in the mechanism of action of the quinoline antimalarials or in modulating their activity against 
a chloroquine-sensitive strain of P. falciparum? As proteins form the vast majority of known 
drug targets,18 interaction of these antimalarials with a further non-protein target in addition to 
Fe(III)PPIX within P. falciparum would be extremely unusual. As described before, interaction 
with DNA is very unlikely as the analogues were not observed to localise to the nucleus, let 
alone at the high concentrations required for the inhibition of DNA replication. Interaction with 
RNA in the cytoplasm cannot be ruled out but is unlikely. Molecules targeting RNA are typically 
antisense oligonucleotides or anti-ribosomal antibiotics; presumably, interaction of the 
quinoline antimalarials with ribosomes would have been detected by the sensitive proteomic 
analysis of the drug-binding sub-proteomes isolated by affinity chromatography. Carbohydrates 
are also unlikely targets. Although glucose consumption of infected erythrocytes increases 
nearly 100-fold compared to uninfected erythrocytes,19 P. falciparum possesses a conserved and 
efficient glycolytic pathway and targeting carbohydrates is unlikely to yield the specificity or 
potency exhibited by the quinoline antimalarials.  
 
On the other hand, direct interaction with lipids is more likely. These antimalarials are all 
somewhat lipophilic, especially the Cinchona alkaloids, and association with membranes and 
membranous organelles was a prominent feature of the analogues as revealed by microscopy. 
Although these analogues are indeed more lipophilic than their parent molecules and more 
brightly fluorescent in low rather than high dielectric media, it has previously been shown that 
these antimalarials interact appreciably with bilayers. Indeed, quinine causes more disruption 
of the phospholipid bilayers than chloroquine.20,21 Hence, it may be speculated that secondary 
effects due to association with membranous organelles such as the ER, the mitochondrion and 
other membranous structures might be responsible for deleterious metabolic disruption caused 
by the quinoline antimalarials, especially the quinoline methanols, in addition to their primary 
roles as haemozoin inhibitors. 






Taken together, these results support haemozoin inhibition by accumulation in the digestive 
vacuole as the primary mechanism of action of the quinoline antimalarials, with Fe(III)PPIX as 
the primary target of these antimalarials. This was in agreement with live-cell localisation 
studies in which the digestive vacuole was a primary site of accumulation of the drug analogues, 
particularly in the case of chloroquine. Only a single protein binding target was identified which 
most likely plays a role as a transporter responsible for modulating the activity of these 
compounds but is not a drug target as such. While live-cell imaging and affinity chromatography 
did not reveal significant differences between the two major classes of these antimalarials that 
might be responsible for their differential effects against P. falciparum,8 one may speculate that 
their fundamentally different interactions with Fe(III)PPIX may be responsible for these 
differential effects. Free Fe(III)PPIX itself is deleterious to cells and the complex between 
chloroquine and Fe(III)PPIX enhances the lytic effects on cells that have been observed with 
Fe(III)PPIX alone.22,23 Quinine, quinidine and chloroquine all form stable complexes with 
Fe(III)PPIX, lending support to this hypothesis. 
 
Overall, this study has generated and evaluated new tools to investigate the mechanism of 
action of the quinoline antimalarials against P. falciparum. A systematic approach has confirmed 
that Fe(III)PPIX, and hence haemozoin inhibition, is the primary target of these molecules with 
room for a secondary role resulting from direct interaction with lipid components such as 
phospholipid bilayers and/or membranous organelles. These quinoline antimalarials bind to 
PfMRP1 which is unlikely to be a drug target but probably modulates their activity within  
P. falciparum.  
 
It is remarkable that, despite decades or even centuries of use, the mechanistic details relating 
to the action of the quinoline antimalarials against P. falciparum has remained elusive. The 
insights generated in this study have made some progress in addressing this matter. 
Nevertheless, the historical value of the Cinchona alkaloids and the impact of their synthetic 
derivative, chloroquine, cannot be understated. It is likely that these molecules will continue to 
play a valuable role in the future, especially as mechanistic probes. These investigations may 
still lead to hitherto undiscovered insights into the metabolism of this pathogen and hopefully 









7.2. Further work  
 
In this work, PfMRP1 was identified as a binding target of the quinoline antimalarials using SDS-
Page and proteomic analysis. In order to confirm unequivocally the identity of this protein band, 
Western blotting using an anti-PfMRP1 antibody should be performed. Similarly, binding 
relationships between the quinoline antimalarials and this protein may also be verified using 
antibodies that are specific for these drugs. For this, it is necessary that the free drug which was 
used to elute PfMRP1 is still bound to the protein in its denatured form on the SDS-Page gel. 
Proteomic analysis should also be carried out to identify the bands corresponding to the 
proteins pulled down from uninfected erythrocytes. Of particular importance are the two bands 
corresponding to putative chloroquine-binding proteins (41 kDa and 58 kDa), the latter of 
which is expected to correspond to human ALDH1 as identified by Graves et al.15 A further band 
at approximately 61 kDa that was detected for all three quinoline antimalarials should also be 
identified and may provide insights into binding targets within the uninfected host cell. 
 
PfMRP1 was identified from the chloroquine-sensitive NF54 strain of P. falciparum. Resistant 
strains of P. falciparum have mutations in the genes corresponding to other known quinoline 
transporters such as PfCRT.16 Mutations in this gene confers resistance by actively extruding 
these quinoline antimalarials from the digestive vacuole.16 As this mutation results in more 
efficient transport of these quinoline antimalarials, the mutated protein is likely to bind more 
strongly to these drugs. Hence, it would be interesting to investigate whether PfCRT may be 
identified by affinity chromatography using these resistant strains. It would also be interesting 
to investigate how the patterns of accumulation of the fluorescent analogues prepared in this 
work differ in resistant strains, especially under the super-resolution microscope. 
 
Of particular interest is the interaction of the quinoline antimalarials with lipid or membranous 
components within P. falciparum. In order to investigate whether these drugs cause deleterious 
effects to the organelles in which their analogues accumulate, such as the ER, mitochondrion 
and membrane bilayers, further experiments should be performed. If treatment with the 
quinoline antimalarials leads to generation of reactive oxygen species within these organelles, 
for example, this could be probed using fluorescent indicators developed for this purpose. The 
ER is a calcium store in P. falciparum; thus, calcium redistribution in the parasitic cell following 
treatment with the drugs could be probed with suitable fluorescent dyes and may be an 
indication of disruption of this organelle caused by an accumulation of the drug.24 Cytoskeletal 
components such as actin are involved in endocytosis in P. falciparum25 and this may be related 
to the effects of quinine and chloroquine to modulate endocytosis in P. falciparum in a 
differential manner.8 Morphological changes in actin could be monitored using a suitable actin-





specific dye such as SiR-actin.26 While the chloroquine complex with Fe(III)PPIX is known to 
have a deleterious effect on cells,22,23 the effects of the complexes of Fe(III)PPIX with the 
Cinchona alkaloids should be investigated to determine whether these may in some way be 
responsible for the differential effects against P. falciparum exhibited by the two major classes 
of these drugs. 
 
As demonstrated in this study, fluorescently-labelled analogues provide useful tools with which 
to probe the localisation of drugs in cells. Although NBD was selected for this study on account 
of the specific properties described above, namely, its small size and photophysical attributes, 
alternative reporter dyes may be used in the preparation of additional novel derivatives of the 
quinoline antimalarials. Boron-dipyrromethane (BODIPY) dyes, for example, offer superior 
photochemical stability, high fluorescence quantum yields and good solubility27,28 and, if these 
drug conjugates are validated as suitable analogues of the parent molecules, they may generate 
further insights into the localisation of the quinoline antimalarials within P. falciparum. While it 
was anticipated that these novel derivatives would provide new tools for investigations into 
malaria parasite biology, quinine and quinidine have also been used as a muscle relaxant and as 
a cardiac depressant, respectively, and so these new compounds might also be useful in 
applications beyond malaria research.29 Although this study made use of SR-SIM, more 
sophisticated super-resolution techniques are likely to reveal deeper insights into the patterns 
of localisation of the drug analogues within P. falciparum. However, these techniques, of which 
STORM and STED are likely to be the most suitable, usually require fluorescence reporters with 
distinctive photophysical properties. On the other hand, transmission electron microscopy 
could also be harnessed to improve resolution with a correlative light and electron microscopy 
(CLEM) approach bridging the gap between these two imaging paradigms.  
 
While this work has developed new tools for generating novel insights into the modes of action 
of the quinoline antimalarials, further mechanistic details still remain unresolved. In order to 
generate additional insights, other representative antimalarials from the two major structural 
classes of quinoline antimalarials should be investigated. For example, mefloquine might be a 
suitable representative quinoline methanol and amodiaquine a suitable 4-aminoquinoline.  This 
work has also shown the value of taking a holistic approach to investigating a problem by 
exploiting different tools and techniques in a complementary manner. A cross-disciplinary 
approach such as this is arguably more powerful than single techniques in isolation and should 
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Experimental Methods and  




8.1. Synthetic organic chemistry 
 
8.1.1. General synthetic methods 
 
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich and used without 
further purification. Monobromobimane was procured from Synchem UG & Co. KG. Solvents 
were generally purchased from Kimix Chemicals. Anhydrous CHCl3 and CH2Cl2 were freshly 
distilled over CaCl2 and P4O10, respectively. THF was distilled from sodium wire and 
benzophenone. Double-distilled deionised water (dH2O) was provided by a Millipore Direct-Q3 
water purification system.  
 
For photoinitatied reactions, a Philips Actinic BL TL-D 15 W/10 1SL tubular low-pressure 
mercury vapour lamp with an emission maximum of 368 nm was used. Photosensitive reactions 
were protected from ambient light by aluminium foil. All purifications were performed under 
dim light. Thin-layer chromatography (TLC) was carried out on aluminium-backed silica gel 60 
F254 plates (Merck). Compounds were visualised under short-wavelength UV light (254 nm) or 
long-wavelength UV light for fluorescence detection (365 nm). Plates were sprayed with a 2.5% 
solution of anisaldehyde in a mixture of sulfuric acid and ethanol (1:10 v/v) or with a 0.3% 
solution of ninhydrin in absolute ethanol acidified with 3% glacial acetic acid.1  






For column chromatography, silica gel with pore size 60 Å and particle size 35-70 μm was used. 
Occasionally, flash chromatography was performed using a Biotage Isolera (silica gel with pore 
size 60 Å and particle size 63-200 μm).  
 
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 400 MHz spectrometer. 
Chemical shifts were recorded relative to residual chloroform in CDCl3 (δ7.26 ppm in 1H NMR 
and δ77.16 ppm in 13C NMR), residual DMSO in DMSO-d6 (δ2.50 ppm in 1H NMR and δ39.52 in 
13C NMR) or residual methanol in CD3OD (δ3.31 ppm in 1H NMR and δ49.00 in 13C NMR).2  
 
Melting points were determined on a Reichert-Jung Thermovar hot-stage microscope. Optical 
rotation measurements were taken on a PerkinElmer Model 343 Polarimeter. Infrared (IR) 
spectra were recorded using either a PerkinElmer Spectrum Two FT-IR spectrometer with a 
PerkinElmer UATR attachment or a Bruker Tensor 27 FT-IR spectrometer with a Bruker 
Platinum ATR attachment. Absorption spectra were recorded at 25°C on a Varian Cary 100 UV-
Vis or a Shimadzu UV-1800 spectrophotometer and were baseline-corrected.  
 
Electron ionisation (EI) mass spectrometry was executed on a JEOL GCmate II. High-resolution 
mass spectrometry (HRMS) was performed at the Central Analytical Facility at Stellenbosch 
University using a Waters Synapt G2 with an electrospray ionisation (ESI) positive source. CHNS 
analysis was performed using a Thermo Flash EA 1112 series combustion analyser. High-
performance liquid chromatography (HPLC) was performed using an Agilent 1220 LC System 
VL equipped with an Agilent ZORBAX Eclipse Plus C18 column (5 μm, 4.6 mm x 150 mm). 
Compounds dissolved in acetonitrile (0.3 mg/mL) were run at a flow rate of 1 mL/min with UV 
detection at 254 nm. 
 
Systematic names were generated using ChemBioDraw (Version 13.0.2.3021, CambridgeSoft, 
2013). The systematic numbering differs from the numbering indicated in blue on the 
structures which has been selected to aid NMR assignments. Overall percentage yields were 
calculated from the lowest-yielding route to a final product. 
  









This method was adapted from a previously-reported procedure.3 The reaction was found not 
to be sensitive to oxygen or trace water; it is therefore unnecessary to use an inert atmosphere 
or anhydrous solvent. The reaction can be performed on a large scale (up to 2 g) enabling large 
amounts of thiolated derivatives to be easily prepared. Progress of the reaction is difficult to 
visualise using TLC due to ‘smearing’ of the amines across the silica substrate. Furthermore, the 
Rf values of the alkaloid starting materials and their products were often identical. 
 
Alkaloid 1, 2 or 17 (1 eq) and radical photoinitiator 2,2-dimethoxy-2-phenyl-acetophenone 
(DMPA, 1 eq) were both dissolved in CHCl3 in a round-bottomed flask equipped with a stirrer 
bar. The thiol tert-butyl (2-mercaptoethyl)carbamate (6 eq) was added via syringe and the 
mixture was stirred thoroughly for several minutes. The flask was covered with a septum and 
placed on a stirrer plate against the centre of a Philips Actinic BL TL-D 15 W/10 1SL tubular 
low-pressure mercury vapour lamp. The entire apparatus was wrapped in aluminium foil and 
irradiated for ten minutes while stirring. During irradiation, the reaction mixture changed from 
colourless to light yellow.  
 
The solvent was removed on a rotary evaporator and the reaction mixture was taken up in ethyl 
acetate (25 mL). This was transferred into a separating funnel and the organic component was 
washed with ice-cold 0.5 M citric acid (4 x 25 mL) to move the (protonated) product to the 
aqueous phase (pH 2-3). (The concentration, identity and temperature of the acid are important 
to avoid cleaving the N-Boc protecting group.)  
 





Afterwards, the organic phase containing unreacted DMPA, the degradation products of DMPA 
and remaining thiol reactant was discarded. The aqueous phase was then basified to pH 11-12 
with approximately ice-cold 5 M NaOH (40 mL). The neutral organic product was then extracted 
with ethyl acetate (3 x 25 mL). The extracts were combined and this was then washed with 
citric acid, basified and extracted as before to remove further impurities.  
 
After a final wash with brine, magnesium sulfate was added to remove trace water. Following 
filtration, the solvent was removed under reduced pressure and the product 11, 12 or 18 was 
dried on a vacuum pump. While 1H NMR analysis indicated sufficient purity for subsequent 
reactions (> 95%), for combustion analysis these compounds were recrystallised from aqueous 












yl)methyl)quinuclidin-3-yl)ethyl)thio)ethyl)carbamate (11).  
The general procedure above was followed. The alkaloid quinine (1, 1.000 g, 3.08 mmol), DMPA 
(790 mg, 3.08 mmol) and the thiol tert-butyl (2-mercaptoethyl)carbamate (3.12 mL, 18.48 
mmol) were mixed in CHCl3 (10 mL) and irradiated for ten minutes. Subsequent acid-base 
extraction yielded 11 as a white powder (1.340 g, 2.67 mmol, 87%). 11 was then further 
recrystallised from aqueous ethanol (1.084 g, 2.16 mmol, 70%). MP 69-71°C. [α D20 -82.6° (c. 
0.797, EtOH). UV (EtOH)  max, nm (ε, M-1 cm-1): 333 (5 000). ATR-FTIR vmax/cm-1 1705 (strong, 
sharp C=O stretching vibration in the region expected for a secondary carbamate).4 1H NMR 
(400 MHz, CDCl3) δH 8.57 (1H, d, J 4.6 Hz, H-2), 7.8 (1H, d, J 9.2 Hz, H-8), 7.49 (1H, d, J 4.6 Hz, H-
3), 7.20 (1H, dd, J 9.2, 2.7 Hz, H-7), 7.15 (1H, d, J 2.7 Hz, H-5), 5.71 (1H, br s, H-10), 4.88 (2H, br s, 
-NH- secondary amide H-23 and hydroxyl -OH), 3.80 (3H, s, H-9), 3.65 (1H, m, H-15a), 3.21 (2H, 
q, J 6.1 Hz, H-22), 3.10 (2H, m, H-11 and H-17a), 2.68 (1H, m, H15-b), 2.53 (2H, t, J 6.7 Hz, H-21), 
2.39 (3H, m, H-20 and H-17b), 1.78 (4H, m, H-18, H-14a, H-12a and H-13), 1.46 (3H, m, H-19 and 
H-14b), 1.38 (10H, m, H-26 and H-12b). 13C NMR (100 MHz, CDCl3) δC 158.0 (C-6), 155.9 (C-24), 
147.4 (C-2), 147.1 (C-4), 144.2 (C-8a), 131.5 (C-8), 126.5 (C-4a), 121.7 (C-7), 118.6 (C-3), 101.3 
(C-5), 79.6 (C-25), 70.6 (C-10), 60.0 (C-11), 57.9 (C-17), 56.1 (C-9), 43.4 (C-15), 39.9 (C-22), 34.4 
(C-19), 34.3 (C-18), 32.5 (C-21), 29.8 (C-20), 28.5 (C-26), 27.4 (C-14), 25.6 (C-13), 20.8 (C-12). 
HRMS (ESI-TOF) m/z: [M+H]+ calculated for C27H40N3O4S 502.2740, found 502.2752. Anal. Calcd 












yl)methyl)quinuclidin-3-yl)ethyl)thio)ethyl)carbamate (12).  
The general procedure above was followed. The alkaloid quinidine (2, 500 mg, 1.54 mmol), 
DMPA (395 mg, 1.54 mmol) and the thiol tert-butyl (2-mercaptoethyl)carbamate (1.56 mL, 9.23 
mmol) were mixed in CHCl3 (5 mL) and irradiated for ten minutes. Subsequent acid-base 
extraction yielded 12 as a white powder (668 mg, 1.32 mmol, 86%). 12 was then recrystallised 
from aqueous ethanol (556 mg, 1.11 mmol, 72%). MP 168-170°C. [α D20 +137.5° (c. 0.797, 
EtOH). UV (EtOH)  max, nm (ε, M-1 cm-1): 333 (5 000). ATR-FTIR vmax/cm-1 1705 (strong, sharp 
C=O stretching vibration in the region expected for a secondary carbamate).4 1H NMR (400 MHz, 
CDCl3) δH 8.64 (1H, d, J 4.6 Hz, H-2), 7.95 (1H, d, J 9.2 Hz, H-8), 7.51 (1H, d, J 4.6 Hz, H-3), 7.29 
(1H, dd, J 9.2, 2.6 Hz, H-7), 7.18 (1H, d, J 2.6 Hz, H-5), 5.59 (1H, d, J 3.9 Hz, H-10), 5.01 (1H, br s,  
-NH- secondary amide H-23), 3.85 (3H, s, H-9), 3.29 (2H, q, J 6.4 Hz, H-22), 3.14 (1H, dq, J 7.3, 2.4 
Hz, H-15a), 3.02 (1H, td, J 9.3, 4.0 Hz, H-11), 2.86 (2H, m, H-17a and H15-b), 2.74 (1H, m, H-17b), 
2.61 (2H, m, H-21), 2.46 (2H, t, J 7.7 Hz, H-20), 2.00 (1H, m, H-12a), 1.81 (1H, m, H-19a), 1.70 
(1H, m, H-19b), 1.66 (1H, m, H-13), 1.59 (1H, t, J 8.0 Hz, H-18), 1.47 (2H, m, H-14), 1.41 (9H, s,  
H-26), 1.08 (1H, m, H-12b). 13C NMR (100 MHz, CDCl3) δC 157.8 (C-6), 156.1 (C-24), 148.0 (C-4), 
147.7 (C-2), 144.3 (C-8a), 131.7 (C-8), 126.7 (C-4a), 121.6 (C-7), 118.5 (C-3), 101.5 (C-5), 79.7 
(C-25), 72.1 (C-10), 59.9 (C-11), 55.7 (C-9), 50.8 (C-15), 50.3 (C-17), 40.2 (C-22), 34.9 (C-18), 
32.8 (C-19), 32.1 (C-21), 29.8 (C-20), 28.5 (C-26), 27.2 (C-13), 26.8 (C-14), 20.7 (C-12). HRMS 
(ESI-TOF) m/z: [M+H]+ calculated for C27H40N3O4S 502.2740, found 502.2750. Anal. Calcd for 
C27H39N3O4S: C, 64.64; H, 7.84; N, 8.38; S, 6.39. Found: C, 64.38; H, 7.79; N, 8.52; S, 6.35. 
 
  








yl)ethyl)thio)ethyl)carbamate (18).  
The general procedure above was followed. The alkaloid cinchonine (17, 908 mg, 3.08 mmol), 
DMPA (790 mg, 3.08 mmol) and the thiol tert-butyl (2-mercaptoethyl)carbamate (3.12 mL, 
18.48 mmol) were dissolved in a 1:1 mixture of CHCl3:MeOH (v/v, 10 mL) and irradiated for ten 
minutes. Subsequent acid-base extraction yielded 18 as a white powder (1.490 g, 2.99 mmol, 
97%). 18 was then further recrystallised from aqueous ethanol (1.002 g, 2.13 mmol, 69%). MP 
151-153°C [α D20 +110.8° (c. 0.749, EtOH). UV (EtOH)  max, nm (ε, M-1 cm-1): 315 (3 500). ATR-
FTIR vmax/cm-1 1710 (strong, sharp C=O stretching vibration in the region expected for a 
secondary carbamate).4 1H NMR (400 MHz, CDCl3) δH 8.81 (1H, d, J 4.5 Hz, H-2), 8.08 (1H, dd, J 
8.4, 1.2 Hz, H-8), 7.94 (1H, dd, J 8.4, 1.2 Hz, H-5), 7.64 (1H, ddd, J 8.4, 7.0, 1.2 Hz, H-7), 7.60 (1H, 
d, J 4.5 Hz, H-3), 7.40 (1H, ddd, J 8.4, 7.0, 1.2 Hz, H-6), 5.70 (1H, d, J 3.5 Hz, H-10), 5.00 (1H, br s, -
NH- secondary amide H-23), 4.76 (1H, br s, secondary hydroxyl -OH), 3.27 (2H, dt, J 13.3, 6.9 Hz, 
H-22), 3.15 (1H, ddd, J 13.5, 7.6, 2.0 Hz, H-15a), 2.98 (1H, td, J 9.1 Hz, H-11), 2.81 (2H, m, H-17a 
and H-15b), 2.61 (3H, m, H-17b and H-21), 2.45 (2H, t, J 7.8 Hz, H-20), 2.01 (1H, dd, J 12.7 Hz, H-
12a), 1.82 (1H, m, H-19a), 1.70 (1H, dt, J 14.2, 7.1 Hz, H-19b), 1.64 (1H, br s, H-13), 1.56 (1H, 
quin, J 2.9 Hz, H-18), 1.41 (11H, m, H-14 and H-26), 1.06 (1H, m, H-12b). 13C NMR (100 MHz, 
CDCl3) δC 156.1 (C-24), 150.2 (C-2), 149.7 (C-4), 148.3 (C-8a), 130.4 (C-8), 129.1 (C-7), 126.7 (C-
6), 125.8 (C-4a), 123.2 (C-5), 118.3 (C-3), 79.7 (C-25), 72.1 (C-10), 60.2 (C-11), 50.8 (C-15), 50.3 
(C-17), 40.1 (C-22), 35.0 (C-18), 32.9 (C-19), 32.1 (C-21), 29.8 (C-20), 28.5 (C-26), 27.3 (C-14), 
26.8 (C-13), 20.6 (C-12). HRMS (ESI-TOF) m/z: [M+H]+ calculated for C26H38N3O3S 472.2634, 
found 472.2630. Anal. Calcd for C26H37N3O3S: C, 66.21; H, 7.91; N, 8.91; S, 6.80. Found: C, 66.01; 









8.1.3. General procedure for the cleavage of N-Boc-protected amines 
 
 
The N-Boc protected amine 11 or 12 (1 eq) was dissolved in CH2Cl2 in a round-bottomed flask 
equipped with a stirrer bar and cooled in an ice-bath to 0°C. Trifluoroacetic acid (TFA, 10 eq) 
was added dropwise over ten minutes during which time the reaction mixture changed from 
colourless to bright yellow. After two hours no further change was observed by TLC. During this 
time the ice-bath was not replenished, allowing the reaction mixture to warm slowly to room 
temperature. Excess TFA was removed under reduced pressure and the resulting oil was 
purified by column chromatography over an elution gradient of 0-25% MeOH:CH2Cl2. The 
appropriate fractions were collected, the volume was reduced and the product was dried on a 













Following the general method above, 11 (0.885 g, 1.76 mmol) was dissolved in CH2Cl2 (10 mL) 
and cooled to 0°C. TFA (1.35 mL, 2.007 g, 17.6 mmol) was added dropwise. After two hours the 
excess solvent was evaporated and column chromatography yielded the salt 9 (0.589 g, 0.79 
mmol, 45%) as a sticky white amorphous solid. UV (EtOH)  max, nm (ε, M-1 cm-1): 333 (5 000). Rf 
0.36 (MeOH:CH2Cl2 15:85). ATR-FTIR vmax/cm-1 1675 (strong, sharp C=O stretching vibration). 
1H NMR (400 MHz, CD3OD) δH 8.87 (1H, d, J 5.1 Hz, H-2), 8.11 (1H, d, J 9.3 Hz, H-8), 8.06 (1H, d, J 
5.1 Hz, H-3), 7.64 (1H, dd, J 9.3, 2.7 Hz, H-7), 7.56 (1H, d, J 2.7 Hz, H-5), 6.19 (1H, s, H-10), 4.25 
(1H, m, H-15a), 4.05 (3H, s, H-9), 3.71 (1H, m, H-11), 3.64 (1H, dd, J 13.0, 10.8 Hz, H-17a), 3.31 
(1H, m, H-15b), 3.06 (3H, m, H-22 and H-17b), 2.74 (2H, t, J 6.8 Hz, H-21), 2.54 (2H, t, J 7.5 Hz, H-
20), 2.26 (3H, m, H-18, H-14a and H-12a), 2.11 (1H, m, H-13), 1.91 (1H, m, H-14b), 1.63 (3H, m, 
H-19 and H-12b). 13C NMR (100 MHz, CD3OD) δC 163.3 (C=O TFA anion), 161.2 (C-6), 151.6 (C-
4), 145.6 (C-2), 140.9 (C-8a), 128.6 (C-8), 128.2 (C-4a), 129.9 (C-7), 120.9 (C-3), CF3 from TFA 
anion not observed, 102.5 (C-5), 68.3 (C-10), 61.2 (C-11), 57.14 (C-17), 57.05 (C-9), 45.2 (C-15), 
39.8 (C-22), 33.90 (C-19), 33.86 (C-18), 29.72 (C-21), 29.69 (C-20), 26.1 (C-13), 25.6 (C-14), 
19.0 (C-12). HRMS (ESI-TOF) m/z: [M+H]+ Calculated for C22H32N3O2S 402.2215; found 













Following the general method above, 12 (0.963 g, 1.92 mmol) was dissolved in CH2Cl2 (10 mL) 
and cooled to 0°C. TFA (1.48 mL, 2.190 g, 19.2 mmol) was added dropwise. After two hours the 
excess solvent was evaporated and column chromatography yielded the salt 10 (0.617 g, 0.83 
mmol, 43%) as a clear gum. UV (EtOH)  max, nm (ε, M-1 cm-1): 333 (5 000). Rf 0.36 (MeOH:CH2Cl2 
15:85). ATR-FTIR vmax/cm-1 1675 (strong, sharp C=O stretching vibration). 1H NMR (400 MHz, 
CD3OD) δH 8.87 (1H, d, J 5.1 Hz, H-2), 8.10 (1H, d, J 9.3 Hz, H-8), 8.07 (1H, d, J 5.1 Hz, H-3), 7.63 
(1H, dd, J 9.3, 2.7 Hz, H-7), 7.56 (1H, d, J 2.7 Hz, H-5), 6.31 (1H, s, H-10), 4.05 (4H, m, H-9 and H-
15a), 3.69 (1H, t, J 9.4 Hz, H-11), 3.54 (2H, m, H-15b and H-17a), 3.34 (1H, m, H-17b), 3.19 (2H, t, 
J 6.8 Hz, H-22), 2.87 (2H, t, J 6.8 Hz, H-21), 2.67 (2H, m, H-20), 2.48 (1H, m, H-12a), 2.21 (1H, m, 
H-18), 2.04 (1H, br s, H-13), 1.94 (4H, m, H-19 and H-14), 1.27 (1H, m, H-12b). 13C NMR (100 
MHz, CD3OD) δC 163.4 (C=O TFA anion), 160.5 (C-6), 148.1 (C-4), 147.4 (C-2), 143.7 (C-8a), 
130.8 (C-8), 127.6 (C-4a), 124.4 (C-7), 120.4 (C-3), CF3 from TFA anion not observed, 102.0 (C-
5), 68.6 (C-10), 61.2 (C-11), 56.8 (C-9), 51.1 (C-15), 50.5 (C-17), 39.9 (C-22), 33.6 (C-18), 32.3 
(C-19), 29.9 (C-20 and C-21), 26.6 (C-13), 24.5 (C-14), 18.8 (C-12). HRMS (ESI-TOF) m/z: 














The trifluoroacetate salt 9 or 10 (1 eq) was dissolved in MeOH in a two-necked round-bottomed 
flask equipped with a stirrer bar. N,N-Diisopropylethylamine (DIPEA, 3 eq) was added and the 
mixture was stirred for ten minutes to liberate the amines from the trifluoroacetate anions. A 
septum was attached to one neck of the flask while a reflux condenser was attached to the other 
neck and the mixture was heated to 75°C. Solid NaHCO3 (3 eq) was added. 4-Chloro-7-
nitrobenzo[c][1,2,5]oxadiazole (NBD-Cl, 1 eq) was dissolved in CH3CN (10 mL) and added 
dropwise. The mixture was incubated for two hours, during which time the colour changed from 
bright yellow to deep brown which indicated successful displacement of the chlorine by the 
terminal amine of the alkaloid to form the fluorescent NBD adduct. After this time TLC indicated 
that all NBD-Cl was consumed. The reaction mixture was cooled and filtered through a pad of 
Celite. The volume was reduced on the rotary evaporator and the mixture was purified using 
column chromatography (0-20% MeOH:CH2Cl2 elution gradient). The appropriate fractions 
were selected, the volume was reduced and the resultant product 3 or 4 was recrystallised from 












4-yl)amino)ethyl)thio)ethyl)quinuclidin-2-yl)methanol, “Quinine-NBD” (3). 
Following the general method above, 9 (1.497 g, 2.01 mmol) was dissolved in MeOH (20 mL) 
and neutralised with DIPEA (1.05 mL, 6.03 mmol). NaHCO3 (507 mg, 6.03 mmol) was added and 
the mixture heated to 75°C, after which NBD-Cl (401 mg, 2.01 mmol) was added. The product 3 
was isolated by column chromatography and purified by recrystallisation from aqueous MeOH 
(294 mg, 0.52 mmol, 26%, 10% overall). UV (EtOH)  max, nm (ε, M-1 cm-1): 333 (11 500), 464 (18 
500); UV (20 mM Hepes, pH 7.5)  max, nm (ε, M-1 cm-1): 335 (8 500), 473 (17 500). Rf 0.61 
(MeOH:CH2Cl2 10:90). ATR-FTIR vmax/cm-1 1295 (strong, sharp NO2 symmetric stretching 
vibration). 1H NMR (400 MHz, DMSO-d6) δH 8.74 (1H, d, J 4.5 Hz, H-2), 8.45 (1H, d, J 8.9 Hz, H-b), 
7.95 (1H, d, J 9.2 Hz, H-8), 7.63 (1H, d, J 4.5 Hz, H-3), 7.51 (1H, d, J 2.8 Hz, H-5), 7.41 (1H, dd, J 
9.2, 2.8 Hz, H-7), 6.41 (2H, m, H-a and aryl -NH-), 6.04 (1H, d, J 2.6 Hz, H-10), 3.99 (4H, m, H-9 
and H-15a), 3.60 (3H, m, H-22 and H-11), 3.47 (1H, t, J 11.6 Hz, H-17a), 3.20 (1H, m, H-15b), 2.94 
(1H, dd, J 12.1, 5.6 Hz, H-17b), 2.79 (2H, t, J 7.0 Hz, H-21), 2.59 (2H, m, H-20), 2.05 (3H, m, H-18, 
H-14a and H-12a), 1.96 (1H, br s, H-13), 1.73 (1H, m, H-14b), 1.57 (2H, m, H-19), 1.47 (1H, m, H-
12b). 13C NMR (100 MHz, DMSO-d6) δC 157.7 (C-6), 147.3 (C-2), 145.1 (C-4), 144.7, 144.2, 143.9 
(C-A, C-B and C-C), 143.7 (C-8a), 137.6 (C-b), 131.3 (C-8), 125.6 (C-4a), 121.5 (C-7), 120.8 (C-D), 
119.0 (C-3), 101.9 (C-5), 99.3 (C-a), 65.9 (C-10), 59.0 (C-11), 56.4 (C-9), 54.5 (C-17), 43.2 (C-22), 
42.8 (C-15), 32.3 (C-19), 32.1 (C-18), 29.3 (C-21), 28.6 (C-20), 24.3 (C-14 and C-13), 17.6 (C-12). 
HRMS (ESI-TOF) m/z: [M+H]+ Calculated for C28H33N6O5S 565.2233; found 565.2229. HPLC: 
96.1%. 
  








4-yl)amino)ethyl)thio)ethyl)quinuclidin-2-yl)methanol, “Quinidine-NBD” (4). 
Following the general method above, 10 (1.542 g, 2.02 mmol) was dissolved in MeOH (20 mL) 
and neutralised with DIPEA (1.06 mL, 6.06 mmol). NaHCO3 (509 mg, 6.06 mmol) was added and 
the mixture heated to 75°C, after which NBD-Cl (403 mg, 2.02 mmol) was added. The product 4 
was isolated by column chromatography and purified by recrystallisation from aqueous MeOH 
(311 mg, 0.55 mmol, 27%, 10% overall). UV (EtOH)  max, nm (ε, M-1 cm-1): 332 (11 000), 463 (17 
000); UV (20 mM Hepes, pH 7.5)  max, nm (ε, M-1 cm-1): 335 (9 000), 479 (19 000). Rf 0.61 
(MeOH:CH2Cl2 10:90). ATR-FTIR vmax/cm-1 1300 (strong, sharp NO2 symmetric stretching 
vibration). 1H NMR (400 MHz, DMSO-d6) δH 8.75 (1H, d, J 4.5 Hz, H-2), 8.51 (1H, d, J 8.9 Hz, H-b), 
7.97 (1H, d, J 9.3 Hz, H-8), 7.64 (1H, d, J 4.5 Hz, H-3), 7.43 (1H, dd, J 9.3, 2.9 Hz, H-7), 7.37 (1H, d, 
J 2.9 Hz, H-5), 6.54 (1H, d, J 4.0 Hz, aryl -NH-), 6.50 (1H, d, J 8.9 Hz, H-a), 6.02 (1H, d, J 2.3 Hz, H-
10), 3.96 (3H, s, H-9), 3.76 (3H, m, H-22 and H-15a), 3.56 (1H, t, J 9.2 Hz, H-11), 3.45 (2H, m, H-
17a and H-15b), 3.22 (1H, m, H-17b), 2.91 (2H, t, J 6.9 Hz, H-21), 2.65 (2H, m, H-20), 2.28 (1H, t, J 
11.2 Hz, H-12a), 2.04 (1H, quin, J 8.2 Hz, H-18), 1.92 (1H, br s, H-13), 1.80 (4H, m, H-19 and H-
14), 1.15 (1H, m, H-12b). 13C NMR (100 MHz, DMSO-d6) δC 157.7 (C-6), 147.4 (C-2), 144.7 (C-4), 
144.3, 144.2, 144.1 (C-A, C-B and C-C), 143.7 (C-8a), 137.7 (C-b), 131.4 (C-8), 125.4 (C-4a), 121.6 
(C-7), 121.0 (C-D), 118.8 (C-3), 101.2 (C-5), 99.4 (C-a), 66.4 (C-10), 59.0 (C-11), 55.8 (C-9), 48.9 
(C-15), 48.3 (C-17), 43.3 (C-22), 31.7 (C-18), 31.1 (C-19), 29.4 (C-21), 28.7 (C-22), 24.5 (C-13), 
23.0 (C-14), 17.2 (C-12). HRMS (ESI-TOF) m/z: [M+H]+ Calculated for C28H33N6O5S 565.2233; 













The procedures of Novotný et al. and Haldar et al. were followed for the preparation of the NBD-
labelled amino acids of 13 and 14.5,6 Briefly, the amino acid (1.2 eq) and NaHCO3 (3 eq) were 
dissolved in dH2O (10 mL) in a two-necked round-bottomed flask equipped with a stirrer bar. A 
septum was attached to one neck and a reflux condenser was attached to the other. The mixture 
was heated to 65°C. 4-Chloro-7-nitrobenzo[c][1,2,5]oxadiazole (NBD-Cl, 1 eq) was dissolved in 
CH3CN (10 mL) and added dropwise via syringe. The mixture was incubated for two hours, 
during which time the colour changed from bright yellow to deep brown. After two hours, TLC 
indicated that all the NBD-Cl had been consumed. The mixture was cooled and the CH3CN was 
removed on the rotary evaporator. The remaining aqueous phase was acidified to 
approximately pH 2 with 1 M HCl. Thereafter it was extracted three times with EtOAc (20 mL), 
washed with brine, dried with MgSO4, filtered and the solvent removed. The resultant NBD-











6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoic acid (13).5 
The NBD-labelled amino acid 13 was prepared from 6-aminohexanoic acid (679.7 mg, 4.81 
mmol) as described above and recrystallised from aqueous MeOH to yield bright orange crystals 
(1.077 g, 3.66 mmol, 91%). MP 153-155°C (lit.5 MP 158-159°C). UV (EtOH)  max, nm (ε, M-1 cm-1): 
333 (8 500), 456 (19 500). ATR-FTIR vmax/cm-1 1700 (strong, sharp C=O stretching vibration 





12-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)dodecanoic acid (14).5  
The NBD-labelled amino acid 14 was prepared from 12-aminododecanoic acid (327 mg, 1.52 
mmol) as described above and recrystallised from aqueous MeOH to yield dark orange crystals 
(501 mg, 1.32 mmol, 87%). MP 92-94°C (lit.5 MP 94-96°C). UV (EtOH)  max, nm (ε, M-1 cm-1): 333 
(8 000), 464 (19 000). ATR-FTIR vmax/cm-1 1720 (strong, sharp C=O stretching vibration 
indicates saturated carboxylic acid). MS (EI+) m/z: [M]+ 378. 
 
  









A procedure previously described for the preparation of the NBD-labelled amino acid 
succinimidyl esters was followed.5 Briefly, dry CHCl3 (10 mL) was added to a two-necked round-
bottomed flask equipped with a stirrer bar under an inert atmosphere (N2) to which the NBD-
labelled amino acid 13 or 14 (1 eq), N-hydroxysuccinimide (NHS, 1.2 eq) and catalytic 4-
dimethylaminopyridine (DMAP, 0.15 eq) had already been added. This was cooled in an ice-bath 
to 0°C. N,N'-Dicyclohexylcarbodiimide (DCC, 1.5 eq) was dissolved in dry CHCl3 (2 mL) and 
added dropwise. If necessary, additional dry CH3CN (5 mL) was added to ensure that the NBD-
labelled amino acid was completely dissolved.  
 
The flask was left to stir overnight and was gradually allowed to reach room temperature. After 
24 hours, TLC indicated that the NBD-labelled amino acid was completed consumed. Solvents 
were evaporated and the residue was resuspended in a half-brine/half-water mixture to 
remove the urea by-product. The desired product was extracted three times with EtOAc, dried 
with brine and Na2SO4, filtered and the solvent removed. NBD-labelled amino acid succinimidyl 
esters 15 and 16 were labile but flash chromatography (100% EtOAc) could be used to furnish 













The NBD-labelled succinimidyl ester 15 was prepared from 13 (221 mg, 0.75 mmol) as 
described above and purified by column chromatography to yield bright orange crystals (232 
mg, 0.59 mmol, 79%). MP 177-179°C (lit.5 MP 189-191°C). UV (EtOH)  max, nm (ε, M-1 cm-1): 333 
(8 500), 456 (19 500). ATR-FTIR vmax/cm-1 1815 and 1785 (medium, sharp C=O stretching 
vibrations typical of succinimidyl carbonyls), 1730 (strong, sharp C=O stretching vibration 







The NBD-labelled succinimidyl ester 16 was prepared from 14 (504 mg, 1.06 mmol) as 
described above and purified by column chromatography to yield bright orange crystals (264 
mg, 0.56 mmol, 53%). MP 160-162°C (lit.5 MP 162-164°C). UV (EtOH)  max, nm (ε, M-1 cm-1): 333 
(8 000), 464 (19 000). ATR-FTIR vmax/cm-1 1815 and 1785 (medium, sharp C=O stretching 
vibrations typical of succinimidyl carbonyls), 1730 (strong, sharp C=O stretching vibration 
typical of succinimidyl ester). MS (EI+) m/z: [M]+ 475. 
  





8.1.7. General procedure for the nucleophilic substitution of succinimidyl esters 




To a round-bottomed flask equipped with a stirrer under an inert atmosphere (N2) charged 
with the salt 10 (1 eq) was added dry CH2Cl2. This was cooled to -78°C, to which DIPEA (3 eq) 
was added dropwise. This was stirred for ten minutes to ensure neutralisation of the salt. Then 
the NBD-labelled amino acid succinimidyl ester 15 or 16 (1 eq) in dry CH2Cl2 was added 
dropwise. After three hours of continuous stirring the mixture was allowed to warm to room 
temperature. TLC indicated that the succinimidyl ester starting material had been completely 
consumed. The mixture was diluted with CH2Cl2 (10 mL) and washed three times with water to 
remove the NHS by-product. The volume was reduced. Column chromatography was performed 
(0-25% MeOH:CH2Cl2 elution gradient), the appropriate fractions collected, the volume reduced 














Following the general method above, 10 (410 mg, 0.55 mmol) was dissolved in dry CH2Cl2 (10 
mL) and cooled to -78°C. DIPEA (0.29 mL, 1.65 mmol) was added dropwise. 15 (215 mg, 0.55 
mmol) in dry CH2Cl2 (5 mL) was added. After three hours of stirring, excess solvent was 
evaporated and, following dilution and extraction, column chromatography yielded 5 (110 mg, 
0.16 mmol, 29%, 11% overall) as an orange solid. UV (EtOH)  max, nm (ε, M-1 cm-1): 332 (10 
500), 464 (15 500); UV (20 mM Hepes, pH 7.5)  max, nm (ε, M-1 cm-1): 335 (6 500), 487 (14 500). 
Rf 0.40 (MeOH:CH2Cl2 10:90). ATR-FTIR vmax/cm-1 1625 (medium, sharp C=O stretching 
vibration for amide). 1H NMR (400 MHz, DMSO-d6) δH 8.66 (1H, d, J 4.6 Hz, H-2), 8.43 (1H, d, J 8.8 
Hz, H-b), 7.90 (2H, m, aryl -NH- and H-8), 7.50 (1H, d, J 4.6 Hz, H-3), 7.46 (1H, d, J 2.8 Hz, H-5), 
7.36 (1H, dd, J 9.3, 2.8 Hz, H-7), 6.34 (1H, d, J 8.8 Hz, H-a), 5.63 (1H, br s, amide -NH-), 5.53 (1H, 
d, J 6.6 Hz, H-10), 3.90 (3H, s, H-9), 3.43 (2H, br s, H-vi), 3.22 (2H, dt, J 7.8, 6.1 Hz, H-22), 2.98 
(1H, m, H-11), 2.86 (1H, m, H-15a), 2.72 (1H, dd, J 13.0, 7.2 Hz, H-15b), 2.62 (1H, m, J 10.1 Hz, H-
17a), 2.55 (3H, t, J 7.2 Hz, H-21 and H-17b), 2.50 (2H, m, H-20), 2.09 (2H, t, J 7.3 Hz, H-ii), 1.88 
(1H, t, J 11.7 Hz, H-12a), 1.68 (5H, m, H-13, H-19 and H-v), 1.56 (3H, m, H-18 and H-iii), 1.47 (1H, 
m, H-14a), 1.36 (4H, m, H-iv, H-14b and H-12b). 13C NMR (100 MHz, DMSO-d6) δC 172.0 (C-i), 
156.7 (C-6), 149.2 (C-4), 147.4 (C-2), 143.3, 144.5, 144.2 (C-A, C-B and C-C), 143.8 (C-8a), 137.5 
(C-b), 131.0 (C-8), 126.9 (C-4a), 120.9 (C-7), 120.0 (C-D), 118.8 (C-3), 102.4 (C-4), 99.1 (C-a), 
70.4 (C-10), 60.6 (C-11), 55.4 (C-9), 49.7 (C-15), 49.1 (C-17), 43.5 (C-iv), 38.5 (C-22), 35.2 (C-ii), 
34.3 (C-18), 32.2 (C-19), 30.8 (C-21), 29.1 (C-20), 27.5 (C-v), 26.8 (C-14), 26.0 (C-iv), 26.0 (C-
13), 24.8 (C-iii), 22.9 (C-12). HRMS (ESI-TOF) m/z: [M+H]+ Calculated for C34H44N7O6S 678.3074; 
found 678.3082. HPLC: 96.4%. 
 
 









Following the general method above, 10 (404 mg, 0.53 mmol) was dissolved in dry CH2Cl2 (10 
mL) and cooled to -78°C. DIPEA (0.28 mL, 1.59 mmol) was added dropwise. 16 (252 mg, 0.53 
mmol) in dry CH2Cl2 (5 mL) was added. After three hours of stirring, excess solvent was 
evaporated and, following dilution and extraction, column chromatography yielded 6 (271 mg, 
0.36 mmol, 68%, 25% overall) as an orange solid. UV (EtOH)  max, nm (ε, M-1 cm-1): 333 (6 000), 
466 (10 000); UV (20 mM Hepes, pH 7.5)  max, nm (ε, M-1 cm-1): 339 (3 000), 485 (4 000). Rf 0.31 
(MeOH:CH2Cl2 10:90). ATR-FTIR vmax/cm-1 1625 (medium, sharp C=O stretching vibration for 
amide). 1H NMR (400 MHz, DMSO-d6) δH 8.73 (1H, d, J 4.6 Hz, H-2), 8.47 (1H, d, J 9.2 Hz, H-b), 
7.93 (2H, m, aryl -NH- and H-8), 7.64 (1H, d, J 4.6 Hz, H-3), 7.55 (1H, d, J 2.6 Hz, H-5), 7.40 (1H, 
dd, J 9.2, 2.6 Hz, H-7), 6.46 (1H, br s, amide -NH-), 6.38 (1H, d, J 9.2 Hz, H-a), 6.29 (1H, br s,  
H-10), 4.00 (3H, s, H-9), 3.74 (1H, m, H-15a), 3.46 (4H, m, H-11, H-15b and H-xii), 3.32 (1H, m, 
H-17a), 3.24 (2H, dt, J 7.8, 6.1, H-22), 3.16 (1H, m, H-17b), 2.56 (4H, m, H-20 and H-21), 2.29 
(1H, t, J 11.4 Hz, H-12a), 2.03 (3H, m, H-18 and H-ii), 1.91 (1H, br s, H-13), 1.80 (3H, m, H-19 and 
H-14a), 1.68 (3H, m, H-xi and H-14b), 1.48 (2H, t, J 7.5 Hz, H-iii), 1.34 (2H, m, H-x), 1.22 (12H, m, 
H-iv, H-v, H-vi, H-vii, H-viii and H-ix), 1.15 (1H, m, H-12b). 13C NMR (100 MHz, DMSO-d6) δC 
172.1 (C-i), 157.7 (C-6), 147.3 (C-2), 145.2 (C-4), 145.1, 144.3, 144.1 (C-A, C-B and C-C), 143.7 
(C-8a), 137.8 (C-b), 131.2 (C-8), 125.6 (C-4a), 121.7 (C-7), 120.5 (C-D), 118.8 (C-3), 101.7 (C-5), 
99.0 (C-a),66.1 (C-10), 59.0 (C-11), 56.5 (C-9), 48.6 (C-15), 48.1 (C-17), 43.3 (C-xii), 38.4 (C-22), 
35.4 (C-ii), 31.8 (C-18), 31.1 (C-19), 30.7 (C-21), 28.9 (C-20), 28.9, 28.9, 28.7, 28.6, 28.6, 28.5 (C-
iv, C-v, C-vi, C-vii, C-viii and C-ix), 27.6 (C-xi), 26.3 (C-x), 25.2 (C-iii), 24.6 (C-13), 23.2 (C-14), 
17.2 (C-12). HRMS (ESI-TOF) m/z: [M+H]+ Calculated for C40H56N7O6S 762.4013; found 
762.4017. HPLC: 95.2%. 











dione, “Quinine-Bimane” (19). 
To a stirring solution of 9 (345 mg, 0.46 mmol) in dry CH2Cl2 under N2 at room temperature was 
added dry triethylamine (0.25 mL, 1.79 mmol) dropwise. After ten minutes, monobromobimane 
(91 mg, 0.34 mmol) which had been dissolved in a minimum volume of dry CH2Cl2 was added 
dropwise. This was stirred in the dark for 18 hours, after which TLC analysis indicated that the 
monobromobimane had been completely consumed. The solvent was removed and the residue 
was taken up in ethyl acetate (20 mL), to which half an equivalent volume of brine (10 mL) was 
added to encourage retention of the polar product in the organic phase. A second extraction was 
performed and the extracts were combined and dried with sodium sulfate, which was 
subsequently washed with methanol during filtration to remove any adsorbed product. 
Following removal of the solvent, the residue was adsorbed onto silica and column 
chromatography was performed over an elution gradient of 0-15% MeOH:CH2Cl2. The 
appropriate fractions were combined and the volume was reduced to isolate pure product 19 as 
a pale yellow crystalline solid (64 mg, 0.11 mmol, 32%). UV (EtOH)  max, nm (ε, M-1 cm-1): 335 
(10 000), 387 (8 500); UV (20 mM Hepes, pH 7.5)  max, nm (ε, M-1 cm-1): 333 (5 500), 388 (4 
000). Rf 0.50 (MeOH:CH2Cl2 12:88). MP 116-118°C. ATR-FTIR vmax/cm-1 1740, 1675 (strong C=O 
stretches). 1H NMR (400 MHz, CDCl3) δH 8.55 (1H, d, J 4.4 Hz, H-2), 7.71 (1H, d, J 9.2 Hz, H-8), 
7.55 (1H, d, J 4.4 Hz, H-3), 7.05 (1H, dd, J 9.2, 2.4 Hz, H-7), 6.95 (1H, d, J 2.4 Hz, H-5), 6.12 (1H, s, 
H-10), 4.20 (1H, m, H-15a), 3.70 (3H, s, H-9), 3.62 (2H, s, H-24), 3.42 (1H, t, J 11.6 Hz, H-17a), 
3.25 (1H, t, J 9.2 Hz, H-11), 2.99 (1H, m, H-15b), 2.71 (3H, m, H-22 and H-17b), 2.55 (2H, t, J 6.2 





Hz, H-21), 2.36 (2H, t, J 7.2 Hz, H-20), 2.31 (3H, s, H-6’’), 2.13 (2H, m H-14a and H-12a), 2.03 (1H, 
m, H-18), 1.94 (1H, br s, H-13), 1.71 (3H, s, H-3’’), 1.66 (4H, m, H-14b and H-7’’), 1.47 (2H, q, J 7.2 
Hz, H-19), 1.38 (1H, m, H-12b); -OH and -NH- not observed. 13C NMR (100 MHz, CDCl3) δC 160.7 
(C-2’), 160.3 (C-8’), 158.3 (C-6), 147.1 (C-4), 146.9 (C-2), 146.5 (C-3’), 145.0 (C-7’), 143.7 (C-8a), 
131.2 (C-8), 125.6 (C-4a), 122.2 (C-7), 118.8 (C-3), 113.7 (C-4’), 111.6 (C-6’), 100.0 (C-5), 66.9 
(C-10), 60.2 (C-11), 56.6 (C-17), 56.2 (C-9), 47.9 (C-22), 43.8 (C-15), 42.7 (C-24), 33.6 (C-19), 
33.1 (C-18), 32.3 (C-21), 29.5 (C-20), 25.2 (C-13), 25.1 (C-14), 18.3 (C-12), 11.3 (C-6’’), 6.9 (C-
3’’), 6.7 (C-7’’). HRMS (ESI-TOF) m/z: [M+H]+ calculated for C32H42N5O4S 592.2958, found 
592.2958. HPLC: 97.2%. 
 
  









N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine, chloroquine free base (7). 
Chloroquine diphosphate was converted to the free base as previously described, with minor 
modifications.7 Briefly, chloroquine diphosphate (5.000 g, 9.69 mmol) was dissolved in 100 mL 
H2O to which 5 M NaOH (100 mL) was slowly added. After three successive extractions with 
CH2Cl2 (100 mL each), the organic fractions were combined and dried with MgSO4. Following 
filtration and removal of the solvent, the residue was washed with diethyl ether (20 mL) and the 
solvent removed once more. Drying on the vacuum pump yielded chloroquine free base 1 as a 
white crystalline solid (2.964 g, 9.27 mmol, 96%). 1H NMR (400 MHz, CDCl3) δH 8.49 (1H, d, J 5.4 
Hz, H-2), 7.93 (1H, d, J 2.2 Hz, H-8), 7.66 (1H, d, J 9.0 Hz, H-5), 7.31 (1H, dd, J 9.0, 2.2 Hz, H-6), 
6.41 (1H, d, J 5.4 Hz, H-3), 5.26 (1H, d, J 6.4 Hz, -NH-), 3.70 (1H, m, H-9), 2.50 (4H, q, J 7.2 Hz, H-
14), 2.43 (2H, t, J 6.8 Hz, H-13), 1.62 (4H, m, H-11 and H-12), 1.30 (3H, d, J 6.4 Hz, H-10), 0.99 
(6H, t, J 7.2 Hz, H-15). 13C NMR (100 MHz, CDCl3) δC 152.1 (C-2), 149.4 (C-4 and C-8a), 134.9 (C-
7), 129.0 (C-8), 125.1 (C-6), 121.3 (C-5), 117.5 (C-4a), 99.4 (C-3), 52.7 (C-13), 48.4 (C-9), 47.0 











2,2,2-Trichloroethyl (4-((7-chloroquinolin-4-yl)amino)pentyl)(ethyl)carbamate (20) and 
7-chloro-4-(2-methylpyrrolidin-1-yl)quinoline (20’). 
A previously-reported procedure was followed with slight modifications.8 To a clear solution of 
chloroquine 7 (2 964 mg, 9.27 mmol, 1 eq) in anhydrous THF (40 mL) under N2 was added NaH 
(60% oil dispersion, 444 mg, 11.1 mmol, 1.2 eq) at room temperature. The solution was heated 
to 70°C and refluxed for two hours. The resulting cloudy yellow mixture was then cooled to 
room temperature and 2,2,2-trichchoroethyl chloroformate (1.53 mL, 11.1 mmol, 1.2 eq) was 
added dropwise. The mixture was stirred for 20 minutes at room temperature and then 
refluxed for 18 hours, during which time it turned brown. After cooling, the reaction was 
quenched with H2O dropwise. THF was removed and the residue was treated with additional 
H2O (80 mL) and extracted with diethyl ether (3 x 80 mL). Combined extracts were washed 
(H2O, brine), dried (Na2SO4), filtered and reduced. Column chromatography (0-100% EtOAc) 
gave a mixture of the chloroformate 20 and pyrrolidine 20’ as a yellow gum (1 802 mg) which 
did not yield to separation. Unreacted chloroquine starting material was recovered from the 
column (109 mg, 0.34 mmol, 4%). ATR-FTIR vmax/cm-1 1715 (strong, sharp C=O stretching 











N4-(7-chloroquinolin-4-yl)-N1-ethylpentane-1,4-diamine, desethylchloroquine (21).  
A previously-reported procedure was followed with slight modifications.8 To a flask containing 
a mixture of 20 and 20’ (overall mass 1.532 g) was added glacial acetic acid (10 mL) and a small 
volume of CH2Cl2 (3 mL) to dissolve the starting material. Zinc dust (2 079 mg, 33.33 mmol) was 
added in small portions and the mixture was stirred at room temperature for six hours. The 
contents were filtered through Celite, which was subsequently washed with hot MeOH. The 
volume was reduced and cold 5 M NH4OH (100 mL) was added. The mixture was extracted with 
CH2Cl2 (3 x 100 mL) and the combined extracts were washed (H2O, brine), dried (MgSO4), 
filtered and reduced. The residue was dissolved in a minimum amount of CH2Cl2, and purified 
using column chromatography using 0-40% MeOH:CH2Cl2 followed by increasing additions of 
Et3N (0-4%) to the 40% MeOH:CH2Cl2 mobile phase for the elution of 21. The removal of solvent 
yielded 21 as a sticky yellow-brown gum (678 mg, 2.15 mmol, 41% over two steps), whose 
ATR-FTIR spectrum was indistinguishable from that of chloroquine 1. 1H NMR (400 MHz, CDCl3) 
δH 8.47 (1H, d, J 5.4 Hz, H-2), 7.91 (1H, d, J 2.2 Hz, H-8), 7.81 (1H, d, J 9.0 Hz, H-5), 7.31 (1H, dd, J 
9.0, 2.2 Hz, H-6), 6.35 (1H, d, J 5.4 Hz, H-3), 5.67 (1H, br s, -NH-, exchanged with D2O), 3.93 (1H, 
br s, -NH-, exchanged with D2O), 3.66 (1H, m, H-9), 2.68 (4H, m, H-13 and H-14), 1.78 (1H, m, H-
11a), 1.66 (3H, m, H-11b and H-12), 1.27 (3H, t, J 6.4 Hz, H-10), 1.14 (3H, t, J 7.1 Hz, H-15). 13C 
NMR (100 MHz, CDCl3) δC 152.0 (C-2), 149.4 (C-4 and C-8a), 134.9 (C-7), 128.7 (C-8), 125.1 (C-
6), 121.5 (C-5), 117.6 (C-4a), 99.2 (C-3), 48.8, 48.5, 43.9 (C-14, C-13, C-9; cannot assign), 34.0 (C-











tert-Butyl (2-oxoethyl)carbamate, N-Boc-glycinal.  
A previously-reported procedure was followed with slight modifications.9 Freshly-distilled THF 
(40 mL) was added to a two-necked round-bottomed flask under N2. The flask was cooled to 0°C 
in an ice bath and LiAlH4 (217 mg, 5.73 mmol), which had been carefully weighed into a dry 
sample vial, was added in small portions over several minutes. Weinreb amide tert-butyl (2-
(methoxy(methyl)amino)-2-oxoethyl)carbamate (1 000 mg,  4.58 mmol) was dissolved in dry 
THF (10 mL) and added dropwise to the LiAlH4 slurry via syringe. The mixture was stirred for 
one hour after which the TLC spot corresponding to the starting material, visualised using an 
anisaldehyde stain, disappeared. The reaction was quenched by slow dropwise addition of ice-
cold saturated Na2SO4 and the mixture was allowed to warm to room temperature. The mixture 
was transferred to a separating funnel, diluted with H2O (25 mL) and extracted with EtOAc (3 x 
25 mL). The organic layers were combined and washed with 1 M HCl (3 x 25 mL), saturated 
NaHCO3 (2 x 25 mL) and brine (2 x 25 mL). The solution was dried with Na2SO4, filtered and the 
solvent was reduced. The crude N-Boc-glycinal (724 mg, 99% crude) was used immediately in 













A previously-reported procedure was followed with slight modifications.10 To a flask containing 
desethylchloroquine 21 (918 mg, 3.15 mmol) and N-Boc-glycinal (752 mg, 4.73 mmol) in MeOH 
(20 mL) was added a catalytic amount of glacial acetic acid (five drops). This was stirred at 
room temperature for 15 minutes. Thereafter, NaBH3CN (594 mg, 9.45 mmol) was added in 
small portions and the mixture was refluxed at 80°C for four hours. The mixture was then 
cooled and quenched dropwise with H2O. The solvent was removed, saturated NaHCO3 (30 mL) 
added and the organic material extracted into CH2Cl2 (3 x 30 mL). The organic fractions were 
combined, dried (Na2SO4) and reduced. Column chromatography was performed with an elution 
gradient of 0-40% MeOH:CH2Cl2 to afford product 22 (941 mg, 2.20 mmol, 70%) as a light-
brown oil.  ATR-FTIR vmax/cm-1 1700 (strong, sharp C=O stretching vibration indicates 
carbamate). 1H NMR (400 MHz, CDCl3) δH 8.48 (1H, d, J 5.4 Hz, H-2), 7.94 (1H, d, J 2.2 Hz, H-8), 
7.74 (1H, d, J 8.8 Hz, H-5), 7.33 (1H, dd, J 8.8, 2.2 Hz, H-6), 6.40 (1H, d, J 5.4 Hz, H-3), 5.15 (1H, d, 
J 7.8 Hz, NH), 4.95 (1H, br s, carbamate -NH-) 3.71 (1H, m, H-9), 3.17 (2H, q, J 6.0 Hz, H-17), 2.52 
(4H, m, H-14 and H-16), 2.46 (2H, t, J 6.8 Hz, H-13), 1.72 (1H, m, H-11a), 1.59 (3H, m, H-11b and 
H-12), 1.41 (9H, s, H-20), 1.32 (3H, d, J 6.4 Hz, H-10), 0.99 (3H, t, J 7.0, H-15). 13C NMR (100 MHz, 
CDCl3) δC 156.2 (C-18), 151.8 (C-2), 149.4, 149.2 (C-4, C-8a), 135.1 (C-7), 128.6 (C-8), 125.6 (C-
6), 121.3 (C-5), 117.4 (C-4a), 99.3 (C-3), 79.3 (C-19), 55.4 (C-13), 52.9 (C-14 or C-16), 48.6 (C-9), 
47.8 (C-14 or C-16), 38.4 (C-17), 34.5 (C-11), 28.6 (C-20), 24.0 (C-12), 20.5 (C-10), 11.6 (C-15). 











N1-(2-aminoethyl)-N4-(7-chloroquinolin-4-yl)-N1-methylpentane-1,4-diamine (23).  
A previously-reported procedure was followed with slight modifications.10 To a stirring solution 
of 22 (586 mg, 1.35 mmol, 1 eq) in CH2Cl2 at 0°C was added dropwise trifluoroacetic acid (TFA, 
2.1 mL, 27 mmol, 20 eq). The mixture was left to stir for eight hours while coming gradually to 
room temperature, after which TLC analysis indicated the reaction was complete. Excess 
solvent and TFA was removed. At this stage the product was considered pure enough by TLC to 
use in the subsequent step as a tris-trifluoroacetate salt. To isolate the free base, the residue 
was dissolved in 1 M NaOH and extracted with CH2Cl2 (3 x 50 mL). The organic layers were 
combined, washed with brine, dried (Na2SO4), filtered and reduced. Purification was achieved 
by column chromatography using an eluent of 0-100% MeOH:CH2Cl2 followed by the addition of 
0-5% Et3N, after which product 23 was isolated as a light-yellow oil (271 mg, 0.81 mmol, 60%). 
1H NMR (400 MHz, CDCl3) δH 8.50 (1H, d, J 5.4 Hz, H-2), 7.93 (1H, d, J 2.2 Hz, H-8), 7.71 (1H, d, J 
9.0 Hz, H-5), 7.33 (1H, dd, J 9.0, 2.2 Hz, H-6), 6.40 (1H, d, J 5.4 Hz, H-3), 5.07 (1H, d, J 7.6 Hz, -NH-, 
exchangeable in D2O), 3.70 (1H, m, H-9), 2.72 (2H, m, H-17), 2.48 (6H, m, H-13, H-14 and H-16), 
1.73 (3H, m, H-11a and NH2, the latter exchangeable in D2O), 1.59 (3H, m, H-11b and H-12), 1.31 
(3H, d, J 6.4 Hz, H-10), 0.99 (3H, t, J 7.0, H-15). 13C NMR (100 MHz, CDCl3) δC 152.2 (C-2), 149.9, 
149.2 (C-4, C-8a; cannot assign), 134.9 (C-7), 129.1 (C-8), 125.2 (C-6), 121.2 (C-5), 117.5 (C-4a), 
99.4 (C-3), 56.5, 53.6, 47.9 (C-13, C-14, C-16; cannot assign), 48.5 (C-9), 39.9 (C-17), 34.5 (C-11), 
24.2 (C-12), 20.5 (C-10), 11.9 (C-15). MS (EI+) m/z: [M]+ 335.  
 
  








yl)amino)ethyl)pentane-1,4-diamine, “Chloroquine-NBD” (8).  
The crude tris-trifluoroacetate salt of 20 (400 mg, 0.59 mmol) was dissolved in methanol (10 
mL) in a round-bottomed flask charged with a stirrer bar. N,N-Diisopropylethylamine (0.31 mL, 
1.77 mmol) was added dropwise and stirred for ten minutes after which NaHCO3 (150 mg, 1.77 
mmol) was added and the temperature raised to 75°C. NBD-Cl (120 mg, 0.59 mmol) in MeOH (5 
mL) was added dropwise. After 2.5 hours, the TLC indicated consumption of both starting 
materials. The reaction mixture was cooled and the methanol was removed. Water (30 mL) was 
added and the residue was extracted using CH2Cl2 (3 x 30 mL). The combined extracts were 
dried (Na2SO4), filtered and reduced. The residue was then adsorbed onto silica and column 
chromatography was performed with an elution gradient of 0-30% MeOH:CH2Cl2. The 
appropriate fractions were combined and the volume was reduced to isolate product 8 as a 
dark-red crystalline solid (71 mg, 0.14 mmol, 24%). MP 61-63°C. ATR-FTIR vmax/cm-1 1450 
(medium, -NO2 asymmetric stretch lowered by conjugation), 1300 (strong, -NO2 symmetric 
stretch lowered by conjugation).11 1H NMR (400 MHz, DMSO-d6) δH 8.44 (1H, d, J 9.5 Hz, H-b), 
8.31 (2H, m, H-2 and H-8), 7.71 (1H, d, J 2.2 Hz, H-5), 7.37 (1H, dd, J 9.0, 2.2 Hz, H-6), 6.85 (1H, d, 
J 8.5 Hz, aryl -NH-), 6.42 (1H, d, J 6.0 Hz, H-3), 6.34 (1H, d, J 9.5 Hz, H-a), -NH- adjacent to NBD 
heterocycle not observed, 3.62 (1H, m, H-9), 3.48 (2H, m, H-17), 2.71 (2H, t, J 6.6 Hz, H-16), 2.55 
(2H, m, H-14), 2.46 (2H, t, J 6.8 Hz, H-13), 1.65 (1H, m, H-11a), 1.48 (3H, m, H-11b and H-12), 
1.16 (3H, d, J 6.4 Hz, H-10), 0.93 (3H, t, J 7.0, H-15). 13C NMR (100 MHz, DMSO-d6) δC 151.5 (C-2), 
149.5, 149.0 (C-4, C-8a; cannot assign), 145.0, 144.3, 144.0 (C-A, C-B and C-C; cannot assign), 
137.7 (C-b), 133.3 (C-7), 127.2 (C-5), 124.2 (C-8), 123.7 (C-6), 120.5 (C-D), 117.3 (C-4a), 99.1 (C-
a), 98.6 (C-3), 52.4 (C-13), 50.8 (C-16), 47.5 (C-9), 47.0 (C-14), 41.5 (C-17), 33.1 (C-11), 23.5 (C-
12), 19.7 (C-10), 11.7 (C-15). HRMS (ESI-TOF) m/z: [M+H]+ calculated for C24H29ClN7O3 









8.2. Physicochemical and in vitro evaluation of fluorescent derivatives 
 
8.2.1. General physicochemical methods 
 
Unless otherwise stated, all compounds were purchased from Sigma-Aldrich and used without 
further purification. Solvents were generally purchased from Kimix Chemicals. Bovine haemin 
(Fe(III)PPIX-Cl) was obtained from Fluka. NP-40 was obtained from Pierce Biotechnology, 
Rockford, IL, USA. Double-distilled deionised water (dH2O) was provided by a Millipore Direct-
Q3 water purification system. Hoechst 33342, LysoTracker Red, ER-Tracker Red and 
MitoTracker Deep Red were all obtained from Molecular Probes (Oregon, USA) and later 
Thermo Fisher Scientific. Nile Red was obtained from Sigma-Aldrich. 
 
Absorption spectra were recorded on a Varian Cary 100 UV-Vis or a Shimadzu UV-1800 
spectrophotometer and were baseline-corrected. Fluorescence spectra were measured using a 
Varian Cary Eclipse spectrofluorimeter. Assay plates were read using a SpectraMax 340 PC 384 
Absorbance Microplate Reader (Molecular Devices). Magnetic circular dichroism (MCD) spectra 
were recorded on a ChiraScan-Plus CD spectrophotometer with an MCD attachment (0.997 T) at 
22°C. 
 
All stock solutions were stored in the dark and working solutions were made up immediately 
prior to use. Unless otherwise stated, the temperature was maintained at 25.0  0.2°C by means 
of a thermostatted water bath. Aliquots of solutions were delivered into quartz cuvettes (1.00 
mm or 10.00 mm) using a Hamilton syringe. Cuvettes were scrupulously washed with 0.2 M 
NaOH, followed by several rinsings with water, then addition of 1 M HNO3 and several final 
rinsings with water to remove adsorbed Fe(III)PPIX.12  
 
Titration curves were analysed using a non-linear least squares fitting in HypSpec (Version 
1.1.33, Protonic Software). Sigmoidal dose-response curves were fitted to absorbance data 
using GraphPad Prism (Version 6.05, GraphPad Software). All measurements were performed in 
triplicate.  
 
8.2.2. Relative fluorescence quantum yields 
 
Relative fluorescence quantum yields were calculated according to Equation 8.1 in which Φ 
represents the relative fluorescence quantum yield, A is the absorbance of the sample at the 
excitation wavelength, F is the area under the fluorescence emission curve and n is the 
refractive index of the solvent system. The subscripts S and X refer to the standard and to the 





unknown samples, respectively.13 The reported measurement by Melhuish of Φ   0.546 for 
quinine sulfate in 0.5 M sulfuric acid was used as a standard value.14  
 















Absorbance values were kept below 0.1 in order to minimise inner filter-effects. In each case, 
the area under the fluorescence emission curve was determined by summing the fluorescence 
intensities across the entire emission range. Refractive indices of 1.346, 1.3614 and 1.3885 
were used for sulfuric acid, ethanol and 40% DMSO (v/v) in 20 mM Hepes, pH 7.5, respectively. 
The final value was calculated by interpolation.15 
 
8.2.3. Quantitative measurements of thermal and photodecomposition 
 
Approximately 1 mg of the NBD-labelled quinoline (> 95% pure) was deposited in a small glass 
vial. This was either left as a solid or dissolved in HPLC-grade acetonitrile (1 mL). The vials were 
then closed and sealed before being left for three months under the test conditions described in 
Section 4.2.4. After three months, the vials were opened and each sample was made up to a total 
of 2 mL HPLC-grade acetonitrile and filtered through a 0.22 μm nylon membrane. Quantitative 
analysis was performed using HPLC in which each sample was run for 15 minutes on a 5-100% 
acetonitrile gradient in 0.1% trifluoroacetic acid at a flow rate of 1 mL/min. In each case, the 
decomposition was measured by expressing the area under the peak corresponding to the 
retention time of the original sample as a fraction of the total signal recorded for the sample.  
 
8.2.4. Job plots to determine binding stoichiometries with Fe(III)PPIX 
 
To construct Job plots to determine the binding stoichiometries of complexes with Fe(III)PPIX, 
the absorption spectra of solutions of varying ligand and Fe(III)PPIX mole fractions were 
recorded in 40% DMSO (v/v) in 20 mM Hepes, pH 7.5, according to a method previously 
described.16 The total concentration of the system was constrained to 0.75 mM and absorbance 
was measured at 400 nm in a 1.00 mm path length cuvette. Depending on expected binding, 
fifteen working solutions were prepared with mole fractions of Fe(III)PPIX between 0 and 1. 
Spectrophotometric data were analysed at 400 nm.  
 
  





8.2.5. Spectrophotometric titrations to determine association constants with 
Fe(III)PPIX 
 
Thermodynamic association constants were measured in 40% DMSO (v/v) in 20 mM Hepes, pH 
7.5, according to a method previously described.17 Stock solutions of quinolines were prepared 
at concentrations of 0.5 mM or 1 mM depending on the strength of association with Fe(III)PPIX. 
Each stock compound was titrated into a 5 μM Fe(III)PPIX working solution. The resulting 
spectrophotometric data were analysed using an appropriate complexation model with 
HypSpec.  
 
8.2.6. Magnetic circular dichroism (MCD) 
 
MCD spectra were recorded as previously described.16 Solutions were prepared by diluting a 
stock solution of Fe(III)PPIX (1 mM in 0.1 M NaOH) to a final concentration of 7.5 μM. For the 
quinolines, stock solutions (20 mM in DMSO) were diluted to a final concentration of 15 μM. 
 
8.2.7. Turbidimetric assay to assess aqueous solubility 
 
Test compounds were prepared in a 96-well plate at concentrations ranging from 0-200 μM in 
DMSO and 20 mM Hepes, pH 7.5, diluted from a stock solution of 20 mM in DMSO. The final 
concentration of DMSO in 20 mM Hepes, pH 7.5, did not exceed 1% (v/v). After preparing the 
plate, it was covered and left to equilibrate for two hours at ambient temperature. Absorbances 
of the wells were then measured at 620 nm. Absorbance values were corrected by subtracting 
the absorbance of each DMSO sample from the absorbance of each aqueous sample. 
 
8.2.8. Diffusion measurements 
 
Diffusion measurements were performed using a diffusion cell approach.12,18 The analyte, 
typically with a concentration between 100-400 μM, was loaded into the lower chamber of the 
diffusion apparatus and allowed to diffuse into the corresponding blank solution in an adjacent 
upper chamber for several hours at ambient temperature. The absorbance of the solution 
isolated from the upper chamber was measured and its concentration determined. Diffusion 
coefficients and hydrodynamic radii were then calculated from Equations 4.4 and 4.5, 
respectively. If necessary, diffusion coefficients were corrected to 298 K using Equation 8.2 
where D represents the diffusion coefficient (m2/s), η is the viscosity (Pa s) and T is the 
temperature (K). 
 





    
  
 






8.2.9. NP-40 detergent-mediated assay to measure β-haematin inhibition 
 
The β-haematin formation inhibition assay method described by Carter et al. was modified for 
manual liquid delivery.19,20 20 mM stock solutions of the samples were prepared by dissolving 
the pre-weighed compounds in DMSO. These were delivered to a 96-well plate in triplicate to 
give concentrations ranging from 0 to 1000 μM (final well concentration) with a total DMSO 
volume of 10 μL in each well, after which deionised water (70 μL) and NP-40 (20 μL; 30.55 μM) 
were added. The absorbances of plate wells were pre-read at 405 nm on a SpectraMax 340 
PC384 Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). A 25 mM 
haematin stock solution was prepared by sonicating haemin in DMSO for one minute and then 
suspending 178 μL of this in a 1 M acetate buffer (pH 4.8). The homogenous suspension (100 
μL) was then added to the wells to give final buffer and haematin concentrations of 0.5 M and 
100 μM, respectively. The plate was covered and incubated at 37°C for 5-6 hours. After 
incubation, free haem was detected using the pyridine-ferrichrome method developed by 
Ncokazi and Egan.21 A solution of 50% (v/v) pyridine, 30% (v/v) water, 20% (v/v) acetone and 
0.2 M Hepes was prepared and 32 μL added to each well to give a final pyridine concentration of 
5% (v/v). Acetone (60 μL) was then added to assist with haematin dispersion. The absorbances 
of plate wells were again read at 405 nm, from which the pre-read values were subtracted. 
Sigmoidal dose-response curves with variable slopes were fitted to the absorbance data using 
GraphPad Prism v6.05 to obtain a 50% inhibitory concentration (IC50) for each compound. Data 
were fitted to Equation 8.3 where the IC50 is the midpoint of the curve and H is the Hill slope 
which describes the steepness of the curve. T and B are the lower and upper baselines of the 
curve, respectively. 
 
    
     





8.2.10. Plasmodium falciparum culturing 
 
Continuous in vitro cultures of asexual erythrocyte stages of chloroquine-sensitive Plasmodium 
falciparum (NF54 strain) were maintained using a modified method of Trager and Jensen.22 The 





cultures were maintained between 4-8% parasitaemia and 3-6% haematocrit. The culture was 
synchronised at the ring stage by incubating with D-sorbitol.  
 
8.2.11. In vitro activity testing against P. falciparum 
 
Samples were tested in triplicate on separate occasions at the Division of Pharmacology, 
Department of Medicine, University of Cape Town. Quantitative assessment of antiplasmodial 
activity in vitro was determined via the parasite lactate dehydrogenase assay using a modified 
method described by Makler.23 The test samples were prepared to a 20 mg/mL stock solution in 
DMSO and were tested as a suspension if not completely dissolved. A full dose-response was 
performed for all compounds to determine the concentration inhibiting 50% of parasite growth 
(IC50). A starting concentration (100 µg/mL) was serially diluted two-fold in complete medium 
to give ten concentrations, the lowest of which was 0.2 µg/mL. Reference drugs were tested at a 
starting concentration of 1000 ng/mL. Active compounds were re-tested at a starting 
concentration of 1000 ng/mL. The highest concentration of solvent to which the parasites were 
exposed had no measurable effect on the parasite viability (data not shown). The IC50 values 
were obtained using a non-linear dose-response curve fitting analysis in GraphPad Prism. 
  





8.3. Live-cell fluorescence microscopy 
 
8.3.1. General methods 
 
Nunc Lab-Tek II eight-well chamber slides (Thermo Fisher Scientific, Massachusetts, USA) with 
cover glass of No. 1.5 thickness were coated with 150 μL of 0.01% (w/v) poly-L-lysine solution. 
After ten minutes, the solution was removed and the plates were left to air-dry. Ringer’s 
solution was prepared according to the recipe in Table 8.1, as previously described.24 The pH 
was adjusted to 7.4 after which the solution was filtered through a 0.22 μm nylon syringe filter. 
 
Table 8.1. Constituents of Ringer’s solution for live-cell imaging of P. falciparum.24 
 
Component Molecular weight Final concentration Mass required for 100 mL 
NaCl 58.44 122.5 mM 715.9 mg 
KCl 74.56 5.4 mM 40.3 mg 
CaCl2 (dihydrate) 147.02 1.2 mM 17.6 mg 
MgCl2 (anhydrous) 95.21 0.8 mM 7.6 mg 
D-Glucose 180.16 11 mM 198.2 mg 
Hepes 238.30 25 mM 595.8 mg 
NaH2PO4 119.98 1 mM 12.0 mg 
 
Human erythrocytes infected with P. falciparum trophozoites (NF54 strain) were generously 
donated by colleagues at the Division of Pharmacology, Department of Medicine, University of 
Cape Town. After harvesting and centrifugation of the cells, 5 µL of the parasitised erythrocyte 
pellet were resuspended in 5 mL Ringer’s solution and were vortexed to reduce clumping of the 
erythrocytes. 150 µL aliquots of suspended cells were placed in each well of the chamber slide 
and incubated for at least twenty minutes to allow the erythrocytes to adhere to the cover glass. 
After this, the Ringer’s solution was removed and replaced with a fresh aliquot of Ringer’s 
solution (150 μL) to remove non-adhered cells. This solution was then removed again and 
replaced with Ringer’s solution (150 μL) containing appropriate concentration(s) of the 
fluorescent dye(s) as listed in Tables 8.2 and 8.3.  
 
8.3.2. Live-cell confocal fluorescence microscopy 
 
Confocal microscopy was performed using a Zeiss Axiovert 200 M LSM 150-META confocal 
microscope at the Confocal and Light Microscope Imaging Facility at the University of Cape 





Town. A Plan-Apochromat 63/1.40 Oil DIC M27 objective lens was used and the cells were 
incubated at 37C. Images were captured and processed with ZEN 2011 (Carl Zeiss Microscopy 
GmbH). Laser transmission was kept as low as possible to minimise phototoxicity to the cells.25 
Dye concentrations with respective excitation and emission settings are listed in Table 8.2. 
 
Table 8.2. Concentrations of fluorescent dyes used for confocal imaging of P. falciparum  
with respective excitation lasers and emission filter settings. 
  
Dye Concentration Excitation laser Emission filter 
Hoechst 33342 2 μM 750 nm (two-photon) Spectral 415-500 
Novel fluorescent derivative 500 nM 488 nm BP 500-550 
LysoTracker Red 200 nM 561 nm BP 575-630  
Nile Red 200 nM 561 nm BP 575-630  
ER-Tracker Red 500 nM 561 nm BP 575-630  
MitoTracker Deep Red 200 nM 633 nm BP 650-710 IR 
 
8.3.3. Live-cell super-resolution structured-illumination microscopy (SR-SIM) 
 
SR-SIM was performed using a Zeiss LSM 780 ELYRA S1 microscope at the CAF Fluorescence 
Microscopy Unit at Stellenbosch University. Thin (0.1 μm) z-stacks of high-resolution image 
frames were collected in three rotations by utilising an alpha Plan-Apochromat 63/1.4 Oil DIC 
M27 ELYRA objective lens. Images were reconstructed using ZEN 2011 (Carl Zeiss Microscopy 
GmbH) based on a structured-illumination algorithm. To ensure accurate colocalisation 
analysis, a channel alignment procedure was followed using a slide of three-colour fluorescent 
beads #1783-455 Tool for Calibration Multi Spek (supplied by Carl Zeiss Microscopy GmbH). 
Dye concentrations with respective excitation and emission settings are listed in Table 8.3. 
 
Table 8.3. Concentrations of fluorescent dyes used for SR-SIM imaging of P. falciparum  
with respective excitation lasers and emission filter settings. 
 
Dye Concentration Grating  Excitation laser  Emission filter 
Hoechst 33342 2 μM 35.0 μm 405 nm BP 420-480 + LP 750 
Novel fluorescent derivative 500 nM 42.0 μm 488 nm BP 495-550 + LP 750 
LysoTracker Red 200 nM 51.0 μm 561 nm BP 570-620 + LP 750 
Nile Red 200 nM 51.0 μm 561 nm BP 570-620 + LP 750 
ER-Tracker Red 500 nM 51.0 μm 561 nm BP 570-620 + LP 750 
MitoTracker Deep Red 200 nM 51.0 μm 642 nm 655 LP 





8.4. Affinity detection and proteomic identification of binding targets 
 
8.4.1. Preparation of biological material for affinity detection experiments 
 
8.4.1.1. Saponin lysis of erythrocytes 
Mature-stage P. falciparum-infected erythrocytes were harvested and generously donated by 
colleagues at the Division of Pharmacology, Department of Medicine, University of Cape Town. 
Parasites were liberated from the erythrocytes using a 1% saponin solution in 0.01 M 
phosphate-buffered saline (PBS) at pH 7.4. This was incubated at room temperature for 15 
minutes and then centrifuged at 1 500 rcf for ten minutes. The supernatant was removed and 
the pellet was washed with 3 x 20 mL PBS to remove erythrocyte debris. Trophozoites were 
stored at -80°C. 
 
8.4.1.2. Rupture of the digestive vacuole membrane by freeze-thaw lysis 
Storage at -80°C and subsequent thawing resulted in lysis of the trophozoites but left the 
digestive vacuoles intact. This was confirmed by viewing a Giemsa-stained slide. A 10x protease 
inhibitor cocktail solution was prepared by dissolving one tablet of the SigmaFAST Protease 
Inhibitor Cocktail in 10 mL acidified dH2O (pH 4.5-5.5). 500 μL of this 10x solution was added to 
the trophozoite pellet (approximately 5 mL in total). This mixture was split into six fractions of 
approximately 1 mL each. Each fraction was centrifuged at 10 900 rpm for five minutes and the 
supernatants were collected, pooled and stored at -20°C. To the pellet of each fraction was 
added approximately 1 mL of the 1x protease inhibitor solution followed by thorough mixing. 
Fractions were frozen at -80°C for 20 minutes and then thawed at 37°C for ten minutes. 
Fractions were vortexed, centrifuged for two minutes at 10 900 rpm and the supernatants were 
removed and pooled. The freeze-thaw cycle was continued over several days. Digestive vacuole 
lysis was judged to be complete when a wet mount showed no distinct shapes or aggregates 
under 100-fold magnification. Following lysis, the haemozoin was washed and collected. The 
pooled lysate was stored at -20°C. 
 
8.4.1.3. Ultracentrifugation, ultrafiltration and quantification 
The pooled lysate was thawed and poured into Beckman polyallomer centrifuge tubes (#331 
374, 14 mm x 95 mm, 15 mL) and filled with acidified water. In order to separate soluble and 
insoluble (membrane) fractions, a Beckman centrifuge model L7-65 ultracentrifuge with a 
SW40-TI rotor was used. The samples were centrifuged at 31 000 rpm (120 000 x g) for one 
hour at 4°C to pellet out the insoluble membrane material. The supernatants were transferred 
to Merck Amicon Ultra-15 Centrifugal Filter Devices with a 3 kDa molecular weight cut-off 
(#UFC900308, 15 mL). These were spun using a Beckman J2-21M/E centrifuge with a JA-14 





rotor at 7 000 rpm for 15 minutes at 4°C at least three times. The insoluble fraction was 
resuspended with a minimum volume of 1% (w/v) CHAPS detergent and triturated to promote 
mixing. Finally, the protein concentrations of all fractions were quantified using the Bio-Rad 
Quick Start Bradford Protein Assay using the instructions supplied by the manufacturer. Bovine 
serum albumin was used as a standard.  
 
8.4.1.4. Lysis and quantification of human erythrocyte material 
Uninfected human erythrocytes were lysed in the presence of the buffer previously described 
by Graves et al. with slight modifications.26 The recipe is given in Table 8.4 and is hereafter 
referred to as “affinity buffer”. 250 μL pelleted human erythrocytes were mixed with 250 μL 
affinity buffer (2x) and lysed by rocking gently for half an hour at 4°C with occasional single-
second bursts of sonication. This was followed by centrifugation at 4°C for ten minutes at 13 
500 x g. This lysate was quantified using the Bio-Rad Quick Start Bradford Protein Assay using 
the instructions supplied by the manufacturer. 
 
Table 8.4. Constituents of affinity buffer required for a 2x concentration in 100 mL.26  
To this was added one SigmaFAST Protease Inhibitor Cocktail tablet. The pH was adjusted to 7.5. 
 





for 200 mL 
NaCl 58.44 100 mM 0.584 g 
MgCl2 91.21 20 mM 0.190 g 
Hepes 238.30 100 mM 2.383 g 
CHAPS 614.88 0.2% (w/v) 200 mg 
 
8.4.2. Preparation of drug-labelled agarose beads 
 
Approximately 500 μL packed beads of NHS-activated Sepharose 4 Fast Flow (GE Healthcare) 
were washed three times with 1 mM cold HCl (1 mL). Thereafter, the beads were incubated with 
a coupling solution which comprised a sufficient number of moles of the derivatised ligand 
necessary for a 3 μmol/mL loading capacity dissolved in 100 mM Hepes at pH 8.3. This was 
rotated at room temperature for one hour after which the sample was washed three times with 
100 mM Hepes at pH 8.3, this time containing no ligand. The supernatant from each wash step 
was collected and made up to a known volume for quantification by spectrophotometry to 
determine the amount of derivatised ligand remaining. The beads were then incubated in 
“blocking solution”, comprising 100 mM Tris at pH 8.5, and rotated at room temperature for one 





hour. Following centrifugation, the blocking solution was removed and the beads were washed 
with Hepes buffer (100 mM, pH 8.3) followed by acetate buffer (100 mM, pH 4.5). This wash 
routine, alternating between high and low pH values, was repeated three times. The beads were 
stored in 20% aqueous ethanol to avoid microbial contamination. 
 
8.4.3. Matrix-based affinity chromatography 
 
An aliquot of 150 μL suspended beads (approximately 100 μL packed beads) was equilibrated 
by washing three times with 1x affinity buffer (1 mL). For erythrocyte experiments, up to 3 mg 
of erythrocyte lysate was added to the beads and the total volume was made up to 1 mL with 
affinity buffer (1x). Alternatively, 40 μg of P. falciparum lysate was added to the beads and the 
total volume was made up to 500 μL. This mixture was gently rocked at 4°C for half an hour. The 
beads were centrifuged at 4°C for two minutes at 13 500 x g and the supernatant was removed. 
The beads were then resuspended in 800 μL affinity buffer (1x) and washed six times in total.  
 
For solid-phase elution, 40 μL sample application buffer (4x) was added to the samples followed 
by mixing, centrifugation and dry-boiling at 95°C for five minutes. Samples were then loaded 
onto the gel directly. Alternatively, for competition elution, 450 μL of a concentrated solution of 
the drug in affinity buffer (1x) was added to the beads and this was rotated at 4°C for 20 
minutes. Concentrations were 5 mM for chloroquine and 2.5 mM for quinine and quinidine. 
Following centrifugation, the supernatant was loaded onto a Pall Nanosep Centrifugal Device 
with Omega Membrane with a 3 kDa molecular weight cut-off. This was concentrated at  
13 500 x g at 4°C for about six minutes until approximately 40-50 μL of each sample remained. 
The remaining supernatant was removed and placed in a new microfuge tube. To this was 
added 15 μL sample application buffer (4x) followed by mixing, centrifugation and dry boiling at 
95°C for five minutes. Samples were then loaded onto the SDS-Page gel directly.  
 
8.4.4. SDS-polyacrylamide gel electrophoresis (SDS-Page) 
 
8.4.4.1. Recipes 
 For the separating (resolving) gel buffer, 18.2 g Tris and 0.4 g SDS were made up to 
100 mL and adjusted to pH 8.8. This gave concentrations of 150 mM Tris and 0.4% SDS.  
 For the stacking gel buffer, 6.05 g Tris and 0.4 g SDS were made up to 100 mL and 
adjusted to pH 6.8. This gave concentrations of 50 mM Tris and 0.4% SDS.  
 For the running buffer (5x), 15.1 g Tris, 72 g glycine and 5 g SDS were made up to 1 L. 
The pH was not adjusted. When diluted to 1x, this gave concentrations of 25 mM Tris, 
200 mM glycine and 0.1% SDS.   





 To make approximately 20 mL of the sample application buffer (4x), 10 mL of the 
stacking buffer was added to 8 mL glycerol, 0.8 g SDS, 0.8 mL β-mercaptoethanol, 0.2 mg 
bromophenol blue indicator and 1.2 mL dH2O. 
 
The relative proportions of reagents required to cast the separating and stacking gels, at 
acrylamide concentrations of 15% and 5% (w/v), respectively, are listed in Table 8.5. APS was 
stored in the freezer and re-prepared weekly. 40% (w/v) acrylamide was prepared using a 29:1 
(w/v) monomer:crosslinker ratio. The monomer was acrylamide and the crosslinker was  
N,N’-methylenebisacrylamide. TEMED refers to tetramethylethylenediamine. 
 
Table 8.5. Components required to make separating and stacking gels at acrylamide concentrations of 15% 
and 5% (w/v), respectively. These amounts are sufficient for casting two gels. 
 
 Separating gel (15%) Stacking gel (5%) 
Water 7.1 mL 2.96 mL 
40% (w/v) acrylamide  7.5 mL 500 μL 
Buffer 5.2 mL (Separating buffer) 540 μL (Stacking buffer) 
10% (w/v) APS  200 μL 40 μL 
TEMED 12 μL 8 μL 
Total 20 mL 4.048 mL 
 
8.4.4.2. Casting the gels; electrophoresis 
Equipment was thoroughly cleaned with 70% (v/v) aqueous ethanol. 1.0 mm gels were cast as 
per standard procedure. Briefly, the solution for the separating gel was prepared and inserted 
into the casting apparatus. Isopropanol was used to level out the gel surface. After 
polymerisation, the isopropanol was removed and the stacking gel was prepared. This was 
added to the casting apparatus and a ten-lane comb was gently inserted. Once the stacking gel 
had set, the apparatus was placed in the running chamber of a Bio-Rad Mini-PROTEAN Tetra 
System. The comb was removed and running buffer (1x) was added. Samples were prepared by 
diluting an appropriate volume of sample application buffer (4x) followed by dry-boiling for five 
minutes at 95°C using a Thermo Scientific Reacti-Therm I #TS-18822 heating mantle with a 
Reacti-Block #TS-18819 attachment for microfuge tubes. 15 μL of sample was loaded on the gel. 
5 μL of the PageRuler Pre-Stained Protein Ladder 10 to 180 kDa (Thermo Fischer Scientific 
#26616) was also loaded on each gel. 5 μL sample application buffer (1x) was added to empty 
wells. For electrophoresis, a Bio-Rad PowerPac Basic was used. Single gels were run at 20 mA 
for 70 minutes and double gels were run at 30 mA for 85 minutes. After the run, the plates were 
gently prised apart and placed in dH2O. 






For Coomassie staining, the gel was incubated with Coomassie Brilliant Blue R-250 Staining 
Solution (Bio-Rad #1610436) and gently rocked at room temperature overnight. This staining 
solution was also prepared in-house by dissolving 0.1% Coomassie Brilliant Blue R-250 (w/v) 
in 50:40:10 (v/v/v) methanol:water:acetic acid. Following staining, gels were destained using 
Coomassie Brilliant Blue R-250 Destaining Solution (Bio-Rad #1610438) by washing the gel 
with water and then covering the gel with destaining solution. This was gently rocked at room 
temperature for several hours, during which the destaining solution was changed at least three 
times. The destaining solution was also prepared in-house by mixing 50:40:10 (v/v/v) 
water:methanol:acetic acid. Alternatively, gels were silver-stained using the procedure 
described in the Sigma-Aldrich ProteoSilver Plus Silver Stain Kit. Gels were imaged using a Bio-
Rad ChemiDoc XRS+ with ImageLab software (Version 5.2.1, Bio-Rad Laboratories, Inc.).  
 
8.4.5. Proteomic analysis 
 
Proteomic analysis was carried out at the CAF Proteomics Unit at Stellenbosch University. All 
reagents were analytical grade or equivalent and were supplied as indicated. 
 
8.4.5.1. Sample preparation 
Protein solutions were precipitated overnight at -20°C with five volumes of ice-cold acetone. 
The pellets were solubilised by dissolving them in 100 mM triethylammonium bicarbonate 
(TEAB; Sigma). 
 
8.4.5.2. In-solution digestion 
Samples were reduced by adding 50 mM tris(2-carboxyethyl)phosphine (TCEP; Fluka) in 100 
mM TEAB (final concentration 5 mM TCEP) followed by incubation at room temperature for 30 
minutes. Following reduction, cysteine residues were modified to methylthio using 200 mM 
methane methylthiosulfonate (MMTS; Sigma) in 100 mM TEAB (final concentration 20 mM) for 
30 minutes. After modification, the samples were diluted to 98 μL with 100 mM TEAB. Proteins 
were digested by adding 5 μL trypsin (1 μg/μL; Promega) and incubating for 18 hours at 37°C. 




Residual digest reagents were removed using an in-house manufactured C18 stage tip (Empore 
C18 extraction discs; Supelco). The 20 μL sample was loaded onto the stage tip after activating 
the C18 membrane with 30 μL methanol (Sigma) and equilibration with 30 μL 2% 
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acetonitrile:0.05% FA. The bound sample was washed with 30 μL 2% acetonitrile:0.1% FA 
before elution with 30 μL 50% acetonitrile:0.1% FA. The eluate was evaporated to dryness. The 
dried peptides were dissolved in 20 μL 2% acetonitrile:0.1% FA for LC-MS analysis. 
8.4.5.4. Liquid chromatography 
Liquid chromatography was performed on a Thermo Scientific Dionex UltiMate 3000 RSLCnano 
equipped with a 0.5 cm x 300 μm C18 trap column and a 35 cm x 75 μm in-house manufactured 
C18 analytical column (Luna C18, 3.6 μm; Phenomenex). The solvent systems were: 
Loading:  2% acetonitrile:0.1% FA 
Solvent A:  2% acetonitrile:0.1% FA  
Solvent B:  100% acetonitrile:water 
The samples were loaded onto the trap column using loading solvent at a flow rate of 15 μL/min 
from a temperature-controlled autosampler. Loading was performed for five minutes before the 
sample was eluted onto the analytical column. The flow rate was set to 500 nL/min and the 
gradient generated as follows: 2%-10% Solvent B over five minutes; 5%-25% Solvent B from 5-
50 minutes using Chromeleon non-linear gradient 6; 25%-45% Solvent B from 50-65 minutes, 
using Chromeleon non-linear gradient 6. Chromatography was performed at 50°C and the 
outflow was delivered to the mass spectrometer through a stainless steel nano-bore emitter.  
8.4.5.5. Mass spectrometry 
Mass spectrometry was performed using a Thermo Scientific Fusion mass spectrometer 
equipped with a Nanospray Flex ionisation source. The sample was introduced through a 
stainless steel emitter. Data were collected in positive mode with spray voltage set to 2 kV and 
ion transfer capillary set to 275°C. Spectra were internally calibrated using polysiloxane ions at 
m/z = 445.12003 and 371.10024. MS1 scans were performed using the orbitrap detector set at 
120 000 resolution over the scan range 350-1650 with AGC target at 3E5 and maximum 
injection time of 40 ms. Data were acquired in profile mode. MS2 acquisitions were performed 
using monoisotopic precursor selection for ions with charges +2 to +6 with error tolerance set 
to ± 0.02 ppm. Precursor ions were excluded from fragmentation once for a period of 30 s. 
Precursor ions were selected for fragmentation in HCD mode using the quadrupole mass 
analyser with HCD energy set to 32.5%. Fragment ions were detected in the orbitrap mass 
analyser set to 15 000 resolution. The AGC target was set to 1E4 and the maximum injection 
time to 45 ms. These data were acquired in centroid mode.   





8.4.5.6. Data analysis 
The raw files generated by the mass spectrometer were imported into Proteome Discoverer 
(Version 1.4, Thermo Scientific) and processed using the SequestHT algorithm. Data analysis 
was structured to allow for methylthio as a fixed modification as well as deamidation and 
oxidation. Precursor tolerance was set to 10 ppm and fragment ion tolerance to 0.02 Da. 
Databases for P. falciparum and H. sapiens were obtained from UniProt (www.uniprot.org). The 
raw files generated were converted to Mascot generic format (mgf) and the files interrogated 
using the Myrimatch algorithm through SearchGUI. Search parameters were set as for the 
Sequest HT search. The results files were imported into Scaffold (Version 1.4.4, Proteome 
Software Inc.) and identified peptides validated using the X!Tandem search algorithm included 
in Scaffold. Peptide and Protein validation were done using the Peptide and Protein Prophet 
algorithms. Further analysis was performed using Scaffold Viewer (Version 4.5.3, Proteome 
Software Inc.). 
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